TOHOKU UNIVERSITY Researchers

Details of the Researcher

Home

日本語 English

Nariyasu Mano

Section

Tohoku University Hospital

Job title

Professor

Degree

博士（薬学）（東北大学）

researchmap

https://researchmap.jp/7000010089

J-GLOBAL ID

201401082862271887

Research History 4

2003/04 - 2007/03

東北大学大学院薬学研究科　助教授
2002/04 - 2003/03

東北大学大学院薬学研究科　講師
2000/04 - 2002/03

東北大学大学院薬学研究科　助手
1991/04 - 2000/03

エーザイ株式会社

Education 2

Tohoku University　Graduate School of Pharmaceutical Sciences

- 1991/03
Tohoku University　Faculty of Pharmaceutical Science

- 1989/03/31

Committee Memberships 56

日本病院薬剤師会　副会長

2022/07 - Present
日本薬学会　代議員

2021/04 - Present
日本医療機能評価機構　評価委員会

2020/04 - Present
宮城県病院薬剤師会　副会長

2018/07 - Present
厚生労働省　医療用医薬品の流通の改善に関する懇談会

2018/06 - Present
宮城県　災害薬事連絡会議

2018/04 - Present
厚生労働省　保険医療専門審査員

2018/04 - Present
クロマトグラフィー科学会　理事

2016/01 - Present
日本臨床化学会　評議員

2009/04 - Present
日本医用マススペクトル学会　評議員

2007/04 - Present
日本分析化学会　役員等候補者選考委員会

2020/04 - Present
日本臨床化学会　東北支部長

2019/10 - Present
日本臨床救急医学会　編集委員会

2019/06 - Present
日本医療薬学会　医療事故調査制度協力学会東北ブロック個別調査部会員推薦窓口

2017/04 - Present
医用マススペクトル学会　保険診療推進委員会

2016/04 - Present
日本臨床救急医学会　評議員

2013/01 - Present
日本病院薬剤師会　理事

2012/07 - Present
日本医療薬学会　評議員

2011/04 - Present
日本臨床化学会　あり方委員会

2011/04 - Present
仙台市地域医療対策協議会　理事

2010/09 - Present
医薬品相互作用研究会　副会長

2010/06 - Present
医薬品相互作用研究会　評議員

2008/06 - Present
日本薬学会東北支部　支部幹事

2007/04 - Present
クロマトグラフィー科学会　評議員

2004/01 - Present
日本分析化学会　東北支部幹事

2000/04 - Present
日本病院薬剤師会　タスク・シフティング推進事業特別委員会

2020/07 - 2022/06
日本病院薬剤師会　病院診療所における薬剤師業務の在り方検討委員会

2018/07 - 2022/06
日本病院薬剤師会　医療政策部長

2018/07 - 2022/06
日本病院薬剤師会　常務理事

2014/07 - 2022/06
日本臨床化学会　理事

2017/04 - 2021/03
医用マススペクトル学会　編集委員会

2017/04 - 2021/03
医用マススペクトル学会　理事

2017/04 - 2021/03
日本臨床化学会　集会・広報委員会

2015/04 - 2021/03
日本臨床化学会　編集委員

2011/04 - 2021/03
クロマトグラフィー科学会　編集委員

2018/01 - 2020/12
日本臨床救急医学会　理事

2011/09 - 2019/06
宮城県病院薬剤師会　常任理事

2016/07 - 2018/06
日本病院薬剤師会　将来検討委員会

2014/07 - 2018/06
日本病院薬剤師会　総務部長

2014/07 - 2018/06
日本病院薬剤師会　災害対策委員長

2012/07 - 2018/06
診療行為に関連した死亡の調査分析モデル事業　東北地区窓口

2011/04 - 2017/03
宮城県病院薬剤師会　会長

2012/07 - 2016/06
日本薬学会　編集委員会

2012/04 - 2016/03
厚生労働省　薬剤師国家試験委員

2011/04 - 2016/03
日本分析化学会　役員等候補者選考委員会

2010/04 - 2016/03
日本臨床化学会　理事

2011/04 - 2015/03
日本病院薬剤師会　薬学教育モデル・コアカリキュラム改訂特別委員会

2012/07 - 2014/06
日本病院薬剤師会　広報・出版部副部長

2012/06 - 2014/06
日本病院薬剤師会　災害対策特別委員会

2011/07 - 2012/06
日本病院薬剤師会　代議員

2010/07 - 2012/06
宮城県病院薬剤師会　副会長

2010/04 - 2012/03
クロマトグラフィー科学会　理事

2008/01 - 2011/12
独立行政法人学術振興会　科学研究費専門委員会委員

2010/12 - 2011/11
独立行政法人学術振興会　科学研究費専門委員会委員

2010/12 - 2011/11
日本分析化学会　Analytical Sciences編集委員会

2005/04 - 2007/03
日本薬学会　広報委員会

2004/04 - 2007/03

Show all ︎Show first 5

Professional Memberships 29

日本医療薬学会(2011/04-2012/03 診療行為に関連した死亡の調査分析モデル窓口協力薬剤師)
日本臨床救急医学会(2013/01-2016/12 評議員)
日本臨床救急医学会(2011/09-2013/07 理事)
日本医療薬学会(2011/04- 代議員)
日本臨床化学会(2011/04- 東北支部役員)
日本臨床化学会(2011/04-2015/03 集会・広報委員会)
日本臨床化学会(2011/04-2015/03 あり方検討委員会)
日本臨床化学会(2011/04-2015/03 編集委員)
日本臨床化学会(2011/04-2015/03 理事)
クロマトグラフィー科学会(2008/04- 編集委員)
クロマトグラフィー科学会(2011/04- 評議員)
バイオメディカル分析科学シンポジウム(2008/04-2010/03 世話人)
胆汁酸研究会(2008/04- 世話人)
日本臨床化学会(2009/04-2012/03 評議員)
クロマトグラフィー科学会(2008/04-2011/12 理事)
日本医用マススペクトル学会(2007/04- 評議員)
医薬品相互作用研究会(2007/09- 副会長)
日本薬学会(2007/04- 東北支部幹事)
日本分析化学会(2000/04- 東北支部幹事)
日本臨床救急医学会(2011/09-2013/07)
日本臨床薬理学会(2011/04-)
日本医療薬学会(2007/04-)
日本薬物動態学会(2006/04-)
アメリカ質量分析学会(2005/04-)
日本臨床化学会(2002/04-)
日本医用マススペクトル学会(2000/04-)
クロマトグラフィー科学会(1999/04-)
日本分析化学会(1988/04-)
日本薬学会(1988/04-)

︎Show all ︎Show first 5

Research Interests 2

臨床化学
分析化学

Research Areas 2

Other / Other / Laboratory medicine
Life sciences / Pharmaceuticals - analytical and physicochemistry /

Awards 3

学会賞

2017/11　クロマトグラフィー科学会　高精密分離分析技術の臨床化学分析への応用
奨励賞

2005/09　医用マススペクトル学会　質量分析法による蛋白質の高精密解析に関する研究
奨励賞

2002/10　クロマトグラフィー科学会　液体クロマトグラフィーによる生体成分の高精密分子認識と捕捉に関する研究

Papers 438

Inclination of antidepressant medication continuation during pregnancy between 2012 and 2023 in Japan: A cohort study. International-journal

Tomofumi Ishikawa, Takamasa Sakai, Aoi Noda, Saya Kikuchi, Natsuko Kobayashi, Hiroaki Tomita, M Hidekazu Nishigori, Shinichi Kuriyama, Nariyasu Mano, Taku Obara

Journal of affective disorders　2025/01/10

DOI： 10.1016/j.jad.2025.01.044 　

More details Close

BACKGROUND: As multiple Japanese academic societies have recently issued treatment guidelines for perinatal antidepressant treatments, it is considered worthwhile to evaluate the latest trends and continuation of antidepressant medication during pregnancy to optimize antenatal prescriptions. METHODS: The prevalence, trend, and continuation of antidepressant use during pregnancy in Japan from 2012 to 2023 were evaluated, using a large administrative claims database, in women whose pregnancies ended in live births. Annual changes were evaluated using a multivariate logistic regression model adjusted for maternal age at delivery. RESULTS: Of 179,797 women with a mean maternal age at delivery of 32.5 years, 1870 (1.04 %) were prescribed antidepressants during pregnancy. The prevalence significantly increased (P < 0.0001) from 0.63 % in 2012 to 1.67 % in 2023. Antidepressants were prescribed to 1730 women (0.96 %) during the first trimester. Of these, 670 (38.7 %) were antidepressant continuers throughout pregnancy, showing a significant increase (P < 0.0001) from 19.51 % in 2012 to 50.70 % in 2023. The most frequently prescribed class of antidepressants during pregnancy was serotonin reuptake inhibitors (0.74 %), especially sertraline (0.33 %) and escitalopram (0.23 %), with a significant increase in their annual prevalence. LIMITATIONS: Prescriptions for women whose pregnancies ended in abortion or stillbirth could not be evaluated. CONCLUSIONS: Given that antidepressant use and its continuation during pregnancy have become more common, it is important to further disseminate knowledge of the guidelines to healthcare professionals and women of childbearing age, including the promotion of preconception care and shared decision-making.
Effect of Organic Anion Transporting Polypeptide 1B1 on Plasma Concentration Dynamics of Clozapine in Patients with Treatment-Resistant Schizophrenia

Toshihiro Sato, Takeshi Kawabata, Masaki Kumondai, Nagomi Hayashi, Hiroshi Komatsu, Yuki Kikuchi, Go Onoguchi, Yu Sato, Kei Nanatani, Masahiro Hiratsuka, Masamitsu Maekawa, Hiroaki Yamaguchi, Takaaki Abe, Hiroaki Tomita, Nariyasu Mano

International Journal of Molecular Sciences　25　(23)　2024/12

DOI： 10.3390/ijms252313228 　

ISSN： 1661-6596

eISSN： 1422-0067
Fundamental Investigation of Signal Drift in Continuous Liquid Chromatography/High Resolution Mass Spectrometric Plasma Analysis Toward Global Metabolomics

Masahiro WATANABE, Masamitsu MAEKAWA, Toshihiro SATO, Yu SATO, Masaki KUMONDAI, Masafumi KIKUCHI, Nariyasu MANO

CHROMATOGRAPHY　2024/09/25
Publisher: The Society for Chromatographic Sciences
DOI： 10.15583/jpchrom.2023.023 　

ISSN： 1342-8284

eISSN： 1348-3315
Global and Targeted Metabolomics for Revealing Metabolomic Alteration in Niemann-Pick Disease Type C Model Cells

Masahiro Watanabe, Masamitsu Maekawa, Keitaro Miyoshi, Toshihiro Sato, Yu Sato, Masaki Kumondai, Masayoshi Fukasawa, Nariyasu Mano

Metabolites　14　(10)　515-515　2024/09/24
Publisher: MDPI AG
DOI： 10.3390/metabo14100515 　

eISSN： 2218-1989

More details Close

Background: Niemann-Pick disease type C (NPC) is an inherited disorder characterized by a functional deficiency of cholesterol transport proteins. However, the molecular mechanisms and pathophysiology of the disease remain unknown. Methods: In this study, we identified several metabolite characteristics of NPC that may fluctuate in a cellular model of the disease, using both global and targeted metabolomic analyses by liquid chromatography/tandem mass spectrometry (LC-MS/MS). Three cell lines, HepG2 cells (wild-type[WT]) and two NPC model HepG2 cell lines in which NPC1 was genetically ablated (knockout [KO]1 and KO2), were used for metabolomic analysis. Data were subjected to enrichment analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Results: The enrichment analysis of global metabolomics revealed that 8 pathways in KO1 and 16 pathways in KO2 cells were notably altered. In targeted metabolomics for 15 metabolites, 4 metabolites in KO1 and 10 metabolites in KO2 exhibited statistically significant quantitative changes in KO1 or KO2 relative to WT. Most of the altered metabolites were related to creatinine synthesis and cysteine metabolism pathways. Conclusions: In the future, our objective will be to elucidate the relationship between these metabolic alterations and pathophysiology.
Liquid Chromatography/Tandem Mass Spectrometry-Based Simultaneous Analysis of 32 Bile Acids in Plasma and Conventional Biomarker-Integrated Diagnostic Screening Model Development for Hepatocellular Carcinoma

Minami Yamauchi, Masamitsu Maekawa, Toshihiro Sato, Yu Sato, Masaki Kumondai, Mio Tsuruoka, Jun Inoue, Atsushi Masamune, Nariyasu Mano

Metabolites　14　(9)　513-513　2024/09/23
Publisher: MDPI AG
DOI： 10.3390/metabo14090513 　

eISSN： 2218-1989

More details Close

Imaging tests, tumor marker (TM) screening, and biochemical tests provide a definitive diagnosis of hepatocellular carcinoma (HCC). However, some patients with HCC may present TM-negative results, warranting a need for developing more sensitive and accurate screening biomarkers. Various diseases exhibit increased blood levels of bile acids, biosynthesized from cholesterol in the liver, and they have been associated with HCC. Herein, we analyzed plasma bile acids using liquid chromatography/tandem mass spectrometry and integrated them with conventional biomarkers to develop a diagnostic screening model for HCC. Plasma samples were obtained from patients diagnosed with chronic hepatitis, hepatic cirrhosis (HC), and HCC. A QTRAP 6500 mass spectrometer and a Nexera liquid chromatograph with a YMC-Triart C18 analytical column were used. The mobile phase A was a 20 mmol/L ammonium formate solution, and mobile phase B was a methanol/acetonitrile mixture (1:1, v/v) with 20 mmol/L ammonium formate. After determining the concentrations of 32 bile acids, statistical analysis and diagnostic screening model development were performed. Plasma concentrations of bile acids differed between sample groups, with significant differences observed between patients with HC and HCC. By integrating bile acid results with conventional biochemical tests, a potential diagnostic screening model for HCC was successfully developed. Future studies should increase the sample size and analyze the data in detail to verify the diagnostic efficacy of the model.
Association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage. International-journal

Tomofumi Ishikawa, Takamasa Sakai, Noriyuki Iwama, Ryo Obara, Kei Morishita, Motohiko Adomi, Aoi Noda, Mami Ishikuro, Saya Kikuchi, Natsuko Kobayashi, Hiroaki Tomita, Masatoshi Saito, Hidekazu Nishigori, Shinichi Kuriyama, Nariyasu Mano, Taku Obara

Acta psychiatrica Scandinavica　2024/09/05

DOI： 10.1111/acps.13755 　

More details Close

OBJECTIVE: To evaluate the association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage. MATERIAL AND METHODS: This nested case-control study used a large Japanese administrative database. Pregnancy onset and outcomes were estimated using previously reported algorithms, classifying cases as women becoming pregnant between 2013 and 2022 and ending in a miscarriage. Controls were randomly selected from the entire pregnancy cohort by risk-set sampling with replacement and were individually matched to the cases (3:1). The association between exposure to atypical antipsychotics and risk of miscarriage was assessed using conditional logistic regression adjusted for confounders. The association between benzodiazepine exposure and the risk of miscarriage was assessed as a positive control. RESULTS: In the cohort, 44,118 patients were matched with 132,317 controls. The mean ages (standard deviations) of the case and control groups were 33.3 (5.7) and 33.2 (5.5) years, respectively. The prevalence of atypical antipsychotics was 0.5% in both groups. Aripiprazole is an individual antipsychotic with the highest prescription prevalence. The adjusted odds ratios (aOR) for miscarriage were 0.966 (95% confidence interval [CI], 0.796-1.173) for atypical antipsychotics and 0.998 (0.784-1.269) for aripiprazole. A higher aOR (1.431, 95% CI 1.303-1.573) suggested an association with benzodiazepines. A sensitivity analysis that limited the population to women diagnosed with schizophrenia alone did not suggest an association between atypical antipsychotics and the risk of miscarriage. CONCLUSIONS: The results of this study do not suggest an association between exposure to atypical antipsychotics during pregnancy and the risk of miscarriage.
Combination of taking neuropsychiatric medications and psychological distress in pregnant women, with behavioral problems in children at 2 years of age: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study. International-journal

Ippei Takahashi, Taku Obara, Saya Kikuchi, Natsuko Kobayashi, Ryo Obara, Aoi Noda, Minoru Ohsawa, Tomofumi Ishikawa, Nariyasu Mano, Hidekazu Nishigori, Fumihiko Ueno, Genki Shinoda, Keiko Murakami, Masatsugu Orui, Mami Ishikuro, Hiroaki Tomita, Shinichi Kuriyama

PCN reports : psychiatry and clinical neurosciences　3　(3)　e226　2024/09

DOI： 10.1002/pcn5.226 　

More details Close

AIM: To examine the association of the combination of taking neuropsychiatric medications from the onset of pregnancy to mid-pregnancy and maternal psychological distress at mid-pregnancy, with children's behavioral problems. METHODS: Neuropsychiatric medication use from the onset of pregnancy to mid-pregnancy was defined by the self-reported name of the neuropsychiatric medication in the questionnaire in early and mid-pregnancy. Maternal psychological distress was defined by the Kessler Psychological Distress Scale (K6) ≥13 on the questionnaire in mid-pregnancy. We classified the participants into four categories based on the combination of taking neuropsychiatric medications and psychological distress: "None," "Medications only," "K6 ≥ 13 only," and "Both." Children's behavioral problems were assessed using the Child Behavior Checklist for Ages 1½-5 (CBCL) at 2 years of age. The clinical ranges of the internalizing and externalizing scales of the CBCL were defined as behavioral problems. We conducted a multivariable logistic regression analysis to examine the associations between the four categories of maternal exposure and children's behavioral problems. RESULTS: Compared with the "None" category (n = 9873), the "K6 ≥ 13 only" category (n = 308) was statistically significantly associated with internalizing and externalizing problems. In contrast, the "Medications only" (n = 93) and "Both" (n = 22) categories were not statistically significantly associated with internalizing and externalizing problems, although the point estimates of the odds ratio in the "Both" category were relatively high (1.58 for the internalizing problem and 2.50 for the externalizing problem). CONCLUSION: The category of mothers taking neuropsychiatric medications and having no psychological distress during pregnancy was not associated with children's behavioral problems in the present population.
Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial. International-journal

Emi Yamazaki, Taku Fujimura, Manami Takahashi-Watanabe, Satsuki Tada, Chisako Kitayama, Ryo Amagai, Yumi Kambayashi, Masahiro Watanabe, Masamitsu Maekawa, Nariyasu Mano, Yoshihide Asano

The British journal of dermatology　2024/08/31

DOI： 10.1093/bjd/ljae343 　
Development of Simultaneous Drug Concentration Measurement Method Using an Automated Pretreatment Liquid Chromatography/Tandem Mass Spectrometry System for Therapeutic Drug Monitoring

Yu Sato, Hiroki Kondo, Yuji Sato, Ai Abe, Masafumi Kikuchi, Toshihiro Sato, Masaki Kumondai, Kohei Yoshikawa, Yoshihiro Hayakawa, Masamitsu Maekawa, Nariyasu Mano

Pharmaceutics　16　(9)　1138-1138　2024/08/28
Publisher: MDPI AG
DOI： 10.3390/pharmaceutics16091138 　

eISSN： 1999-4923

More details Close

Therapeutic drug monitoring (TDM) is a personalized treatment approach that involves optimizing drug dosages based on patient-specific factors, such as drug plasma concentrations, therapeutic efficacy, or adverse reactions. The plasma concentration of drugs is determined using liquid chromatography/tandem mass spectrometry (LC-MS/MS) or various immunoassays. Compared with immunoassays, LC-MS/MS requires more pretreatment time as the number of samples increases. Recently, fully automated pretreatment LC-MS/MS systems have been developed to automatically perform whole-sample pretreatment for LC-MS/MS analysis. In this study, we developed a method for simultaneous concentration determination of five analytes (clozapine, mycophenolic acid, sunitinib, N-desethylsunitinib, and voriconazole) using LC-MS/MS for clinical TDM using a fully automated LC-MS/MS pretreatment system. In the developed method, the intra- and inter-assay relative error (RE) values ranged between −14.8% and 11.3%; the intra- and inter-assay coefficient of variation (CV) values were <8.8% and <10.5%, respectively. The analytes showed good stability, with RE values ranging between −13.6% and 10.9% and CV values <8.9%. Furthermore, the plasma concentrations in clinical samples using this method and the conventional manual pretreatment method showed similar results. Therefore, the method developed in this study could be considered a useful pretreatment method for routine TDM in patients.
Determination of Choline-Containing Compounds in Rice Bran Fermented with Aspergillus oryzae Using Liquid Chromatography/Tandem Mass Spectrometry

Masamitsu Maekawa, Anna Iwahori, Masaki Kumondai, Yu Sato, Toshihiro Sato, Nariyasu Mano

Mass Spectrometry　13　(1)　A0151-A0151　2024/08/08
Publisher: The Mass Spectrometry Society of Japan
DOI： 10.5702/massspectrometry.a0151 　

ISSN： 2187-137X

eISSN： 2186-5116
Functional significance of CYP2B6 gene rare allelic variants identified in Japanese individuals

Shuki Yamazaki, Eiji Hishinuma, Yuma Suzuki, Akiko Ueda, Caroline Kijogi, Tomoki Nakayoshi, Akifumi Oda, Sakae Saito, Shu Tadaka, Kengo Kinoshita, Masamitsu Maekawa, Yu Sato, Masaki Kumondai, Nariyasu Mano, Noriyasu Hirasawa, Masahiro Hiratsuka

Biochemical Pharmacology　116515-116515　2024/08
Publisher: Elsevier BV
DOI： 10.1016/j.bcp.2024.116515 　

ISSN： 0006-2952
Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice. International-journal

Masaki Kumondai, Reika Ogawa, Nagomi Hayashi, Yurika Ishida, Hanae Oshikiri, Yuji Sato, Masafumi Kikuchi, Yu Sato, Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano

Pharmacology research & perspectives　12　(4)　e1241　2024/08

DOI： 10.1002/prp2.1241 　

More details Close

Lenvatinib (LEN), a multitarget tyrosine kinase inhibitor used in various cancer treatments, is mainly metabolized by cytochrome P450 3A (CYP3A) enzymes. The importance of therapeutic drug monitoring (TDM) in patients administered LEN has been proposed. Although some biomarkers of endogenous CYP3A activity have been reported, their utility in dosage adjustments has not been well evaluated. This study investigated the correlation between plasma LEN concentrations and endogenous urinary CYP3A biomarkers in clinical practice. Concentrations of plasma LEN (N = 225) and CYP3A biomarkers (cortisol, 6β-hydroxycortisol, deoxycholic acid, and 1β-hydroxydeoxycholic acid) in urine (N = 214) from 20 patients (hepatocellular carcinoma, N = 6; thyroid cancer, N = 3; endometrial cancer, N = 8; and renal cell carcinoma, N = 3) collected for consultation for up to 1 year were evaluated using liquid chromatography-tandem mass spectrometry. Moreover, plasma trough LEN concentrations were predicted using a three-compartment model with linear elimination for outpatients administered LEN before sample collection. Moderate correlations were observed between the quantified actual concentrations and the predicted trough concentrations of LEN, whereas there was no correlation with endogenous urinary CYP3A biomarkers. The utility of endogenous urinary CYP3A biomarkers could not be determined. However, TDM for outpatients administered orally available medicines may be predicted using a nonlinear mixed effect model (NONMEM). This study investigated the utility of endogenous urinary CYP3A biomarkers for personalized medicine and NONMEM for predicting plasma trough drug concentrations. These findings will provide important information for further clinical investigation and detailed TDM.
乳癌患者の療養環境を病院-地域間でシームレスにつなぐ CDK4/6阻害薬使用患者に対する薬薬連携の有用性

押切華映, 菊地正史, 前川麻央, 松浦正樹, 原田成美, 眞野成康

日本乳癌学会総会プログラム抄録集　32回　20-20　2024/07
Publisher: (一社)日本乳癌学会
Development of a simultaneous LC-MS/MS analytical method for plasma: 16 antipsychotics approved in Japan and 4 drug metabolites. International-journal

Masamitsu Maekawa, Maki Yokota, Toshihiro Sato, Yu Sato, Masaki Kumondai, Yuji Sato, Masato Suzuka, Daisuke Kobayashi, Kotaro Sakamoto, Masaki Matsuura, Masafumi Kikuchi, Hiroshi Komatsu, Kumiko Fujii, Yuji Ozeki, Hiroaki Tomita, Nariyasu Mano

Analytical sciences : the international journal of the Japan Society for Analytical Chemistry　2024/06/25

DOI： 10.1007/s44211-024-00619-2 　

More details Close

The increased risk of adverse drug reactions due to the concomitant use of antipsychotics is problematic in the treatment of schizophrenia. Therefore, the simultaneous analysis of their plasma concentrations is required. In this study, we developed a simultaneous liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for analyzing plasma antipsychotics approved in Japan for therapeutic drug monitoring (TDM) applications. First, we counted the prescriptions for 16 antipsychotics and concomitant drugs used at the Tohoku University Hospital. LC-MS/MS was used for the simultaneous analysis of 16 antipsychotics and four drug metabolites. This analysis was conducted using a combination of selected reaction monitoring mode and reversed-phase chromatography. Following the examination of the MS/MS and LC conditions, an analytical method validation test was conducted. The developed method was used to analyze plasma antipsychotic levels in patients with schizophrenia. One-third of the patients received treatment with multiple antipsychotics. Under LC-MS/MS conditions, LC separation was performed using a combination of a C18 column and ammonium formate-based mobile phases with a gradient flow. The calibration curves were optimized by adjusting the ion abundance, and 11 compounds met the criteria for intra- and inter-day reproducibility tests. Some stability test results did not meet these criteria; therefore, further investigation is required. The developed method permitted the measurement of all the plasma parameters, including concentrations above the therapeutic range. Therefore, this method may be useful in the daily TDM practice of antipsychotics.
免疫関連有害事象マネジメントに向けた地域連携の取り組み保険薬局薬剤師の認識と多職種連携研修会の効果

山田稜, 菊地正史, 今野壮太, 押切華映, 堀川美帆, 赤坂和俊, 五十嵐敏明, 佐藤裕, 松浦綾子, 原田成美, 眞野成康

日本臨床腫瘍薬学会雑誌　36　459-459　2024/05
Publisher: (一社)日本臨床腫瘍薬学会
eISSN： 2189-129X
免疫関連有害事象マネジメントに向けた地域連携の取り組み保険薬局薬剤師の認識と多職種連携研修会の効果

山田稜, 菊地正史, 今野壮太, 押切華映, 堀川美帆, 赤坂和俊, 五十嵐敏明, 佐藤裕, 松浦綾子, 原田成美, 眞野成康

日本臨床腫瘍薬学会雑誌　36　459-459　2024/05
Publisher: (一社)日本臨床腫瘍薬学会
eISSN： 2189-129X
Wide-targeted semi-quantitative analysis of acidic glycosphingolipids in cell lines and urine to develop potential screening biomarkers for renal cell carcinoma International-journal Invited Peer-reviewed

Masamitsu Maekawa, Tomonori Sato, Chika Kanno, Izumi Sakamoto, Yoshihide Kawasaki, Akihiro Ito, Nariyasu Mano

International journal of molecular sciences　25　(7)　4098　2024/04/07

DOI： 10.3390/ijms25074098 　
Downregulation of ABCC3 activates MAPK signaling through accumulation of deoxycholic acid in colorectal cancer cells. International-journal

Yukihiro Sato, Minoru Kobayashi, Masahiro Ohira, Ryo Funayama, Masamitsu Maekawa, Hideaki Karasawa, Ryosuke Kashiwagi, Yayoi Aoyama, Nariyasu Mano, Shinobu Ohnuma, Michiaki Unno, Keiko Nakayama

Cancer science　2024/04/02

DOI： 10.1111/cas.16132 　

More details Close

ABCC3 (also known as MRP3) is an ATP binding cassette transporter for bile acids, whose expression is downregulated in colorectal cancer through the Wnt/β-catenin signaling pathway. However, it remained unclear how downregulation of ABCC3 expression contributes to colorectal carcinogenesis. We explored the role of ABCC3 in the progression of colorectal cancer-in particular, focusing on the regulation of bile acid export. Gene expression analysis of colorectal adenoma isolated from familial adenomatous polyposis patients revealed that genes related to bile acid secretion including ABCC3 were downregulated as early as at the stage of adenoma formation. Knockdown or overexpression of ABCC3 increased or decreased intracellular concentration of deoxycholic acid, a secondary bile acid, respectively, in colorectal cancer cells. Forced expression of ABCC3 suppressed deoxycholic acid-induced activation of MAPK signaling. Finally, we found that nonsteroidal anti-inflammatory drugs increased ABCC3 expression in colorectal cancer cells, suggesting that ABCC3 could be one of the targets for therapeutic intervention of familial adenomatous polyposis. Our data thus suggest that downregulation of ABCC3 expression contributes to colorectal carcinogenesis through the regulation of intracellular accumulation of bile acids and activity of MAPK signaling.
Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan. International-journal

Sayumi Takahashi, Yoichi Kakuta, Taku Obara, Tomofumi Ishikawa, Hiroshi Nagai, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Hisashi Shiga, Nariyasu Mano, Yoshitaka Kinouchi, Atsushi Masamune

Journal of gastroenterology and hepatology　2024/03/27

DOI： 10.1111/jgh.16549 　

More details Close

BACKGROUND AND AIM: Inflammatory bowel disease (IBD) frequently affects younger patients and poses various challenges concerning pregnancy and childbirth. Maintaining good disease control throughout pregnancy is crucial, but expectant and pregnant patients may worry about the fetal impact of medications, leading to treatment discontinuation due to uncertainty about this issue. This study investigated the real-world drug-prescribing practices for pregnant patients with IBD in Japan and their potential connection to major congenital malformations (MCMs). METHODS: Overall, 277 female IBD patients who gave birth between 2010 and 2019 were selected from the JMDC claims database. The prescribing patterns of IBD medications and MCMs in the patients' offspring were analyzed. RESULTS: Among pregnant IBD patients, 74.4% received at least one medication from 90 days before pregnancy to 90 days after delivery. Trends in medication prescriptions during pregnancy in 2010-2019 revealed consistent use of oral 5-ASA, variable use of topical medications, a decrease in systemic steroids, and an increase in biologics. The prevalence of MCMs in children born to IBD-affected mothers did not differ significantly between those who did and did not receive IBD medications (8.6% vs 6.8%). Although circulatory system MCMs were slightly more common in the IBD medication group (4.9% vs 1.4%), this difference was not significant. Logistic regression analysis did not reveal an association between MCM risk and first-trimester use of IBD medications, including corticosteroids and biologics. CONCLUSIONS: This study provides insights into medication patterns in pregnant IBD patients and suggests no increased risk of MCMs associated with first-trimester IBD medication use.
Elucidation and regulation of tyrosine kinase inhibitor resistance in renal cell carcinoma cells from the perspective of glutamine metabolism Peer-reviewed

Kento Morozumi, Yoshihide Kawasaki, Tomonori Sato, Masamitsu Maekawa, Shinya Takasaki, Shuichi Shimada, Takanari Sakai, Shinichi Yamashita, Nariyasu Mano, Akihiro Ito

Metabolites　2024/03/19

DOI： 10.3390/metabo14030170 　
簡易懸濁法を用いて在宅でのオシメルチニブ投与に繋げた非小細胞肺癌の一例

水口敦史, 成田佳奈, 宮内栄作, 菊地正史, 眞野成康

日本服薬支援研究会誌　11　(2)　26-26　2024/02
Publisher: 日本服薬支援研究会
Concomitant Use of Clozapine and Suvorexant Doubled Clozapine Plasma Levels: A Case Report. International-journal

Yuki Kikuchi, Toshihiro Sato, Keiichi Murakami, Tatsui Otsuka, Terufumi Machida, Keigo Yoshikawa, Yoshiaki Shiozawa, Hiroshi Komatsu, Masamitsu Maekawa, Nariyasu Mano, Hiroaki Tomita

Journal of clinical psychopharmacology　2024/01/16

DOI： 10.1097/JCP.0000000000001808 　
The use of an antioxidant enables accurate evaluation of the interaction of curcumin on organic anion-transporting polypeptides 4C1 by preventing auto-oxidation Peer-reviewed

Toshihiro Sato, Ayaka Yagi, Minami Yamauchi, Masaki Kumondai, Yu Sato, Masafumi Kikuchi, Masamitsu Maekawa, Hiroaki Yamaguchi, Takaaki Abe, Nariyasu Mano

International journal of molecular sciences　2024/01/12

DOI： 10.3390/ijms25020991 　
Plasma Venetoclax Concentrations in Patients with Acute Myeloid Leukemia Treated with CYP3A4 Inhibitors.

Ayaka Otsuki, Masaki Kumondai, Daisuke Kobayashi, Masafumi Kikuchi, Yugo Ueki, Yuji Sato, Nagomi Hayashi, Ayaka Yagi, Yasushi Onishi, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Masamitsu Maekawa, Nariyasu Mano

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan　144　(7)　775-779　2024

DOI： 10.1248/yakushi.24-00018 　

More details Close

Venetoclax (VEN) is used in patients with acute myeloid leukemia (AML) and is primarily metabolized by CYP3A4, a major drug-metabolizing enzyme. Patients with AML simultaneously administered VEN and CYP3A4 inhibitors require a more appropriate management of drug-drug interactions (DDIs). Here, we report two cases of patients with AML (54-year-old man and 22-year-old woman) administrated VEN and CYP3A4 inhibitors, such as posaconazole, cyclosporine, or danazol. In the first case, we evaluated the appropriateness of timing for adjusting VEN dosage subsequent to the cessation of posaconazole. Consequently, modifying the VEN dosage in conjunction with the cessation of Posaconazole simultaneously may result in elevated plasma VEN levels. In the second case, plasma VEN concentrations were markedly elevated when co-administered with several CYP3A4 inhibitors. Additionally, in vitro assays were conducted for reverse translational studies to analyze CYP3A4 inhibition. CYP3A4 inhibition by combinatorial administration of cyclosporine A and danazol was demonstrated in vitro, which potentially explains the increasing plasma VEN concentrations observed in clinical settings. Although the acquisition of therapeutic effects is a major priority for patients, frequent therapeutic drug monitoring and dosage adjustments considering DDIs would be important factors in chemotherapy.
クロザピン血中濃度変動と薬物動態関連因子の一塩基多型の関連解析

佐藤紀宏, 公文代將希, 林和未, 小野口豪, 小松浩, 平塚真弘, 前川正充, 富田博秋, 眞野成康

日本臨床薬理学会学術総会抄録集　44回　1-5　2024/01
Publisher: (一社)日本臨床薬理学会
eISSN： 2436-5580
Fatty acid binding protein type 7 deficiency preserves auditory function in noise-exposed mice. International-journal

Jun Suzuki, Tomotaka Hemmi, Masamitsu Maekawa, Masahiro Watanabe, Hitoshi Inada, Hiroyuki Ikushima, Tetsuya Oishi, Ryoukichi Ikeda, Yohei Honkura, Yoshiteru Kagawa, Tetsuaki Kawase, Nariyasu Mano, Yuji Owada, Noriko Osumi, Yukio Katori

Scientific reports　13　(1)　21494-21494　2023/12/06

DOI： 10.1038/s41598-023-48702-4 　

More details Close

Fatty acid-binding protein 7 (FABP7) is vital for uptake and trafficking of fatty acids in the nervous system. To investigate the involvement of FABP7 in noise-induced hearing loss (NIHL) pathogenesis, we used Fabp7 knockout (KO) mice generated via CRISPR/Cas9 in the C57BL/6 background. Initial auditory brainstem response (ABR) measurements were conducted at 9 weeks, followed by noise exposure at 10 weeks. Subsequent ABRs were performed 24 h later, with final measurements at 12 weeks. Inner ears were harvested 24 h after noise exposure for RNA sequencing and metabolic analyses. We found no significant differences in initial ABR measurements, but Fabp7 KO mice showed significantly lower thresholds in the final ABR measurements. Hair cell survival was also enhanced in Fabp7 KO mice. RNA sequencing revealed that genes associated with the electron transport chain were upregulated or less impaired in Fabp7 KO mice. Metabolomic analysis revealed various alterations, including decreased glutamate and aspartate in Fabp7 KO mice. In conclusion, FABP7 deficiency mitigates cochlear damage following noise exposure. This protective effect was supported by the changes in gene expression of the electron transport chain, and in several metabolites, including excitotoxic neurotransmitters. Our study highlights the potential therapeutic significance of targeting FABP7 in NIHL.
肝疾患時の腎排泄型薬物の投与設計最適化を目指した胆汁酸-腎薬物トランスポーター相互作用研究

佐藤紀宏, 山内碧, 大竹彩奈, 前川正充, 山口浩明, 阿部高明, 眞野成康

医療の広場　63　(12)　23-26　2023/12
Publisher: (公財)政策医療振興財団
注射用骨粗鬆治療薬の誤投与防止についての取組み

大友千賀, 赤坂和俊, 菊地正史, 松浦正樹, 佐藤真由美, 前川正充, 西條文人, 菅原寛子, 田畑雅央, 眞野成康

医療の質・安全学会誌　18　(Suppl.)　398-398　2023/11
Publisher: (一社)医療の質・安全学会
ISSN： 1881-3658

eISSN： 1882-3254
B型肝炎関連検査の実施率向上に向けたB型肝炎受診勧奨システムのステロイド薬への対象拡大と評価

前嶋隆弘, 松浦正樹, 大柳元, 二瓶貴幸, 堀川美帆, 赤坂和俊, 菊地正史, 前川正充, 井上淳, 眞野成康

医療の質・安全学会誌　18　(Suppl.)　397-397　2023/11
Publisher: (一社)医療の質・安全学会
ISSN： 1881-3658

eISSN： 1882-3254
注射用骨粗鬆治療薬の誤投与防止についての取組み

大友千賀, 赤坂和俊, 菊地正史, 松浦正樹, 佐藤真由美, 前川正充, 西條文人, 菅原寛子, 田畑雅央, 眞野成康

医療の質・安全学会誌　18　(Suppl.)　398-398　2023/11
Publisher: (一社)医療の質・安全学会
ISSN： 1881-3658

eISSN： 1882-3254
Global Proteomics for Identifying the Alteration Pathway of Niemann–Pick Disease Type C Using Hepatic Cell Models

Keitaro Miyoshi, Eiji Hishinuma, Naomi Matsukawa, Yoshitaka Shirasago, Masahiro Watanabe, Toshihiro Sato, Yu Sato, Masaki Kumondai, Masafumi Kikuchi, Seizo Koshiba, Masayoshi Fukasawa, Masamitsu Maekawa, Nariyasu Mano

International Journal of Molecular Sciences　24　(21)　15642-15642　2023/10/27
Publisher: MDPI AG
DOI： 10.3390/ijms242115642 　

eISSN： 1422-0067

More details Close

Niemann–Pick disease type C (NPC) is an autosomal recessive disorder with progressive neurodegeneration. Although the causative genes were previously identified, NPC has unclear pathophysiological aspects, and patients with NPC present various symptoms and onset ages. However, various novel biomarkers and metabolic alterations have been investigated; at present, few comprehensive proteomic alterations have been reported in relation to NPC. In this study, we aimed to elucidate proteomic alterations in NPC and perform a global proteomics analysis for NPC model cells. First, we developed two NPC cell models by knocking out NPC1 using CRISPR/Cas9 (KO1 and KO2). Second, we performed a label-free (LF) global proteomics analysis. Using the LF approach, more than 300 proteins, defined as differentially expressed proteins (DEPs), changed in the KO1 and/or KO2 cells, while the two models shared 35 DEPs. As a bioinformatics analysis, the construction of a protein–protein interaction (PPI) network and an enrichment analysis showed that common characteristic pathways such as ferroptosis and mitophagy were identified in the two model cells. There are few reports of the involvement of NPC in ferroptosis, and this study presents ferroptosis as an altered pathway in NPC. On the other hand, many other pathways and DEPs were previously suggested to be associated with NPC, supporting the link between the proteome analyzed here and NPC. Therapeutic research based on these results is expected in the future.
Functional Characterization of 29 Cytochrome P450 4F2 Variants Identified in a Population of 8,380 Japanese Subjects and Assessment of Arachidonic Acid ω-Hydroxylation. International-journal

Yu Sato, Eiji Hishinuma, Shuki Yamazaki, Akiko Ueda, Masaki Kumondai, Sakae Saito, Shu Tadaka, Kengo Kinoshita, Tomoki Nakayoshi, Akifumi Oda, Masamitsu Maekawa, Nariyasu Mano, Noriyasu Hirasawa, Masahiro Hiratsuka

Drug metabolism and disposition: the biological fate of chemicals　2023/09/29

DOI： 10.1124/dmd.123.001389 　

More details Close

Cytochrome P450 4F2 (CYP4F2) is an enzyme that is involved in the metabolism of arachidonic acid (AA), vitamin E and K (VK), and xenobiotics including drugs. CYP4F2*3 polymorphism (rs2108622; c.1297G>A; p.Val433Met) has been associated with hypertension, ischemic stroke, and variation in the effectiveness of the anticoagulant drug warfarin. In this study, we characterized wild-type CYP4F2 and 28 CYP4F2 variants, including a Val433Met substitution, detected in 8,380 Japanese subjects. The CYP4F2 variants were heterologously expressed in 293FT cells to measure the concentrations of CYP4F2 variant holoenzymes using carbon monoxide-reduced difference spectroscopy, where the wild type and 18 holoenzyme variants showed a peak at 450 nm. Kinetic parameters (Vmax , S50 , and CL int as Vmax /S50 ) of AA ω-hydroxylation were determined for the wild type and 21 variants with enzyme activity. Compared to the wild type, two variants showed significantly decreased CL int values for AA ω-hydroxylation. The values for seven variants could not be determined because no enzymatic activity was detected at the highest substrate concentration used. Three-dimensional structural modeling was performed to determine the reason for reduced enzymatic activity of the CYP4F2 variants. Our findings contribute to a better understanding of CYP4F2 variant-associated diseases and possible future therapeutic strategies. Significance Statement CYP4F2 is involved in the metabolism of AA and VK, and CYP4F2*3 polymorphisms have been associated with hypertension and variation in the effectiveness of the anticoagulant drug warfarin. In this study, we present a functional analysis of 28 CYP4F2 variants identified in Japanese subjects, demonstrating that seven gene polymorphisms cause loss of CYP4F2 function, and propose structural changes that lead to altered function.
Real-world prevalence, time of diagnosis, and co-occurrence patterns of birth defects in live-born infants, 2014-2020: A health administrative database study in Japan. International-journal

Tomofumi Ishikawa, Hiroshi Kawame, Nariyasu Mano, Taku Obara

Birth defects research　115　(18)　1723-1736　2023/09/08

DOI： 10.1002/bdr2.2247 　

More details Close

BACKGROUND: A study evaluating the real-world prevalence of birth defects (BDs), including co-occurrence patterns, will provide the information required to estimate Japan's true BD prevalence and monitor it. Information such as when infants are diagnosed with BDs is crucial for defining the study population and data collection period in future administrative database studies. METHODS: This study utilized the DeSC database, a large claims database comprising multiple health insurance schemes. The prevalence of major BDs, including structural congenital malformations (CMs) and chromosomal abnormalities, was determined in infants born between 2014 and 2020 and continuously insured for ≥1 year. The time of the first BD diagnosis and multiple BD patterns were also evaluated. RESULTS: Among 43,147 infants, 3050 (7.07%) were diagnosed with major BDs, and 3002 (6.96%) with major CMs. The circulatory system (2.95%) was the most frequent organ system affected by CMs, followed by CMs and deformations of the musculoskeletal system (1.94%). The cumulative diagnostic rates of BDs and CMs at month 6 were 85.9% and 85.6%, respectively. The EUROCAT BD subgroups diagnosed in more than 1.0% of the infants were atrial septal defects (1.47%) and patent ductus arteriosus (1.07%). Among the 2997 infants with EUROCAT BDs, 241 (8.04%) were classified as having multiple BDs. CONCLUSIONS: A large claims database is a valuable resource for evaluating and monitoring the prevalence of BDs, including multiple patterns. At least 1 year since birth should be considered in future administrative database studies evaluating BDs as outcomes.
妊娠初期の消化管運動改善薬の大奇形リスク大規模レセプトデータベースを用いた評価

小原拓, 石川智史, 赤沢学, 野田あおい, 大柳元, 森下啓, 都田桂子, 西郡秀和, 川目裕, 八重樫伸生, 栗山進一, 眞野成康

DOHaD研究　11　(3)　38-39　2023/08
Publisher: (一社)日本DOHaD学会
ISSN： 2187-2562

eISSN： 2187-2597
High throughput LC/ESI-MS/MS method for simultaneous analysis of 20 oral molecular-targeted anticancer drugs and the active metabolite of sunitinib in human plasma

Tensei Hirasawa, Masafumi Kikuchi, Shinya Takasaki, Masaki Kumondai, Yu Sato, Toshihiro Sato, Eishi Imoto, Yoshihiro Hayakawa, Masamitsu Maekawa, Nariyasu Mano

Heliyon　9　(6)　e16926-e16926　2023/06
Publisher: Elsevier BV
DOI： 10.1016/j.heliyon.2023.e16926 　

ISSN： 2405-8440
The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database. International-journal

Masami Tsuchiya, Taku Obara, Masafumi Kikuchi, Nariyasu Mano

Cancer chemotherapy and pharmacology　2023/05/08

DOI： 10.1007/s00280-023-04535-6 　

More details Close

PURPOSE: This study aimed to investigate the current status of end-of-life chemotherapy and targeted therapy and explore the aggressiveness of end-of-life care in Japan using the DeSC database, a large administrative claims database. METHODS: We identified fatal cases of at least one cancer-related diagnosis between April 2015 and November 2020. Patients prescribed at least one anticancer drug were analyzed, and chemotherapy regimens were categorized based on the combination of concomitant anticancer drugs prescribed. RESULTS: Among 1,095,713 individuals enrolled in the National Health Insurance database, 7,300 deaths with cancer-related diagnosis were identified. Of these, 4,010 cases were identified in which at least one anticancer drug was prescribed, and 11.6% of 7,300 death had been prescribed anticancer drugs in their last 30 days of life. The most commonly used regimen was S-1 (tegafur, gimeracil, and oteracil potassium combination) monotherapy, followed by nivolumab monotherapy and nab-paclitaxel plus gemcitabine. Immune checkpoint inhibitor monotherapy was more likely prescribed to patients whose last chemotherapy dose was in the last 30 days of life (p = 0.0066, chi-squared test). CONCLUSIONS: This study provides insights into the current status of end-of-life chemotherapy and targeted therapy in Japan, using a large administrative claims database. The results of this study will inform future research on end-of-life chemotherapy and targeted therapy, and help develop strategies to improve the quality of life of patients with advanced cancer.
個別化医療が切り開くがん薬物療法の新しい扉がんゲノム医療におけるがん遺伝子パネル検査の基礎知識

菊地正史, 眞野成康

日本臨床腫瘍薬学会雑誌　30　105-105　2023/05
Publisher: (一社)日本臨床腫瘍薬学会
eISSN： 2189-129X
臨床検査のピットフォール血中薬物濃度測定時の注意点

菊地正史, 眞野成康

検査と技術　51　(5)　580-585　2023/05
Publisher: (株)医学書院
ISSN： 0301-2611

eISSN： 1882-1375
Therapeutic Drug Monitoring of Blood Sirolimus and Tacrolimus Concentrations for Polypharmacy Management in a Lymphangioleiomyomatosis Patient Taking Two Cytochrome P450 3A Inhibitors.

Masaki Kumondai, Masafumi Kikuchi, Atsushi Mizuguchi, Nagomi Hayashi, Masahiro Ui, Takashi Hirama, Yoshinori Okada, Yu Sato, Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano

The Tohoku journal of experimental medicine　260　(1)　29-34　2023/03/02

DOI： 10.1620/tjem.2023.J016 　

More details Close

Patients with lymphangioleiomyomatosis (LAM) and lung transplantations are treated with multiple drugs, such as tacrolimus, mycophenolate mofetil, prednisolone, and itraconazole, for long-term suppression of rejection response and prevention of infection. Additional drugs are required when lung transplant recipients develop graft complications. Therefore, managing polypharmacy is critical because of drug-drug interactions caused by various factors, including drug-metabolizing enzymes such as cytochrome P450 3A (CYP3A). The patient was a 48-year-old woman (height 144.9 cm and weight 38.4 kg) who underwent lung transplantation for LAM. Mycophenolate mofetil, tacrolimus (target blood concentration, 4.0-8.0 ng/mL), and prednisolone were administered for immunosuppression, and itraconazole and clarithromycin were administered to manage graft infection. The patient developed unilateral lymphedema, predominantly in the left leg; therefore, sirolimus was initiated with a target blood concentration of 3.0-5.0 ng/mL. In addition to 1.0 mg/day of sirolimus, tacrolimus (0.3 mg/day), itraconazole (100 mg/day), and clarithromycin (800 mg/day) were added. Blood sirolimus concentrations ranged from 18.8 to 36.9 ng/mL on days 6 to 9; thus, treatment with sirolimus was stopped because of over-target blood concentrations. Blood concentrations of sirolimus and tacrolimus were successfully managed without adverse events using therapeutic drug monitoring (TDM) and azole anti-fungal substitution of azithromycin instead of clarithromycin although sirolimus concentration was relatively lower compared to the target range. Thereby, frequent TDM, management of polypharmacy that influences CYP3A activity, and possibly CYP3A genotyping should be appropriately conducted for personalized medicine.
Development of a Simultaneous Liquid Chromatography-Tandem Mass Spectrometry Analytical Method for Urinary Endogenous Substrates and Metabolites for Predicting Cytochrome P450 3A4 Activity

Masaki Kumondai, Masamitsu Maekawa, Eiji Hishinuma, Yu Sato, Toshihiro Sato, Masafumi Kikuchi, Masahiro Hiratsuka, Nariyasu Mano

Biological and Pharmaceutical Bulletin　46　(3)　455-463　2023/03/01
Publisher: Pharmaceutical Society of Japan
DOI： 10.1248/bpb.b22-00840 　

ISSN： 0918-6158

eISSN： 1347-5215
生産児での先天異常の有病割合および診断時期大規模レセプトデータベースを用いた評価

石川智史, 川目裕, 眞野成康, 小原拓

Journal of Epidemiology　33　(Suppl.1)　146-146　2023/02
Publisher: (一社)日本疫学会
ISSN： 0917-5040

eISSN： 1349-9092
Glutathione depletion results in S-nitrosylation of protein disulfide isomerase in neuroblastoma cells. International-journal

Shinji Ono, Jiro Ogura, Hiroki Sugiura, Minami Yamauchi, Atsushi Tanaka, Toshihiro Sato, Masamitsu Maekawa, Hiroaki Yamaguchi, Nariyasu Mano

Life sciences　316　121442-121442　2023/01/25

DOI： 10.1016/j.lfs.2023.121442 　

More details Close

AIMS: Protein disulfide isomerase (PDI) is an essential enzyme involved in oxidative protein folding. PDI is S-nitrosylated in the brains of Alzheimer's disease patients, and S-nitrosylated PDI is considered one of main causes of Alzheimer's disease. However, the mechanisms underlying PDI S-nitrosylation have not yet been elucidated. Because glutathione (GSH) depletion is a pathological feature of Alzheimer's disease, we investigated the effect of GSH depletion on the S-nitrosylation level of PDI. MAIN METHODS: SH-SY5Y cells, which is a human derived neuroblastoma cells, were used in this study. Glutamate and buthionine sulfoximine (BSO) were used as GSH depletors. S-nitrosylated PDI was detected by biotin-switch assay. KEY FINDINGS: GSH depletion by glutamate, a cystine/glutamate antiporter xCT inhibitor, increased S-nitrosylated PDI at C343 in SH-SY5Y cells, and induced IRE1α phosphorylation. BSO, a γ-glutamylcysteine synthetase inhibitor, also increased S-nitrosylated PDI and phosphorylated IRE1α upon GSH depletion. Because S-nitrosylated PDI at C343 is stable in neuro cells, S-nitrosylated PDI by GSH depletion progresses to neurodegeneration by the induction of endoplasmic reticulum stress via phosphorylated IRE1α signaling from the early to late stage. Furthermore, treatment with neohesperidin, but not N-acetylcysteine (NAC), improved PDI S-nitrosylation level in GSH-depleted SH-SY5Y cells because nitrosylated compound of NAC induces PDI S-nitrosylation. SIGNIFICANCE: The results of our study provide a new insight into the mechanisms of neurodegeneration, and may be useful for the development of drugs for Alzheimer's diseases.
Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019. International-journal

Tomofumi Ishikawa, Hidekazu Nishigori, Manabu Akazawa, Keiko Miyakoda, Aoi Noda, Mami Ishikuro, Hirohito Metoki, Noriyuki Iwama, Masatoshi Saito, Junichi Sugawara, Hiroshi Kawame, Nobuo Yaegashi, Shinichi Kuriyama, Nariyasu Mano, Taku Obara

Pregnancy hypertension　31　73-83　2023/01/09

DOI： 10.1016/j.preghy.2023.01.001 　

More details Close

OBJECTIVES: To evaluate the major congenital malformation (MCM) risk of first-trimester antihypertensive exposure, specifically of amlodipine and methyldopa. STUDY DESIGN: A large administrative claims database was used. MAIN OUTCOME MEASURES: The prevalence of antihypertensive prescriptions during pregnancy was described in 91,390 women giving birth between 2010 and 2019. The MCM risk of first-trimester antihypertensives was evaluated in 1,185 women diagnosed with hypertensive disorders in the first trimester. The MCM risk of first-trimester amlodipine and methyldopa was evaluated in 178 women who were prescribed antihypertensives in the first trimester. RESULTS: Antihypertensives were prescribed to 278 (0.30%) women during their first trimester. The prescription prevalence in the first trimester was highest for methyldopa (115, 0.13%), followed by amlodipine (55, 0.06%). Antihypertensives were prescribed to 2,955 (3.23%) women during pregnancy. Nifedipine (903, 0.99%) and nicardipine (758, 0.83%) were the most frequently prescribed oral and injectable antihypertensives during pregnancy, both with a significant increase in annual prevalence. Of the 1,185 women diagnosed with hypertensive disorders in the first trimester, antihypertensives were prescribed to 178 women. The adjusted odds ratio (aOR) of MCMs in the first-trimester prescription of any antihypertensive medication was 1.124 (95% confidence interval [CI], 0.618-2.045). Amlodipine and methyldopa were prescribed to 44 and 93 of the 178 women, respectively. The aORs of MCMs in the first-trimester prescription of amlodipine and methyldopa were 1.219 (95% CI, 0.400-3.721) and 0.921 (0.331-2.564), respectively. CONCLUSIONS: The MCM risk of first-trimester exposure to antihypertensives, including amlodipine and methyldopa, was not suggested.
Birth Outcomes of Anticancer Drug Prescriptions during Pregnancy: A Case Series from a Japanese Claims Database

Kentaro Tajima, Tomofumi Ishikawa, Masami Tsuchiya, Masafumi Kikuchi, Taku Obara, Nariyasu Mano

Pharmacoepidemiology　2023/01/06

DOI： 10.3390/pharma2010002 　
Safety evaluation of the use of calcineurin inhibitor to prenatal and postpartum women in Japan from a health administrative database. International-journal

K Yashima, A Noda, T Ishikawa, F Matsuzaki, K Miyakoda, H Nishigori, N Mano, T Obara

Journal of neonatal-perinatal medicine　16　(3)　461-473　2023

DOI： 10.3233/NPM-230138 　

More details Close

BACKGROUND: To investigate the use of calcineurin inhibitors (CNIs) in pregnant Japanese women and to evaluate their safety in infants. METHODS: Data were extracted from the claims database of the Japan Medical Data Center. The prevalence of CNIs was evaluated 180 days before pregnancy onset, during pregnancy, and within180-days post partum. We investigated the characteristics of the infants, including the presence of major malformations and their diagnoses, for 1 year after birth. RESULTS: A total of 91,865 pregnancies in 80,049 women were included. Fifty-three women were prescribed CNIs between 180-day before pregnancy onset and 180-day postpartum; 35 of the 53 women were prescribed the drugs during pregnancy, and 10 of their infants were born preterm. Three were diagnosed with major congenital malformations, such as patent ductus arteriosus. Six preterm infants presented with infant respiratory distress syndrome. CONCLUSIONS: No congenital anomalies were clearly attributable to the use of CNIs during pregnancy.
Investigation of cystine as differential diagnostic biomarker between astrocytomas and oligodendrogliomas based on global- and targeted analysis using liquid chromatography/tandem mass spectrometric analysis

Masahiro Watanabe, Masamitsu Maekawa, Masayuki Kanamori, Minami Yamauchi, Ai Abe, Yoshiteru Shimoda, Ryuta Saito, Hidenori Endo, Nariyasu Mano

Advances in Biomarker Sciences and Technology　5　76-85　2023
Publisher: Elsevier BV
DOI： 10.1016/j.abst.2023.09.001 　

ISSN： 2543-1064
LC-MS/MS for Endogenous Metabolites for Developing Diagnostic Biomarkers of Niemann-Pick Diseases

Maekawa Masamitsu, Mano Nariyasu

Proteome Letters　8　(1)　19-33　2023
Publisher: Japanese Proteomics Society
DOI： 10.14889/jpros.8.1_19 　

eISSN： 2432-2776

More details Close

To analyze of endogenous metabolites in diseases is useful for discovering diagnostic biomarkers and elucidating molecular mechanisms of pathogenesis. Niemann-Pick disease type C (NPC) is a autosomal recessive disease with diverse onset times and clinical symptoms, and there were some problems with conventional diagnostic methods. Therefore, we have worked on the developing the biomarkers for NPC using LC-MS/MS analysis. First, we focused on conjugated cholesterol metabolites excreted in large amounts in the urine of NPC patients, and our analysis using LC-MS/MS revealed that several metabolites are useful as diagnostic markers. Next, we aimed to identify the unknown molecule lysosphingomyelin-509, which has been used for screening in Europe and America, and successfully determined its structure using microchemical approaches. In addition, we also developed a novel diagnostic strategy for Niemann-Pick diseases based on simultaneous analysis of two phospholipids in blood. In conclusion, the use of LC-MS/MS analysis for endogenous metabolite analysis was found to be useful in the development of diagnostic biomarkers for NPC.
No association between major congenital malformations and exposure to Kampo medicines containing rhubarb rhizome: A Japanese database study. International-journal

Satoko Suzuki, Taku Obara, Tomofumi Ishikawa, Aoi Noda, Fumiko Matsuzaki, Ryutaro Arita, Minoru Ohsawa, Nariyasu Mano, Akiko Kikuchi, Shin Takayama, Tadashi Ishii

Frontiers in pharmacology　14　1107494-1107494　2023

DOI： 10.3389/fphar.2023.1107494 　

More details Close

Traditional Japanese (Kampo) medicines containing rhubarb rhizome are prescribed for constipation during pregnancy; however, detailed safety information of their use for pregnant women is lacking. The aim of current study was to clarify the association between prescription Kampo-containing rhubarb rhizome (KRR) in the first trimester of pregnancy and congenital malformations in newborns. Using a large Japanese health insurance claims database, we included pregnant women who enrolled the same health insurance society from 3 months before pregnancy to the delivery date, who gave birth between 2010 and 2019, and those with data related to their infants. Pregnant women who were prescribed magnesium oxide (MgO), commonly used for constipation, during the first trimester of pregnancy and their infants were extracted as controls. Associations between KRR prescribed in the first pregnancy trimester and major congenital malformations (MCM) in the infants were examined using multivariate logistic regression analysis. Of 75,398 infants, 4,607 (6.1%) were diagnosed with MCMs within the first year after birth. Furthermore, 9,852 infants were born to women prescribed MgO, among whom 680 (6.9%) had MCMs; 450 infants were born to women prescribed KRR, among whom 28 (6.2%) had MCMs. Multivariate logistic regression analysis identified no difference in MCM risk between the two types of prescriptions [crude odds ratio (OR) 0.895, 95% confidence interval (CI) 0.606-1.322, adjusted OR 0.889, 95% CI 0.599-1.320]. In conclusion, the risk of MCMs did not differ between those prescribed KRR or MgO in the first trimester of pregnancy.
Functional characterization of 12 dihydropyrimidinase allelic variants in Japanese individuals for the prediction of 5-fluorouracil treatment-related toxicity. International-journal

Eiji Hishinuma, Yoko Narita, Evelyn Marie Gutiérrez Rico, Akiko Ueda, Kai Obuchi, Yoshikazu Tanaka, Sakae Saito, Shu Tadaka, Kengo Kinoshita, Masamitsu Maekawa, Nariyasu Mano, Tomoki Nakayoshi, Akifumi Oda, Noriyasu Hirasawa, Masahiro Hiratsuka

Drug metabolism and disposition: the biological fate of chemicals　51　(2)　165-173　2022/11/22

DOI： 10.1124/dmd.122.001045 　

More details Close

The drug 5-fluorouracil (5-FU) is the first-choice chemotherapeutic agent against advanced-stage cancers. However, 10-30% of treated patients experience grade 3-4 toxicity. The deficiency of dihydropyrimidinase (DHPase), which catalyzes the second step of the 5-FU degradation pathway, is correlated with the risk of developing toxicity. Thus, genetic polymorphisms within DPYS, the DHPase-encoding gene, could potentially serve as predictors of severe 5-FU-related toxicity. We identified 12 novel DPYS variants in 3,554 Japanese individuals, but the effects of these mutations on function remain unknown. In the current study, we performed in vitro enzymatic analyses of the 12 newly identified DHPase variants. Dihydrouracil or dihydro-5-FU hydrolytic ring-opening kinetic parameters, Km and Vmax , and intrinsic clearance (CLint = Vmax /Km ) of the wild-type DHPase and eight variants were measured. Five of these variants (R118Q, H295R, T418I, Y448H, and T513A) showed significantly reduced CLint compared with that in the wild-type. The parameters for the remaining four variants (V59F, D81H, T136M, and R490H) could not be determined as dihydrouracil and dihydro-5-FU hydrolytic ring-opening activity was undetectable. We also determined DHPase variant protein stability using cycloheximide and bortezomib. The mechanism underlying the observed changes in the kinetic parameters was clarified using blue-native polyacrylamide gel electrophoresis and three-dimensional structural modeling. The results suggested that the decrease or loss of DHPase enzymatic activity was due to reduced stability and oligomerization of DHPase variant proteins. Our findings support the use of DPYS polymorphisms as novel pharmacogenomic markers for predicting severe 5-FU-related toxicity in the Japanese population. Significance Statement DHPase contributes to the degradation of 5-fluorouracil, and genetic polymorphisms that cause decreased activity of DHPase can cause severe toxicity. In this study, we performed functional analysis of 12 DHPase variants in the Japanese population and identified 9 genetic polymorphisms that cause reduced DHPase function. In addition, we found that the ability to oligomerize and the conformation of the active site are important for the enzymatic activity of DHPase.
妊婦への大黄含有漢方薬の処方と出生児の先天奇形との関連に関する研究大規模レセプトデータベースを用いて

鈴木聡子, 小原拓, 石川智史, 有田龍太郎, 大澤稔, 野田あおい, 松崎芙実子, 菊地章子, 高山真, 眞野成康, 石井正

DOHaD研究　10　(2)　66-66　2022/10
Publisher: (一社)日本DOHaD学会
ISSN： 2187-2562

eISSN： 2187-2597
妊婦に対する抗菌薬処方の実態レセプトデータベースに基づく検討

森下啓, 石川智史, 小原竜, 野田あおい, 松崎芙実子, 石黒真美, 眞野成康, 栗山進一, 小原拓

DOHaD研究　10　(2)　79-79　2022/10
Publisher: (一社)日本DOHaD学会
ISSN： 2187-2562

eISSN： 2187-2597
ポリファーマシー対策目的に入院し,薬物療法適正化に成功した1例

高橋麻由子, 冨田尚希, 山田稜, 武藤理恵, 黒澤桂子, 鈴木寿樹, 松浦正樹, 武藤達士, 瀧靖之, 眞野成康

日本老年医学会雑誌　59　(4)　575-575　2022/10
Publisher: (一社)日本老年医学会
ISSN： 0300-9173
Analytical evaluation of fatty acid esters of hydroxy fatty acid quantity in fermented brown rice and rice bran (FRBA)

Ayu Watanabe, Laurence Balas, Daisuke Saigusa, Jiro Ogura, Thierry Durand, Nariyasu Mano, Hiroaki Yamaguchi

Food Chemistry Advances　1　100040-100040　2022/10
Publisher: Elsevier BV
DOI： 10.1016/j.focha.2022.100040 　

ISSN： 2772-753X
Liver steatosis and fibrosis markers' association with cardiovascular and renal damage in Japanese adults: the TMM BirThree cohort study. International-journal

Toshiya Machida, Taku Obara, Mami Ishikuro, Keiko Murakami, Fumihiko Ueno, Aoi Noda, Tomomi Onuma, Fumiko Matsuzaki, Jun Inoue, Shinichi Kuriyama, Nariyasu Mano

Annals of hepatology　28　(1)　100761-100761　2022/09/27

DOI： 10.1016/j.aohep.2022.100761 　

More details Close

INTRODUCTION AND OBJECTIVES: Patients with non-alcoholic fatty liver disease (NAFLD) are at risk for cardiovascular and chronic kidney diseases. Liver steatosis and fibrosis were assessed using the fatty liver index and fibrosis-4 index, respectively. This study aimed to examine the association between these two parameters in patients with atherosclerosis and chronic kidney disease. METHODS: The two parameters were calculated for 11,867 adults who participated in the Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study. Intima-media thickness and estimated glomerular filtration rate were also measured. Logistic regression models were used to estimate the odds ratios (OR). RESULTS: Overall, 4,257 (35.9%) and 4,733 (39.9%) participants had a higher probability of liver steatosis and fibrosis, respectively. The adjusted OR of higher fatty liver index compared to lower fatty liver index for atherosclerosis and chronic kidney disease were 0.98 (95% confidence interval [CI], 0.77-1.24) and 1.79 (95% CI, 1.19-2.69), and those of higher FIB-4 compared to lower FIB-4 were 1.03 (95% CI, 0.82-1.30) and 0.79 (95% CI, 0.52-1.19) for atherosclerosis and chronic kidney disease, respectively. CONCLUSIONS: A higher FLI was associated with CKD independent of other risk factors. Further research is required to identify the causal relationship between liver fat accumulation and CKD.
Development of a Highly Sensitive and Rapid Liquid Chromatography–Tandem Mass Spectrometric Method Using a Basic Mobile Phase Additive to Determine the Characteristics of the Urinary Metabolites for Niemann–Pick Disease Type C

Masamitsu Maekawa, Keitaro Miyoshi, Aya Narita, Toshihiro Sato, Yu Sato, Masaki Kumondai, Masafumi Kikuchi, Katsumi Higaki, Torayuki Okuyama, Yoshikatsu Eto, Hiroshi Sakamaki, Nariyasu Mano

Biological and Pharmaceutical Bulletin　45　(9)　1259-1268　2022/09/01
Publisher: Pharmaceutical Society of Japan
DOI： 10.1248/bpb.b22-00185 　

ISSN： 0918-6158

eISSN： 1347-5215
LC/MS/MSを用いるニーマンピック病C型モデル細胞におけるステロイドホルモンの代謝変動解析

阿部愛, 前川正充, 佐藤紀宏, 佐藤裕, 公文代將希, 高橋勇人, 菊地正史, 檜垣克美, 小倉次郎, 眞野成康

JSBMS Letters　47　(Suppl.)　110-110　2022/08
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
Bile Acid–Drug Interaction via Organic Anion-Transporting Polypeptide 4C1 Is a Potential Mechanism of Altered Pharmacokinetics of Renally Excreted Drugs

Minami Yamauchi, Toshihiro Sato, Ayana Otake, Masaki Kumondai, Yu Sato, Masafumi Kikuchi, Masamitsu Maekawa, Hiroaki Yamaguchi, Takaaki Abe, Nariyasu Mano

International Journal of Molecular Sciences　23　(15)　8508-8508　2022/07/31
Publisher: MDPI AG
DOI： 10.3390/ijms23158508 　

eISSN： 1422-0067

More details Close

Patients with liver diseases not only experience the adverse effects of liver-metabolized drugs, but also the unexpected adverse effects of renally excreted drugs. Bile acids alter the expression of renal drug transporters, however, the direct effects of bile acids on drug transport remain unknown. Renal drug transporter organic anion-transporting polypeptide 4C1 (OATP4C1) was reported to be inhibited by chenodeoxycholic acid. Therefore, we predicted that the inhibition of OATP4C1-mediated transport by bile acids might be a potential mechanism for the altered pharmacokinetics of renally excreted drugs. We screened 45 types of bile acids and calculated the IC50, Ki values, and bile acid–drug interaction (BDI) indices of bile acids whose inhibitory effect on OATP4C1 was >50%. From the screening results, lithocholic acid (LCA), glycine-conjugated lithocholic acid (GLCA), and taurine-conjugated lithocholic acid (TLCA) were newly identified as inhibitors of OATP4C1. Since the BDI index of LCA was 0.278, LCA is likely to inhibit OATP4C1-mediated transport in clinical settings. Our findings suggest that dose adjustment of renally excreted drugs may be required in patients with renal failure as well as in patients with hepatic failure. We believe that our findings provide essential information for drug development and safe drug treatment in clinics.
Evaluation of a Capillary Microsampling Device for Analyzing Plasma Lenvatinib Concentration in Patients with Hepatocellular Carcinoma

Akihiro Saito, Masafumi Kikuchi, Yuko Matsumoto, Erina Sugawara, Gesshu Takao, Hayato Inomata, Akane Takahashi, Yuji Sato, Masaki Kumondai, Yu Sato, Toshihiro Sato, Masashi Ninomiya, Jun Inoue, Masamitsu Maekawa, Nariyasu Mano

Therapeutic Drug Monitoring　Publish Ahead of Print　2022/07/21
Publisher: Ovid Technologies (Wolters Kluwer Health)
DOI： 10.1097/ftd.0000000000001013 　

ISSN： 0163-4356
Development and validation of claims-based algorithms to identify pregnancy based on data from a university hospital in Japan. International-journal

Kentaro Tajima, Tomofumi Ishikawa, Aoi Noda, Fumiko Matsuzaki, Kei Morishita, Ryusuke Inoue, Noriyuki Iwama, Hidekazu Nishigori, Junichi Sugawara, Masatoshi Saito, Taku Obara, Nariyasu Mano

Current medical research and opinion　38　(9)　1-8　2022/07/14

DOI： 10.1080/03007995.2022.2101817 　

More details Close

OBJECTIVE: When using administrative data, validation is essential since these data are not collected for research purposes and misclassification can occur. Thus, this study aimed to develop algorithms identifying pregnancy and to evaluate the validity of administrative claims data in Japan. METHODS: All females who visited the Tohoku University Hospital Department of Obstetrics in 2018 were included. The diagnosis, medical procedure, medication, and medical service addition fee data were utilized to identify pregnancy, with the electronic medical records set as the gold standard. Combination algorithms were developed using predefined pregnancy-related claims data with a positive predictive value (PPV) ≥80%. Sensitivity (SE), specificity (SP), PPV, and negative predictive value (NPV) with their corresponding 95% confidence intervals (CIs) were calculated for these combination algorithms. RESULTS: This study included 1,757 females with a mean age of 32.8 (standard deviation: 5.9) years. In general, the individual claims data were able to identify pregnancy with a PPV ≥80%; however, the number of pregnancies identified using a single claims data was limited. Based on the combination algorithm with all of the categories, including diagnosis, medical procedure, medication, and medical service addition, the calculated SE, SP, PPV, and NPV were 73.4% (95% CI: 71.2%-75.4%), 96.9% (95% CI: 89.3%-99.6%), 99.8%,(95% CI: 99.4%-100.0%), and 12.3% (95% CI: 9.6%-15.4%), respectively. CONCLUSIONS: The combination algorithm to identify pregnancy demonstrated a high PPV and moderate SE. The algorithm validated in this study is expected to accelerate future studies that aim to identify pregnancies and evaluate pregnancy outcome.
薬剤師業務における情報収集ツールに関するアンケート調査

今野壮太, 前川麻央, 佐藤紀宏, 小原拓, 臼井拓也, 佐藤祐司, 公文代將希, 佐藤裕, 前川正充, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　24回　133-133　2022/06
Publisher: (一社)日本医薬品情報学会
妊娠初期の消化管運動改善薬の大奇形リスク大規模レセプトデータベースを用いた評価

石川智史, 小原拓, 赤沢学, 野田あおい, 大柳元, 都田桂子, 西郡秀和, 川目裕, 八重樫伸生, 栗山進一, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　24回　98-98　2022/06
Publisher: (一社)日本医薬品情報学会
2010-2019年の妊婦に対する降圧薬処方状況大規模レセプトデータベースを用いた評価

石川智史, 西郡秀和, 赤沢学, 都田桂子, 野田あおい, 石黒真美, 目時弘仁, 八重樫伸生, 栗山進一, 眞野成康, 小原拓

日本医薬品情報学会総会・学術大会講演要旨集　24回　99-99　2022/06
Publisher: (一社)日本医薬品情報学会
周産期におけるカルシニューリン阻害薬の処方状況と出生児に対する安全性の評価

八島一史, 野田あおい, 石川智史, 松崎芙実子, 都田桂子, 西郡秀和, 眞野成康, 小原拓

日本医薬品情報学会総会・学術大会講演要旨集　24回　100-100　2022/06
Publisher: (一社)日本医薬品情報学会
【早期に見極めすばやく対応!重篤副作用の予防と治療】副作用報告を実践しよう副作用報告の質向上を目指して

小原拓, 土屋雅美, 眞野成康

薬事　64　(8)　1609-1613　2022/06
Publisher: (株)じほう
ISSN： 0016-5980
イトラコナゾール錠へのリルマザホン混入事例 JADERを用いた解析

土屋雅美, 小原拓, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　24回　99-99　2022/06
Publisher: (一社)日本医薬品情報学会
レセプトデータベースを用いた妊娠中のがん薬物療法および出産転帰の調査

田島健太郎, 土屋雅美, 石川智史, 小原拓, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　24回　104-104　2022/06
Publisher: (一社)日本医薬品情報学会
Shifting the linear range of the calibration curves for the quantification of oral molecular-targeted anticancer drugs and the active metabolite in human plasma using LC-ESI-MS/MS Peer-reviewed

Tensei Hirasawa, Masafumi Kikuchi, Shinya Takasaki, Masaki Kumondai, Yu Sato, Toshihiro Sato, Eishi Imoto, Yoshihiro Hayakawa, Masamitsu Maekawa, Nariyasu Mano

Medical Mass Spectrometry　6　(1)　52-63　2022/06
Publisher: (一社)日本医用マススペクトル学会
DOI： 10.24508/mms.2022.06.006 　

ISSN： 2432-7441
【早期に見極めすばやく対応!重篤副作用の予防と治療】副作用報告を実践しよう副作用報告の質向上を目指して

小原拓, 土屋雅美, 眞野成康

薬事　64　(8)　1609-1613　2022/06
Publisher: (株)じほう
ISSN： 0016-5980
Itraconazole Contaminated with Rilmazafone in Japan: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database. International-journal

Masami Tsuchiya, Taku Obara, Nariyasu Mano

Drugs - real world outcomes　9　(3)　315-319　2022/05/23

DOI： 10.1007/s40801-022-00306-6 　

More details Close

BACKGROUND: In early December 2020, the antifungal medication, itraconazole (ITCZ), was mistakenly contaminated with rilmazafone in Japan. Healthcare professionals reported adverse drug reaction reports associated with ITCZ and included central nervous system-depression symptoms such as dizziness, lightheadedness, loss of consciousness, and intense drowsiness. OBJECTIVE: We examined ITCZ-associated suspicious cases using the Japanese Adverse Drug Event Report (JADER) database to determine the impact of adverse drug reaction reporting on post-marketing safety measures. METHODS: Adverse drug reaction reports in which the suspicious or concomitant medication was ITCZ or fluconazole (FLCZ) were extracted from the JADER dataset. The number of adverse drug reaction reports associated with central nervous system-depression adverse drug reactions were counted, and chronological changes were compared with ITCZ and FLCZ. RESULTS: Of the 713,893 adverse drug reaction reports in the JADER database, 5048 cases were associated with ITCZ and 6007 cases with FLCZ. When ITCZ contamination occurred, the number of adverse drug reaction reports associated with ITCZ increased rapidly, while those with FLCZ did not. In addition, the proportion of central nervous system-depression adverse drug reactions increased only in the ITCZ-associated report. CONCLUSIONS: An incident of ITCZ contamination with rilmazafone was detected on the JADER retrospectively. This case highlights the importance of spontaneous adverse drug reaction reporting, even if the causal relationship between the drug and adverse drug reaction is unknown.
Cutting-edge LC-MS/MS applications in clinical mass spectrometry: Focusing on analysis of drugs and metabolites. International-journal

Masamitsu Maekawa, Nariyasu Mano

Biomedical chromatography : BMC　36　(5)　e5347　2022/05

DOI： 10.1002/bmc.5347 　

More details Close

In recent years, liquid chromatography with tandem mass spectrometry (LC-MS/MS) has become a fundamental technology in clinical practice. In Japan, the LC-MS/MS system is used in many large hospitals. It has become popular among pharmacists and laboratory technicians. LC-MS/MS has some advantages in terms of accuracy, speed, and comprehensiveness compared to conventional automated chemical testing equipment. However, LC-MS/MS is by no means a universal method, and it is necessary to understand its characteristics before using it. In the field of therapeutic drug monitoring (TDM), there is an issue with linearity in comprehensive measurement; however, ion-abundance adjustment methods, such as in-source collision-induced dissociation, have been proposed as a solution to this problem. The development of a biomarker analysis includes search, identification, and quantification, and it is necessary to select an appropriate mass spectrometric method for each step. In this paper, we review cutting-edge technologies that can expand the performance of LC-MS/MS in the clinical field and consider current issues and future prospects.
Identification cholesterol metabolites altered before the onset of nonalcoholic steatohepatitis by targeted metabolomics. International-journal

Saori Shoji, Masamitsu Maekawa, Jiro Ogura, Toshihiro Sato, Nariyasu Mano

Biochimica et biophysica acta. Molecular and cell biology of lipids　1867　(5)　159135-159135　2022/05

DOI： 10.1016/j.bbalip.2022.159135 　

More details Close

Nonalcoholic steatohepatitis (NASH) is a disease with symptoms similar to those of alcoholic liver inflammation without alcohol intake. As an effective treatment strategy has not been established for this disease, a detailed understanding of the pathological progression mechanism is required. We focused on cholesterol metabolites, which are suspected to regulate NASH pathology, and investigated their relationship with the pathological progression in the early stages of NASH. First, the LC/MS/MS methods for bile acids and sterols were optimized and validated. Next, NASH model mice were established by feeding a choline-deficient, methionine-reduced high-fat diet, and the levels of hepatic cholesterol metabolites were measured. As a result, before the onset of NASH, desmosterol, 4β-hydroxycholesterol, campesterol, sitosterol, secondary bile acids such as taurodeoxycholic acid significantly decreased by up to 1/38 of NASH model group. Autoxidation-generated sterols significantly increased 2- to 5-fold, and various primary bile acids such as conjugated β-muricholic acids and cholic acids significantly increased 2- to 7-fold. In this study, the levels of cholesterol metabolites changed in the before the onset of NASH. These metabolic alterations involved in inflammation induction and detoxification for NASH may help the discovery of early diagnostic biomarkers in the future.
Metabolic Alteration Analysis of Steroid Hormones in Niemann-Pick Disease Type C Model Cell Using Liquid Chromatography/Tandem Mass Spectrometry. International-journal

Ai Abe, Masamitsu Maekawa, Toshihiro Sato, Yu Sato, Masaki Kumondai, Hayato Takahashi, Masafumi Kikuchi, Katsumi Higaki, Jiro Ogura, Nariyasu Mano

International journal of molecular sciences　23　(8)　2022/04/18

DOI： 10.3390/ijms23084459 　

More details Close

Niemann-Pick disease type C (NPC) is an autosomal recessive disease caused by a functional deficiency of cholesterol-transporting proteins in lysosomes, and exhibits various clinical symptoms. Since mitochondrial dysfunction in NPC has recently been reported, cholesterol catabolism to steroid hormones may consequently be impaired. In this study, we developed a comprehensive steroid hormone analysis method using liquid chromatography/tandem mass spectrometry (LC-MS/MS) and applied it to analyze changes in steroid hormone concentrations in NPC model cells. We investigated the analytical conditions for simultaneous LC-MS/MS analysis, which could be readily separated from each other and showed good reproducibility. The NPC phenotype was verified as an NPC model with mitochondrial abnormalities using filipin staining and organelle morphology observations. Steroid hormones in the cell suspension and cell culture medium were also analyzed. Steroid hormone analysis indicated that the levels of six steroid hormones were significantly decreased in the NPC model cell and culture medium compared to those in the wild-type cell and culture medium. These results indicate that some steroid hormones change during NPC pathophysiology and this change is accompanied by mitochondrial abnormalities.
Validity of Administrative Data for Identifying Birth-Related Outcomes with the End Date of Pregnancy in a Japanese University Hospital. International-journal

Kentaro Tajima, Tomofumi Ishikawa, Fumiko Matsuzaki, Aoi Noda, Kei Morishita, Ryusuke Inoue, Noriyuki Iwama, Hidekazu Nishigori, Junichi Sugawara, Masatoshi Saito, Taku Obara, Nariyasu Mano

International journal of environmental research and public health　19　(8)　2022/04/16

DOI： 10.3390/ijerph19084864 　

More details Close

This study aimed to develop and validate claims-based algorithms for identifying live birth, fetal death, and cesarean section by utilizing administrative data from a university hospital in Japan. We included women who visited the Department of Obstetrics at a university hospital in 2018. The diagnosis, medical procedures, and medication data were used to identify potential cases of live birth, fetal death, and cesarean section. By reviewing electronic medical records, we evaluated the positive predictive values (PPVs) and the accuracy of the end date of pregnancy for each claims datum. "Selected algorithm 1" based on PPVs and "selected algorithm 2" based on both the PPVs and the accuracy of the end date of pregnancy were developed. A total of 1757 women were included, and the mean age was 32.8 years. The PPVs of "selected algorithm 1" and "selected algorithm 2" were both 98.1% for live birth, 99.0% and 98.9% for fetal death, and 99.7% and 100.0% for cesarean section, respectively. These findings suggest that the developed algorithms are useful for future studies for evaluating live birth, fetal death, and cesarean section with an accurate end date of pregnancy.
A Pilot Study for Return of Individual Pharmacogenomic Results to Population-Based Cohort Study Participants.

Kinuko Ohneda, Masahiro Hiratsuka, Hiroshi Kawame, Fuji Nagami, Yoichi Suzuki, Kichiya Suzuki, Akira Uruno, Mika Sakurai-Yageta, Yohei Hamanaka, Makiko Taira, Soichi Ogishima, Shinichi Kuriyama, Atsushi Hozawa, Hiroaki Tomita, Naoko Minegishi, Junichi Sugawara, Inaho Danjoh, Tomohiro Nakamura, Tomoko Kobayashi, Yumi Yamaguchi-Kabata, Shu Tadaka, Taku Obara, Eiji Hishimuma, Nariyasu Mano, Masaki Matsuura, Yuji Sato, Masateru Nakasone, Yohei Honkura, Jun Suzuki, Yukio Katori, Yoichi Kakuta, Atsushi Masamune, Yoko Aoki, Masaharu Nakayama, Shigeo Kure, Kengo Kinoshita, Nobuo Fuse, Masayuki Yamamoto

JMA journal　5　(2)　177-189　2022/04/15

DOI： 10.31662/jmaj.2021-0156 　

More details Close

Introduction: Pharmacogenomic (PGx) testing results provide valuable information on drug selection and appropriate dosing, maximization of efficacy, and minimization of adverse effects. Although the number of large-scale, next-generation-sequencing-based PGx studies has recently increased, little is known about the risks and benefits of returning PGx results to ostensibly healthy individuals in research settings. Methods: Single-nucleotide variants of three actionable PGx genes, namely, MT-RNR1, CYP2C19, and NUDT15, were returned to 161 participants in a population-based Tohoku Medical Megabank project. Informed consent was obtained from the participants after a seminar on the outline of this study. The results were sent by mail alongside sealed information letter intended for clinicians. As an exception, genetic counseling was performed for the MT-RNR1 m.1555A > G variant carriers by a medical geneticist, and consultation with an otolaryngologist was encouraged. Questionnaire surveys (QSs) were conducted five times to evaluate the participants' understanding of the topic, psychological impact, and attitude toward the study. Results: Whereas the majority of participants were unfamiliar with the term PGx, and none had undergone PGx testing before the study, more than 80% of the participants felt that they could acquire basic PGx knowledge sufficient to understand their genomic results and were satisfied with their potential benefit and use in future prescriptions. On the other hand, some felt that the PGx concepts or terminology was difficult to fully understand and suggested that in-person return of the results was desirable. Conclusions: These results collectively suggest possible benefits of returning preemptive PGx information to ostensibly healthy cohort participants in a research setting.
Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. International-journal

Toshiya Machida, Taku Obara, Makoto Miyazaki, Jun Inoue, Nariyasu Mano

Annals of hepatology　27　(4)　100699-100699　2022/03/09

DOI： 10.1016/j.aohep.2022.100699 　

More details Close

INTRODUCTION AND OBJECTIVES: Clinical guidelines recommend specific drugs for type 2 diabetes (T2D), hypertension, and dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH). We aimed to investigate the differences in prescription trends of antidiabetic, antihypertensive, and lipid-lowering drugs among adult patients according to the presence of comorbid NAFLD and/or NASH. METHODS: We conducted a cross-sectional analysis using a large claims database from January 2013 to December 2020. RESULTS: Among 7,716,908 people, 47,157 patients with T2D, 180,050 with hypertension, and 191,348 with dyslipidemia were identified. A total of 8,897, 16,451, and 24,762 patients with NAFLD, as well as 435, 523, and 1033 patients with NASH, had T2D, hypertension, and dyslipidemia, respectively. Among antidiabetic drugs, sodium-glucose cotransporter-2 inhibitors (SGLT2is) and thiazolidine were more frequently prescribed to patients with NAFLD than to those without NAFLD (non-NAFLD) (thiazolidine: 1.4% and 2.8% and SGLT2is: 17.8% and 25.9% for non-NAFLD and NAFLD, respectively [2019-2020]). Among antihypertensive drugs, angiotensin II receptor antagonists exhibited a slightly higher prescription ratio in patients with NAFLD (33.6% vs. 39.0%). Regarding lipid-lowering drugs, fibrates were more frequently prescribed to patients with NAFLD (10.3% vs. 18.4%). CONCLUSIONS: Specific drugs tended to be prescribed to patients with NAFLD. However, the differences in prescription ratios were not considerable. Further investigation is required to confirm the effects of drugs on the prognosis of patients with NAFLD or NASH.
東北大学病院における新型コロナウイルスワクチン接種による副反応調査

佐藤智見, 佐藤裕, 鷹尾月舟, 佐藤朗, 菅原英里奈, 鈴木博也, 公文代將希, 佐藤紀宏, 前川正充, 徳田浩一, 眞野成康

日本薬学会年会要旨集　142年会　27G-am05　2022/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
「第6回臨床化学の進歩が変える薬物治療」〜最先端バイオマーカー検査による新たなる個別化療法の創出〜タンパク質ジスルフィド形成酵素protein disulfide isomeraseのS-ニトロシル化位置の同定

小倉次郎, Ruddock Lloyd, 杉浦弘樹, 小野慎司, 眞野成康, 山口浩明

日本薬学会年会要旨集　142年会　S16-5　2022/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Assessment of Information Sharing on Adverse Drug Reactions by Community Pharmacies with Other Medical Institutions. International-journal

Daisuke Kikuchi, Taku Obara, Aoi Noda, Gen Oyanagi, Mami Ishikuro, Kouji Okada, Nariyasu Mano

Pharmacy (Basel, Switzerland)　10　(1)　2022/02/05

DOI： 10.3390/pharmacy10010025 　

More details Close

Widespread coordination and sharing of information regarding adverse drug reactions (ADRs) are important for drug safety assessment. However, the actual status of coordination and sharing of information on ADRs in community pharmacies remains unclear. Therefore, a survey was conducted at community pharmacies to analyze the status. In this cross-sectional study conducted from 31 March 2021 to 9 April 2021, a request letter with the uniform resource locator of the questionnaire form was sent to 302 community pharmacies affiliated with Tsuruha Holdings Inc., and the responses were obtained online. The response rate for the questionnaires was 80.8% (n = 244). In total, 20.9% of the community pharmacies provided information on patients' ADRs to hospitals or clinics prescribing drugs. None of the community pharmacies provided patient ADR information to other community pharmacies. Of the community pharmacies, 98.8% felt that insufficient information was available to monitor ADRs from hospitals or clinics prescribing drugs. For example, the name of the disease (67.6%), considered to be the most common information, was insufficiently provided. Overall, the existing system for providing information on ADRs between community pharmacies and other medical institutions is insufficient and needs to be developed further.
尿中内因性CYP3A4活性バイオマーカーの一斉定量系構築と臨床応用

公文代將希, 前川正充, 菊地正史, 小川玲佳, 岩崎瑞生, 押切華映, 齋藤明博, 二宮匡史, 井上淳, 佐藤真実, 中島範昭, 眞野成康

日本臨床薬理学会学術総会抄録集　43　3-C-O11-3　2022
Publisher: 一般社団法人日本臨床薬理学会
DOI： 10.50993/jsptsuppl.43.0_3-c-o11-3 　

eISSN： 2436-5580

More details Close

【目的】レンバチニブ(LEN)は、肝細胞癌や甲状腺癌などで用いられるマルチキナーゼ阻害薬であり、治療効果や副作用発現率が血中薬物濃度と強く相関する。LENは主にシトクロムP450 (CYP3A4)により代謝され、その酵素活性の個人差が血中LEN濃度を規定する因子の1つであることから、患者個々のCYP3A4活性の考慮は、LEN投与量の最適化に欠かせない。本研究では、尿中内因性CYP3A4活性バイオマーカーの一斉定量系を構築するとともに、LEN服用患者における血中LEN濃度と尿中バイオマーカー濃度の関連を明らかにすることを目的とした。【方法】尿中バイオマーカーとしてコルチゾール、6βヒドロキシコルチゾール、デオキシコールおよび1βヒドロキシデオキシコール酸を対象とした。液体クロマトグラフィーにはNexeraX2 (Shimadzu)を、質量分析計にはQTRAP6500 (SCIEX)を用いた。分析カラムにYMC-Triart C18 (2.1 mm i.d. × 150 mm, 3 μm) を用い、移動相Aには水/アンモニア水溶液 (100:0.1, v/v)を、移動相Bにはメタノール/アセトニトリル/アンモニア水溶液 (50:50:0.1, v/v/v)を用いた。尿中に含まれる各測定対象の抱合体は、βglucuronidase/arylsulfataseおよびcholoylgricine hydrolaseによって脱抱合し、あらかじめ各測定対象の総量として定量した。東北大学病院消化器内科および総合外科におけるLEN服用患者の血液および尿検体を収集し、上述の測定法により尿中バイオマーカー濃度を定量した。また、血中LEN濃度は先行研究で構築した方法(Saito et al., Ther Drug Monit., in press)により定量した。【結果・考察】内標準物質により補正した各測定対象のマトリックス効果は－12.0～2.1%であった。安定性試験の結果、臨床現場で想定しうる保管条件において十分な安定性を示した。日内・日間変動試験において、臨床応用に十分適応可能と判断できる信頼度を示した。各患者における尿中バイオマーカー濃度は本法で設定した検量線範囲に収まり、血中LEN濃度との相関が見られた。以上より、尿中バイオマーカーの一斉定量は臨床応用が可能であり、血中LEN濃度を推定する指標になりうると考えられた。【結論】尿中バイオマーカーが生体内において存在しうる濃度範囲において、本法の信頼性が確認された。また、本法はCYP3A4により代謝される医薬品服用患者における血中薬物濃度との関連解析に有用な測定法であり、今後さらなる臨床研究への応用が期待される。
妊娠初期の消化管運動改善薬処方と児の大奇形との関連大規模レセプトデータベースを用いた評価

石川智史, 小原拓, 赤沢学, 野田あおい, 大柳元, 森下啓, 都田桂子, 西郡秀和, 川目裕, 八重樫伸生, 栗山進一, 眞野成康

Journal of Epidemiology　32　(Suppl.1)　141-141　2022/01
Publisher: (一社)日本疫学会
ISSN： 0917-5040

eISSN： 1349-9092
Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population. International-journal

Eiji Hishinuma, Yoko Narita, Kai Obuchi, Akiko Ueda, Sakae Saito, Shu Tadaka, Kengo Kinoshita, Masamitsu Maekawa, Nariyasu Mano, Noriyasu Hirasawa, Masahiro Hiratsuka

Frontiers in pharmacology　13　930470-930470　2022

DOI： 10.3389/fphar.2022.930470 　

More details Close

Dihydropyrimidine dehydrogenase (DPD), encoded by the DPYD gene, is the rate-limiting enzyme in 5-fluorouracil (5-FU) degradation. In Caucasians, four DPYD risk variants are recognized to be responsible for interindividual variations in the development of 5-FU toxicity. However, these risk variants have not been identified in Asian populations. Recently, 41 DPYD allelic variants, including 15 novel single nucleotide variants, were identified in 3,554 Japanese individuals by analyzing their whole-genome sequences; however, the effects of these variants on DPD enzymatic activity remain unknown. In the present study, an in vitro analysis was performed on 41 DPD allelic variants and three DPD risk variants to elucidate the changes in enzymatic activity. Wild-type and 44 DPD-variant proteins were heterologously expressed in 293FT cells. DPD expression levels and dimerization of DPD were determined by immunoblotting after SDS-PAGE and blue native PAGE, respectively. The enzymatic activity of DPD was evaluated by quantification of dihydro-5-FU, a metabolite of 5-FU, using high-performance liquid chromatography-tandem mass spectrometry. Moreover, we used 3D simulation modeling to analyze the effect of amino acid substitutions on the conformation of DPD. Among the 41 DPD variants, seven exhibited drastically decreased intrinsic clearance (CL int ) compared to the wild-type protein. Moreover, R353C and G926V exhibited no enzymatic activity, and the band patterns observed in the immunoblots after blue native PAGE indicated that DPD dimerization is required for its enzymatic activity. Our data suggest that these variants may contribute to the significant inter-individual variability observed in the pharmacokinetics and pharmacodynamics of 5-FU. In our study, nine DPD variants exhibited drastically decreased or no enzymatic activity due to dimerization inhibition or conformational changes in each domain. Especially, the rare DPYD variants, although at very low frequencies, may serve as important pharmacogenomic markers associated with the severe 5-FU toxicity in Japanese population.
Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations. International-journal

Kento Morozumi, Yoshihide Kawasaki, Masamitsu Maekawa, Shinya Takasaki, Tomonori Sato, Shuichi Shimada, Naoki Kawamorita, Shinichi Yamashita, Koji Mitsuzuka, Nariyasu Mano, Akihiro Ito

Cancer science　113　(1)　182-194　2022/01

DOI： 10.1111/cas.15180 　

More details Close

To improve treatment outcomes in real practice, useful biomarkers are desired when predicting postoperative recurrence for renal cell carcinoma (RCC). We collected data from patients who underwent definitive surgery for RCC and for benign urological tumor at our department between November 2016 and December 2019. We evaluated the differences in pre- and postoperative urinary metabolites with our precise quantitative method and identified predictive factors for RCC recurrence. Additionally, to clarify the significance of metabolites, we measured the intracellular metabolite concentration of three RCC cell lines. Among the 56 patients with RCC, nine had a recurrence (16.0%). When comparing 27 patients with T1a RCC and 10 with benign tumor, a significant difference was observed between pre- and postoperative concentrations among 10 urinary metabolites. In these 10 metabolites, multiple logistic regression analysis identified five metabolites (lactic acid, glycine, 2-hydroxyglutarate, succinic acid, and kynurenic acid) as factors to build our recurrence prediction model. The values of area under the receiver operating characteristic curve, sensitivity, and specificity in this predictive model were 0.894%, 88.9%, and 88.0%, respectively. When stratified into low and high risk groups of recurrence based on this model, we found a significant drop of recurrence-free survival rates among the high risk group. In in vitro studies, intracellular metabolite concentrations of metastatic tumor cell lines were much higher than those of primary tumor cell lines. By using our quantitative evaluation of urinary metabolites, we could predict postoperative recurrence with high sensitivity and specificity. Urinary metabolites could be noninvasive biomarkers to improve patient outcome.
Prenatal folic acid supplementation and autism spectrum disorder in 3-year-old offspring: the Japan environment and children's study. International-journal

Hidekazu Nishigori, Taku Obara, Toshie Nishigori, Mami Ishikuro, Nozomi Tatsuta, Kasumi Sakurai, Masatoshi Saito, Junichi Sugawara, Takahiro Arima, Kunihiko Nakai, Nariyasu Mano, Hirohito Metoki, Shinichi Kuriyama, Nobuo Yaegashi

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians　35　(25)　1-10　2021/12/02

DOI： 10.1080/14767058.2021.2007238 　

More details Close

OBJECTIVE: We evaluated the relationship between prenatal folic acid supplementation and autism spectrum disorder (ASD) in 3-year-old offspring. METHODS: We used data from the Japan Environment and Children's Study, a nationwide prospective birth cohort study. We analyzed the data to determine the association between folic acid supplement use and the incidence of ASD in offspring, and classified participants into three groups based on the time of initiation of folic acid supplementation, as follows: (1) preconception users of folic acid supplements and (2) post-conception users, and (3) non-users. The dietary folate intake of study participants was also classified into three groups (<200 µg, 200 µg to <400 µg, ≥400 µg). RESULTS: Overall, 361 offspring of 96,931 participants with single pregnancies were diagnosed with ASD (0.37%). A total of 7,046 participants (7.3%) used folic acid supplements before conception, 29,984 (30.9%) took them after detection of pregnancy, and 59,901 (61.8%) never received them. Multivariate logistic regression analyses demonstrated no association between prenatal folic acid supplementation and ASD in offspring (preconception use: adjusted odds ratio [AOR], 1.189; 95% confidence interval [CI], 0.819-1.727 and post-conception use: AOR, 1.072; 95% CI, 0.840-1.368); additionally, no association was observed with the use of folic acid supplements and/or multivitamin supplements (preconception use: AOR, 1.273; 95% CI, 0.921-1.760 and post-conception use: AOR, 1.132; 95% CI, 0.885-1.449). Moreover, no significant association was observed in participants with combined prenatal supplement use and dietary folate intake. CONCLUSIONS: Maternal use of folic acid supplements from the pre- or post-conception period was not significantly associated with ASD in 3-year-old offspring in Japan. Evaluation of the dietary folate intake from preconception also showed no significant association.
SGLT-1-specific inhibition ameliorates renal failure and alters the gut microbial community in mice with adenine-induced renal failure. International-journal

Hsin-Jung Ho, Koichi Kikuchi, Daiki Oikawa, Shun Watanabe, Yoshitomi Kanemitsu, Daisuke Saigusa, Ryota Kujirai, Wakako Ikeda-Ohtsubo, Mariko Ichijo, Yukako Akiyama, Yuichi Aoki, Eikan Mishima, Yoshiaki Ogata, Yoshitsugu Oikawa, Tetsuro Matsuhashi, Takafumi Toyohara, Chitose Suzuki, Takehiro Suzuki, Nariyasu Mano, Yoshiteru Kagawa, Yuji Owada, Takane Katayama, Toru Nakayama, Yoshihisa Tomioka, Takaaki Abe

Physiological reports　9　(24)　e15092　2021/12

DOI： 10.14814/phy2.15092 　

More details Close

Sodium-dependent glucose cotransporters (SGLTs) have attracted considerable attention as new targets for type 2 diabetes mellitus. In the kidney, SGLT2 is the major glucose uptake transporter in the proximal tubules, and inhibition of SGLT2 in the proximal tubules shows renoprotective effects. On the other hand, SGLT1 plays a role in glucose absorption from the gastrointestinal tract, and the relationship between SGLT1 inhibition in the gut and renal function remains unclear. Here, we examined the effect of SGL5213, a novel and potent intestinal SGLT1 inhibitor, in a renal failure (RF) model. SGL5213 improved renal function and reduced gut-derived uremic toxins (phenyl sulfate and trimethylamine-N-oxide) in an adenine-induced RF model. Histological analysis revealed that SGL5213 ameliorated renal fibrosis and inflammation. SGL5213 also reduced gut inflammation and fibrosis in the ileum, which is a primary target of SGL5213. Examination of the gut microbiota community revealed that the Firmicutes/Bacteroidetes ratio, which suggests gut dysbiosis, was increased in RF and SGL5213 rebalanced the ratio by increasing Bacteroidetes and reducing Firmicutes. At the genus level, Allobaculum (a major component of Erysipelotrichaceae) was significantly increased in the RF group, and this increase was canceled by SGL5213. We also measured the effect of SGL5213 on bacterial phenol-producing enzymes that catalyze tyrosine into phenol, following the reduction of phenyl sulfate, which is a novel marker and a therapeutic target for diabetic kidney disease DKD. We found that the enzyme inhibition was less potent, suggesting that the change in the microbial community and the reduction of uremic toxins may be related to the renoprotective effect of SGL5213. Because SGL5213 is a low-absorbable SGLT1 inhibitor, these data suggest that the gastrointestinal inhibition of SGLT1 is also a target for chronic kidney diseases.
Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet International-journal

Naoto Ishikawa, Hanae Oshikiri, Shinya Takasaki, Masafumi Kikuchi, Taku Obara, Kazutoshi Akasaka, Masaki Matsuura, Hiroaki Yamaguchi, Nariyasu Mano

Journal of Pharmaceutical Health Care and Sciences　7　(1)　22-22　2021/12
Publisher: Springer Science and Business Media LLC
DOI： 10.1186/s40780-021-00205-y 　

eISSN： 2055-0294

More details Close

<title>Abstract</title><sec> <title>Background</title> Renal function and use of concomitant medications should be carefully monitored in patients subjected to treatment with direct oral anticoagulants (DOACs); the dose should be individually designed for each patient. Owing to the complex therapeutic indications and dose reduction criteria, pharmacists exercise caution when determining the optimal dose for each patient. A DOAC check sheet has been developed that is automatically printed in the dispensing room at the same time as the prescription and can be used by pharmacists to dispense DOACs promptly and correctly. The purpose of this study was to evaluate the system for dispensing DOACs using a check sheet. </sec><sec> <title>Methods</title> The study was conducted at Tohoku University Hospital in Japan; prescriptions containing DOACs dispensed by the hospital pharmacists were evaluated. The DOAC check sheet described indications, dosage regimens, dose reduction criteria, and contraindications for each drug and included the patient’s information. The check sheet was set to print automatically in the dispensing room at the same time as the prescription when an inpatient was prescribed DOACs. This check sheet was evaluated using a prescription survey and a questionnaire for pharmacists. </sec><sec> <title>Results</title> The usefulness of this check sheet for the correct use of DOACs was evaluated. There were four inquiries out of 642 (0.6%) prescriptions from pharmacists to physicians regarding DOAC prescriptions, such as the dose introduced before DOAC check sheet utilization, and there were 21 out of 905 (2.3%) prescriptions when the DOAC check sheet was used it, showing a significant increase (<italic>p</italic> = 0.0089). After the introduction of this sheet, overdoses of DOACs were identified at the time of dispensing. Of the 52 pharmacists who responded to the questionnaire, 51 (98%) stated that the check sheet was useful. </sec><sec> <title>Conclusion</title> The use of the DOAC check sheet is likely to render safety to DOAC drug therapy for individual patients. </sec>
Impact of local vaccine subsidization programs on the prevention of mumps in Japan. International-journal

Makoto Miyazaki, Taku Obara, Nariyasu Mano

Human vaccines & immunotherapeutics　17　(11)　4216-4224　2021/11/02

DOI： 10.1080/21645515.2021.1974797 　

More details Close

In Japan, although a mumps vaccination is outside the national universal vaccination program, some local governments have implemented their own program. However, little is known regarding the implementation status and the impact of these programs. In this study, we investigated the impact on the prevention of mumps, after identification of the status of the local government subsidization programs. We identified the implementation status of the subsidization programs using the websites of local governments. We retrieved the number of reported mumps cases from designated sentinel sites through the Surveillance of Infectious Diseases System implemented according to the Infectious Disease Control Law. Using this data, the impact of the subsidization program on prevention of mumps was assessed by comparing the number of mumps cases per site during the 2015-2016 outbreak among the areas categorized by the subsidization status, using a Poisson regression model. As of 2019, 26.2% (456/1,739) of the local governments were considered as having subsidization programs. We retrieved 52,719 mumps cases from 2010 to 2019. The number of mumps cases per sentinel site tended to be low in areas implementing a subsidization program, compared with the no-implementation areas throughout the data collection period. The adjusted model confirmed that the subsidization program implemented between 2010 and 2015 impacted on the number of mumps cases during the 2015-2016 outbreak, with a decrease in the numbers. Further studies with detailed data including vaccination coverage should be conducted.
新型コロナウイルス感染症に対応した病院実務実習プログラムの評価

菊地正史, 佐藤裕, 佐藤紀宏, 前川正充, 眞野成康

日本病院薬剤師会雑誌　57　(11)　1256-1261　2021/11
Publisher: (一社)日本病院薬剤師会
ISSN： 1341-8815
Glucose-induced oxidative stress leads to in S-nitrosylation of protein disulfide isomerase in neuroblastoma cells International-journal

Jiro Ogura, Hiroki Sugiura, Atsushi Tanaka, Shinji Ono, Toshiyuki Sato, Toshihiro Sato, Masamitsu Maekawa, Hiroaki Yamaguchi, Nariyasu Mano

Biochimica et Biophysica Acta (BBA) - General Subjects　1865　(11)　129998-129998　2021/11
Publisher: Elsevier BV
DOI： 10.1016/j.bbagen.2021.129998 　

ISSN： 0304-4165

More details Close

BACKGROUND: Dementia places a significant burden on both patients and caregivers. Since diabetes is a risk factor for dementia, it is imperative to identify the relationship between diabetes and cognitive disorders. Protein disulfide isomerase (PDI) is an enzyme for oxidative protein folding. PDI S-nitrosylation is observed in the brain tissues of Alzheimer's disease patients. The aim of this study is to clarify the relationship between PDI S-nitrosylation and diabetes. METHODS: We used SH-SY5Y cells cultured in high-glucose media. RESULTS: S-nitrosylated PDI level increased at 7 days and remained high till 28 days in SH-SY5Y cells cultured in high-glucose media. Using PDI wild-type- or PDI C343S-expressing SH-SY5Y cells, PDI C343 was identified as the site of glucose-induced S-nitrosylation. IRE1α and PERK were phosphorylated at day 14 in the SH-SY5Y cells cultured in high-glucose media, and the phosphorylated status was maintained to day 28. To determine the effect of S-nitrosylated PDI on endoplasmic reticulum stress signaling, SH-SY5Y cells were treated with S-nitrosocystein (SNOC) for 30 min, following which the medium was replaced with SNOC-free media and the cells were cultured for 24 h. Only phosphorylated IRE1α treated with SNOC was associated with PDI S-nitrosylation. Neohesperidin, a flavonoid in citrus fruits, is a natural antioxidant. The treatment with neohesperidin in the final 7 days of glucose loading reversed PDI S-nitrosylation and improved cell proliferation. CONCLUSION: Glucose loading leads to S-nitrosylation of PDI C343 and induces neurodegeneration via IRE1α phosphorylation. GENERAL SIGNIFICANCE: The results may be useful for designing curative treatment strategies for dementia.
Risk of major congenital malformations associated with first-trimester exposure to propulsives: A health administrative database study in Japan. International-journal

Tomofumi Ishikawa, Taku Obara, Manabu Akazawa, Aoi Noda, Gen Oyanagi, Kei Morishita, Keiko Miyakoda, Hidekazu Nishigori, Hiroshi Kawame, Nobuo Yaegashi, Shinichi Kuriyama, Nariyasu Mano

Pharmacoepidemiology and drug safety　31　(2)　196-205　2021/10/10

DOI： 10.1002/pds.5370 　

More details Close

PURPOSE: To evaluate the risk of major congenital malformations (MCMs) associated with first-trimester exposure to propulsives with a special focus on domperidone using a large administrative database in Japan. METHODS: A large claims database was used from January 2005 to August 2016. The dates of pregnancy onset and delivery were estimated using the developed algorithms. Major congenital malformations were defined according to the International Classification of Diseases, 10th revision codes. We compared the infants' risk of overall MCMs between women with or without first-trimester prescriptions of propulsives and estimated the odds ratios (ORs) with unadjusted and adjusted analyses. We also compared the risk of overall MCMs between women with domperidone prescriptions and those with other propulsive prescriptions during the first trimester. RESULTS: Among 38 270 women, propulsives were prescribed to 3197 women (8.4%) in the first trimester, including domperidone to 371 women (1.0%). Propulsive prescriptions in the first trimester were not significantly associated with an increased risk of overall MCMs (adjusted OR [aOR] 1.030, 95% confidence interval [CI] 0.843-1.257). Compared to the prescription of other propulsives in the first trimester, the prescription of domperidone in the first trimester was not associated with an increased risk of overall MCMs (aOR 0.724, 95% CI 0.363-1.447). CONCLUSIONS: The first-trimester prescription of propulsives, including domperidone, was not associated with an increased risk of overall MCMs. This article is protected by copyright. All rights reserved.
Simultaneous analysis of drugs administered to lung-transplanted patients using liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring. International-journal

Shinya Takasaki, Tensei Hirasawa, Yu Sato, Masamitsu Maekawa, Taku Tsukamoto, Masafumi Kikuchi, Jiro Ogura, Yoshihiro Hayakawa, Yasushi Matsuda, Hisashi Oishi, Tetsu Sado, Masafumi Noda, Yoshinori Okada, Hiroaki Yamaguchi, Nariyasu Mano

Biomedical chromatography : BMC　35　(6)　e5067　2021/06

DOI： 10.1002/bmc.5067 　

More details Close

Several drugs are administered to lung-transplanted patients, which are monitored using therapeutic drug monitoring (TDM). Therefore, we developed and validated a liquid chromatography-tandem mass spectrometry method to simultaneously analyze immunosuppressive drugs such as mycophenolic acid, antifungal drugs such as voriconazole and itraconazole, and its metabolite hydroxyitraconazole. Chromatographic separation was achieved using a C18 column and gradient flow of mobile phase comprising 20 mM aqueous ammonium formate and 20 mM ammonium formate-methanol solution. A simple protein precipitation treatment was performed using acetonitrile/methanol and mycophenolic acid-2 H3 , voriconazole-2 H3 , itraconazole-2 H4 , and hydroxyitraconazole-2 H4 as internal standards. The linearity ranges of mycophenolic acid, voriconazole, itraconazole, and hydroxyitraconazole were 100-20,000, 50-10,000, 5-1000, and 5-1000 ng/mL, respectively. The retention time of each target was less than 2 min. The relative errors in intra- and inter-day were within ±7.6%, the coefficient of variation was 8.9% or less for quality control low, medium, and high, and it was 15.8% or less for lower limit of quantitation. Moreover, the patient samples were successfully quantified, and they were within the linear range of measurements. Therefore, our new method may be useful for TDM in lung-transplanted patients.
Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19 International-journal

Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano, Takaaki Abe, Hiroaki Yamaguchi

Journal of Pharmacy & Pharmaceutical Sciences　24　227-236　2021/05/15
Publisher: University of Alberta Libraries
DOI： 10.18433/jpps31813 　

eISSN： 1482-1826

More details Close

Purpose. Remdesivir and its active metabolite are predominantly eliminated via renal route; however, information regarding renal uptake transporters is limited. In the present study, the interaction of remdesivir and its nucleoside analog GS-441524 with OATP4C1 was evaluated to provide the detailed information about its renal handling. Methods. We used HK-2 cells, a proximal tubular cell line derived from normal kidney, to confirm the transport of remdesivir and GS-441524. To assess the involvement of OATP4C1 in handling remdesivir and GS-441524, the uptake study of remdesivir and GS-441524 was performed by using OATP4C1-overexpressing Madin-Darby canine kidney II (MDCKII) cells. Moreover, we also evaluated the IC50 and Ki value of remdesivir. Results. The time-dependent remdesivir uptake in HK-2 cells was observed. The results of inhibition study using OATs and OCT2 inhibitors and OATP4C1 knockdown suggested the involvement of renal drug transporter OATP4C1. Remdesivir was taken up by OATP4C1/MDCKII cells. OATP4C1-mediated uptake of remdesivir increased linearly up to 10 min and reached a steady state at 30 min. Remdesivir inhibited OATP4C1-mediated transport in a concentration-dependent manner with the IC50 and apparent Ki values of 42 ± 7.8 μM and 37 ± 6.9 μM, respectively. Conclusions. We have provided novel information about renal handling of remdesivir. Furthermore, we evaluated the potential drug interaction via OATP4C1 by calculating the Ki value of remdesivir. OATP4C1 may play a pivotal role in remdesivir therapy for COVID-19, particularly in patients with kidney injury.
Prolonged high-intensity exercise induces fluctuating immune responses to herpes simplex virus infection via glucocorticoids. International-journal

Akimasa Adachi, Tetsuya Honda, Teruki Dainichi, Gyohei Egawa, Yosuke Yamamoto, Takashi Nomura, Saeko Nakajima, Atsushi Otsuka, Masamitsu Maekawa, Nariyasu Mano, Naoto Koyanagi, Yasushi Kawaguchi, Toshiaki Ohteki, Takashi Nagasawa, Koichi Ikuta, Akihiko Kitoh, Kenji Kabashima

The Journal of allergy and clinical immunology　148　(6)　1575-1588　2021/05/06

DOI： 10.1016/j.jaci.2021.04.028 　

More details Close

BACKGROUND: Epidemiological studies have yielded conflicting results regarding the influence of a single bout of prolonged high-intensity exercise on viral infection. OBJECTIVE: Here, we show that prolonged high-intensity exercise induces either exacerbation or amelioration of herpes simplex virus type 2 (HSV-2) infection depending on the interval between viral exposure and exercise. METHODS: Mice were intravaginally infected with HSV-2 and exposed to run on the treadmill. RESULTS: Prolonged high-intensity exercise 17 h after infection impaired the clearance of HSV-2, while exercise 8 h after infection enhanced the clearance of HSV-2. These impaired or enhanced immune responses were related to a transient decrease or increase in the number of blood-circulating plasmacytoid dendritic cells (pDCs). Exercise-induced glucocorticoids transiently decreased the number of circulating pDCs by facilitating their homing to the bone marrow via the CXCL12-CXCR4 axis, which led to their subsequent increase in the blood. CONCLUSION: Thus, a single bout of prolonged high-intensity exercise can be either deleterious or beneficial to antiviral immunity.
Real-world anticancer medications for reproductive-age women with breast cancer by using a claims database in Japan. International-journal

Kentaro Tajima, Masami Tsuchiya, Tomofumi Ishikawa, Taku Obara, Nariyasu Mano

Future oncology (London, England)　17　(15)　1907-1921　2021/05

DOI： 10.2217/fon-2020-1053 　

More details Close

Aim: To describe real-world breast cancer medications among reproductive-age women. Patients & methods: Using data from a Japanese claims database, anticancer prescriptions were classified into seven categories of amenorrhea risk based on fertility preservation guidelines. Results: We identified 2999 women with records of breast cancer and anticancer prescription from 2005 to 2018. The proportions of prescriptions were as follows: high, 4.1-12.9%; intermediate: 6.0-16.3%; low: 0.4-2.3%; very low/no: 0.3-12.2%; unknown: 33.9-45.5%; unlisted combination: 12.2-23.4%; and unlisted drug: 12.5-26.7%. The common drugs in the unknown category were trastuzumab (n = 1527), docetaxel (n = 1014), and paclitaxel (n = 995). For medications unlisted in the guidelines, various drugs and drug combinations were observed. Conclusion: Numerous anticancer drugs are currently being prescribed with insufficient evidence regarding amenorrhea risk.
Evaluation of the Safety of Taking Lamotrigine During Lactation Period. International-journal

Kazushi Yashima, Taku Obara, Fumiko Matsuzaki, Chihiro Suzuki, Mika Saeki, Mina Koyama, Moeko Hosono, Aoi Noda, Saya Kikuchi, Tetsuro Hoshiai, Shinichi Sato, Masatoshi Saito, Takushi Hanita, Nariyasu Mano

Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine　16　(5)　432-438　2021/05

DOI： 10.1089/bfm.2020.0210 　

More details Close

Introduction: Evaluation of the safety of taking lamotrigine (LTG) during lactation in breastfed infants varies according to the information sources. As it is possible that prescribers may avoid prescribing LTG despite of it being one of the essential drugs, more information needs to be accumulated to facilitate its use. Materials and Methods: We retrospectively compared the safety of LTG during the lactation period in 20 pairs of mothers and infants with 20 pairs as the control group. Results: The mean dose of LTG in 20 mothers was 161.1 mg/day (range: 50-400 mg/day). None of the infants showed a neonatal withdrawal syndrome score of 2 or more up to 1 month after delivery. Although drowsiness (n = 3), skin rash (n = 11), jaundice (n = 8), heart murmur (n = 1), poor suckling (n = 1), and retractive breathing (n = 1) were observed in infants, none of these adverse events were serious and the infants recovered. Nineteen of 20 pairs could continue lactation until 1 month after delivery. One pair discontinued breastfeeding because of pain in the mother's nipples. All pairs could continue maternal medication. We then compared the results with those of the control group. There were no significant differences in the presence of adverse events between the LTG and control groups. Conclusion: These data suggest that taking low to moderate doses of LTG during the lactation period might be relatively safe, at least for a period of 1 month after delivery.
Validity of congenital malformation diagnoses in healthcare claims from a university hospital in Japan. International-journal

Tomofumi Ishikawa, Gen Oyanagi, Taku Obara, Aoi Noda, Kei Morishita, Shuyu Takagi, Ryusuke Inoue, Hiroshi Kawame, Nariyasu Mano

Pharmacoepidemiology and drug safety　30　(7)　975-978　2021/04/09

DOI： 10.1002/pds.5244 　

More details Close

PURPOSE: This study aimed to assess the validity of diagnoses of congenital malformations (CMs) recorded in claims of a university hospital in Japan. METHODS: Congenital malformations were identified according to Code Q00-Q89 of the International Classification of Diseases, 10th revision. All the children who had been diagnosed with CMs based on their claims in 2015 and within 1 year from their birth month were selected for this study. The infants' medical records were considered as a gold standard. Positive predictive values (PPVs) for CMs were calculated. RESULTS: This study included 227 infants who had a CM diagnosis in their claims. Based on the algorithms established by the Quebec Pregnancy Cohort study group, the PPV for any CM was 90.7% and that for major CMs (MCMs) was 91.5%. Concerning MCMs of specific organ systems, those of the circulatory system (PPV 85.1%) were the most frequent, followed by cleft lip and cleft palate (PPV 100.0%), and other CMs of the digestive system (PPV 96.4%). Based on the EUROCAT classification, the PPV for any MCM was 88.5%. Specific MCMs reported in ≥20 infants were ventricular septal defect (PPV 96.0%), patent ductus arteriosus (PPV 72.7%) and cleft lip with or without cleft palate (PPV 100.0%). CONCLUSIONS: The PPVs for CMs in the Japanese administrative data were high enough to suggest that these data could be utilized for perinatal pharmacoepidemiological evaluations. The results were from a single center, and further validation studies are needed.
High-quality reports and their characteristics in the Japanese Adverse Drug Event Report database (JADER)

Masami Tsuchiya, Taku Obara, Makoto Miyazaki, Aoi Noda, Takamasa Sakai, Ryohkan Funakoshi, Nariyasu Mano

Journal of Pharmacy & Pharmaceutical Sciences　24　161-173　2021/04/08
Publisher: University of Alberta Libraries
DOI： 10.18433/jpps31417 　

eISSN： 1482-1826

More details Close

Purpose: Spontaneous adverse drug reaction reporting is the foundation of postmarketing drug safety monitoring. The present study aimed to analyze and clarify the quality and characteristics of the Japanese Adverse Drug Event Report database (JADER) using the World Health Organization (WHO) documentation grading scheme and the vigiGrade completeness score. The characteristics of reports were described using both schemes simultaneously. The way of proper use of these two schemes was explored. Methods: The WHO documentation grading scheme and the vigiGrade completeness score were applied to the same dataset (JADER202001 dataset). Reports classified as high-quality under both assessment criteria were extracted, and the characteristics of these reports were analyzed. Results: Of the 607,361 adverse drug reaction reports analyzed, 52.8% were ‘well-documented reports’ with a vigiGrade completeness score >0.8. Under the WHO documentation grading scheme, 328,702 reports (54.1%) were Grade 2 and 5,178 (0.9%) were Grade 3 (including rechallenge information). Among well-documented Grade 3 reports, classified as the highest quality, a high proportion of the adverse drug reaction reports were related to disorders of hematopoietic function resulting from anticancer drugs. Because a high proportion of the reports with rechallenge information were for anticancer drugs as suspect drugs, the WHO documentation grading scheme tended to extract reports regarding anticancer drugs as high quality. Conclusions: We conclude that the two schemes need to be used appropriately, depending on the purpose of analysis, the target adverse drug reactions, and suspect drugs.
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. International-journal

Tensei Hirasawa, Masafumi Kikuchi, Kensuke Shigeta, Shinya Takasaki, Yu Sato, Toshihiro Sato, Jiro Ogura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Masamitsu Maekawa, Nariyasu Mano

Biomedical chromatography : BMC　35　(8)　e5124　2021/03/27

DOI： 10.1002/bmc.5124 　

More details Close

Recent studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKIs) could improve treatment efficacy and safety. A simple analytical method using high-performance LC/electrospray ionization-tandem mass spectrometry has been developed and validated for simultaneous quantification of BCR-ABL and Bruton's TKIs used for chronic leukemia (imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib) in human plasma. Although these structures and physical properties are similar, owing to their different linear ranges, simultaneously determining the plasma levels of these five TKIs by applying optimal MS parameters remains difficult. A quantitative range exceeding 60,000-fold was required, and the linear dynamic ranges of imatinib, bosutinib, and nilotinib were limited because of the presence of a saturated detection signal. In this study, we applied the in-source collision-induced dissociation technique to control the ion amounts in mass spectrometry. This new method allowed rapid determination within 5 min with simple pretreatment. The method was validated according to the US Food and Drug Administration guidelines. Moreover, all samples of patients with chronic leukemia were successfully measured and their values were within the linear range of measurement. Therefore, our high-throughput analytical system is useful to measure the plasma concentrations of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in clinical practice.
Establishment of an analytical method for simultaneous quantitation of CDK4/6 inhibitors, aromatase inhibitors, and an estrogen receptor antagonist in human plasma using LC-ESI-MS/MS. International-journal

Yu Sato, Kensuke Shigeta, Tensei Hirasawa, Toshihiro Sato, Jiro Ogura, Masamitsu Maekawa, Akiko Ebata, Yohei Hamanaka, Hiroshi Tada, Takanori Ishida, Masafumi Kikuchi, Nariyasu Mano

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences　1173　122655-122655　2021/03/22

DOI： 10.1016/j.jchromb.2021.122655 　

More details Close

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors (palbociclib, abemaciclib, and ribociclib) are used to treat human epithelial growth factor receptor (HER)-2 negative and hormone receptor (HR) positive advanced breast cancer in combination with aromatase inhibitors (letrozole, anastrozole) or an estrogen receptor antagonist (fulvestrant). Administration of these drugs frequently causes severe side effects, such as neutropenia and diarrhea. Therefore, therapeutic drug monitoring (TDM) of CDK4/6 inhibitors, aromatase inhibitors, and the estrogen receptor antagonist is considered important for ensuring the efficacy and safety of these drugs. In this study, we describe a simple, highly sensitive, and specific liquid chromatography/electrospray ionization tandem mass spectrometry method for simultaneous quantitation of the concentrations of palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and fulvestrant. In addition, we analyzed plasma samples from patients with HER2-negative and HR-positive advanced breast cancer treated with these compounds using this novel method. In our method, the intra-assay relative error (RE) values ranged from -12.8% to 12.9%, the inter-assay RE values ranged from -4.8% to 6.2%, and the coefficient of variation (CV) values for intra- and inter-assay were ≤8.6% and ≤13.3%, respectively. The analytes showed good stability with RE values ranging from -13.5% to 13.6% and CV values <10.4%. Moreover, all the samples from patients were successfully quantified, and were within the range of measurement. This method can be used for TDM of routine anticancer drugs in clinical practice and for pharmacokinetics/pharmacodynamics research in future studies.
The impact of regulation changes in the spontaneous reporting system for vaccines on reporting trends and signal detection in Japan. International-journal

Makoto Miyazaki, Takamasa Sakai, Taku Obara, Nariyasu Mano

Pharmacoepidemiology and drug safety　30　(8)　1091-1100　2021/03/17

DOI： 10.1002/pds.5231 　

More details Close

PURPOSE: Spontaneous reporting constitutes one of the most fundamental and important systems for pharmacovigilance. In Japan, important regulation changes in the vaccine spontaneous reporting were implemented between 2009 and 2013; however, no studies had yet assessed the impact of the changes. The objective of this study was to assess the impact on the reporting trends in vaccine reports and on signal detection for vaccines. METHODS: For assessment of the impact on the reporting trends, we performed the joinpoint trend analysis and descriptively considered number of vaccine reports grouped by the timing of the regulation change. For assessment of the impact on signal detection, we performed signal detection using dataset during the pre or postperiod of the regulation changes, and compared their agreement rates, which was calculated with a reference set for vaccines, created by the Global Research in Paediatrics project. RESULTS: We retrieved 467 635 spontaneous reports, including 12 287 vaccine reports from April 2004 to March 2019. The average number of vaccine reports per year increased from 231 reports during the preperiod to 1227 during the postperiod. The joinpoint trend analysis found two joinpoints and differentiated three trends, significant increased trend of which was observed when regulations had changed. For signal detection, the agreement rate was improved when using data during the postperiod. CONCLUSION: We concluded that the regulation changes increased the number of vaccine reports, and could have improved signal detection performance for vaccines by accelerating accumulation of reports, while more spontaneous reports are necessary to optimize signal detection.
危機管理計画に基づく医薬品副作用モニタリングシステムの実施(Implementation of an Adverse Drug Reaction Monitoring System Based on Risk Management Plans)

Tsuchiya Masami, Esashi Akihisa, Obara Taku, Funakoshi Ryohkan, Mano Nariyasu

医薬品相互作用研究　45　(1)　19-26　2021/03
Publisher: (一社)医薬品相互作用研究会
ISSN： 0385-5015
【病気とくすり2021 基礎と実践Expert's Guide】循環器系の病気とくすり血液・造血器系疾患貧血

斎藤陽, 張替秀郎, 鈴木文子, 眞野成康

薬局　72　(4)　1032-1043　2021/03
Publisher: (株)南山堂
ISSN： 0044-0035
Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6β-Hydroxylation. International-journal

Masaki Kumondai, Evelyn Marie Gutiérrez Rico, Eiji Hishinuma, Akiko Ueda, Sakae Saito, Daisuke Saigusa, Shu Tadaka, Kengo Kinoshita, Tomoki Nakayoshi, Akifumi Oda, Ai Abe, Masamitsu Maekawa, Nariyasu Mano, Noriyasu Hirasawa, Masahiro Hiratsuka

Drug metabolism and disposition: the biological fate of chemicals　49　(3)　212-220　2021/03

DOI： 10.1124/dmd.120.000261 　

More details Close

CYP3A4 is among the most abundant liver and intestinal drug-metabolizing cytochrome P450 enzymes, contributing to the metabolism of more than 30% of clinically used drugs. Therefore, interindividual variability in CYP3A4 activity is a frequent cause of reduced drug efficacy and adverse effects. In this study, we characterized wild-type CYP3A4 and 40 CYP3A4 variants, including 11 new variants, detected among 4773 Japanese individuals by assessing CYP3A4 enzymatic activities for two representative substrates (midazolam and testosterone). The reduced carbon monoxide-difference spectra of wild-type CYP3A4 and 31 CYP3A4 variants produced with our established mammalian cell expression system were determined by measuring the increase in maximum absorption at 450 nm after carbon monoxide treatment. The kinetic parameters of midazolam and testosterone hydroxylation by wild-type CYP3A4 and 29 CYP3A4 variants (K m , k cat , and catalytic efficiency) were determined, and the causes of their kinetic differences were evaluated by three-dimensional structural modeling. Our findings offer insight into the mechanism underlying interindividual differences in CYP3A4-dependent drug metabolism. Moreover, our results provide guidance for improving drug administration protocols by considering the information on CYP3A4 genetic polymorphisms. SIGNIFICANCE STATEMENT: CYP3A4 metabolizes more than 30% of clinically used drugs. Interindividual differences in drug efficacy and adverse-effect rates have been linked to ethnicity-specific differences in CYP3A4 gene variants in Asian populations, including Japanese individuals, indicating the presence of CYP3A4 polymorphisms resulting in the increased expression of loss-of-function variants. This study detected alterations in CYP3A4 activity due to amino acid substitutions by assessing the enzymatic activities of coding variants for two representative CYP3A4 substrates.
Development of a simultaneous analytical method for clozapine and its metabolites in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry with linear range adjusted by in-source collision-induced dissociation. International-journal

Toshihiro Sato, Masato Suzuka, Yuji Sato, Riko Iwabuchi, Daisuke Kobayashi, Jiro Ogura, Shinya Takasaki, Maki Yokota, Taku Tsukamoto, Yoshihiro Hayakawa, Masafumi Kikuchi, Masamitsu Maekawa, Nariyasu Mano

Biomedical chromatography : BMC　35　(7)　e5094　2021/02/18

DOI： 10.1002/bmc.5094 　

More details Close

Clozapine (CLZ) is a key drug in treatment-resistant schizophrenia. Therapeutic drug monitoring (TDM) of CLZ and its metabolites, N-desmethylclozapine and clozapine N-oxide, is required to monitor and manage the risks of side effects. Although quantification methods for TDM have been developed for CLZ and its metabolites, they were not sufficiently accurate for the quantification of CLZ owing to the upper limits of the calibration curves. An analytical method using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry was developed and validated for the simultaneous measurement of CLZ and its metabolites in human plasma. To expand the concentration range of the calibration curves, we used a linear range shift technique using in-source collision-induced dissociation (CID). Using our approach, the linearity and quantitative range were improved compared to those reported by previous studies, and were sufficient for TDM in clinical practice. The intra- and inter-assay accuracy was 84.6%-114.8%, and the intra- and inter-assay precisions were ≤9.1% and ≤9.9%, respectively. Moreover, all samples from patients with treatment-resistant schizophrenia were successfully quantified. Therefore, our novel analytical method using in-source CID had the appropriate performance to measure the plasma concentrations of CLZ and its metabolites for TDM in clinical practice.
Functional Assessment of 12 Rare Allelic CYP2C9 Variants Identified in a Population of 4773 Japanese Individuals. International-journal

Masaki Kumondai, Akio Ito, Evelyn Marie Gutiérrez Rico, Eiji Hishinuma, Akiko Ueda, Sakae Saito, Tomoki Nakayoshi, Akifumi Oda, Shu Tadaka, Kengo Kinoshita, Masamitsu Maekawa, Nariyasu Mano, Noriyasu Hirasawa, Masahiro Hiratsuka

Journal of personalized medicine　11　(2)　2021/02/02

DOI： 10.3390/jpm11020094 　

More details Close

Cytochrome P450 2C9 (CYP2C9) is an important drug-metabolizing enzyme that contributes to the metabolism of approximately 15% of clinically used drugs, including warfarin, which is known for its narrow therapeutic window. Interindividual differences in CYP2C9 enzymatic activity caused by CYP2C9 genetic polymorphisms lead to inconsistent treatment responses in patients. Thus, in this study, we characterized the functional differences in CYP2C9 wild-type (CYP2C9.1), CYP2C9.2, CYP2C9.3, and 12 rare novel variants identified in 4773 Japanese individuals. These CYP2C9 variants were heterologously expressed in 293FT cells, and the kinetic parameters (Km, kcat, Vmax, catalytic efficiency, and CLint) of (S)-warfarin 7-hydroxylation and tolbutamide 4-hydroxylation were estimated. From this analysis, almost all novel CYP2C9 variants showed significantly reduced or null enzymatic activity compared with that of the CYP2C9 wild-type. A strong correlation was found in catalytic efficiencies between (S)-warfarin 7-hydroxylation and tolbutamide 4-hydroxylation among all studied CYP2C9 variants. The causes of the observed perturbation in enzyme activity were evaluated by three-dimensional structural modeling. Our findings could clarify a part of discrepancies among genotype-phenotype associations based on the novel CYP2C9 rare allelic variants and could, therefore, improve personalized medicine, including the selection of the appropriate warfarin dose.
【臨床薬学研究における新たな定量分析法の開発・応用】質量分析法を用いるニーマンピック病C型バイオマーカーの同定と診断性能評価

前川正充, 岩堀杏南, 眞野成康

臨床化学　50　(1)　20-26　2021/01
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
Prescription of Kampo Formulations for Pre-natal and Post-partum Women in Japan: Data From an Administrative Health Database. International-journal

Satoko Suzuki, Taku Obara, Tomofumi Ishikawa, Aoi Noda, Fumiko Matsuzaki, Ryutaro Arita, Minoru Ohsawa, Nariyasu Mano, Akiko Kikuchi, Shin Takayama, Tadashi Ishii

Frontiers in nutrition　8　762895-762895　2021

DOI： 10.3389/fnut.2021.762895 　

More details Close

Introduction: Traditional Japanese (Kampo) medicines are often prescribed for women in Japan before, during, and after pregnancy. However, detailed information on the actual frequency of use and safety of Kampo preparations during pregnancy is lacking. Aim: To investigate the frequency of prescription of Kampo medicines for pregnant women in Japan. Methods: Information on Kampo medicines prescribed during outpatient care and hospitalization of selected mothers from January 2005 to August 2016 were extracted from the Japan Medical Data Center (Tokyo, Japan), which is a large claims database. Results: Of the 33,941 subscribers identified from the database, 16,294 (48%) received at least one prescription of a Kampo medicine. Kakkonto was the formula most prescribed during the study period, followed by shoseiryuto and tokishakuyakusan. In the 180 days before pregnancy, the most prescribed medicine was tokishakuyakusan, followed by kakkonto and shoseiryuto. Shoseiryuto, tokishakuyakusan, and kakkonnto were the formulae most prescribed during pregnancy. The most prescribed medicines during the 180 days postpartum were kakkonto, shoseiryuto, and saireito. Conclusions: Information in the Japanese insurance system shows that Kampo medicines are often prescribed during pregnancy. Most of these prescriptions are generally used for the treatment of common cold. Tokishakuyakusan in particular is usually used in the treatment of various symptoms of pregnancy. Further research is needed to clarify the relationship between the use of Kampo medicines during pregnancy and adverse events in infants in Japan.
Clinical Importance of Plasma Drug Concentration of Oral Molecular Targeted Drugs for Renal Cell Carcinoma. International-journal

Shinya Takasaki, Yoshihide Kawasaki, Akihiro Ito, Hiroaki Yamaguchi, Nariyasu Mano

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques　24　127-136　2021

DOI： 10.18433/jpps31816 　

More details Close

PURPOSE: Therapeutic drug monitoring (TDM) is widely used in clinical practice to maximize drug efficacy and minimize toxicities. Currently, it is also practiced in the use of oral molecular targeted drugs. The objective of this study was to assess the clinical importance of measuring the systemic concentration of oral molecular targeted drugs used to treat renal cell carcinoma (RCC). METHODS: The systemic concentrations of the oral molecular targeted drugs sorafenib, sunitinib, axitinib, pazopanib, and everolimus used for RCC were useful for therapeutic interventions, and clinical outcomes were evaluated retrospectively. RESULTS: The interventional use of systemic drug concentration was confirmed in 26 of 87, and their categories are presented. The systemic concentration of sunitinib was useful in dose reduction and/or discontinuation (n = 10), dose escalation (n = 3), and adherence monitoring (n = 2). Nine of the 10 patients whose dose was reduced showed reduced adverse event. Two patients who were intervened in adherence monitor showed improved adherence. For axitinib, dose reduction and/or discontinuation (n = 1) and dose escalation (n = 6) were confirmed. For pazopanib, dose reduction and/or discontinuation (n = 1) and drug interaction detection (n = 1) were confirmed, both of them were confirmed to have reduced adverse events. For everolimus, dose reduction and/or discontinuation (n = 1) and drug interaction detection (n = 1) were confirmed, a patient with reduced dose recovered from adverse events. Interventions for sorafenib were not identified. CONCLUSIONS: This study demonstrated that systemic concentrations of oral molecular targeted drugs for RCC were considered to be clinically useful for dose adjustment, monitoring of treatment adherence, and the detection of drug interactions. Moreover, this information could be successfully used to guide individualized therapy to maximize the antitumor effects of these drugs.
児の先天奇形に関するレセプト傷病名の妥当性評価

石川智史, 小原拓, 大柳元, 野田あおい, 森下啓, 高木秀侑, 井上隆輔, 川目裕, 眞野成康

Journal of Epidemiology　31　(Suppl.)　131-131　2021/01
Publisher: (一社)日本疫学会
ISSN： 0917-5040

eISSN： 1349-9092
Active Extraction of Experience of Adverse Drug Reactions in Children. International-journal

Aoi Noda, Taku Obara, Michihiro Satoh, Naoto Yagi, Nariyasu Mano, Kenji Kaneko

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG　26　(4)　352-360　2021

DOI： 10.5863/1551-6776-26.4.352 　

More details Close

OBJECTIVE: Safety information regarding the use of medication, over-the-counter drugs, and supplements for Japanese children is scarce. The aim of this study was to clarify adverse drug reaction (ADR) experiences in children and consider the method to collect ADRs efficiently. METHODS: We conducted a questionnaire survey regarding the ADR experiences of 20,412 children who were attending a preschool or kindergarten in the cities of Warabi and Toda, Saitama Prefecture, in May 2013. RESULTS: Responses were received from the guardians of 15,076 children (49.5% girls; 8.2 ± 3.5 yr). A total of 196 guardians (1.3%) responded that their children had experienced ADRs. Among them, a total of 243 suspected drugs and 284 ADRs were reported. Of the 243 suspected drugs, 2.5% were associated with a vaccine. The most frequently reported medication, reaction, and "medication-reaction pair" were antibacterials for systemic use, rash, and "antibacterials for systemic use and rash," respectively. CONCLUSIONS: In this study, we clarified that there were many potential ADRs among children, but all "medication-reaction pairs" reported were consistent with adverse events reported in the clinical trials available in the prescribing information of each medication. This study provides data respective to the frequency of these adverse events in the general pediatric population. Additional education is needed to enlighten guardians of the importance to report ADRs through the Direct Patient Reporting System.
児の先天奇形に関するレセプト傷病名の妥当性評価

石川智史, 小原拓, 大柳元, 野田あおい, 森下啓, 高木秀侑, 井上隆輔, 川目裕, 眞野成康

Journal of Epidemiology　31　(Suppl.)　131-131　2021/01
Publisher: (一社)日本疫学会
ISSN： 0917-5040

eISSN： 1349-9092
A Case of an Increase in Prothrombin Time-International Normalized Ratio by Interaction Between Warfarin and Baloxavir Marboxil in a Patient on Implantable Ventricular Assist Device. International-journal

Keiko Kurosawa, Shinya Takasaki, Hisaki Suzuki, Yuji Sato, Masatoshi Akiyama, Miki Akiba, Yoshikatsu Saiki, Nariyasu Mano

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques　24　37-40　2021

DOI： 10.18433/jpps31375 　

More details Close

BACKGROUND: Baloxavir marboxil (BM) is a novel drug with a cap-dependent endonuclease inhibitory action for influenza A or B; it is highly safe and requires just a single oral dose. Patients with severe heart failure use implantable ventricular assist device (iVAD) until transplantation, but they have an increased risk of thrombosis development. Their warfarin is administered based on point-of-care testing (POCT) with a strict control of prothrombin time-international normalized ratio (PT-INR). CASE REPORT: Here, we report a case of a patient with iVAD whose PT-INR was significantly increased from the target range after BM administration. The patient was a 45-year-old man and transplanted with iVAD; warfarin treatment was started when his PT-INR target range was 3.0-3.5. At home, he frequently self-measured PT-INR by POCT and precisely controlled the warfarin dose. He had a fever, was diagnosed with influenza A and was administered BM 40 mg. Thereafter, his PT-INR continued to increase, reaching 4.8 on day 12 of BM administration, exceeding his target range; warfarin was skipped for 1 day. In this case, based on the history of BM administration and clinical course, the increase in PT-INR could be due to BM. Considering the interaction between warfarin and BM, we suspected a possibility of competition for protein-binding sites. Increased PT-INR in the patient was detected early by POCT and thus severe bleeding was avoided. CONCLUSION: Strict monitoring of PT-INR when using BM in patients taking warfarin is of clinical importance.
Adverse Drug Reaction Reports Regarding Abnormal Behavior After Oseltamivir Use in Children as Reported by Consumers or Healthcare Professionals. International-journal

Aoi Noda, Masami Tsuchiya, Takamasa Sakai, Taku Obara, Nariyasu Mano

Patient preference and adherence　15　533-541　2021

DOI： 10.2147/PPA.S292072 　

More details Close

Purpose: The purpose of this study was to assess the differences between consumer (patient) and healthcare professional submissions of adverse drug reaction (ADR) reports associated with certain antiviral treatments in children. Material and Methods: We extracted ADR reports for children aged <20 years who received oseltamivir or similar drugs (zanamivir and amantadine) between April 2004 and May 2020 from the Japanese Adverse Drug Event Report database. Abnormal behavior after oseltamivir administration was reported frequently in the news in November 2005, and a Dear Healthcare Professional letter about abnormal behavior after oseltamivir use was issued on March 20, 2007. We compared the number of ADR reports by three periods: (1) before the news, (2) between the news and the letter, and (3) after the letter. These reports were tabulated and analyzed after stratification according to the reporter (healthcare professionals only, patients and healthcare professionals, patients only), patient age (<10 years, 10-19 years), and ADR (abnormal behavior, other ADRs). Results: For the reports from healthcare professionals only, the number of reports per quarter associated with oseltamivir was largest during the period between the news about abnormal behavior after oseltamivir use and publication of the Dear Healthcare Professional letter. The reports from patients only about abnormal behavior after oseltamivir use were first reported after publication of the letter. The proportions of reports from patients only about abnormal behavior with oseltamivir were 81.0% and 92.2% for ages <10 and 10-19 years, respectively. A ripple effect of increasing reports was observed with zanamivir or amantadine. Conclusion: Reports from patients only might increase in response to the media more than reports from healthcare professionals only or patients and healthcare professionals do. The ADR reports from patients must be carefully assessed from the perspective of when they were reported.
Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma. International-journal

Tomonori Sato, Yoshihide Kawasaki, Masamitsu Maekawa, Shinya Takasaki, Kento Morozumi, Masahiko Sato, Shuichi Shimada, Naoki Kawamorita, Shinichi Yamashita, Koji Mitsuzuka, Nariyasu Mano, Akihiro Ito

Metabolites　11　(1)　2020/12/22

DOI： 10.3390/metabo11010001 　

More details Close

Metabolomics analysis possibly identifies new therapeutic targets in treatment resistance by measuring changes in metabolites accompanying cancer progression. We previously conducted a global metabolomics (G-Met) study of renal cell carcinoma (RCC) and identified metabolites that may be involved in sunitinib resistance in RCC. Here, we aimed to elucidate possible mechanisms of sunitinib resistance in RCC through intracellular metabolites. We established sunitinib-resistant and control RCC cell lines from tumor tissues of RCC cell (786-O)-injected mice. We also quantified characteristic metabolites identified in our G-Met study to compare intracellular metabolism between the two cell lines using liquid chromatography-mass spectrometry. The established sunitinib-resistant RCC cell line demonstrated significantly desuppressed protein kinase B (Akt) and mesenchymal-to-epithelial transition (MET) phosphorylation compared with the control RCC cell line under sunitinib exposure. Among identified metabolites, glutamine, glutamic acid, and α-KG (involved in glutamine uptake into the tricarboxylic acid (TCA) cycle for energy metabolism); fructose 6-phosphate, D-sedoheptulose 7-phosphate, and glucose 1-phosphate (involved in increased glycolysis and its intermediate metabolites); and glutathione and myoinositol (antioxidant effects) were significantly increased in the sunitinib-resistant RCC cell line. Particularly, glutamine transporter (SLC1A5) expression was significantly increased in sunitinib-resistant RCC cells compared with control cells. In this study, we demonstrated energy metabolism with glutamine uptake and glycolysis upregulation, as well as antioxidant activity, was also associated with sunitinib resistance in RCC cells.
癌細胞代謝からみた腎癌細胞におけるsunitinib耐性獲得機構の解明

佐藤友紀, 川崎芳英, 前川正充, 高崎新也, 諸角謙人, 佐藤真彦, 嶋田修一, 川守田直樹, 山下慎一, 三塚浩二, 眞野成康, 伊藤明宏

日本泌尿器科学会総会　108回　799-799　2020/12
Publisher: (一社)日本泌尿器科学会総会事務局
Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. International-journal

Hiroshi Yabuki, Yasushi Matsuda, Tatsuaki Watanabe, Shunsuke Eba, Fumihiko Hoshi, Takashi Hirama, Hisashi Oishi, Tetsu Sado, Masafumi Noda, Akira Sakurada, Masafumi Kikuchi, Hiroaki Yamaguchi, Nariyasu Mano, Yoshinori Okada

Clinical transplantation　34　(12)　e14088　2020/12

DOI： 10.1111/ctr.14088 　

More details Close

BACKGROUND: The therapeutic drug monitoring of mycophenolic acid (MPA) has been investigated for renal and heart transplantations; however, its usefulness in lung transplantation is unclear. METHODS: The MPA area under the plasma concentration-time curve (AUC) was calculated in 59 adult lung transplant recipients. The MPA AUC0-12 s were compared among the three groups determined by the presence of adverse events (no events, infection, and chronic lung allograft dysfunction [CLAD]). Next, MPA AUC0-12 thresholds for the adverse events were identified by receiver operating characteristic analysis. Cumulative occurrence rate of the adverse events was compared between two groups (adequate and inadequate groups) according to the thresholds. RESULTS: The MPA AUC0-12 s in the no event, infection, and CLAD groups were 30.3 ± 6.5, 36.8 ± 10.7, and 20.6 ± 9.6 µg·h/mL, respectively (P = .0027), while the tacrolimus trough levels were similarly controlled in the groups. The thresholds of MPA AUC0-12 for the occurrence of infection and CLAD were 40.5 and 22.8 µg·h/mL, respectively. The cumulative occurrence rate of adverse events of adequate group (15.3%) was significantly lower than that of inadequate group (56.0%) (P = .0050). CONCLUSIONS: The MPA AUC0-12 may affect the occurrence of adverse events in lung transplant recipients.
Biomarker analysis of Niemann-Pick disease type C using chromatography and mass spectrometry. International-journal

Masamitsu Maekawa, Anna Iwahori, Nariyasu Mano

Journal of pharmaceutical and biomedical analysis　191　113622-113622　2020/11/30

DOI： 10.1016/j.jpba.2020.113622 　

More details Close

Niemann-Pick disease type C (NPC) is an autosomal recessive disorder with progressive degradation of central nervous system. The age of the onset varies from perinatal to adulthood. Patients with NPC are affected in the central nervous system, peripheral nerves, and systemic organs. From these background, it is extremely difficult to discover NPC clinically and diagnose it correctly. The procedure of the conventional laboratory methods are complicated and it takes long time to obtain the result. Because of the importance of early treatments and the shortcomings of conventional diagnostic methods for NPC, remarkable attention has been paid to biomarkers and chemical diagnoses. In the last decade, many NPC biomarkers have been reported. They are classified as cholesterol-related metabolites, sphingolipid metabolites, and novel phospholipid metabolites, respectively. Therefore, these are all lipid metabolites. Various chemical analysis methods have been used for their identification. In addition, chromatography and mass spectrometry are mainly used for their quantification. This review article outlines NPC biomarkers reported in the last decade and their analytical methods.
特定薬剤治療管理料1(TDM)が求める血中薬物濃度測定結果の活用治療効果の最大化を目指した経口抗がん薬の治療薬物モニタリング

高崎新也, 菊地正史, 眞野成康

臨床化学　49　(Suppl.1)　118-118　2020/10
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
Cysteine 343 in the Substrate Binding Domain is the Primary S-Nitrosylated Site in Protein Disulfide Isomerase. International-journal Peer-reviewed

Jiro Ogura, Lloyd W Ruddock, Nariyasu Mano

Free radical biology & medicine　160　103-110　2020/08/05

DOI： 10.1016/j.freeradbiomed.2020.07.029 　

More details Close

Abnormal protein accumulations are typical pathological features for neurodegenerative diseases. Protein disulfide isomerase (PDI) is a critical enzyme in oxidative protein folding. S-nitrosylated PDI has been detected in the postmortem brain in neurodegenerative disease patients, but the effect of S-nitrosylation on PDI function and developing neurodegeneration was not clarified in detail. In this study, we identified that in vitro and in vivo S-nitrosylation of C343 in the b' domain of PDI occurs. Reduced recombinant human PDI (hPDI) reacted quickly with S-nitrosocompounds, with an observed increase in the expected S-nitrosylated species and the appearance of the disulfide state of the active sites. Both Mononitrosylated and dinitrosylated were observed from the S-nitrosylation of hPDI. Dinitrosylated species were S-nitrosylated both cysteines at active site. But, at least in part, mononitrosylated species were S-nitrosylated on cysteine 343 in the substrate binding b' domain. Although active site S-nitrosylation is reversible by reduced glutathione, S-nitrosylation of C343 is comparative stable. S-nitrosylation of PDI in SH-SY5Y cells was observed after the S-nitrosocysteine (SNOC) treatment and S-nitrosylated PDI was still detected 24 h after removing SNOC. While wild-type PDI was S-nitrosylated, the level of S-nitrosylation of the C343S mutant in over-expressed cells was substantially lower and only wild-type PDI of S-nitrosylation remained 24 h after removing SNOC in over-expressed cells. Both of in vitro and in vivo results suggested that S-nitrosylation of C343 in PDI may be the causative effect on physiological changes in neurodegerenative disease patients, and may be useful for the drug development for neurodegenerative diseases.
ATP-Binding Cassette Transporter C4 is a Prostaglandin D2 Exporter in HMC-1 cells. International-journal

Nobuaki Tanaka, Junya Kawai, Noriyasu Hirasawa, Nariyasu Mano, Hiroaki Yamaguchi

Prostaglandins, leukotrienes, and essential fatty acids　159　102139-102139　2020/08

DOI： 10.1016/j.plefa.2020.102139 　

More details Close

ATP-binding cassette transporter C4 (ABCC4) is associated with multidrug resistance and the regulation of cell signalling. Some prostaglandins (PGs), including: PGE2, PGF2α, PGE3, and PGF3α are known substrates of ABCC4, and are released from some types of cells to exert their biological effects. In the present study, we demonstrate that PGD2 is a novel substrate of ABCC4 using a transport assay based on inside-out membrane vesicles prepared from ABCC4-overexpressing cells. Then, we used two types of cell lines with confirmed ABCC4 mRNA and PGD2 release capacity (human mast cell lines HMC-1 cells and human rhabdomyosarcoma cell lines TE671 cells) to evaluate the contribution of ABCC4. The extracellular levels of PGD2 were unchanged following addition of a selective ABCC4 inhibitor in TE671 cells. Pharmacological inhibition and knockdown of ABCC4 significantly reduced the extracellular levels of PGD2 by at least 53% in HMC-1 cells. Moreover, the extracellular levels of PGD2 decreased by at least 20% using the selective ABCC4 inhibitor in the other mast cell line RBL-2H3 cells. Therefore, our results suggest that ABCC4 functions as a PGD2 exporter in HMC-1 cells.
ニーマンピック病の血清メタボローム解析と新規スクリーニング戦略

前川正充, 岩堀杏南, 眞野成康

JSBMS Letters　45　(Suppl.)　33-33　2020/08
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
Characteristics of Adverse Events Following Immunization Reporting in Children: The Japanese Adverse Drug Event Report Database. International-journal Peer-reviewed

Aoi Noda, Takamasa Sakai, Masami Tsuchiya, Gen Oyanagi, Taku Obara, Nariyasu Mano

Vaccines　8　(3)　2020/07/03

DOI： 10.3390/vaccines8030357 　

More details Close

The present study aimed to describe the trends and characteristics of adverse events following immunization (AEFI) reporting for children in the Japanese Adverse Drug Event Report database (JADER). We used 6280 AEFI reports for children aged <19 years among 504,407 ADR reports included in the JADER from 2004 to 2017. The number of AEFI reports gradually increased among children aged <10 years and was the highest in 2011 among children aged 10-19 years. The number of suspected vaccines per AEFI report increased after 2011 among children aged <10 years. The percentage of "death" and "did not recover" as AEFI outcomes reported were 4.3% and 3.7% among children aged <10 years and 0.2% and 21.1% among children aged 10-19 years, respectively. The most frequently reported vaccine-reaction pair was Haemophilus influenzae type b conjugate vaccine and pyrexia among children aged <10 years and recombinant adsorbed bivalent human papillomavirus-like particle vaccine and a loss of consciousness among children aged 10-19 years. It is necessary to consider the Weber effects to understand the trend and characteristics of AEFI reporting because pharmacovigilance activity regarding vaccination is not sufficient in Japan.
Folic acid prescribed to prenatal and postpartum women who are also prescribed antiepileptic drugs in Japan: Data from a health administrative database. International-journal Peer-reviewed

Tomofumi Ishikawa, Taku Obara, Kazutaka Jin, Hidekazu Nishigori, Keiko Miyakoda, Manabu Akazawa, Nobukazu Nakasato, Nobuo Yaegashi, Shinichi Kuriyama, Nariyasu Mano

Birth defects research　112　(16)　1224-1233　2020/07/02

DOI： 10.1002/bdr2.1748 　

More details Close

BACKGROUND: The aim of this study was to evaluate the prevalence of folic acid (FA) prescription to prenatal and postpartum women who have also been prescribed antiepileptic drugs (AED) in Japan. METHODS: The data set used in this study included women covered by health insurance between 2005 and 2016. The prevalence of FA prescriptions between 180 days before pregnancy and 180 days postpartum was determined from a large administrative database, with the FA prescription classified according to dose and timing. RESULTS: For 33,941 women meeting our eligibility criteria, the mean maternal age at delivery was 32.3 years. At least one AED was prescribed to 225 of 33,941 women between 180 days before pregnancy and 180 days postpartum. FA was prescribed to 32 of 225 women (14.2%) during the same period. FA was prescribed to 8.8% of women with AED within 90 days before pregnancy and to 19.8% during the first trimester. FA was prescribed to 10.9% during the first 30 days after conception, all of whom were prescribed FA before the pregnancy. The maximum FA dose prescribed within 90 days before pregnancy was 5 mg/day for 5 of 12 women (41.7%) and >5 mg/day for 4 of 12 women (33.3%). The maximum FA dose prescribed during the first trimester was 5 mg/day for 14 of 22 women (63.6%) and >5 mg/day for 8 of 22 women (36.4%). CONCLUSIONS: The concurrent prescription of FA with AEDs in Japan was an uncommon therapeutic approach both before and during pregnancy.
アデニン誘発腎不全マウスにおけるエロビキシバットの効果

秋山由雅子, 前川正充, 金光祥臣, 菊地晃一, 何欣蓉, 三島英換, 鈴木健弘, 一條真梨子, 鈴木千登世, 眞野成康, 富岡佳久, 阿部高明

日本腎臓学会誌　62　(4)　337-337　2020/07
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385

eISSN： 1884-0728
Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database. International-journal Peer-reviewed

Aoi Noda, Takamasa Sakai, Taku Obara, Makoto Miyazaki, Masami Tsuchiya, Gen Oyanagi, Yuriko Murai, Nariyasu Mano

BMC pharmacology & toxicology　21　(1)　36-36　2020/05/24

DOI： 10.1186/s40360-020-00412-7 　

More details Close

BACKGROUND: There are no reports on investigations of the characteristics of adverse drug reaction (ADR) reports for pediatric patients in the Japanese Adverse Drug Event Report database (JADER) and the utility of database for drug safety surveillance in these patients. METHOD: We aimed to evaluate ADR reports for pediatric patients in the JADER. We used spontaneous ADR reports included in the JADER since April 1, 2004, to December 31, 2017, which was downloaded in April 2018. In a total of 504,407 ADR reports, the number of spontaneous reports was 386,400 (76.6%), in which 37,534 (7.4%) were unknown age reports. After extraction of 27,800 ADR reports for children aged < 10 and 10-19 years, we excepted for ADR reports associated with a vaccine (n = 6355) and no-suspected drug reports (n = 86). A total of 21,359 (4.2%) reports were finally included in this analysis. RESULTS: More than half of the ADR reports were for children aged < 10 years. Approximately 30% of ADR reports had multiple suspected drugs, which did not differ by age. The percentages of fatal outcomes of ADRs among patients aged < 10 and 10-19 years were 4.7 and 3.9%, respectively. The most frequently reported drug, reaction, and drug-reaction pair were oseltamivir, abnormal behavior, and oseltamivir and abnormal behavior, respectively. CONCLUSION: We clarified the characteristics of ADR reports for Japanese children by using the JADER. ADR report databases, especially those for pediatric patients, are valuable pharmacovigilance tools in Japan and other countries. Therefore, a proper understanding of the characteristics of the ADR reports in the JADER is important. Additionally, potential signals for ADRs in pediatric patients should be monitored continuously and carefully.
Changes in community pharmacists' knowledge, attitudes, and practice regarding the management of hypertension before and after educational interventions. International-journal Peer-reviewed

Aoi Noda, Taku Obara, Kazuki Takada, Yukinaga Kishikawa, Shinya Abe, Shoko Yoshimachi, Nariyasu Mano, Yutaka Imai, Teruaki Goto

Clinical and experimental hypertension (New York, N.Y. : 1993)　42　(4)　322-327　2020/05/18

DOI： 10.1080/10641963.2019.1652634 　

More details Close

Objective: To clarify changes in community pharmacists' knowledge, attitudes, and practice regarding the management of hypertension before and after attending educational interventions based on their self-report on a questionnaire survey.Method: We conducted questionnaire surveys regarding the management of hypertension with a sample of community pharmacists before and after educational interventions.Results: The proportions of pharmacists who knew the 2014 Japanese Society of Hypertension Guidelines, guidelines for home blood pressure measurement, reference values for hypertension based on clinic-measured blood pressure, and reference values for hypertension based on home-measured blood pressure after the educational interventions (59.3%, 41.4%, 75.1%, and 70.8% respectively) were significantly higher relative to those recorded before interventions (31.6%, 13.7%, 47.7%, and 25.4% respectively).Conclusions: These findings suggest that in-house training might increase the knowledge of community pharmacists regarding hypertension management.
Global metabolomics analysis of serum from patients with Niemann-Pick disease type C Peer-reviewed

Anna Iwahori, Masamitsu Maekawa, Yoshitomi Kanemitsu, Yotaro Matsumoto, Yoshihisa Tomioka, Aya Narita, Torayuki Okuyama, Yoshikatsu Eto, Daisuke Saigusa, Nariyasu Mano

Medical Mass Spectrometry　4　(1)　1-11　2020/05
Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma. International-journal Peer-reviewed

Tomonori Sato, Yoshihide Kawasaki, Masamitsu Maekawa, Shinya Takasaki, Shuichi Shimada, Kento Morozumi, Masahiko Sato, Naoki Kawamorita, Shinichi Yamashita, Koji Mitsuzuka, Nariyasu Mano, Akihiro Ito

Cancer science　111　(7)　2570-2578　2020/04/29

DOI： 10.1111/cas.14440 　

More details Close

We identified characteristic metabolites related to diagnosis and malignant status of clear cell renal cell carcinoma (ccRCC) using surgically resected tissue. Specifically, we quantified metabolites in urine samples to evaluate their potential as clinically useful noninvasive biomarkers of ccRCC. Between January 2016 and August 2018, we collected urine samples from 87 patients with pathologically diagnosed ccRCC and 60 controls from patients with benign urological conditions. Metabolite concentrations in urine samples were investigated by liquid chromatography-mass spectrometry with an internal standard and adjustment based on urinary creatinine levels. We analyzed associations between metabolite concentrations and predictability of diagnosis and of malignant status by multiple logistic regression and receiver operating characteristics (ROC) curves to establish ccRCC predictive models.Of the 47 metabolites identified in our previous study, we quantified 33 in urine samples. Multiple logistic regression analysis revealed 5 metabolites (L-glutamic acid, lactate, D-sedoheptulose 7-phosphate, 2-hydroxyglutarate, and myoinositol) for a diagnostic predictive model and 4 metabolites (L-kynurenine, L-glutamine, fructose 6-phosphate, and butyrylcarnitine) for a predictive model for clinical stage III/IV. The sensitivity and specificity of the diagnostic predictive model were 93.1% and 95.0%, respectively, yielding an area under the ROC curves (AUC) of 0.966. The sensitivity and specificity of the predictive model for clinical stage were 88.5% and 75.4%, respectively, with an AUC of 0.837. In conclusion, quantitative analysis of urinary metabolites yielded predictive models for diagnosis and malignant status of ccRCC. Urinary metabolites have potential as clinically useful noninvasive biomarkers of ccRCC to improve patient outcomes.
Development of a precise quantitative method for monitoring sirolimus in whole blood using LC/ESI-MS/MS. International-journal Peer-reviewed

Kensuke Shigeta, Masafumi Kikuchi, Masaki Tanaka, Shinya Takasaki, Hisashi Oishi, Tetsu Sado, Yasushi Matsuda, Masafumi Noda, Yoshinori Okada, Nariyasu Mano, Hiroaki Yamaguchi

Biomedical chromatography : BMC　34　(8)　e4853　2020/04/17

DOI： 10.1002/bmc.4853 　

More details Close

Sirolimus is used on patients after solid organ transplantation and on lymphangioleiomyomatosis (LAM) patients, and therapeutic drug monitoring is required in clinical practice. We have previously reported an accurate method for quantitative determination of sirolimus, but its sample preparation step was complicated. In this study, we developed a modified liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) method for sirolimus quantification. A supported liquid extraction cartridge was used to purify sirolimus from whole blood and ion suppression was mostly prevented. The validation results fulfilled the acceptable criteria. This method was compared with the antigen conjugated magnetic immunoassay (ACMIA) and our previously reported method, using whole blood samples from LAM patients. Comparison of the Bland-Altman plots of the currently developed method and the previous method revealed no significant difference between the two methods (mean bias, -2.02%; 95% CI, -7.81 to 3.78). The values obtained by using ACMIA were significantly higher than those obtained by using the current method by 13.87% (95% CI, 6.49 to 21.25) due to cross-reactivity. The degree of cross reactivities in LAM patients and in organ transplant patients were similar, and our LC/ESI-MS/MS method precisely measured blood concentrations of sirolimus.
The quality assessment of the Japanese Adverse Drug Event Report database using vigiGrade. International-journal Peer-reviewed

Masami Tsuchiya, Taku Obara, Makoto Miyazaki, Aoi Noda, Chizuko Takamura, Nariyasu Mano

International journal of clinical pharmacy　42　(2)　728-736　2020/04

DOI： 10.1007/s11096-020-00969-7 　

More details Close

Background The quality of adverse drug reaction reports can have a strong influence on the causality assessment or the detection of safety signals. Various methods have been used to evaluate the quality of adverse drug reaction reports. Objective We used the vigiGrade completeness score to evaluate the quality of the Japanese adverse drug event report database (JADER). Methods Among all reports in the JADER (cases received by regulatory authorities from April 2004 to November 2018), 427,797 cases that did not meet the exclusion criteria were analyzed using vigiGrade. An report was considered a 'well-documented' report if the completeness score > 0.8. For each dimension, the proportion of incomplete information was calculated. Main outcome measure Proportion of 'well-documented' reports. Results A total of 211,774 (49.5%) cases were classified as 'well-documented' reports. When classified by sender, 6240 out of 8257 cases (75.6%) from medical institutions were 'well-documented', while 205,534 out of 419,540 cases (49.0%) from pharmaceutical companies were categorized as such. 'Time-to-onset' could not be calculated in 173,027 (41.2%) cases from the pharmaceutical companies and in 1228 (14.9%) cases from medical institutions. Conclusion In the JADER, the proportion of 'well-documented' adverse drug reaction reports from medical institutions was higher than that from pharmaceutical companies, and reports from medical institutions could help to clarify generated safety signals. We also found that more than 40% of the reports from pharmaceutical companies did not include information that is considered essential for the evaluation of any causal relationship between suspected drugs and adverse drug reactions, which could pose challenges to the detection of safety signals.
インソースCIDを利用したLC-MS/MSによる向精神薬の同時測定法の構築に向けた基礎的検討

鈴鹿雅人, 前川正充, 小林大典, 岩渕理子, 佐藤祐司, 塚本多矩, 早川禎宏, 高崎新也, 小倉次郎, 菊地正史, 眞野成康

日本精神薬学会誌　3　(2)　65-65　2020/03
Publisher: (一社)日本精神薬学会
eISSN： 2435-9920
第4回臨床化学の進歩が変える薬物治療〜解析技術の革新と臨床応用〜質量分析法を基盤とするニーマンピック病C型の新規バイオマーカー探索

前川正充, 眞野成康

日本薬学会年会要旨集　140年会　S01-5　2020/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
LC/MS/MSを用いるクロザピンおよび脱メチル代謝物の血漿中濃度測定法の構築

佐藤紀宏, 鈴鹿雅人, 小林大典, 岩渕理子, 今野壮太, 佐藤祐司, 塚本多矩, 早川禎宏, 高崎新也, 小倉次郎, 菊地正史, 前川正充, 眞野成康

日本薬学会年会要旨集　140年会　26Q-pm025　2020/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Stimulatory effect on the transport mediated by organic anion transporting polypeptide 2B1. International-journal Peer-reviewed

Jiro Ogura, Hiroaki Yamaguchi, Nariyasu Mano

Asian journal of pharmaceutical sciences　15　(2)　181-191　2020/03

DOI： 10.1016/j.ajps.2019.10.004 　

More details Close

Drug-drug interaction (DDI) is one of causes of adverse drug events and can result in life-threatening consequences. Organic anion-transporting polypeptide (OATP) 2B1 is a major uptake transporter in the intestine and contributes to transport various clinically used therapeutic agents. The intestine has a high risk of DDI, because it has a special propensity to be exposed to a high concentration of drugs. Thus, understanding drug interaction mediated by OATP2B1 in the absorption process is important for the prevention of adverse drug events, including decrease in the therapeutic effect of co-administered drugs. Acute drug interaction occurs through the direct inhibitory effect on transporters, including OATP2B1. Moreover, some compounds such as clinically used drugs and food components have an acute stimulatory effect on transport of co-administered drugs by OATP2B1. This review summarizes the acute stimulatory effect on the transport mediated by OATP2B1 and discusses the mechanisms of the acute stimulatory effects of compounds. There are two types of acute stimulatory effects, substrate-independent and -dependent interactions on OATP2B1 function. The facilitating translocation of OATP2B1 to the plasma membrane is one of causes for the substrate-independent acute stimulatory effect. On the contrary, the substrate-dependent effect is based on the direct binding to the substrate-binding site or allosteric progesterone-binding site of OATP2B1.
Antidepressant prescriptions for prenatal and postpartum women in Japan: A health administrative database study. International-journal Peer-reviewed

Tomofumi Ishikawa, Taku Obara, Saya Kikuchi, Natsuko Kobayashi, Keiko Miyakoda, Hidekazu Nishigori, Hiroaki Tomita, Manabu Akazawa, Nobuo Yaegashi, Shinichi Kuriyama, Nariyasu Mano

Journal of affective disorders　264　295-303　2020/03/01

DOI： 10.1016/j.jad.2020.01.016 　

More details Close

BACKGROUND: The prevalence and pattern of perinatal antidepressant prescriptions in Japan are unknown. METHODS: The prevalence of antidepressant prescriptions between 180 days before pregnancy onset and 180 days postpartum was evaluated using a large administrative database. The dates of pregnancy onset and delivery were estimated using developed algorithms. RESULTS: Of 33,941 women, at least one antidepressant was prescribed to 451 (133/10,000 deliveries) between 180 days before pregnancy and 180 days postpartum and to 241 (71/10,000 deliveries) during pregnancy. The prevalence of antidepressant prescriptions decreased during the first and second trimesters and increased in the postpartum period. Of 339 women with antidepressant prescriptions before pregnancy, 151 (44.5%) discontinued it during pregnancy. Selective serotonin-reuptake inhibitors were the most frequently prescribed class of antidepressants in the time period studied (356 women, 105/10,000 deliveries), followed by tricyclic/non-tricyclic antidepressants (101 women, 30/10,000 deliveries). Of the 57 women who had at least one record of paroxetine prescription in the first trimester, 13 (22.8%) were prescribed >25 mg/day. Fifty-seven women (17/10,000 deliveries) were concurrently prescribed two or more classes of antidepressants between 180 days before pregnancy and 180 days postpartum. LIMITATIONS: It may not always have been the case that the prescribed antidepressants were used. Women whose pregnancy ended in an abortion or stillbirth were not included. CONCLUSIONS: Various antidepressants were prescribed to prenatal and postpartum women in Japan. Approximately half of pregnant women discontinued treatment with antidepressants after becoming pregnant. Women of childbearing age should select an appropriate antidepressant considering the risk/benefit profile.
Quality evaluation of the Japanese Adverse Drug Event Report database (JADER). International-journal Peer-reviewed

Masami Tsuchiya, Taku Obara, Takamasa Sakai, Kaori Nomura, Chizuko Takamura, Nariyasu Mano

Pharmacoepidemiology and drug safety　29　(2)　173-181　2020/02

DOI： 10.1002/pds.4944 　

ISSN： 1053-8569

More details Close

INTRODUCTION: The spontaneous adverse drug reaction (ADR) reporting system plays an important role in pharmacovigilance by providing information from clinical settings in the postmarketing environment. The Japanese Adverse Drug Event Report (JADER) database contains a portion of Japanese ADR reports, and no previous study has described the quality or characteristics of ADR reports in the JADER. OBJECTIVE: The aim of this study was to identify the characteristics of the JADER database and to evaluate the quality of ADR reports contained in the JADER using the documentation-grading scheme developed by the World Health Organization. METHODS: Of 478 508 ADR reports in the JADER, the analysis set consisted of 395 091 reports meeting inclusion criteria. An analysis was carried out to evaluate the quality of the reports according to the type of report, the type of sender, and the qualification of the reporter. Annual changes in the number of reports from medical institutions submitted by pharmacists were compared with changes in the number submitted by physicians. RESULTS: The distribution of documentation grade differed according to the type of report, the type of sender, and the qualification of the reporter. Regarding "medical institution reports", the quality of reports was similar among qualification types, while the quality of reports submitted by physicians was higher for "company reports" and "study reports" (P < .0001, respectively). CONCLUSION: Our study showed that the quality of the ADR reports in the JADER differed among the type of report, the sender of the report, and the qualification of the reporter.
Update on the prevalence and determinants of folic acid use in Japan evaluated with 91,538 pregnant women: the Japan Environment and Children's Study. International-journal Peer-reviewed

Tomofumi Ishikawa, Taku Obara, Hidekazu Nishigori, Toshie Nishigori, Hirohito Metoki, Mami Ishikuro, Nozomi Tatsuta, Satoshi Mizuno, Kasumi Sakurai, Ichiko Nishijima, Yuriko Murai, Ikuma Fujiwara, Takahiro Arima, Kunihiko Nakai, Nobuo Yaegashi, Shinichi Kuriyama, Nariyasu Mano

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians　33　(3)　427-436　2020/02

DOI： 10.1080/14767058.2018.1494712 　

ISSN： 1476-7058

More details Close

Objective: To provide the latest and most promising evidence on the prevalence and determinants for folic acid supplementation in pregnant women in Japan, including differences in prevalence between interview years and determinants across regions.Materials and methods: The study participants were enrolled from 15 regional centers across Japan between January 2011 and March 2014. Information on the use of folic acid supplementation before and during pregnancy and the characteristics of the participants were collected using questionnaires, medical chart reviews, and interviews by research coordinators.Results: Data for 91,538 women who provided sufficient data on folic acid supplementation were analyzed. The prevalence of adequate users was 8.0%, which, although low, tended to improve over the 4-year recruitment period. Various kinds of sociodemographic factors, lifestyle habits, and obstetrical and medication use history were significant and independent determinants for folic acid use. Associations between adequate preconception folic acid use and its major determinants tended to be similar across regions.Conclusions: Although the prevalence of adequate folic acid use was low, it increased from 2011 to 2014. Reproductive-aged women who have determinants for inadequate folic acid use should be informed about the need for preconception folic acid supplementation to help prevent neural tube defects.
Development of a diagnostic screening strategy for Niemann–Pick diseases based on simultaneous liquid chromatography/tandem mass spectrometry analyses of N-palmitoyl-O-phosphocholine-serine and sphingosylphosphorylcholine Peer-reviewed

Anna Iwahori, Masamitsu Maekawa, Aya Narita, Akie Kato, Toshihiro Sato, Jiro Ogura, Yu Sato, Masafumi Kikuchi, Atsuko Noguchi, Katsumi Higaki, Torayuki Okuyama, Tsutomu Takahashi, Yoshikatsu Eto, Nariyasu Mano

Biological and Pharmaceutical Bulletin　43　(9)　1398-1406　2020
Publisher: Pharmaceutical Society of Japan
DOI： 10.1248/bpb.b20-00400 　

ISSN： 0918-6158

eISSN： 1347-5215

More details Close

Early diagnosis of Niemann-Pick diseases (NPDs) is important for better prognosis of such diseases. N-Palmitoyl-O-phosphocholine-serine (PPCS) is a new NPD biomarker possessing high sensitivity, and with its combination with sphingosylphosphocholine (SPC) it may be possible to distinguish NPD-C from NPD-A/B. In this study, a rapid liquid chromatography-tandem mass spectrometry (LC-MS/MS) method (method 1) and a validated LC-MS/MS analysis (method 2) of PPCS and SPC were developed, and we have proposed a diagnostic screening strategy for NPDs using a combination of serum PPCS and SPC concentrations. Nexera and API 5000 were used as LC-MS/MS systems. C18 columns with lengths of 10 and 50 mm were used for method 1 and 2, respectively. 2H3-Labeled PPCS and nor-SPC were used as internal standards. Selective reaction monitoring in positive-ion mode was used for MS/MS. Run times of 1.2 and 8 min were set for methods 1 and 2, respectively. In both methods 1 and 2, two analytes showed high linearity in the range of 1-4000 ng/mL. Method 2 provided high accuracy and precision in method validation. Serum concentrations of both analytes were significantly higher in NPD-C patients than those of healthy subjects in both methods. Serum PPCS correlated between methods 1 and 2; however, it was different in the case of SPC. The serum PPCS/SPC ratio was different in healthy subjects, NPD-C, and NPD-A/B. These results suggest that using a combination of the two LC-MS/MS analytical methods for PPCS and SPC is useful for diagnostic screening of NPDs.
Importance of Therapeutic Drug Monitoring to Detect Drug Interaction between Pazopanib and Warfarin: A Case Report. International-journal Peer-reviewed

Shinya Takasaki, Hisanobu Adachi, Yoshihide Kawasaki, Masafumi Kikuchi, Akihiro Ito, Nariyasu Mano

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques　23　200-205　2020

DOI： 10.18433/jpps30868 　

More details Close

Pazopanib is an orally available multi-tyrosine kinase inhibitor and has been used to treat renal cell carcinoma (RCC). Here, we report the case of a patient with RCC with an increased prothrombin time- international normalized ratio (PT-INR) due to pazopanib therapy. In addition, we have reported the change in the blood levels of pazopanib. A 75-year-old man underwent a left nephrectomy for RCC. Four years later, his cancer recurred and pazopanib therapy was initiated. He was also taking warfarin for atrial fibrillation and his PT-INR was constant at approximately 2. His warfarin dose was reduced from 3.5 mg/day to 3.0 mg/day on day 10 because his PT-INR increased from 2.19 to 3.07 compared to that before starting pazopanib. On day 28, his PT-INR further increased to 4.34, and his aspartate aminotransferase, alanine transaminase, and alkaline phosphatase levels increased. The target concentration of pazopanib was 20.5 to 50.3 µg/mL, but his blood concentrations were 92.1 µg/mL on day 6 and 93.7 µg/mL on day 13. Therefore, both pazopanib and warfarin were discontinued. One week later, his laboratory tests recovered, and hence, warfarin treatment was resumed. However, pazopanib therapy was terminated due to concerns about liver dysfunction. His hepatic dysfunction and increased PT-INR were considered to be due to pazopanib treatment. Pazopanib has been reported to have no effect on the pharmacokinetics of warfarin in clinical patients. In this case, blood levels of pazopanib were abnormally high, possibly causing liver dysfunction and drug interactions, leading to his PT-INR prolongation. TDM monitoring, in addition to the recommended monitoring for pazopanib hepatotoxicity, may help identify patients at risk for drug interactions. For patients receiving concomitant pazopanib and warfarin, close monitoring of PT-INR is warranted.
The present situation of home blood pressure measurement among outpatients in Japan. International-journal Peer-reviewed

Aoi Noda, Taku Obara, Shinya Abe, Shoko Yoshimachi, Michihiro Satoh, Mami Ishikuro, Azusa Hara, Hirohito Metoki, Nariyasu Mano, Takayoshi Ohkubo, Teruaki Goto, Yutaka Imai

Clinical and experimental hypertension (New York, N.Y. : 1993)　42　(1)　67-74　2020

DOI： 10.1080/10641963.2019.1571601 　

ISSN： 1064-1963

More details Close

Objective: To clarify the present situation of home blood pressure (HBP) measurement among Japanese patients.Methods: A nationwide questionnaire survey regarding HBP measurement was conducted on patients aged 20 years or older who had visited 20 community pharmacies to have their prescriptions filled.Results: In total, 76.7% of 1,103 hypertensives and 40.9% of 1,106 normotensives had their own devices for HBP measurement. Compared with normotensives, a higher proportion of hypertensives recognized the guideline-based reference values for HBP and clinic BP. Compared with hypertensives who did not have a physician's recommendation, those who did more often had their own devices, recognized the guideline-based reference values for HBP, and measured HBP every day (70.4%, 1.5%, and 31.6% vs. 91.1%, 6.9%, and 65.4%, respectively). Among 793 hypertensives who measured HBP, a higher proportion of those with a physician's recommendation measured HBP according to optimal guideline-based procedures compared with those without. Among 560 hypertensives who recorded HBP readings, a higher proportion of those with a physician's recommendation (74.6%) showed all HBP readings to their physicians compared with those without (35.3%).Conclusions: Our findings suggest that physicians should recommend measuring HBP in accordance with the Japanese Society of Hypertension guidelines more aggressively, and provide more detailed explanations to patients regarding how to measure HBP.
Drug Prescriptions for Children With ADHD in Japan: A Study Based on Health Insurance Claims Data Between 2005 and 2015. International-journal Peer-reviewed

Makiko Yoshida, Taku Obara, Saya Kikuchi, Michihiro Satoh, Yoshihiko Morikawa, Nobuhiro Ooba, Hiroaki Yamaguchi, Nariyasu Mano

Journal of attention disorders　24　(2)　175-191　2020/01

DOI： 10.1177/1087054719843179 　

ISSN： 1087-0547

More details Close

Objective: The aim of this study is to investigate the trend of prescription drugs for children with ADHD in Japan. Method: Using health insurance claims data of 3,672,951 people between January 2005 and December 2015, we investigated the trend of prescription drugs for 7,856 children with ADHD. Results: After approval in 2007, the proportion of prescriptions for methylphenidate-osmotic-controlled release oral delivery system tablets was 31.4% in 2009 (adjusted odds ratio [AOR] = 2.72; 95% confidence interval [CI] = [2.12, 3.51]) and reached a plateau approximately after 2009 (AOR = 0.96; 95% CI = [0.94, 0.98]). The proportion of prescriptions for atomoxetine increased from 6.1% in 2008 to 21.8% in 2014 (AOR = 1.12; 95% CI = [1.13, 1.18]). The proportion of prescriptions for aripiprazole and ramelteon increased (all trend p < .001). Conclusion: Prescriptions of drugs for children with ADHD have changed. We need to monitor the safety of ADHD medications among children with ADHD.
Comprehensive and semi-quantitative analysis of carboxyl-containing metabolites related to gut microbiota on chronic kidney disease using 2-picolylamine isotopic labeling LC-MS/MS. International-journal Peer-reviewed

Yoshitomi Kanemitsu, Eikan Mishima, Masamitsu Maekawa, Yotaro Matsumoto, Daisuke Saigusa, Hiroaki Yamaguchi, Jiro Ogura, Hiroki Tsukamoto, Yoshihisa Tomioka, Takaaki Abe, Nariyasu Mano

Scientific reports　9　(1)　19075-19075　2019/12/13

DOI： 10.1038/s41598-019-55600-1 　

More details Close

Carboxyl-containing metabolites, such as bile acids and fatty acids, have many important functions and microbiota is involved in the production of them. In the previous study, we found that the chronic kidney disease (CKD) model mice raised under germ-free conditions provided more severe renal damage than the mice with commensal microbiota. However, the precise influence by the microbiome and carboxyl-containing metabolites to the renal functions is unknown. In this study, we aimed to develop a novel chemical isotope labeling-LC-MS/MS method using the 2-picolylamine and its isotopologue and applied the analysis of effects of microbiome and CKD pathophysiology. The developed semi-quantitative method provided the high accuracy not inferior to the absolute quantification. By comparing of four groups of mice, we found that both microbiota and renal function can alter the composition and level of these metabolites in both plasma and intestine. In particular, the intestinal level of indole-3-acetic acid, short-chain fatty acids and n-3 type of polyunsaturated fatty acid, which play important roles in the endothelial barrier function, were significantly lower in germ-free conditions mice with renal failure. Accordingly, it is suggested these metabolites might have a renoprotective effect on CKD by suppressing epithelial barrier disruption.
Investigation of diagnostic performance of five urinary cholesterol metabolites for Niemann-Pick disease type C. International-journal Peer-reviewed

Masamitsu Maekawa, Isamu Jinnoh, Aya Narita, Takashi Iida, Daisuke Saigusa, Anna Iwahori, Hiroshi Nittono, Torayuki Okuyama, Yoshikatsu Eto, Kousaku Ohno, Peter T Clayton, Hiroaki Yamaguchi, Nariyasu Mano

Journal of lipid research　60　(12)　2074-2081　2019/12

DOI： 10.1194/jlr.M093971 　

More details Close

Niemann-Pick disease type C (NPC) is an autosomal recessive disorder characterized by progressive nervous degeneration. Because of the diversity of clinical symptoms and onset age, the diagnosis of this disease is difficult. Therefore, biomarker tests have attracted significant attention for earlier diagnostics. In this study, we developed a simultaneous analysis method for five urinary conjugated cholesterol metabolites, which are potential diagnostic biomarkers for a rapid, convenient, and noninvasive chemical diagnosis, using LC/MS/MS. By the method, their urinary concentrations were quantified and the NPC diagnostic performances were evaluated. The developed LC/MS/MS method showed high accuracy and satisfied all analytical method validation criteria. When the urine of healthy controls and patients with NPC was analyzed, three of five urinary conjugated cholesterol metabolite concentrations corrected by urinary creatinine were significantly higher in the patients with NPC. As a result of receiver operating characteristics analysis, these urinary metabolites might have excellent diagnostic marker performance. 3β-Sulfooxy-7β-hydroxy-5-cholenoic acid showed particularly excellent diagnostic performance with both 100% clinical sensitivity and specificity, suggesting that it is a useful NPC diagnostic marker. The urinary conjugated cholesterol metabolites exhibited high NPC diagnostic marker performance and could be used for NPC diagnosis.
Structural Determination of Lysosphingomyelin-509 and Discovery of Novel Class Lipids from Patients with Niemann-Pick Disease Type C. International-journal Peer-reviewed

Masamitsu Maekawa, Isamu Jinnoh, Yotaro Matsumoto, Aya Narita, Ryuichi Mashima, Hidenori Takahashi, Anna Iwahori, Daisuke Saigusa, Kumiko Fujii, Ai Abe, Katsumi Higaki, Shosei Yamauchi, Yuji Ozeki, Kazutaka Shimoda, Yoshihisa Tomioka, Torayuki Okuyama, Yoshikatsu Eto, Kousaku Ohno, Peter T Clayton, Hiroaki Yamaguchi, Nariyasu Mano

International journal of molecular sciences　20　(20)　2019/10/10

DOI： 10.3390/ijms20205018 　

More details Close

Niemann-Pick disease type C (NPC) is an autosomal recessive disorder caused by the mutation of cholesterol-transporting proteins. In addition, early treatment is important for good prognosis of this disease because of the progressive neurodegeneration. However, the diagnosis of this disease is difficult due to a variety of clinical spectrum. Lysosphingomyelin-509, which is one of the most useful biomarkers for NPC, was applied for the rapid and easy detection of NPC. The fact that its chemical structure was unknown until recently implicates the unrevealed pathophysiology and molecular mechanisms of NPC. In this study, we aimed to elucidate the structure of lysosphingomyelin-509 by various mass spectrometric techniques. As our identification strategy, we adopted analytical and organic chemistry approaches to the serum of patients with NPC. Chemical derivatization and hydrogen abstraction dissociation-tandem mass spectrometry were used for the determination of function groups and partial structure, respectively. As a result, we revealed the exact structure of lysosphingomyelin-509 as N-acylated and O-phosphocholine adducted serine. Additionally, we found that a group of metabolites with N-acyl groups were increased considerably in the serum/plasma of patients with NPC as compared to that of other groups using targeted lipidomics analysis. Our techniques were useful for the identification of lysosphingomyelin-509.
Development of a simultaneous analytical method for five conjugated cholesterol metabolites in urine and investigation of their performance as diagnostic markers for Niemann-Pick disease type C. Peer-reviewed

Maekawa M, Jinnoh I, Narita A, Iida T, Saigusa D, Iwahori A, Nittono H, Okuyama T, Eto Y, Ohno K, Clayton PT, Yamaguchi H, Mano N

Journal of lipid research　60　(12)　2074-2081　2019/10

DOI： 10.1194/jlr.M093971 　

ISSN： 0022-2275
An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy. International-journal Peer-reviewed

Hiroki Tsukamoto, Kanae Kubota, Ayumi Shichiku, Masamitsu Maekawa, Nariyasu Mano, Hideo Yagita, Shoichiro Ohta, Yoshihisa Tomioka

Immunology　158　(2)　136-149　2019/10

DOI： 10.1111/imm.13095 　

More details Close

Immune-checkpoint blockade antibodies have been approved for the treatment of cancer. However, poorly immunogenic tumours are less responsive to such therapies. Agonistic anti-Toll-like receptor 4 (TLR4) monoclonal antibodies (mAbs) activate only cell-surface TLR4; in contrast, lipopolysaccharide (LPS) activates both TLR4 and intracellular inflammatory caspases. In this study, we investigated the adjuvant activity of an anti-TLR4 mAb in T-cell-mediated antitumour immunity. The anti-TLR4 mAb induced the activation of antigen-specific T-cells in adoptive transfer studies. The growth of ovalbumin (OVA)-expressing tumours was significantly suppressed by administration of OVA and the anti-TLR4 mAb in combination, but not individually. The antitumour effect of anti-PD-1 mAb was enhanced in mice administered with OVA plus the anti-TLR4 mAb. The OVA-specific IFN-γ-producing CD8 T-cells were induced by administration of OVA and the anti-TLR4 mAb. The suppression of tumour growth was diminished by depletion of CD8, but not CD4, T-cells. The inflammatory response to the anti-TLR4 mAb was of significantly lesser magnitude than that to LPS, as assessed by NF-κB activation and production of TNF-α, IL-6 and IL-1β. Administration of LPS (at a dose that elicited levels of proinflammatory cytokines comparable to those by the anti-TLR4 mAb) plus OVA induced no or less-marked activation of OVA-specific T-cells and failed to suppress tumour growth in mice. In conclusion, the agonistic anti-TLR4 mAb induces potent CD8 T-cell-dependent antitumour immunity and an inflammatory response of lesser magnitude than does LPS. The agonistic anti-TLR4 mAb has potential as an adjuvant for use in vaccines against cancer.
Estimation of Blood Sirolimus Concentration Based on Tacrolimus Concentration/Dose Normalized by Body Weight Ratio in Lung Transplant Patients. International-journal Peer-reviewed

Masafumi Kikuchi, Kensuke Shigeta, Masaki Tanaka, Shinya Takasaki, Miki Akiba, Hisashi Oishi, Tetsu Sado, Yasushi Matsuda, Masafumi Noda, Yoshinori Okada, Nariyasu Mano, Hiroaki Yamaguchi

Therapeutic drug monitoring　41　(5)　615-619　2019/10

DOI： 10.1097/FTD.0000000000000649 　

ISSN： 0163-4356

More details Close

BACKGROUND: Sirolimus and tacrolimus require accurate drug dosing based on their target blood levels to produce better clinical outcomes, specifically, the avoidance of drug-induced adverse effects and the maintenance of efficacy. However, because the ideal dose of sirolimus and the schedule for measuring its blood levels are unclear in lung transplant patients, an index is required for estimating sirolimus blood concentrations. The aim of this work is to study the correlation between the trough concentration/dose normalized by body weight (C0/D) ratios of sirolimus and tacrolimus in lung transplant patients. METHODS: Thirteen lymphangiomyomatosis patients who underwent lung transplantation and were treated with sirolimus and tacrolimus from February 2015 to July 2018 were divided into 2 groups, one receiving twice-daily (TD, n = 6) and the other once-daily (OD, n = 7) tacrolimus formulations. The correlation between the C0/D ratio of sirolimus and patient background was evaluated using Spearman's rank correlation coefficient. Correlations between sirolimus and tacrolimus C0/D ratios or doses were analyzed by single regression analysis. RESULTS: Significant correlations were found between the C0/D ratios of sirolimus and tacrolimus. The regression equations from the initial data of TD and OD groups at steady state were y = 1.880x + 32.636 (adjusted R = 0.743, P = 0.017) and y = 1.684x + 38.816 (adjusted R = 0.919, P < 0.001), respectively. In addition, the regression equations from all data of TD and OD groups were y = 1.883x + 4.170 (adjusted R = 0.546, P < 0.001) and y = 1.950x + 43.188 (adjusted R = 0.898, P < 0.001), respectively. A significant correlation between the dosage of sirolimus and tacrolimus was observed only in the OD group, with relatively low accuracy. CONCLUSIONS: Blood sirolimus concentrations can be estimated using the C0/D ratio of tacrolimus, suggesting that the C0/D ratio of tacrolimus is an index of required sirolimus dosage and the frequency of blood sirolimus concentration measurements.
Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. International-journal Peer-reviewed

Suga T, Yamaguchi H, Ogura J, Shoji S, Maekawa M, Mano N

Toxicology and applied pharmacology　379　114664-114664　2019/09

DOI： 10.1016/j.taap.2019.114664 　

ISSN： 0041-008X

More details Close

Non-alcoholic steatohepatitis (NASH) is a progressive inflammatory and fibrotic disease. However, the progression mechanism of NASH is not well understood. Bile acids are endogenous molecules that regulate cholesterol homeostasis, lipid solubilization in the intestinal lumen, and metabolic signaling via several receptors. In this study, we investigated the relationship between bile acid composition and NASH-associated fibrosis using a mouse model fed choline-deficient, L-amino-acid-defined, high-fat diet with 0.1% methionine (CDAHFD). C57BL/6 J mice fed CDAHFD developed NASH and fibrosis within few weeks. With the progress of NASH-associated liver fibrosis, altered bile acid composition was observed in the liver, bile, and peripheral plasma. Decreased mRNA levels of bile acid metabolizing enzymes such as Cyp7a1 and Baat were observed in contrast to increased Sult2a1 level in the liver. Increased mRNA levels of Ostβ and Abcc4 and decreased in mRNA levels of Bsep, Abcc2, Ntcp, and Oatp1b2, suggesting that bile acids efflux from hepatocytes into the peripheral plasma rather than into bile. In conclusion, the changes in bile acid metabolizing enzymes and transporters expression, resulting in increasing the total bile acid concentration in the plasma, signify a protection mechanism by the hepatocyte to reduce hepatotoxicity during disease progression to NASH but may promote liver fibrosis.
LC-MS/MSを用いる脂質メディエーター網羅的解析の基礎的検討 Peer-reviewed

横田真希, 前川正充, 福田隼, 眞野成康, 山口浩明

臨床化学　48　(Suppl.1)　290-290　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
Involvement of H⁺-gradient dependent transporter in PGE₂ release from A549 cells. International-journal Peer-reviewed

Tanaka N, Yamaguchi H, Mano N

Prostaglandins, leukotrienes, and essential fatty acids　149　30-36　2019/08

DOI： 10.1016/j.plefa.2019.08.003 　

ISSN： 0952-3278

More details Close

The purpose of this study was to identify the transporter involved in the release of prostaglandin E2 (PGE2). In the present study, transport assays were conducted using membrane vesicles prepared from human lung adenocarcinoma A549 cells, thus enabling identification of the novel exporter present in A549 cells. PGE2 transport into A549 vesicles was higher in the presence of a proton (H+)-gradient, thus suggesting the involvement of PGE2H+ symporter in PGE2 transport. Results from our experiments showed enhanced PGE2 release in A549 cells in the presence of H+-gradient ([H+]extracellular < [H+]intracellular). Moreover, in vesicular transport assays, H+-gradient-dependent transport of PGE2 did not show saturation up to 500 μM PGE2, and 10 mM aromatic monocarboxylic acids (acetylsalicylic acid, salicylic acid, and p-nitrobenzoic acid) significantly inhibited PGE2 transport by 62-70%. These results suggest, the involvement of monocarboxylate transporters in the H+-gradient-dependent PGE2 export.
Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma. International-journal Peer-reviewed

Tomonori Sato, Yoshihide Kawasaki, Masamitsu Maekawa, Shinya Takasaki, Daisuke Saigusa, Hideki Ota, Shuichi Shimada, Shinichi Yamashita, Koji Mitsuzuka, Hiroaki Yamaguchi, Akihiro Ito, Kengo Kinoshita, Seizo Koshiba, Nariyasu Mano, Yoichi Arai

International journal of cancer　145　(2)　484-493　2019/07/15

DOI： 10.1002/ijc.32115 　

ISSN： 0020-7136

More details Close

Renal cell carcinoma (RCC) is a malignant tumor that currently lacks clinically useful biomarkers indicative of early diagnosis or disease status. RCC has commonly been diagnosed based on imaging results. Metabolomics offers a potential technology for discovering biomarkers and therapeutic targets by comprehensive screening of metabolites from patients with various cancers. We aimed to identify metabolites associated with early diagnosis and clinicopathological factors in RCC using global metabolomics (G-Met). Tumor and nontumor tissues were sampled from 20 cases of surgically resected clear cell RCC. G-Met was performed by liquid chromatography mass spectrometry and important metabolites specific to RCC were analyzed by multivariate statistical analysis for cancer diagnostic ability based on area under the curve (AUC) and clinicopathological factors (tumor volume, pathological T stage, Fuhrman grade, presence of coagulation necrosis and distant metastasis). We identified 58 metabolites showing significantly increased levels in tumor tissues, 34 of which showed potential early diagnostic ability (AUC >0.8), but 24 did not discriminate between tumor and nontumor tissues (AUC ≤0.8). We recognized 6 pathways from 9 metabolites with AUC >0.8 and 7 pathways from 10 metabolites with AUC ≤0.8 about malignant status. Clinicopathological factors involving malignant status correlated significantly with metabolites showing AUC ≤0.8 (p = 0.0279). The tricarboxylic acid cycle (TCA) cycle, TCA cycle intermediates, nucleotide sugar pathway and inositol pathway were characteristic pathways for the malignant status of RCC. In conclusion, our study found that metabolites and their pathways allowed discrimination between early diagnosis and malignant status in RCC according to our G-Met protocol.
Preconception folic acid supplementation use and the occurrence of neural tube defects in Japan: A nationwide birth cohort study of the Japan Environment and Children's Study. International-journal Peer-reviewed

Hidekazu Nishigori, Taku Obara, Toshie Nishigori, Mami Ishikuro, Kasumi Sakurai, Tetsuro Hoshiai, Masatoshi Saito, Ikuma Fujiwara, Takahiro Arima, Kunihiko Nakai, Shinichi Kuriyama, Nariyasu Mano, Hirohito Metoki, Nobuo Yaegashi

Congenital anomalies　59　(4)　110-117　2019/07

DOI： 10.1111/cga.12293 　

ISSN： 0914-3505

More details Close

We evaluated the relationship between preconception folic acid supplementation and the occurrence of neural tube defects (NTDs) in offspring, using data from the Japan Environment and Children's Study (a nationwide prospective birth cohort study) database. Of 92 269 participants with single pregnancies, 74 cases (offspring or fetuses) had NTDs, including 32 cases of spina bifida, 24 cases of anencephaly, and 19 cases of encephalocele. A total of 7634 participants (8.27%) used preconception folic acid supplementation, and of these, 621 (0.67%) also took in dietary folic acid at ≥480 μg/day. Multivariate logistic regression analyses demonstrated no association between preconception folic acid supplementation and NTDs in offspring or fetuses (odds ratio [OR] 0.622; 95% confidence interval [CI]: 0.226-1.713). Moreover, the participants who combined preconception folic acid supplement use with dietary folic acid intake ≥480 μg/day demonstrated no incidence of NTDs in offspring or fetuses. Our analysis is limited by the absence of the data on the daily amount of supplementary folic acid intake, requiring careful attention to the interpretation. Additional surveys are required in Japan to resolve those limitations for further comprehensive assessment.
Diagnostic performance evaluation of sulfate-conjugated cholesterol metabolites as urinary biomarkers of Niemann-Pick disease type C. International-journal Peer-reviewed

Maekawa M, Narita A, Jinnoh I, Iida T, Marquardt T, Mengel E, Eto Y, Clayton PT, Yamaguchi H, Mano N

Clinica chimica acta; international journal of clinical chemistry　494　58-63　2019/07

DOI： 10.1016/j.cca.2019.03.1610 　

ISSN： 0009-8981

More details Close

BACKGROUND: Niemann-Pick disease type C (NPC) is an autosomal recessive inherited disorder with progressive neuronal degeneration. Because conventional diagnostic methods are complicated and invasive, biomarker tests have drawn attention. We aimed to evaluate three urinary conjugated cholesterol metabolites as diagnostic biomarkers for NPC. METHODS: Urine samples from 23 patients with NPC, 28 healthy controls, and 7 patients with inherited metabolic disorders were analyzed. 3β-Sulfooxy-7β-N-acetylglucosaminyl-5-cholen-24-oic acid and its glycine and taurine conjugates in urine were quantified by liquid chromatography-tandem mass spectrometry. The diagnostic performance of the three metabolites and their total concentration was evaluated. RESULT: Creatinine-corrected concentrations of three metabolites and their total concentration were all significantly higher in NPC patients (0.0098 < P < .0448). The area under the receiver operating curve for all metabolites exceeded 0.95, the clinical specificity was 92-100%, and the clinical sensitivity was ~95%. In the urine of patients with other inherited metabolic diseases, the concentrations of the metabolites were lower than those in the urine of patients with NPC. CONCLUSION: These conjugated cholesterol metabolites in urine can serve as useful diagnostic markers for noninvasive screening of NPC.
Analysis of membrane transport mechanisms of endogenous substrates using chromatographic techniques. Peer-reviewed

Yamaguchi H, Mano N

Biomedical chromatography : BMC　33　(6)　e4495　2019/06

DOI： 10.1002/bmc.4495 　

ISSN： 0269-3879
Examination of the prescription of antiepileptic drugs to prenatal and postpartum women in Japan from a health administrative database. International-journal Peer-reviewed

Tomofumi Ishikawa, Taku Obara, Kazutaka Jin, Hidekazu Nishigori, Keiko Miyakoda, Masato Suzuka, Yasuko Ikeda-Sakai, Manabu Akazawa, Nobukazu Nakasato, Nobuo Yaegashi, Shinichi Kuriyama, Nariyasu Mano

Pharmacoepidemiology and drug safety　28　(6)　804-811　2019/06

DOI： 10.1002/pds.4749 　

ISSN： 1053-8569

More details Close

PURPOSE: To evaluate the prevalence and patterns of prescriptions of antiepileptic drugs (AEDs) to prenatal and postpartum women in Japan using a large administrative database. METHODS: The dates of pregnancy onset and delivery were estimated using published algorithms and infant birth months. The prevalence of prescribed AEDs, the maximum dose of some AEDs, and the frequency of potential combination therapy with AEDs were evaluated for the 180 days before pregnancy onset, during pregnancy, and at 180-day postpartum. RESULTS: In total, 33 941 pregnant women were eligible for analysis. At least one AED was prescribed to 225 women (66 per 10 000 deliveries) between 180 days before pregnancy and 180-day postpartum and for 135 women (40 per 10 000 deliveries) during pregnancy. The prevalence of AED prescription declined during the first and second trimesters and increased in the third trimester and postpartum. Valproate was the most frequently prescribed drug, followed by clonazepam, lamotrigine, and carbamazepine. Nine (18.4%) of the 49 women with at least one prescription record of valproate in the first trimester were prescribed more than 600 mg/day of valproate. Concerning potential combination therapy, 40 (12 per 10 000 deliveries) concurrently received two or more AEDs between 180 days before pregnancy and 180-day postpartum, respectively, 31 (9 per 10 000 deliveries) women received these drugs during pregnancy. CONCLUSIONS: Various AEDs were prescribed to pregnant Japanese women. Women of reproductive age should select the appropriate AED before becoming pregnant, depending on the risk benefit profile.
Fundamental Study of Behaviors of In-Source Collision Induced Dissociation and Shifting the Linear Range of Calibration Curves of Various Drugs and the Metabolites Used for Therapeutic Drug Monitoring. Peer-reviewed

Maekawa M, Tsukamoto T, Takasaki S, Kikuchi M, Sato Y, Ogura J, Hayakawa Y, Yamaguchi H, Mano N

Chromatography　40　(2)　71-78　2019/05
Characterization of conjugated and unconjugated bile acid transport via human organic solute transporter α/β. Peer-reviewed

Suga T, Yamaguchi H, Ogura J, Mano N

Biochimica et biophysica acta. Biomembranes　1861　(5)　1023-1029　2019/05

DOI： 10.1016/j.bbamem.2019.03.003 　

ISSN： 0005-2736
Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. International-journal Peer-reviewed

Koichi Kikuchi, Daisuke Saigusa, Yoshitomi Kanemitsu, Yotaro Matsumoto, Paxton Thanai, Naoto Suzuki, Koki Mise, Hiroaki Yamaguchi, Tomohiro Nakamura, Kei Asaji, Chikahisa Mukawa, Hiroki Tsukamoto, Toshihiro Sato, Yoshitsugu Oikawa, Tomoyuki Iwasaki, Yuji Oe, Tomoya Tsukimi, Noriko N Fukuda, Hsin-Jung Ho, Fumika Nanto-Hara, Jiro Ogura, Ritsumi Saito, Shizuko Nagao, Yusuke Ohsaki, Satoshi Shimada, Takehiro Suzuki, Takafumi Toyohara, Eikan Mishima, Hisato Shima, Yasutoshi Akiyama, Yukako Akiyama, Mariko Ichijo, Tetsuro Matsuhashi, Akihiro Matsuo, Yoshiaki Ogata, Ching-Chin Yang, Chitose Suzuki, Matthew C Breeggemann, Jurgen Heymann, Miho Shimizu, Susumu Ogawa, Nobuyuki Takahashi, Takashi Suzuki, Yuji Owada, Shigeo Kure, Nariyasu Mano, Tomoyoshi Soga, Takashi Wada, Jeffrey B Kopp, Shinji Fukuda, Atsushi Hozawa, Masayuki Yamamoto, Sadayoshi Ito, Jun Wada, Yoshihisa Tomioka, Takaaki Abe

Nature communications　10　(1)　1835-1835　2019/04/23

DOI： 10.1038/s41467-019-09735-4 　

More details Close

Diabetic kidney disease is a major cause of renal failure that urgently necessitates a breakthrough in disease management. Here we show using untargeted metabolomics that levels of phenyl sulfate, a gut microbiota-derived metabolite, increase with the progression of diabetes in rats overexpressing human uremic toxin transporter SLCO4C1 in the kidney, and are decreased in rats with limited proteinuria. In experimental models of diabetes, phenyl sulfate administration induces albuminuria and podocyte damage. In a diabetic patient cohort, phenyl sulfate levels significantly correlate with basal and predicted 2-year progression of albuminuria in patients with microalbuminuria. Inhibition of tyrosine phenol-lyase, a bacterial enzyme responsible for the synthesis of phenol from dietary tyrosine before it is metabolized into phenyl sulfate in the liver, reduces albuminuria in diabetic mice. Together, our results suggest that phenyl sulfate contributes to albuminuria and could be used as a disease marker and future therapeutic target in diabetic kidney disease.
Development of a Highly Potent Analogue and a Long-Acting Analogue of Oxytocin for the Treatment of Social Impairment-Like Behaviors. International-journal Peer-reviewed

Wataru Ichinose, Stanislav M Cherepanov, Anna A Shabalova, Shigeru Yokoyama, Teruko Yuhi, Hiroaki Yamaguchi, Ayu Watanabe, Yasuhiko Yamamoto, Hiroshi Okamoto, Shinichi Horike, Junpei Terakawa, Takiko Daikoku, Mizuki Watanabe, Nariyasu Mano, Haruhiro Higashida, Satoshi Shuto

Journal of medicinal chemistry　62　(7)　3297-3310　2019/04/11

DOI： 10.1021/acs.jmedchem.8b01691 　

ISSN： 0022-2623

More details Close

The nonapeptide hormone oxytocin (OT) has pivotal brain roles in social recognition and interaction and is thus a promising therapeutic drug for social deficits. Because of its peptide structure, however, OT is rapidly eliminated from the bloodstream, which decreases its potential therapeutic effects in the brain. We found that newly synthesized OT analogues in which the Pro7 of OT was replaced with N-( p-fluorobenzyl)glycine (2) or N-(3-hydroxypropyl)glycine (5) exhibited highly potent binding affinities for OT receptors and Ca2+ mobilization effects by selectively activating OT receptors over vasopressin receptors in HEK cells, where 2 was identified as a superagonist ( EMax = 131%) for OT receptors. Furthermore, the two OT analogues had a remarkably long-acting effect, up to 16-24 h, on recovery from impaired social behaviors in two strains of CD38 knockout mice that exhibit autism spectrum disorder-like social behavioral deficits, whereas the effect of OT itself rapidly diminished.
Effect of Educational Interventions on Adverse Drug Reaction Reporting in a Cancer Institute in Japan: A Questionnaire Study. International-journal Peer-reviewed

Masami Tsuchiya, Akihisa Esashi, Taku Obara, Kyoko Inooka, Nariyasu Mano, Chizuko Takamura

Hospital pharmacy　54　(2)　93-99　2019/04

DOI： 10.1177/0018578718769242 　

ISSN： 0018-5787

More details Close

Background: Limited data regarding knowledge and factors related to understanding the adverse drug reaction (ADR) reporting system of health care professionals are available in Japan. Objective: The objective of this study was to identify factors related to understanding the ADR reporting system in Miyagi Cancer Center and to find ways to increase the number and quality of ADR reports. Methods: Self-administered questionnaire surveys were administered before and after the educational meeting among health care professionals who were working in our hospital during the study period. Subanalyses restricted to nurses were also performed. Main Outcome Measure: Understanding ADR reporting system among healthcare professionals. Results: The percentage of respondents who understood the ADR reporting system in the questionnaire after the educational meeting was significantly higher than that in the questionnaire before the educational meeting. In the questionnaire after the educational meeting, multivariate logistic regression analysis found that having over 30 years of practical experience (odds ratio [OR], 3.852; 95% confidence interval [CI], 1.228-12.081 for 20-29 years, 7.695; 1.650-35.881 for over 30 years), being a physician (8.071; 1.923-33.878), being a pharmacist (18.357; 3.847-87.585), and participating in the educational meeting (5.111; 1.700-15.365) were factors associated with understanding the ADR reporting system. Multivariate logistic regression analysis of the questionnaire results before the educational meeting among nurses showed that working at outpatient departments (8.330; 3.008-23.069) was significantly and independently associated with understanding the ADR reporting system. Conclusions: The present study demonstrated that many years of practical experience, profession (physicians, pharmacists), and educational interventions were associated with good understanding of the ADR reporting system among health care professionals.
Knowledge, Attitudes, and Practice of Hospital Pharmacists Regarding Pharmacovigilance and Adverse Drug Reaction Reporting in Japan Peer-reviewed

Tomonori Kobayashi, Aoi Noda, Taku Obara, Masami Tsuchiya, Kazutoshi Akasaka, Makiko Yoshida, Masaki Matsuura, Mayumi Sato, Yuriko Murai, Hiroaki Yamaguchi, Fumito Tsuchiya, Kenji Kihira, Nariyasu Mano

Hospital Pharmacy　2019

DOI： 10.1177/0018578719851455 　

ISSN： 0018-5787

eISSN： 1945-1253
Limited Sampling Strategy for the Estimation of Mycophenolic Acid and its Acyl Glucuronide Metabolite Area under the Concentration-Time Curve in Japanese Lung Transplant Recipients. International-journal Peer-reviewed

Masaki Tanaka, Masafumi Kikuchi, Shinya Takasaki, Tensei Hirasawa, Kensuke Sigeta, Aoi Noda, Miki Akiba, Yasushi Matsuda, Hisashi Oishi, Tetsu Sado, Masafumi Noda, Yoshinori Okada, Nariyasu Mano, Hiroaki Yamaguchi

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques　22　(1)　407-417　2019

DOI： 10.18433/jpps30505 　

More details Close

PURPOSE: The dose of mycophenolate mofetil (MMF) used to prevent rejection after lung transplantation is often adjusted based on the 12-hour area under the concentration-time curve (AUC0-12) of mycophenolic acid (MPA). A limited sampling strategy (LSS) is useful to define the pharmacokinetic (PK) profiles of MPA and mycophenolic acid acyl glucuronide (AcMPAG). Therefore, this study aimed to design a LSS based on multiple linear regression for estimating the AUC0-12 of MPA and AcMPAG at the minimum blood sampling points in Japanese lung transplant patients with concomitant tacrolimus. METHODS: Forty-five lung transplantation recipients were enrolled in a PK study of MPA, mycophenolic acid glucuronide (MPAG), and AcMPAG. The plasma MPA, MPAG, and AcMPAG concentrations were determined just before and at 0.5, 1, 2, 4, 8, and 12 hours after dosing. The AUC0-12 of MPA and AcMPAG was calculated using a linear trapezoidal rule from the plasma concentration of each blood sampling time. LSS was used to develop models for estimated AUC in the model group (n = 23) and was evaluated in the validation group (n = 22). RESULTS: The best three time-point equation was 4.04 + 1.64·C1 + 3.08·C4 + 5.17·C8 for MPA, and -0.13 + 3.01·C1 + 3.51·C4 + 5.74·C8 for AcMPAG. The prediction errors (PE) and the absolute prediction errors (APE) were within the clinically acceptable ± 5% and 15% range, respectively (MPA: PE = 2.00%, APE = 11.66%, AcMPAG: PE = 0.98%, APE = 14.69%). The percentage of estimated AUC0-12 within ± 15% of the observed AUC0-12 was 77.27% for MPA and 81.82% for AcMPAG. CONCLUSION: LSS using three time-point (C1, C4, and C8) provides the most reliable and accurate simultaneous estimation of the AUC0-12 of MPA and AcMPAG in Japanese lung transplant patients.
Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. International-journal Peer-reviewed

Shinya Takasaki, Hiroaki Yamaguchi, Yoshihide Kawasaki, Masafumi Kikuchi, Masaki Tanaka, Akihiro Ito, Nariyasu Mano

Journal of pharmaceutical health care and sciences　5　6-6　2019

DOI： 10.1186/s40780-019-0135-5 　

More details Close

Background: Everolimus is an oral inhibitor of mammalian target of rapamycin, approved for metastatic renal cell carcinoma (mRCC). Recently, personalized medicine through therapeutic drug monitoring (TDM) is recommended in cancer therapy. In this study, the relationship between everolimus blood concentration and clinical outcomes on a long-term were evaluated in Japanese patients with mRCC. Methods: Patients with mRCC were enrolled following treatment with everolimus at Tohoku University Hospital between April 2012 and December 2016. The relationship between everolimus trough blood concentration on day 8 of everolimus therapy and just before discontinuation or dose reduction, and their adverse events were evaluated. Patients were divided into two groups based on the median of everolimus blood concentration on day 8 of treatment, and the profiles of adverse events, and efficacy [time to treatment failure (TTF) and progression-free survival (PFS)] were evaluated. Results: The median (range) everolimus blood concentrations on day 8 after starting everolimus administration and just before discontinuation or dose reduction were 15.3 (8.1-28.0) ng/mL and 14.8 (6.4-58.4) ng/mL, respectively, with no significant difference between these values (P = 0.3594). Patients (n = 6) with discontinuation or dose reduction following adverse events in everolimus therapy had significantly higher blood concentrations than patients (n = 4) with dose maintenance on both day 8 (median, 18.0 vs 8.2 ng/mL; P = 0.0139) and just before discontinuation or dose reduction (median, 22.9 vs 9.7 ng/mL; P = 0.0142). Median TTF and PFS of the total patients (n = 10) were 96 days (95% confidence interval [CI], 26-288) and 235 days (95% CI, 28-291), respectively. Subgroup analysis showed that TTF of the patients with > 15.3 ng/mL (n = 5) was not significantly different from that of the patients with ≤15.3 ng/mL (n = 5; P = 0.5622). Similarly, PFS of the patients with > 15.3 ng/mL was not significantly different from that of the patients with ≤15.3 ng/mL (P = 0.3436). Conclusions: This study demonstrated the long-term relationship between everolimus blood level and clinical outcomes and adverse events in Japanese patients with mRCC. Thus, TDM in everolimus therapy could be a useful tool for the early prediction of adverse events for Japanese patients with mRCC.
[Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents]. Peer-reviewed

Hiroaki Yamaguchi, Shinya Takasaki, Masafumi Kikuchi, Yoshihide Kawasaki, Yoichi Arai, Nariyasu Mano

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan　139　(6)　911-915　2019
Publisher: The Pharmaceutical Society of Japan
DOI： 10.1248/yakushi.18-00213-2 　

ISSN： 0031-6903

eISSN： 1347-5231

More details Close

Oral molecular-targeted agents are used clinically for the treatment of various types of cancer. However, even when treatment is started at the dosage indicated in the medical package insert, we have experienced many cases in which treatment had to be stopped early owing to the occurrence of serious side effects or an insufficient therapeutic effect. In recent years, a wide range of studies has been conducted on the therapeutic drug monitoring (TDM) of oral molecular-targeted therapeutic agents to prevent serious side effects and maximize the therapeutic effect. In Japan, the TDM of imatinib has been covered by insurance since 2012, and the TDM of sunitinib has been covered since 2018. In contrast, tyrosine kinase inhibitors may have severe side effects, but their TDM is not covered by medical insurance. We aimed to identify a safe, highly effective chemotherapy regimen based on scientific evidence gathered from Japanese patients. We examined the relationship between the plasma concentration of drugs and clinical findings, such as side effects and treatment effects, at our hospital. In this symposium review, we introduce our results based on the treatment of patients with renal cell carcinoma.
Antihypertensives prescribed for pregnant women in Japan: Prevalence and timing determined from a database of health insurance claims. International-journal Peer-reviewed

Tomofumi Ishikawa, Taku Obara, Hidekazu Nishigori, Keiko Miyakoda, Mami Ishikuro, Hirohito Metoki, Takayoshi Ohkubo, Junichi Sugawara, Nobuo Yaegashi, Manabu Akazawa, Shinichi Kuriyama, Nariyasu Mano

Pharmacoepidemiology and drug safety　27　(12)　1325-1334　2018/12

DOI： 10.1002/pds.4654 　

ISSN： 1053-8569

More details Close

PURPOSE: The purpose of the study is to evaluate the status of prescribed antihypertensives primarily during pregnancy, but also before pregnancy and after delivery, using a large claims database in Japan. METHODS: The dates of pregnancy onset and delivery were identified using reported algorithms and the birth months of infants. The prevalence and timing of prescribed antihypertensives during pregnancy were descriptively evaluated. Time trends in prescriptions were evaluated using multivariate logistic regression analyses. We also evaluated the prevalence of antihypertensives prescribed within 180 days before pregnancy and 180 days after delivery among women who were covered by health insurers during the entire period. RESULTS: At least one antihypertensive agent was prescribed for 1144 (2.74%) of 41 693 pregnant women. The most frequently prescribed oral antihypertensive during pregnancy was nifedipine, followed by methyldopa, hydralazine, and furosemide. Drugs targeting the renin-angiotensin system were prescribed for 21 pregnant women (0.05%), including angiotensin II receptor blockers that were prescribed for 19 (0.05%) of them. Nicardipine was the most frequently prescribed injectable antihypertensive during pregnancy, followed by furosemide, hydralazine, and nitroglycerin. Annual prescription trends remained similar except for a significant decrease in those for oral and injectable furosemide and an annual increase in those for organic nitrate. Based on an evaluation of 33 941 pregnant women, the number of prescriptions for antihypertensives increased particularly during the third trimester, then decreased from 91 to 180 days after delivery. CONCLUSIONS: Various types of antihypertensives are prescribed for Japanese pregnant women. The effects of exposing pregnant Japanese women to these agents should be evaluated.
ニーマンピック病C型の尿中診断バイオマーカーとして有用な抱合型コレステロール代謝物

前川正充, 山口浩明, 眞野成康

JSBMS Letters　43　(3)　45-50　2018/11
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma. Peer-reviewed

Shinya Takasaki, Yoshihide Kawasaki, Masafumi Kikuchi, Masaki Tanaka, Masato Suzuka, Aoi Noda, Yuji Sato, Shinichi Yamashita, Koji Mitsuzuka, Hideo Saito, Akihiro Ito, Hiroaki Yamaguchi, Yoichi Arai, Nariyasu Mano

International journal of clinical oncology　23　(5)　936-943　2018/10

DOI： 10.1007/s10147-018-1302-7 　

ISSN： 1341-9625

More details Close

BACKGROUND: The aim was to investigate the relationships between total sunitinib plasma concentrations (sunitinib plus its active metabolite; N-desethyl sunitinib) and clinical outcomes in Japanese patients with metastatic renal cell carcinoma (mRCC). METHODS: Twenty patients with mRCC were enrolled following treatment with sunitinib. To assess safety, the total sunitinib concentration range up to discontinuation of treatment and dosage reduction associated with adverse events within 6 weeks from initiating administration were analyzed. The longest administered sunitinib dosage was defined as the maintenance dose, and the relationship between total sunitinib concentration at the maintenance dosage and sunitinib efficacy was investigated. RESULTS: Total sunitinib concentration was significantly higher in patients who discontinued treatment or had dosage reduction due to adverse events within 6 weeks after initiation of sunitinib than in patients who continued treatment with the initial dosage. The time to treatment failure, progression-free survival, and overall survival were better in patients with total sunitinib concentrations < 50 ng/mL than in those with concentrations ≥ 50 ng/mL. CONCLUSIONS: The present study demonstrated that the effective range of total sunitinib concentration in Japanese patients with mRCC was lower than 50-100 ng/mL which was previously reported. These results indicate that therapeutic drug monitoring could maintain the therapeutic effect of sunitinib while minimizing adverse events by personalizing sunitinib dosages for Japanese patients with mRCC.
Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation. International-journal Peer-reviewed

Watanabe T, Saito T, Rico EMG, Hishinuma E, Kumondai M, Maekawa M, Oda A, Saigusa D, Saito S, Yasuda J, Nagasaki M, Minegishi N, Yamamoto M, Yamaguchi H, Mano N, Hirasawa N, Hiratsuka M

Biochemical pharmacology　156　420-430　2018/10

DOI： 10.1016/j.bcp.2018.09.010 　

ISSN： 0006-2952

More details Close

Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-individual variation in the metabolism of clinically important drugs, including cyclophosphamide, bupropion, methadone and efavirenz (EFZ). In this study, we performed an in vitro analysis of 40 CYP2B6 allelic variant proteins including seven novel variants identified in 1070 Japanese individuals. Wild-type and 39 variant proteins were heterologously expressed in 293FT cells to estimate the kinetic parameters (Km, Vmax, and CLint) of EFZ 8-hydroxylation and 7-ethoxy-4-trifluoromethylcoumarin (7-ETC) O-deethylation activities. The concentrations of CYP2B6 variant holo-enzymes were measured by using carbon monoxide (CO)-reduced difference spectroscopy, and the wild-type and 28 variants showed a peak at 450 nm. The kinetic parameters were measured for the wild-type and 24 variant proteins. The values for the remaining 15 variants could not be determined because the enzymatic activity was not detected at the highest substrate concentration used. Compared to wild-type, six variants showed significantly decreased EFZ 8-hydroxylation CLint values, while these values were significantly increased in another six variants, including CYP2B6.6. Although 7-ETC O-deethylation CLint values of CYP2B6 variants did not differ significantly from that of CYP2B6.1, the CLint ratios obtained for 7-ETC O-deethylation were highly correlated with EFZ 8-hydroxylation. Furthermore, three-dimensional structural modeling analysis was performed to elucidate the mechanism of changes in the kinetics of CYP2B6 variants. Our findings could provide evidence of the specific metabolic activities of the CYP2B6 proteins encoded by these variant alleles.
Functional Characterization of 21 Allelic Variants of Dihydropyrimidine Dehydrogenase Identified in 1070 Japanese Individuals. International-journal Peer-reviewed

Hishinuma E, Narita Y, Saito S, Maekawa M, Akai F, Nakanishi Y, Yasuda J, Nagasaki M, Yamamoto M, Yamaguchi H, Mano N, Hirasawa N, Hiratsuka M

Drug metabolism and disposition: the biological fate of chemicals　46　(8)　1083-1090　2018/08

DOI： 10.1124/dmd.118.081737 　

ISSN： 0090-9556

More details Close

Dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2), encoded by the DPYD gene, is the rate-limiting enzyme in the degradation pathway of endogenous pyrimidine and fluoropyrimidine drugs such as 5-fluorouracil (5-FU). DPD catalyzes the reduction of uracil, thymine, and 5-FU. In Caucasians, DPYD mutations, including DPYD*2A, DPYD*13, c.2846A>T, and c.1129-5923C>G/hapB3, are known to contribute to interindividual variations in the toxicity of 5-FU; however, none of these DPYD polymorphisms has been identified in the Asian population. Recently, 21 DPYD allelic variants, including some novel single-nucleotide variants (SNVs), were identified in 1070 healthy Japanese individuals by analyzing their whole-genome sequences (WGSs), but the functional alterations caused by these variants remain unknown. In this study, in vitro analysis was performed on 22 DPD allelic variants by transiently expressing wild-type DPD and 21 DPD variants in 293FT cells and characterizing their enzymatic activities using 5-FU as a substrate. DPD expression levels and dimeric forms were determined using immunoblotting and blue-native PAGE, respectively. Additionally, the values of three kinetic parameters-the Michaelis constant (Km ), maximum velocity (Vmax ), and intrinsic clearance (CLint = Vmax/Km )-were determined for the reduction of 5-FU. Eleven variants exhibited significantly decreased intrinsic clearance compared with wild-type DPD. Moreover, the band patterns observed in the immunoblots of blue-native gels indicated that DPD dimerization is required for enzymatic activity in DPD. Thus, the detection of rare DPYD variants might facilitate severe adverse effect prediction of 5-FU-based chemotherapy in the Japanese population.
Development of algorithms to determine the onset of pregnancy and delivery date using health care administrative data in a university hospital in Japan. International-journal Peer-reviewed

Tomofumi Ishikawa, Taku Obara, Hidekazu Nishigori, Keiko Miyakoda, Ryusuke Inoue, Tetsuro Hoshiai, Masatoshi Saito, Nobuo Yaegashi, Nariyasu Mano

Pharmacoepidemiology and drug safety　27　(7)　751-762　2018/07

DOI： 10.1002/pds.4444 　

ISSN： 1053-8569

More details Close

PURPOSE: To develop and assess algorithms to determine the onset of pregnancy and delivery date using health administrative data from a university hospital in Japan. METHODS: All women who were hospitalized in the maternity ward and had at least one pregnancy that ended with a delivery during the period of January 2014 and December 2015 were included in this study. The true delivery date was obtained from the electronic medical records and was used as a gold standard. The onset of pregnancy was calculated by subtracting the gestational age at birth from the delivery date based on the electronic medical records and was also used as a gold standard. The administrative data-based algorithms to identify (1) the onset of pregnancy estimated from the gestational age recorded as part of a diagnosis during a specific visit and (2) the delivery date estimated using the delivery-related diagnosis, procedure, or prescription were compared with the gold-standard data. RESULTS: Of the 1705 women included in this study, the onset of pregnancy was determined in 1704 subjects with 1582 (92.8%) within ± 7 days from the gold-standard date of pregnancy onset. The delivery date was determined in 1654 subjects, and 1594 (96.4%) were within ± 7 days before the true delivery date using the algorithm of "selected" diagnosis and a surgical procedure followed by some other delivery-related data. CONCLUSIONS: The algorithms developed in this study are expected to accelerate future studies for real-world exposure and quantify drug safety during pregnancy using Japanese health care administrative databases.
医薬品情報データベースを活用したこれからの薬剤師業務〜Web上のオープンデータをどう活かすか〜医薬品副作用データベースを薬剤師業務に生かすには JADERを例に Peer-reviewed

土屋雅美, 小原拓, 眞野成康, 高村千津子

日本医薬品情報学会総会・学術大会講演要旨集　21回　64-64　2018/06
Publisher: (一社)日本医薬品情報学会
Simultaneous analysis of oral anticancer drugs for renal cell carcinoma in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. International-journal Peer-reviewed

Shinya Takasaki, Masaki Tanaka, Masafumi Kikuchi, Masamitsu Maekawa, Yoshihide Kawasaki, Akihiro Ito, Yoichi Arai, Hiroaki Yamaguchi, Nariyasu Mano

Biomedical chromatography : BMC　32　(6)　e4184　2018/06

DOI： 10.1002/bmc.4184 　

ISSN： 0269-3879

More details Close

An analytical method using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry has been developed and validated for simultaneous measurement of four tyrosine kinase inhibitors used for renal cell carcinoma and their metabolites in human plasma. Despite their similar structures, it is difficult to measure plasma levels of these compounds simultaneously using optimal MS parameters for each compound because a quantitative range exceeding 50,000-fold is required. To overcome this problem, we used a linear range shift technique using in-source collision-induced dissociation. Linearity ranges of sorafenib, sorafenib N-oxide, sunitinib, N-desethyl sunitinib, axitinib and pazopanib were 100-10,000, 10-1,000, 1-100, 1-100, 1-100 and 500-50,000 ng/mL, respectively. The intra- and inter-day precision and accuracy were high, and coefficients of variation and relative error were <10.3% and within ±11.8%, respectively. The matrix effects of all analytes ranged from 87.7 to 114.8%. Extraction recoveries and overall recoveries showed small extraction loss (<15.0%) for all analytes. Moreover, all cancer patient samples used in this study were successfully quantified and fell within the linear range of measurement. Therefore, this novel analytical system using in-source collision-induced dissociation has sufficient performance to measure plasma concentrations of these four tyrosine kinase inhibitors and their metabolites for therapeutic drug monitoring.
Elevation of plasma lysosphingomyelin-509 and urinary bile acid metabolite in Niemann-Pick disease type C-affected individuals. International-journal Peer-reviewed

Ryuichi Mashima, Masamitsu Maekawa, Aya Narita, Torayuki Okuyama, Nariyasu Mano

Molecular genetics and metabolism reports　15　90-95　2018/06

DOI： 10.1016/j.ymgmr.2018.03.005 　

More details Close

Niemann-Pick disease type C (NPC) is a neurovisceral disorder associated with the accumulation of lipids such as cholesterol and sphingolipids. NPC is caused by either NPC1 or NPC2, which encode lysosomal proteins located at membraneous and soluble fractions, respectively. For the past decade, the oxidation products of cholesterol, such as cholestane-3β,5α,6β-triol and 7-ketocholesterol, have been considered selective biomarkers for NPC. However, recent evidence has indicated numerous novel biomarkers for NPC, which raises the possibility that the diagnosis of NPC might be associated with the elevation of multiple lipid biomarkers, rather than a single biomarker. Sphingosylphosphorylcholine (SPC) has been suggested to be one such biomarker for NPC, in which elevated sphingomyelin is a potential precursor. Thus, we first performed a validation study of plasma SPC using LC-MS/MS. The results showed the following plasma concentrations in the NPC-affected and control individuals, respectively: 8.2 ± 2.8 nM (mean ± SD; median, 7.0 nM; max, 11.7 nM; min, 5.1 nM; n = 5) and 3.1 ± 1.4 nM (median, 2.9 nM; max, 4.8 nM; min, 1.5 nM; n = 7). We further extended the study to plasma lysophingomyelin-509 for NPC, a newly reported biomarker with uncharacterized chemical nature. Based on these result with plasma SPC as a surrogate marker, the value of mean of median of plasma lysophingomyelin-509 in NPC-affected individuals elevated at 65.2 (max, 73.2; min, 26.7; n = 5). Furthermore, the efficacy of plasma SPC and lysosphingomyelin-509 as promising biomarkers for this disorder was supported by the finding that the urinary concentration of 3β-sulfooxy-7β-N-acetylglucosaminyl-5-cholen-24-oic acid, an established biomarker for NPC, was also elevated in the NPC-affected individuals. These results suggest that a novel combination of plasma biomarkers, such as SPC and/or lysophingomyelin-509, and urinary bile acid metabolite could offer a promising platform for the diagnosis of NPC.
Entrainment of the Circadian Clock in Neural Stem Cells by Epidermal Growth Factor is Closely Associated with ERK1/2-mediated Induction of Multiple Clock-related Genes Peer-reviewed

Asuka Mogi, Ryo Yomoda, Syunya Kimura, Chisato Tsushima, Jun Takouda, Miho Sawauchi, Tomoko Maekawa, Hidenobu Ohta, Satoshi Nishino, Masatake Kurita, Nariyasu Mano, Noriko Osumi, Takahiro Moriya

Neuroscience　379　45-66　2018/05/21
Publisher: Elsevier Ltd
DOI： 10.1016/j.neuroscience.2018.02.045 　

ISSN： 1873-7544 0306-4522
フォーカスドメタボロミクスによるニーマンピック病C型の診断マーカー探索

前川正充, 山口浩明, 眞野成康

臨床化学　47　(2)　161-168　2018/04
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics Peer-reviewed

Akihiro Kanaya, Toshihiro Sato, Nobuo Fuse, Hiroaki Yamaguchi, Nariyasu Mano, Masanori Yamauchi

Journal of Anesthesia　32　(2)　236-243　2018/04/01
Publisher: Springer Tokyo
DOI： 10.1007/s00540-018-2470-3 　

ISSN： 1438-8359 0913-8668
Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry. Peer-reviewed

Masayuki Kanamori, Masamitsu Maekawa, Ichiyo Shibahara, Ryuta Saito, Masashi Chonan, Miki Shimada, Yukihiko Sonoda, Toshihiro Kumabe, Mika Watanabe, Nariyasu Mano, Teiji Tominaga

Brain tumor pathology　35　(2)　90-96　2018/04

DOI： 10.1007/s10014-018-0317-0 　

ISSN： 1433-7398

More details Close

The 2016 World Health Organization classification of tumors of the central nervous system was recently revised. Mutations in the isocitrate dehydrogenase 1 (IDH1) and IDH2 genes and chromosome 1p/19q codeletion are especially important for both the integrated diagnosis and the determination of surgical strategy. To establish a method for intraoperative molecular diagnosis, a simple, rapid method was developed for the measurement of 2-hydroxyglutarate (2-HG), a specific oncometabolite formed in the presence of IDH gene mutation, using liquid chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS). This method requires only 10 min to measure the level of 2-HG from tissue preparation to completion of examination. Using this method, the level of 2-HG was analyzed in 105 patients with diffuse infiltrating glioma, and showed that IDH mutated glioma had significantly higher level of 2-HG compared to IDH wild-type glioma. Receiver operating characteristic curve analysis showed the area under the curve, sensitivity, and specificity were 0.9815, 97.5, and 100%, respectively. In contrast, tumor grade and presence of chromosome 1p/19q codeletion in the IDH mutated glioma could not be predicted from the level of 2-HG. Measurement of 2-HG level using LC/ESI-MS/MS can provide rapid and accurate information of mutation status in the IDH gene.
個包装開封後の注射剤を適正に保管管理するツールの作成とその評価 Peer-reviewed

前川麻央, 中川直人, 草場美津江, 尾崎芙実, 松浦正樹, 久道周彦, 村井ユリ子, 眞野成康

医薬品相互作用研究　42　(1)　44-52　2018/02
Publisher: 医薬品相互作用研究会
ISSN： 0385-5015
Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation Peer-reviewed

Masaki Kumondai, Hiroki Hosono, Masamitsu Maekawa, Hiroaki Yamaguchi, Nariyasu Mano, Akifumi Oda, Noriyasu Hirasawa, Masahiro Hiratsuka

Drug Metabolism and Pharmacokinetics　33　(1)　82-89　2018/02/01
Publisher: Japanese Society for the Study of Xenobiotics
DOI： 10.1016/j.dmpk.2017.11.004 　

ISSN： 1880-0920 1347-4367

eISSN： 1880-0920
A Direct Injection LC/ESI-MS/MS Analysis of Urinary Cyclophosphamide as an Anticancer Drug for Monitoring Occupational Exposure Peer-reviewed

Masamitsu MAEKAWA, Masaru MORI, Masachika FUJIYOSHI, Hisaki SUZUKI, Kazunari YANAI, Aoi NODA, Masaki TANAKA, Shinya TAKASAKI, Masafumi KIKUCHI, Kazutoshi AKASAKA, Shigeki KISARA, Masaki MATSUURA, Kanehiko HISAMICHI, Mayumi SATO, Junichi GOTO, Miki SHIMADA, Hiroaki YAMAGUCHI, Nariyasu MANO

CHROMATOGRAPHY　39　(1)　41-47　2018
Publisher: The Society for Chromatographic Sciences
DOI： 10.15583/jpchrom.2017.023 　

ISSN： 1342-8284

eISSN： 1348-3315
Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3 Peer-reviewed

Toshihiro Sato, Hajime Ito, Ayaka Hirata, Takaaki Abe, Nariyasu Mano, Hiroaki Yamaguchi

XENOBIOTICA　48　(1)　73-78　2018

DOI： 10.1080/00498254.2016.1275880 　

ISSN： 0049-8254

eISSN： 1366-5928
Comparison of PETINIA and LC-MS/MS for determining plasma mycophenolic acid concentrations in Japanese lung transplant recipients. International-journal Peer-reviewed

Masafumi Kikuchi, Masaki Tanaka, Shinya Takasaki, Akiko Takahashi, Miki Akiba, Yasushi Matsuda, Masafumi Noda, Kanehiko Hisamichi, Hiroaki Yamaguchi, Yoshinori Okada, Nariyasu Mano

Journal of pharmaceutical health care and sciences　4　7-7　2018

DOI： 10.1186/s40780-018-0101-7 　

More details Close

Background: Mycophenolic acid (MPA) treatment requires therapeutic drug monitoring to improve the outcome after organ transplantation. The aim of this study was to compare two methods, a particle enhanced turbidimetric inhibition immunoassay (PETINIA) and a reference liquid chromatography tandem mass spectrometry (LC-MS/MS) for determining plasma MPA concentrations from Japanese lung transplant recipients. Methods: Plasma MPA concentrations were determined from 20 Japanese lung transplant recipients using LC-MS/MS and the PETINIA on the Dimension Xpand Plus-HM analyzer. Results: The mean MPA concentration measured by PETINIA was significantly higher than that measured by LC-MS/MS (3.26 ± 2.73 μg/mL versus 2.82 ± 2.71 μg/mL, P < 0.0001). The result of the Passing Bablok analysis was a slope of 1.104 (95% confidence interval [CI], 1.036-1.150) and an intercept of 0.229 (95%CI, 0.144-0.315). Bland-Altman analysis revealed PETINIA overestimates plasma MPA concentration by 26.25% and 95%CI from 21.43 to 31.07%. Conclusion: The measurement of MPA by the PETINIA in Japanese lung transplant patients should evaluate the result with attention to positive bias.
Development of a Liquid Chromatography-Tandem Mass Spectrometric Method for Quantification of Mycophenolic Acid and Its Glucuronides in Dried Blood Spot Samples. International-journal Peer-reviewed

Hiromasa Iboshi, Hiroaki Yamaguchi, Hiroyuki Suzuki, Masafumi Kikuchi, Masaki Tanaka, Shinya Takasaki, Akiko Takahashi, Masamitsu Maekawa, Miki Shimada, Yasushi Matsuda, Yoshinori Okada, Nariyasu Mano

Therapeutic drug monitoring　39　(6)　648-653　2017/12

DOI： 10.1097/FTD.0000000000000458 　

ISSN： 0163-4356

More details Close

BACKGROUND: Personalized immunosuppressive therapy, including accurate drug dosing based on the drug blood level, leads to better clinical outcomes, specifically regarding avoidance of drug-induced adverse effects and maintenance of efficacy. Mycophenolic acid (MPA) is used as an immunosuppressant in transplantation of various solid organs. The aim of this study was to develop a method for quantification of MPA and its metabolites, mycophenolic acid 7-O-glucuronide (MPAG) and mycophenolic acid acyl glucuronide, in dried blood spot (DBS) samples, using liquid chromatography/electrospray ionization/tandem mass spectrometry. METHODS: For sample preparation, a microwave-drying approach was used to deactivate enzymes and reduce drying time. Blood volume was calculated in a DBS disk of 3 mm diameter. Concentrations of analytes in plasma from patients receiving mycophenolate mofetil were compared with DBS samples after hematocrit correction. RESULTS: The method yielded good recoveries of all 3 analytes (90.3%-104.2%). Blood volume in the disk was calculated as 3.0 ± 0.2 μL. Linearity over concentration ranges of 0.1-30 mcg/mL MPA, 0.1-200 mcg/mL MPAG, and 0.125-10 mcg/mL mycophenolic acid acyl glucuronide was obtained with r ≥0.999. Intraday and interday variations were less than 14.6%, and accuracy was within ±11.9%. Passing-Bablok analysis showed no significant differences between plasma concentrations and DBS concentrations after hematocrit correction of MPA and MPAG. CONCLUSIONS: We developed and validated a liquid chromatography/electrospray ionization-tandem mass spectrometry method for analysis of MPA in DBS samples. The method is useful for monitoring the MPA blood level.
Functional characterization of 21 allelic variants of dihydropyrimidinase Peer-reviewed

Eiji Hishinuma, Fumika Akai, Yoko Narita, Masamitsu Maekawa, Hiroaki Yamaguchi, Nariyasu Mano, Akifumi Oda, Noriyasu Hirasawa, Masahiro Hiratsuka

BIOCHEMICAL PHARMACOLOGY　143　118-128　2017/11

DOI： 10.1016/j.bcp.2017.06.121 　

ISSN： 0006-2952

eISSN： 1873-2968
ジェネリック薬へ処方変更時の過量投与事故を減らす

田畑雅央, 佐藤真由美, 土肥千秋, 藤盛啓成, 及川千代, 赤坂和俊, 眞野成康, 杉山哲朗, 安田あゆ子, 長尾能雅

医療の質・安全学会誌　12　(Suppl.)　303-303　2017/10
Publisher: (一社)医療の質・安全学会
ISSN： 1881-3658
臨床化学の基盤を支える薬学研究コレステロール代謝物の疾患メタボロミクス

前川正充, 山口浩明, 眞野成康

臨床化学　46　(Suppl.1)　161-161　2017/09
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
5種の硫酸抱合型コレステロール代謝物同時定量法の構築とニーマンピック病C型化学診断への有用性評価

前川正充, 神納勇, 成田綾, 山口浩明, 眞野成康

臨床化学　46　(Suppl.1)　300-300　2017/09
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
Unconjugated bile acids in rat brain: Analytical method based on LC/ESI-MS/MS with chemical derivatization and estimation of their origin by comparison to serum levels Peer-reviewed

Tatsuya Higashi, Shui Watanabe, Koki Tomaru, Wataru Yamazaki, Kazumi Yoshizawa, Shoujiro Ogawa, Hidenori Nagao, Kouichi Minato, Masarnitsu Maekawa, Nariyasu Mano

STEROIDS　125　107-113　2017/09

DOI： 10.1016/j.steroids.2017.07.001 　

ISSN： 0039-128X

eISSN： 1878-5867
Potential Drug Interactions Mediated by Renal Organic Anion Transporter OATP4C1 Peer-reviewed

Toshihiro Sato, Eikan Mishima, Nariyasu Mano, Takaaki Abe, Hiroaki Yamaguchi

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS　362　(2)　271-277　2017/08

DOI： 10.1124/jpet.117.241703 　

ISSN： 0022-3565

eISSN： 1521-0103
Mitochonic Acid 5 (MA-5) Facilitates ATP Synthase Oligomerization and Cell Survival in Various Mitochondrial Diseases Peer-reviewed

Tetsuro Matsuhashi, Takeya Sato, Shin-ichiro Kanno, Takehiro Suzuki, Akihiro Matsuo, Yuki Oba, Motoi Kikusato, Emi Ogasawara, Tai Kudo, Kosuke Suzuki, Osamu Ohara, Hiroko Shimbo, Fumika Nanto, Hiroaki Yamaguchi, Daisuke Saigusa, Yasuno Mukaiyama, Akiko Watabe, Koichi Kikuchi, Hisato Shima, Eikan Mishima, Yasutoshi Akiyama, Yoshitsugu Oikawa, Hsin-Jung Ho, Yukako Akiyama, Chitose Suzuki, Mitsugu Uematsu, Masaki Ogata, Naonori Kumagai, Masaaki Toyomizu, Atsushi Hozawa, Nariyasu Mano, Yuji Owada, Setsuya Aiba, Teruyuki Yanagisawa, Yoshihisa Tomioka, Shigeo Kure, Sadayoshi Ito, Kazuto Nakada, Ken-ichiro Hayashi, Hitoshi Osaka, Takaaki Abe

EBIOMEDICINE　20　27-38　2017/06

DOI： 10.1016/j.ebiom.2017.05.016 　

ISSN： 2352-3964
Activation of the Hypoxia Inducible Factor 1 alpha Subunit Pathway in Steatotic Liver Contributes to Formation of Cholesterol Gallstones Peer-reviewed

Yoichiro Asai, Tetsuya Yamada, Sohei Tsukita, Kei Takahashi, Masamitsu Maekawa, Midori Honma, Masanori Ikeda, Keigo Murakami, Yuichiro Munakata, Yuta Shirai, Shinjiro Kodama, Takashi Sugisawa, Yumiko Chiba, Yasuteru Kondo, Keizo Kaneko, Kenji Uno, Shojiro Sawada, Junta Imai, Yasuhiro Nakamura, Hiroaki Yamaguchi, Kozo Tanaka, Hironobu Sasano, Nariyasu Mano, Yoshiyuki Ueno, Tooru Shimosegawa, Hideki Katagiri

GASTROENTEROLOGY　152　(6)　1521-+　2017/05

DOI： 10.1053/j.gastro.2017.01.001 　

ISSN： 0016-5085

eISSN： 1528-0012
Matrix effect-corrected liquid chromatography/tandem mass-spectrometric method for determining acylcarnitines in human urine Peer-reviewed

Kazuki Abe, Hiroyuki Suzuki, Masamitsu Maekawa, Miki Shimada, Hiroaki Yamaguchi, Nariyasu Mano

CLINICA CHIMICA ACTA　468　187-194　2017/05

DOI： 10.1016/j.cca.2017.03.001 　

ISSN： 0009-8981

eISSN： 1873-3492
Drug Use before and during Pregnancy in Japan: The Japan Environment and Children's Study. International-journal Peer-reviewed

Hidekazu Nishigori, Taku Obara, Toshie Nishigori, Hirohito Metoki, Mami Ishikuro, Satoshi Mizuno, Kasumi Sakurai, Nozomi Tatsuta, Ichiko Nishijima, Ikuma Fujiwara, Takahiro Arima, Kunihiko Nakai, Nariyasu Mano, Shinichi Kuriyama, Nobuo Yaegashi

Pharmacy (Basel, Switzerland)　5　(2)　2017/04/10

DOI： 10.3390/pharmacy5020021 　

More details Close

Purpose: To elucidate drug use before and during pregnancy in Japan. Methods: The Japan Environment and Children's Study (JECS) is an ongoing nationwide birth cohort study. We analyzed data from JECS involving cases where drugs were used for 12 months before pregnancy was diagnosed, between the time of diagnosis of pregnancy until week 12 of pregnancy, and after week 12 of pregnancy. Results: We analyzed data from 97,464 pregnant women. The percentages of pregnant women who had taken one or more drugs and supplements before diagnosis of pregnancy, between the time of diagnosis of pregnancy until week 12 of pregnancy, and after week 12 of pregnancy, were 78.4%, 57.1%, and 68.8% respectively. Excluding iron supplements, folic acid, and other vitamins and minerals, the percentages of women taking supplements were 75.3%, 36.0%, and 51.7% at each respective time point. The following drugs and supplements were frequently used for 12 months before pregnancy diagnosis: Commercially available antipyretics, analgesics, and/or medicine for treating common cold (34.7%), antipyretics, analgesics, and/or medicine for treating common colds, which were prescribed in hospitals (29.8%), antimicrobial drugs (14.0%), and anti-allergy drugs (12.5%). The following drugs and supplements were frequently used from the time of pregnancy diagnosis until week 12 of pregnancy, and after week 12 of pregnancy: folic acid (28.9% and 26.2%), antipyretics, analgesics and/or medicines for treating common cold, that were prescribed in hospitals (7.8% and 13.3%), Chinese herbal medicines (6.0% and 9.4%, and uterine relaxants (5.1% and 15.2%). Conclusions: The analysis of a nationwide cohort study showed that a high percentage of Japanese pregnant women were taking medicinal drugs. Further research is required to elucidate the relationship between drug use during pregnancy and birth defects in Japan.
服薬アセスメント指標の現状と確立の必要性

村井ユリ子, 赤坂和俊, 小原拓, 木皿重樹, 佐藤真由美, 久道周彦, 松浦正樹, 山口浩明, 佐藤博, 富岡佳久, 眞野成康

日本薬学会年会要旨集　137年会　(4)　150-150　2017/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
OATP1B1及びOATP1B3による胆汁酸輸送特性の評価

須賀隆浩, 山口浩明, 佐藤紀宏, 前川正充, 眞野成康

日本薬学会年会要旨集　137年会　(4)　78-78　2017/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
マススペクトロメトリーを駆使した生体分子解析によるバイオメディカル研究の新展開質量分析法を活用したニーマンピック病C型化学診断法の開発

前川正充, 山口浩明, 眞野成康

日本薬学会年会要旨集　137年会　(1)　256-256　2017/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
誘導体化LC/ESI-MS/MSを用いるコレステロール代謝物の網羅的分析系の構築

河俣圭太, 前川正充, 三枝大輔, 小川祥二郎, 東達也, 山口浩明, 眞野成康

日本薬学会年会要旨集　137年会　(2)　285-285　2017/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Prevalence and determinants of inadequate use of folic acid supplementation in Japanese pregnant women: the Japan Environment and Children's Study (JECS) Peer-reviewed

Taku Obara, Hidekazu Nishigori, Toshie Nishigori, Hirohito Metoki, Mami Ishikuro, Nozomi Tatsuta, Satoshi Mizuno, Kasumi Sakurai, Ichiko Nishijima, Yuriko Murai, Ikuma Fujiwara, Takahiro Arima, Kunihiko Nakai, Nariyasu Mano, Nobuo Yaegashi, Shinichi Kuriyama

JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE　30　(5)　588-593　2017/03

DOI： 10.1080/14767058.2016.1179273 　

ISSN： 1476-7058

eISSN： 1476-4954
Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities Peer-reviewed

Hiroki Hosono, Masaki Kumondai, Masamitsu Maekawa, Hiroaki Yamaguchi, Nariyasu Mano, Akifumi Oda, Noriyasu Hirasawa, Masahiro Hiratsuka

DRUG METABOLISM AND DISPOSITION　45　(3)　279-285　2017/03

DOI： 10.1124/dmd.116.073494 　

ISSN： 0090-9556

eISSN： 1521-009X
Severe toxicity induced by accumulation of active sunitinib metabolite in a Japanese patient with renal cell carcinoma: a case report. International-journal Peer-reviewed

Shinya Takasaki, Masafumi Kikuchi, Yoshihide Kawasaki, Akihiro Ito, Yoichi Arai, Hiroaki Yamaguchi, Nariyasu Mano

Journal of medical case reports　11　(1)　28-28　2017/02/01

DOI： 10.1186/s13256-016-1185-z 　

More details Close

BACKGROUND: Sunitinib is a multi-targeted tyrosine kinase inhibitor that is approved for treatment of renal cell carcinoma as an oral anticancer drug. Therapeutic drug monitoring of total sunitinib (sunitinib and N-desethyl sunitinib) is used in our hospital to improve therapeutic efficacy, while preventing adverse effects. Here, we report the first case of a patient with metastatic renal cell carcinoma undergoing hemodialysis and presenting severe adverse events induced by the accumulation of N-desethyl sunitinib. CASE PRESENTATION: A 60-year-old Japanese man was diagnosed with metastatic renal cell carcinoma requiring hemodialysis. On day 26 of the first cycle of sunitinib therapy, our patient presented grade 3 thrombocytopenia and leukopenia, which required interruption of therapy although the plasma levels of total sunitinib in the patient were less than the effective concentration of 50 ng/mL. The elimination half-life of sunitinib was normal at 50.8 hours, but that of N-desethyl sunitinib was an extended 211.4 hours. Moreover, the N-desethyl sunitinib/sunitinib trough level ratio was higher than 1.0. We attribute our patient's severe adverse events to the excessive accumulation of N-desethyl sunitinib owing to its delayed excretion. Although the reason for the delayed excretion of N-desethyl sunitinib in this patient was unknown, it may have been caused by genetic polymorphisms related to the pharmacokinetics of sunitinib rather than the hemodialysis. In this case, the patient was homozygous for the ABCG2 421C allele, but was capable of potentially harboring polymorphisms in other genes, such as ABCB1, an efflux pump of sunitinib. In addition, even though there is no clear evidence, urinary excretion of the metabolic products of N-desethyl sunitinib could be inhibited by the interaction of transporters such as the organic ion transporter. CONCLUSIONS: The monitoring of not only total sunitinib concentration but also N-desethyl sunitinib concentration and their elimination half-lives during sunitinib therapy is recommended to avoid critical adverse events.
Expanding the Versatility of a Quantitative Determination Range Adjustment Technique using In-Source CID in LC/MS/MS

ISHII Hideaki, YAMAGUCHI Hiroaki, MANO Nariyasu

CHROMATOGRAPHY　59-63　2017
Publisher: The Society for Chromatographic Sciences
DOI： 10.15583/jpchrom.2017.004 　

ISSN： 1342-8284

More details Close

The aim of this study was to investigate the applicability of a new technique using in-source collision induced dissociation (CID) for improving quantitative linear range of various compounds in liquid chromatography tandem mass spectrometry (LC/MS/MS). To determine whether the linear range shift due to in-source CID occurs under various MS conditions, we investigated the quantitative linear ranges of reserpine, indomethacin, and furosemide in both electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) in positive- and negative-ion detection modes. We observed 3–30-fold linear range shifts upon changing the declustering potential to adjust in-source CID in positive- and negative-ion detection modes in both ESI and APCI. These results indicated that this new technique could be applied for arbitrary adjustment of linear range regardless of ionization process and polarities in LC/MS/MS. Therefore, this technique could be applied to simultaneous quantification, in biological fluids, of compounds with quite different sensitivities under various MS conditions.
A Rapid and Simple UHPLC-UV Method for Quantitative Determination of Erlotinib and Its Active Metabolite OSI-420 in Human Serum, and Its Application in a Non-Small Cell Lung Cancer Patient Peer-reviewed

Suga Takahiro, Shimada Miki, Maekawa Masamitsu, Suzuki Hiroyuki, Mori Masaru, Okazaki Tatsuma, Inoue Akira, Yamaguchi Hiroaki, Mano Nariyasu

CHROMATOGRAPHY　38　(3)　95-100　2017

DOI： 10.15583/jpchrom.2017.007 　

ISSN： 1342-8284
エベロリムス誘発肝機能障害により血中エベロリムス濃度高値と高血糖を示した腎細胞癌患者の1例

高崎新也, 菊地正史, 川崎芳英, 伊藤明宏, 荒井陽一, 山口浩明, 眞野成康

癌と化学療法　44　(1)　87-89　2017/01
Publisher: (株)癌と化学療法社
ISSN： 0385-0684
Trends in Antihypertensive Drug Prescriptions Based on Claims Data in a Japanese Hospital

Satoh Michihiro, Kurosawa Keiko, Obara Taku, Matsuura Masaki, Inoue Ryusuke, Takahashi Nobuyuki, Sato Hiroshi, Murai Yuriko, Mano Nariyasu

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)　43　(1)　9-17　2017
Publisher: 一般社団法人日本医療薬学会
DOI： 10.5649/jjphcs.43.9 　

ISSN： 1346-342X

eISSN： 1882-1499

More details Close

Details regarding trends in the prescription rates of antihypertensive drugs after 2011 are unclear. Therefore, we compared the prescription rates of antihypertensive drugs in 2009 with those in 2014 using claim records. Data were extracted from claims data provided from April-July 2009 and from April-July 2014 in Tohoku University Hospital, Sendai, Japan. Prescription rates were presented as the percentage of patients who were prescribed each drug. We compared the prescription rates in 2009 (n = 3,954, mean age 63.8 years, men 53.4％) with those in 2014 (n = 5,196, mean age 63.3 years, men 52.9％). The two most prescribed classes of antihypertensive drugs were angiotensin II receptor blockers and calcium channel blockers in both years (≥ 60％). No significant changes in the prescription rates for these two classes were observed between 2009 and 2014. The prescription rate for aldosterone blockers and αβ-blockers increased from 12.6％ and 8.4％ in 2009 to 16.9％ and 13.5％ in 2014 (P < 0.0001), respectively. In contrast, the prescription rate for angiotensin converting enzyme inhibitors and α-blockers decreased from 23.5％ and 10.4％ in 2009 to 15.6％ and 7.7％ in 2014 (P < 0.0001), respectively. The prescription rates for thiazide diuretics, non-thiazide diuretics other than aldosterone blockers, β-blockers, and other classes of antihypertensive did not differ significantly between 2009 and 2014. The prescription rates of antihypertensive drugs have changed based on new evidence regarding the drugs' mechanisms of action on hypertension or their adverse effects.
Preference of Conjugated Bile Acids over Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3 Peer-reviewed

Takahiro Suga, Hiroaki Yamaguchi, Toshihiro Sato, Masamitsu Maekawa, Junichi Goto, Nariyasu Mano

PLOS ONE　12　(1)　e0169719　2017/01

DOI： 10.1371/journal.pone.0169719 　

ISSN： 1932-6203
[A Case of Renal Cell Carcinoma with High Everolimus Blood Concentrations and Hyperglycemia Due to Everolimus-Induced Hepatic Dysfunction]. Peer-reviewed

Shinya Takasaki, Masafumi Kikuchi, Yoshihide Kawasaki, Akihiro Ito, Yoichi Arai, Hiroaki Yamaguchi, Nariyasu Mano

Gan to kagaku ryoho. Cancer & chemotherapy　44　(1)　87-89　2017/01

ISSN： 0385-0684

More details Close

We report the case of a patient who had renal cell carcinoma with high everolimus blood concentrations and hyperglycemia due to everolimus-induced hepatic dysfunction. A 74-year-old man who underwent right nephrectomy for renal cell carcinoma was administered everolimus for multiple lung metastases. Everolimus caused grade 3 hepatic dysfunction and hyperglycemia; hence, high blood levels of everolimus were observed. Although the patient was re-administrated everolimus after recovering from hepatic dysfunction, hepatic function test values worsened again. Everolimus was discontinued before its blood concentration increased, and the patient was switched to axitinib treatment. Therefore, the measurement of everolimus blood level is considered useful for the management of adverse events in renal cell carcinoma.
Multidisciplinary Cooperation for Developing a Chemotherapy Treatment Handbook and Holding of Seminars in Cancer Chemotherapy

菊地正史, 小林美奈子, 中川直人, 木皿重樹, 松浦正樹, 久道周彦, 山田卓郎, 佐々木孝雄, 石岡千加史, 眞野成康

日本病院薬剤師会雑誌 = Journal of Japanese Society of Hospital Pharmacists　52　(12)　1493-1498　2016/12
Publisher: 日本病院薬剤師会
ISSN： 1341-8815
A simultaneous determination method for 5-fluorouracil and its metabolites in human plasma with linear range adjusted by in-source collision-induced dissociation using hydrophilic interaction liquid chromatography-electrospray ionization-tandem mass spectrometry Peer-reviewed

Hideaki Ishii, Miki Shimada, Hiroaki Yamaguchi, Nariyasu Mano

BIOMEDICAL CHROMATOGRAPHY　30　(11)　1882-1886　2016/11

DOI： 10.1002/bmc.3743 　

ISSN： 0269-3879

eISSN： 1099-0801
Prescription trends in children with pervasive developmental disorders: a claims data-based study in Japan. International-journal Peer-reviewed

Michihiro Satoh, Taku Obara, Hidekazu Nishigori, Nobuhiro Ooba, Yoshihiko Morikawa, Mami Ishikuro, Hirohito Metoki, Masahiro Kikuya, Nariyasu Mano

World journal of pediatrics : WJP　12　(4)　443-449　2016/11

DOI： 10.1007/s12519-016-0036-8 　

ISSN： 1708-8569

eISSN： 1867-0687

More details Close

BACKGROUND: The only drug approved for pervasive developmental disorders (PDD) in Japan is pimozide. Several psychotropic drugs are also prescribed for offlabel use in Japan, but details regarding their prescription and use are largely unknown. The purpose of this study was to clarify the use of drug treatment in Japanese children with PDD. METHODS: Data were extracted from claims data from the Japan Medical Data Center for children younger than 18 years of age who were newly diagnosed with PDD (International Classification of Diseases version 10 codes: F84) from 2005 to 2010 (total of 3276 patients as of 2010). The prescription rates were presented as the percentage of PDD patients who were prescribed each drug. RESULTS: Prior to 2010, the prescription rates for atypical antipsychotics, other antipsychotics, psychostimulants, all other central nervous system drugs, anticovnvulsants, non-barbiturates, and Parkinson's disease/syndrome drugs significantly increased among the Anatomical Therapeutic Chemical classifications defined as the "nervous system" (trend P≤0.02). The prescription rate for risperidone consistently increased, reaching 6.9% in 2010 (trend P<0.0001), the highest rate of the surveyed drugs among the antipsychotics. The prescription rate for aripiprazole also increased (trend P<0.0001), reaching 1.9% in 2010. The prescription rate for pimozide showed no annual changes, with a low rate of 0.4% in 2010. CONCLUSION: Compared with pimozide, the prescription rates for risperidone, aripiprazole and other psychotropic drugs have increased. Because safety data for these drugs in Japanese children are sparse, there is a need for future safety evaluations of these drugs in Japanese children.
臨床化学と薬学のクロストークフォーカスドメタボロミクスによるニーマンピック病C型の診断マーカー探索

前川正充, 山口浩明, 眞野成康

臨床化学　45　(Suppl.1)　138-138　2016/10
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
出生児の神経管閉鎖障害リスク低下を目的とした葉酸摂取に関する地域の薬剤師の認識と推奨の割合と要因

浅野二未也, 小原拓, 佐藤倫広, 大原宏司, 山口浩明, 早坂正孝, 眞野成康, 村井ユリ子

医薬品相互作用研究　40　(1-2)　14-20　2016/09
Publisher: 医薬品相互作用研究会
ISSN： 0385-5015
Reference values and associated factors for Japanese newborns' blood pressure and pulse rate: the babies' and their parents' longitudinal observation in Suzuki Memorial Hospital on intrauterine period (BOSHI) study Peer-reviewed

Michihiro Satoh, Ryusuke Inoue, Hideko Tada, Miki Hosaka, Hirohito Metoki, Kei Asayama, Takahisa Murakami, Nariyasu Mano, Takayoshi Ohkubo, Katsuyo Yagihashi, Kazuhiko Hoshi, Masakuni Suzuki, Yutaka Imai

JOURNAL OF HYPERTENSION　34　(8)　1578-1585　2016/08

DOI： 10.1097/HJH.0000000000000976 　

ISSN： 0263-6352

eISSN： 1473-5598
Optimum serum level of mycophenolate mofetil in chronic phase after lung transplantation Peer-reviewed

Matsuda Yasushi, Mitomo Hideki, Onodera Ken, Yabuki Hiroshi, Noda Masafumi, Hoshi Fumihiko, Sakurada Akira, Hoshikawa Yasushi, Akiba Miki, Kikuchi Masafumi, Mano Nariyasu, Okada Yoshinori

TRANSPLANTATION　100　(7)　S827-S827　2016/07

ISSN： 0041-1337

eISSN： 1534-6080
Mitochonic Acid 5 Binds Mitochondria and Ameliorates Renal Tubular and Cardiac Myocyte Damage Peer-reviewed

Takehiro Suzuki, Hiroaki Yamaguchi, Motoi Kikusato, Osamu Hashizume, Satoru Nagatoishi, Akihiro Matsuo, Takeya Sato, Tai Kudo, Tetsuro Matsuhashi, Kazutaka Murayanna, Yuki Ohba, Shun Watanabe, Shin-ichiro Kanno, Daichi Minaki, Daisuke Saigusa, Hiroko Shinbo, Nobuyoshi Mori, Akinori Yuri, Miyuki Yokoro, Eikan Mishima, Hisato Shima, Yasutoshi Akiyama, Yoichi Takeuchi, Koichi Kikuchi, Takafumi Toyohara, Chitose Suzuki, Takaharu Ichimura, Jun-ichi Anzai, Masahiro Kohzuki, Nariyasu Mano, Shigeo Kure, Teruyuki Yanagisawa, Yoshihisa Tomioka, Masaaki Toyomizu, Kohei Tsumoto, Kazuto Nakada, Joseph V. Bonventre, Sadayoshi Ito, Hitoshi Osaka, Ken-ichi Hayashi, Takaaki Abe

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY　27　(7)　1925-1932　2016/07

DOI： 10.1681/ASN.2015060623 　

ISSN： 1046-6673

eISSN： 1533-3450
Identification of novel bile acids as biomarkers for the early diagnosis of Niemann-Pick C disease Peer-reviewed

Francesca Mazzacuva, Philippa Mills, Kevin Mills, Stephane Camuzeaux, Paul Gissen, Elena-Raluca Nicoli, Christopher Wassif, Danielle te Vruchte, Forbes D. Porter, Masamitsu Maekawa, Nariyasu Mano, Takashi Iida, Frances Platt, Peter T. Clayton

FEBS LETTERS　590　(11)　1651-1662　2016/06

DOI： 10.1002/1873-3468.12196 　

ISSN： 1873-3468
The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements Peer-reviewed

Michihiro Satoh, Toshikazu Haga, Miki Hosaka, Taku Obara, Hirohito Metoki, Takahisa Murakami, Masahiro Kikuya, Ryusuke Inoue, Kei Asayama, Nariyasu Mano, Takayoshi Ohkubo, Yutaka Imai

JOURNAL OF HYPERTENSION　34　(6)　1218-1223　2016/06

DOI： 10.1097/HJH.0000000000000902 　

ISSN： 0263-6352

eISSN： 1473-5598
Identification of novel bile acids as biomarkers for the early diagnosis of Niemann-Pick C disease Peer-reviewed

Francesca Mazzacuva, Philippa Mills, Kevin Mills, Stephane Camuzeaux, Paul Gissen, Elena-Raluca Nicoli, Christopher Wassif, Danielle te Vruchte, Forbes D. Porter, Masamitsu Maekawa, Nariyasu Mano, Takashi Iida, Frances Platt, Peter T. Clayton

FEBS Letters　590　(11)　1651-1662　2016/06/01
Publisher: Wiley Blackwell
DOI： 10.1002/1873-3468.12196 　

ISSN： 1873-3468 0014-5793
薬物性肝障害に関与する免疫細胞の解析とin vitroでの病態再現

藤坂泰之, 近藤泰輝, 諸沢樹, 佐々木崇光, 山口浩明, 小暮高之, 井上淳, 嘉数英二, 涌井祐太, 岩田朋晃, 梅津輝行, 高井智, 眞野成康, 永田清, 下瀬川徹

肝臓　57　(Suppl.1)　A166-A166　2016/04
Publisher: (一社)日本肝臓学会
ISSN： 0451-4203

eISSN： 1881-3593
Shifting the Linear Range in Electrospray Ionization by In-Source Collision-Induced Dissociation Peer-reviewed

Hideaki Ishii, Hiroaki Yamaguchi, Nariyasu Mano

CHEMICAL & PHARMACEUTICAL BULLETIN　64　(4)　356-359　2016/04

DOI： 10.1248/cpb.c15-00741 　

ISSN： 0009-2363
本邦の薬剤師におけるファーマコビジランスに関する認識と展望

小原拓, 吉田真貴子, 山口浩明, 赤坂和俊, 松浦正樹, 佐藤真由美, 村井ユリ子, 土屋文人, 北田光一, 眞野成康

日本薬学会年会要旨集　136年会　(4)　229-229　2016/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Home blood pressure level and decline in renal function among treated hypertensive patients: the J-HOME-Morning Study Peer-reviewed

Kazuki Ishikura, Taku Obara, Masahiro Kikuya, Michihiro Satoh, Miki Hosaka, Hirohito Metoki, Hidekazu Nishigori, Nariyasu Mano, Masaaki Nakayama, Yutaka Imai, Takayoshi Ohkubo

HYPERTENSION RESEARCH　39　(2)　107-112　2016/02

DOI： 10.1038/hr.2015.110 　

ISSN： 0916-9636

eISSN： 1348-4214
Trough blood levels of sunitinib for Asian (Japanese) patients with metastatic renal cell carcinoma and therapeutic drug monitoring. Peer-reviewed

Kawasaki Yoshihide, Takasaki Shinnya, Ito Akihiro, Mitsuzuka Koji, Yamashita Shinichi, Kawamorita Naoki, Izumi Hideaki, Adachi Hisanobu, Kaiho Yasuhiro, Tanaka Masaki, Kikuchi Masafumi, Yamaguchi Hiroaki, Mano Nariyasu, Arai Yoichi

JOURNAL OF CLINICAL ONCOLOGY　34　(2)　2016/01/10

DOI： 10.1200/jco.2016.34.2_suppl.508 　

ISSN： 0732-183X
The current statuses and future of the pharmacy services in the emergency department and critical care unit

KATO Takahiro, KUWAHARA Takeshi, SHINOHARA Takao, MINEMURA Atsuko, MANO Nariyasu, NISHIZAWA Kenji, SADAMITSU Daikai, TANAKA Satoshi, WATANABE Akihiro, ODA Jun, ASAKA Emiko, ARUGA Toru, UNEI Hiroko, KABURAGI Morio, KIKUCHI Norikazu

Journal of Japanese Society for Emergency Medicine　19　(6)　725-734　2016
Publisher: 一般社団法人日本臨床救急医学会
ISSN： 1345-0581

eISSN： 2187-9001
Long-Term Stroke Risk Due to Partial White-Coat or Masked Hypertension Based on Home and Ambulatory Blood Pressure Measurements The Ohasama Study Peer-reviewed

Michihiro Satoh, Kei Asayama, Masahiro Kikuya, Ryusuke Inoue, Hirohito Metoki, Miki Hosaka, Megumi Tsubota-Utsugi, Taku Obara, Aya Ishiguro, Keiko Murakami, Ayako Matsuda, Daisaku Yasui, Takahisa Murakami, Nariyasu Mano, Yutaka Imai, Takayoshi Ohkubo

HYPERTENSION　67　(1)　48-55　2016/01

DOI： 10.1161/HYPERTENSIONAHA.115.06461 　

ISSN： 0194-911X

eISSN： 1524-4563
Identification of Two Sulfated Cholesterol Metabolites Found in the Urine of a Patient with Niemann-Pick Disease Type C as Novel Candidate Diagnostic Markers. Peer-reviewed

Maekawa M, Omura K, Sekiguchi S, Iida T, Saigusa D, Yamaguchi H, Mano N

Mass spectrometry (Tokyo, Japan)　5　(2)　S0053　2016

DOI： 10.5702/massspectrometry.S0053 　

ISSN： 2187-137X

More details Close

In the urine of a Niemann-Pick disease type C (NPC) patient, we have identified three characteristic intense peaks that have not been observed in the urine of a 3β-hydroxysteroid-Δ5-C27-steroid dehydrogenase deficiency patient or a healthy infant and adult. Based on accurate masses of the protonated molecules, we focused on two of them as candidate NPC diagnostic markers. Two synthesized authentic preparations agreed with the two compounds found in NPC patient urine in regard to both chromatographic behavior and accurate masses of the deprotonated molecules. Moreover, the isotopic patterns of the deprotonated molecules, twin peaks unique to the sulfur-containing compounds appearing in their second isotope positions, and accurate masses of product ions observed at m/z 97 also agreed between the target compounds and authentic preparations. We identified the two compounds as the sulfated cholesterol metabolites as 3β-sulfooxy-7β-hydroxy-5-cholen-24-oic acid and 3β-sulfooxy-7-oxo-5-cholen-24-oic acid. These two compounds represent more promising candidate diagnostic markers for NPC diagnosis than three other candidates that are multiple conjugates of cholesterol metabolites, 3β-sulfooxy-7β-N-acetylglucosaminyl-5-cholen-24-oic acid and its glycine and taurine conjugates, although we have reported an analytical method for determining the urinary levels of these compounds using liquid chromatography/electrospray ionization tandem mass spectrometry, because of their lack of N-acetylglucosamine conjugation.
Prescription of drugs for children with with attention-defict/hyperactivity disorder (ADHD) in Japan: a study based on health insurance claims data. Peer-reviewed

Obara T, Satoh M, Ooba N, Morikawa Y, Nishigori H, Mano N

Journal of drug interaction research　39　(2)　1-7　2015/12
高機能注射用抗がん薬自動混合調製装置の開発

眞野成康, 久道周彦, 佐藤真由美

薬事新報　(2915)　25-29　2015/11
Publisher: (株)薬事新報社
ISSN： 0289-3290
Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma Peer-reviewed

Miki Shimada, Hoshimi Okawa, Yasuteru Kondo, Takahiro Maejima, Yuta Kataoka, Kanehiko Hisamichi, Masamitsu Maekawa, Masaki Matsuura, Yuko Jin, Masaru Mori, Hiroyuki Suzuki, Tooru Shimosegawa, Nariyasu Mano

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　237　(3)　173-182　2015/11

DOI： 10.1620/tjem.237.173 　

ISSN： 0040-8727

eISSN： 1349-3329
ニーマンピック病C型の診断マーカーとしての尿中抱合型コレステロール代謝物の性能評価

前川正充, 成田綾, 大野耕策, 飯田隆, 島田美樹, 山口浩明, 眞野成康

臨床化学　44　(Suppl.1)　253-253　2015/10
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
尿中抱合型コレステロール代謝物によるニーマンピック病C型の化学診断の可能性

前川正充, 飯田隆, 成田綾, 大野耕策, 島田美樹, 山口浩明, 眞野成康

日本先天代謝異常学会雑誌　31　133-133　2015/10
Publisher: 日本先天代謝異常学会
ISSN： 0912-0122
Functional characterization of 12 allelic variants of CYP2C8 by assessment of paclitaxel 6 alpha-hydroxylation and amodiaquine N-deethylation Peer-reviewed

Chiharu Tsukada, Takahiro Saito, Masamitsu Maekawa, Nariyasu Mano, Akifumi Oda, Noriyasu Hirasawa, Masahiro Hiratsuka

DRUG METABOLISM AND PHARMACOKINETICS　30　(5)　366-373　2015/10

DOI： 10.1016/j.dmpk.2015.07.003 　

ISSN： 1347-4367

eISSN： 1880-0920
Prevalence, determinants, and reasons for the non-reporting of adverse drug reactions by pharmacists in the Miyagi and Hokkaido Regions of Japan Peer-reviewed

Taku Obara, Hiroaki Yamaguchi, Michihiro Satoh, Yutaro Iida, Takamasa Sakai, Yoshiko Aoki, Yuriko Murai, Masaki Matsuura, Mayumi Sato, Takayoshi Ohkubo, Ken Iseki, Nariyasu Mano

Adv Pharmacoepidemiol Drug Saf　4　(5)　191　2015/09

DOI： 10.4172/2167-1052.1000191 　
Focused metabolomics using liquid chromatography/electrospray ionization tandem mass spectrometry for analysis of urinary conjugated cholesterol metabolites from patients with Niemann-Pick disease type C and 3-hydroxysteroid dehydrogenase deficiency Peer-reviewed

Masamitsu Maekawa, Miki Shimada, Kousaku Ohno, Masami Togawa, Hiroshi Nittono, Takashi Iida, Alan F. Hofmann, Junichi Goto, Hiroaki Yamaguchi, Nariyasu Mano

ANNALS OF CLINICAL BIOCHEMISTRY　52　(5)　576-587　2015/09

DOI： 10.1177/0004563214568871 　

ISSN： 0004-5632

eISSN： 1758-1001
Bioanalytical insights into mediator lipidomics Peer-reviewed

Kie Kasuga, Takahiro Suga, Nariyasu Mano

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS　113　151-162　2015/09

DOI： 10.1016/j.jpba.2015.02.011 　

ISSN： 0731-7085

eISSN： 1873-264X
Association between N-terminal pro B-type natriuretic peptide and day-to-day blood pressure and heart rate variability in a general population: the Ohasama study Peer-reviewed

Michihiro Satoh, Miki Hosaka, Kei Asayama, Masahiro Kikuya, Ryusuke Inoue, Hirohito Metoki, Megumi Tsubota-Utsugi, Azusa Hara, Takuo Hirose, Taku Obara, Kazuhito Totsune, Haruhisa Hoshi, Nariyasu Mano, Koichi Node, Yutaka Imai, Takayoshi Ohkubo

JOURNAL OF HYPERTENSION　33　(8)　1536-1541　2015/08

DOI： 10.1097/HJH.0000000000000570 　

ISSN： 0263-6352

eISSN： 1473-5598
Salt intake and the validity of a salt intake assessment system based on a 24-h dietary recall method in pregnant Japanese women Peer-reviewed

Michihiro Satoh, Yumi Tanno, Miki Hosaka, Hirohito Metoki, Taku Obara, Kei Asayama, Kazuhiko Hoshi, Masakuni Suzuki, Nariyasu Mano, Yutaka Imai

CLINICAL AND EXPERIMENTAL HYPERTENSION　37　(6)　459-462　2015/08

DOI： 10.3109/10641963.2015.1057832 　

ISSN： 1064-1963

eISSN： 1525-6006
Simultaneous quantification of leukotrienes and hydroxyeicosatetraenoic acids in cell culture medium using liquid chromatography/tandem mass spectrometry Peer-reviewed

Ayako Furugen, Hiroaki Yamaguchi, Nariyasu Mano

BIOMEDICAL CHROMATOGRAPHY　29　(7)　1084-1093　2015/07

DOI： 10.1002/bmc.3395 　

ISSN： 0269-3879

eISSN： 1099-0801
Outcomes of a Long-term Case Review Program during the On-site Training of Pharmacy Students Peer-reviewed

Yuriko Murai, Hiroyuki Suzuki, Masaru Mori, Hidehisa Tasaka, Naoto Suzuki, Miki Shimada, Hiroshi Sato, Noriyasu Hirasawa, Nariyasu Mano, Yoshihisa Tomioka

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN　135　(7)　917-923　2015/07

DOI： 10.1248/yakushi.15-00001 　

ISSN： 0031-6903
Mitochonic Acid 5 (MA-5), a Derivative of the Plant Hormone Indole-3-Acetic Acid, Improves Survival of Fibroblasts from Patients with Mitochondrial Diseases Peer-reviewed

Takehiro Suzuki, Hiroaki Yamaguchi, Motoi Kikusato, Tetsuro Matsuhashi, Akihiro Matsuo, Takeya Sato, Yuki Oba, Shun Watanabe, Daichi Minaki, Daisuke Saigusa, Hiroko Shimbo, Nobuyoshi Mori, Eikan Mishima, Hisato Shima, Yasutoshi Akiyama, Yoichi Takeuchi, Akinori Yuri, Koichi Kikuchi, Takafumi Toyohara, Chitose Suzuki, Masahiro Kohzuki, Jun-ichi Anzai, Nariyasu Mano, Shigeo Kure, Teruyuki Yanagisawa, Yoshihisa Tomioka, Masaaki Toyomizu, Sadayoshi Ito, Hitoshi Osaka, Ken-ichiro Hayashi, Takaaki Abe

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　236　(3)　225-232　2015/07

DOI： 10.1620/tjem.236.225 　

ISSN： 0040-8727

eISSN： 1349-3329
Determination of omega-6 and omega-3 PUFA metabolites in human urine samples using UPLC/MS/MS (vol 407, pg 1625, 2015) Peer-reviewed

Ai Sasaki, Hayato Fukuda, Narumi Shiida, Nobuaki Tanaka, Ayako Furugen, Jiro Ogura, Satoshi Shuto, Nariyasu Mano, Hiroaki Yamaguchi

ANALYTICAL AND BIOANALYTICAL CHEMISTRY　407　(10)　2939-2940　2015/04

DOI： 10.1007/s00216-015-8512-x 　

ISSN： 1618-2642

eISSN： 1618-2650
Determination of omega-6 and omega-3 PUFA metabolites in human urine samples using UPLC/MS/MS Peer-reviewed

Ai Sasaki, Hayato Fukuda, Narumi Shiida, Nobuaki Tanaka, Ayako Furugen, Jiro Ogura, Satoshi Shuto, Nariyasu Mano, Hiroaki Yamaguchi

ANALYTICAL AND BIOANALYTICAL CHEMISTRY　407　(6)　1625-1639　2015/02

DOI： 10.1007/s00216-014-8412-5 　

ISSN： 1618-2642

eISSN： 1618-2650
A Novel Extraction Method Based on a Reversible Chemical Conversion for the LC/MS/MS Analysis of the Stable Organic Germanium Compound Ge-132 Peer-reviewed

Hiroaki Yamaguchi, Yasuhiro Shimada, Tomoya Takeda, Takashi Nakamura, Nariyasu Mano

ANALYTICAL CHEMISTRY　87　(4)　2042-2047　2015/02

DOI： 10.1021/ac504466u 　

ISSN： 0003-2700

eISSN： 1520-6882
Association of Aldosterone-to-Renin Ratio With Hypertension Differs by Sodium Intake: The Ohasama Study Peer-reviewed

Michihiro Satoh, Masahiro Kikuya, Miki Hosaka, Kei Asayama, Ryusuke Inoue, Hirohito Metoki, Megumi Tsubota-Utsugi, Azusa Hara, Takuo Hirose, Taku Obara, Takefumi Mori, Kazuhito Totsune, Haruhisa Hoshi, Nariyasu Mano, Yutaka Imai, Takayoshi Ohkubo

AMERICAN JOURNAL OF HYPERTENSION　28　(2)　208-215　2015/02

DOI： 10.1093/ajh/hpu115 　

ISSN： 0895-7061

eISSN： 1941-7225
P1201-22-PM 向精神薬服用妊婦に対して行った授乳に関する情報提供の現状(妊婦・授乳婦,ポスター発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-) Peer-reviewed

八島一史, 菊地紗耶, 小林奈津子, 久道周彦, 眞野成康, 中川直人, 小原拓, 千葉和美, 山本美由紀, 西郡秀和, 加藤佳子, 松浦正樹, 秋山志津子

日本医療薬学会年会講演要旨集　25　(0)　466-466　2015
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.25.0_466_1 　
Does Camostat Mesilate Improve Abdominal Symptoms and Visceral Pain Sensitivity in Patients with Irritable Bowel Syndrome (IBS)? Peer-reviewed

Kanazawa Motoyori, Morishita Joe, Tanaka Yukari, Inooka Kyoko, Kano Michiko, Hisamichi Kanehiko, Mano Nariyasu, Fukudo Shin

DIGESTION　91　(1)　92　2015

ISSN： 0012-2823
Effects of an evidence-based medicine workshop on Japanese pharmacy students' awareness regarding the importance of reading current clinical literature. Peer-reviewed

Nakagawa N, Murai Y, Yoshida M, Suzuki H, Mano N

Journal of pharmaceutical health care and sciences　1　23　2015

DOI： 10.1186/s40780-015-0024-5 　
Quantification of intracellular and extracellular digoxin and ouabain by liquid chromatography/electrospray ionization tandem mass spectrometry Peer-reviewed

Hiroaki Yamaguchi, Kazuaki Miyamori, Toshihiro Sato, Jiro Ogura, Masaki Kobayashi, Takehiro Yamada, Nariyasu Mano, Ken Iseki

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　972　73-80　2014/12

DOI： 10.1016/j.jchromb.2014.09.043 　

ISSN： 1570-0232

eISSN： 1873-376X
A Survey of Self-medication Practices and Related Factors in the General Population: the Ohasama Study Peer-reviewed

Michihiro Satoh, Akihiro Matsumoto, Azusa Hara, Saki Iwamori, Taku Obara, Masahiro Kikuya, Hirohito Metoki, Miki Hosaka, Kei Asayama, Nobuyuki Takahashi, Hiroshi Sato, Nariyasu Mano, Yutaka Imai, Takayoshi Ohkubo

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN　134　(12)　1347-1355　2014/12

ISSN： 0031-6903
Transport of Eicosapentaenoic Acid-Derived PGE(3), PGF(3 alpha), and TXB3 by ABCC4 Peer-reviewed

Nobuaki Tanaka, Hiroaki Yamaguchi, Nariyasu Mano

PLOS ONE　9　(10)　e109270　2014/10

DOI： 10.1371/journal.pone.0109270 　

ISSN： 1932-6203
Quantification of intracellular and extracellular eicosapentaenoic acid-derived 3-series prostanoids by liquid chromatography/electrospray ionization tandem mass spectrometry Peer-reviewed

Nobuaki Tanaka, Hiroaki Yamaguchi, Ayako Furugen, Jiro Ogura, Masaki Kobayashi, Takehiro Yamada, Nariyasu Mano, Ken Iseki

PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS　91　(3)　61-71　2014/09

DOI： 10.1016/j.plefa.2014.04.005 　

ISSN： 0952-3278

eISSN： 1532-2823
分子標的薬の相互作用臨床現場からの発信

島田美樹, 眞野成康

医薬品相互作用研究　38　(1)　71-71　2014/08
Publisher: (一社)医薬品相互作用研究会
ISSN： 0385-5015
Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation International-journal Peer-reviewed

Takahashi, M, Saito, T, Ito, M, Tsukada, C, Katono, Y, Hosono, H, Maekawa, M, Shimada, M, Mano, N, Oda, A, Hirasawa, N, Hiratsuka, M

Pharmacogenomics J.　2014　(1)　26-32　2014/06/08

DOI： 10.1038/tpj.2014.30 　

More details Close

Genetic variations in cytochrome P450 2C19 (CYP2C19) contribute to interindividual variability in the metabolism of therapeutic agents such as clopidogrel. Polymorphisms in CYP2C19 are associated with large interindividual variations in the therapeutic efficacy of clopidogrel. This study evaluated the in vitro oxidation of clopidogrel by 21 CYP2C19 variants harboring amino acid substitutions. These CYP2C19 variants were heterologously expressed in COS-7 cells, and the kinetic parameters of clopidogrel 2-oxidation were estimated. Among the 21 CYP2C19 variants, 12 (that is, CYP2C19.5A, CYP2C19.5B, CYP2C19.6, CYP2C19.8, CYP2C19.9, CYP2C19.10, CYP2C19.14, CYP2C19.16, CYP2C19.19, CYP2C19.22, CYP2C19.24 and CYP2C19.25) showed no or markedly low activity compared with the wild-type protein CYP2C19.1B. This comprehensive in vitro assessment provided insights into the specific metabolic activities of CYP2C19 proteins encoded by variant alleles, and this may to be valuable when interpreting the results of in vivo studies.
A Quantitative HPLC-UV Method for Determination of Serum Sorafenib and Sorafenib N-Oxide and Its Application in Hepatocarcinoma Patients Peer-reviewed

Miki Shimada, Hoshimi Okawa, Takahiro Maejima, Toshiki Yanagi, Kanehiko Hisamichi, Masaki Matsuura, Kazutoshi Akasaka, Masami Tsuchiya, Yasuteru Kondo, Tooru Shimosegawa, Masaru Mori, Masamitsu Maekawa, Hiroyuki Suzuki, Nariyasu Mano

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　233　(2)　103-112　2014/06

DOI： 10.1620/tjem.233.103 　

ISSN： 0040-8727

eISSN： 1349-3329
A Quantitative HPLC-UV Method for Determination of Serum Sorafenib and Sorafenib N-Oxide and Its Application in Hepatocarcinoma Patients Peer-reviewed

Miki Shimada, Hoshimi Okawa, Takahiro Maejima, Toshiki Yanagi, Kanehiko Hisamichi, Masaki Matsuura, Kazutoshi Akasaka, Masami Tsuchiya, Yasuteru Kondo, Tooru Shimosegawa, Masaru Mori, Masamitsu Maekawa, Hiroyuki Suzuki, Nariyasu Mano

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE　233　(2)　103-112　2014/06

DOI： 10.1620/tjem.233.103 　

ISSN： 0040-8727

eISSN： 1349-3329
A NOVEL AND SENSITIVE ASSAY OF KIDNEY HEME OXYGENASE ACTIVITY Peer-reviewed

Saki Iwamori, Emiko Sato, Kouichi Yoshinari, Nariyasu Mano, Sadayoshi Ito, Hiroshi Sato, Nobuyuki Takahashi

NEPHROLOGY　19　185　2014/05

ISSN： 1320-5358
コーチング手法を取り入れた薬学長期実務実習における実習生指導

吉田真貴子, 鈴木裕之, 佐藤祐司, 田坂英久, 島田美樹, 村井ユリ子, 眞野成康

日本薬学会年会要旨集　134年会　(4)　231-231　2014/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
カラムスイッチングUHPLC-UVによるエルロチニブ及び代謝物の血中濃度測定法

須賀隆浩, 前川正充, 森大, 鈴木裕之, 島田美樹, 眞野成康

日本薬学会年会要旨集　134年会　(4)　62-62　2014/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
尿中のカルニチン及びアシルカルニチンとセフジトレンの同時分析法の構築

阿部一樹, 鈴木裕之, 前川正充, 島田美樹, 眞野成康

日本薬学会年会要旨集　134年会　(4)　63-63　2014/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
[Quantitative analysis of clinical samples using tandem mass spectrometers]. Peer-reviewed

Chiba H, Mano N

Rinsho byori. The Japanese journal of clinical pathology　62　(3)　267-268　2014/03

ISSN： 0047-1860
[Fundamental knowledge and master of mass spectrometry: important reminder and pitfall in quantitative analysis]. Peer-reviewed

Mano N

Rinsho byori. The Japanese journal of clinical pathology　62　(3)　269-275　2014/03
Publisher:
ISSN： 0047-1860
Tandem mass spectrometric characterization of bile acids and steroid conjugates based on low-energy collision-induced dissociation Peer-reviewed

Masamitsu Maekawa, Miki Shimada, Takashi Iida, Junichi Goto, Nariyasu Mano

STEROIDS　80　80-91　2014/02

DOI： 10.1016/j.steroids.2013.11.016 　

ISSN： 0039-128X

eISSN： 1878-5867
An accurate quantitative HPLC-UV method for determination of sorafenib and sorafenib N-oxide in human serum Peer-reviewed

Shimada M, Okawa H, Maejima T, Yanagi T, Hisamichi K, Matsuura M, Akasaka K, Tsuchiya M, Kondo Y, Shimosegawa T, Mori M, Maekawa M, Suzuki H, Mano N

Tohoku J Exp Med. 2014;233(2):103-12.　2014

DOI： 10.1620/tjem.233.103 　
Comparison of Drug Information Practice Experience between Tohoku University Hospital Pharmacy in Japan and College of Pharmacy at Nova Southeastern University in the United States

Nakagawa Naoto, Mano Nariyasu, Kusaba Mizue, Ozaki Fumi, Maekawa Mao, Matsuura Masaki, Hisamichi Kanehiko, Murai Yuriko, Gershman Jennifer, Lai Leanne

Iyakuhin Johogaku　16　(3)　143-151　2014
Publisher: 一般社団法人日本医薬品情報学会
DOI： 10.11256/jjdi.16.143 　

ISSN： 1345-1464

More details Close

Objective: This study aimed to enhance Drug Information Practice Experiences (DIPE) in Japan by comparing DIPEs at Tohoku University Hospital (TUH) with Nova Southeastern University (NSU) in the United States, and propose an advanced model of drug information (DI) education in Japan. Methods: We performed the following: (i) comparison of both DIPEs based on Model Core Curriculum (MCC) content; (ii) identification of practices which were not part of NSU or TUH DIPE; (iii) comparison of students&rsquo; DIPE performance based on MCC: (A) students&rsquo; performance without the preceptors and their post-performance approval, (A&rsquo;) students&rsquo; performance without the preceptors and their pre-performance approval, and (B) students&rsquo; performance under direct preceptor supervision; (iv) highlighting differences between TUH and NSU DIPEs; and (v) proposing an advanced model of DI education in Japan. Results: (i) The NSU DIPE is similar to the MCC.&nbsp;&nbsp;An example difference between NSU and TUH learning strategies was that NSU students responded to the inquiries made by the phone whereas TUH students receive assignments and explanation from preceptors.&nbsp;&nbsp;(ii) DIPE at NSU utilized oral presentations and student interaction in many forms (e.g. journal club, reflection regarding learned topics).&nbsp;&nbsp;On the other hand, DIPE at TUH helped students learn about Medical Representative jobs and educated them in tablet/capsule identification practices.&nbsp;&nbsp;(iii) In contrast, the TUH curriculum limits students&rsquo; performance to &ldquo;experience via dissemination with health professional needs and patients&rsquo; needs&rdquo;.&nbsp;&nbsp;(iv) These clarified points are considered to be differences between DIPE at TUH and NSU.&nbsp;&nbsp;(v) Following analysis of these points, an advanced model of DI education based on responses to DI phone inquiries and oral presentations including a journal club was proposed. Conclusions: This study will contribute to improving DI education in Japan.
Organic Anion Transporting Polypeptides 1B1 and 1B3 Play an Important Role in Uremic Toxin Handling and Drug-Uremic Toxin Interactions in the Liver Peer-reviewed

Toshihiro Sato, Hiroaki Yamaguchi, Takuma Kogawa, Takaaki Abe, Nariyasu Mano

JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES　17　(4)　475-484　2014

ISSN： 1482-1826
The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis Peer-reviewed

Noha Elnagar, Michihiro Satoh, Miki Hosaka, Kei Asayama, Kazuki Ishikura, Taku Obara, Nariyasu Mano, Takayoshi Ohkubo, Yutaka Imai

CLINICAL AND EXPERIMENTAL HYPERTENSION　36　(2)　83-91　2014

DOI： 10.3109/10641963.2014.892117 　

ISSN： 1064-1963

eISSN： 1525-6006
Aldosterone-to-renin ratio and nocturnal blood pressure decline assessed by self-measurement of blood pressure at home: the Ohasama Study Peer-reviewed

Michihiro Satoh, Miki Hosaka, Kei Asayama, Masahiro Kikuya, Ryusuke Inoue, Hirohito Metoki, Megumi T. Utsugi, Azusa Hara, Takuo Hirose, Taku Obara, Takefumi Mori, Kazuhito Totsune, Haruhisa Hoshi, Nariyasu Mano, Yutaka Imai, Takayoshi Ohkubo

CLINICAL AND EXPERIMENTAL HYPERTENSION　36　(2)　108-114　2014

DOI： 10.3109/10641963.2014.892121 　

ISSN： 1064-1963

eISSN： 1525-6006
LC/ESI-MS/MS analysis of urinary 3 beta-sulfooxy-7 beta-N-acetylglucosaminyl-5-cholen-24-oic acid and its amides: New biomarkers for the detection of Niemann-Pick type C disease Peer-reviewed

Masamitsu Maekawa, Yasushi Misawa, Ayako Sotoura, Hiroaki Yamaguchi, Masami Togawa, Kousaku Ohno, Hiroshi Nittono, Genta Kakiyama, Takashi Iida, Alan F. Hofmann, Junichi Goto, Miki Shimada, Nariyasu Mano

STEROIDS　78　(10)　967-972　2013/10

DOI： 10.1016/j.steroids.2013.05.017 　

ISSN： 0039-128X
An efficient synthesis of 4 alpha- and 4 beta-hydroxy-7-dehydrocholesterol, biomarkers for patients with and animal models of the Smith-Lemli-Opitz syndrome Peer-reviewed

Hiroaki Kawamoto, Yuusuke Ohmori, Masamitsu Maekawa, Miki Shimada, Nariyasu Mano, Takashi Iida

CHEMISTRY AND PHYSICS OF LIPIDS　175　73-78　2013/10

DOI： 10.1016/j.chemphyslip.2013.07.004 　

ISSN： 0009-3084

eISSN： 1873-2941
臨床検査への質量分析の応用治療薬物モニタリングにおける質量分析法の活用

島田美樹, 眞野成康

臨床病理　61　(9)　816-816　2013/09
Publisher: (一社)日本臨床検査医学会
ISSN： 0047-1860
肝がん治療の最前線肝細胞癌患者におけるソラフェニブ投与に伴う副作用発現と薬物動態学的因子の関連

島田美樹, 大川星美, 前嶋隆弘, 近藤泰輝, 下瀬川徹, 久道周彦, 松浦正樹, 眞野成康

日本癌治療学会誌　48　(3)　795-795　2013/09
Publisher: (一社)日本癌治療学会
ISSN： 0021-4671
Influence of the Meal and Genotype of CYP2C19 on the Pharmacokinetics of Proton Pump Inhibitors in Healthy Japanese Subjects Peer-reviewed

Hirohiko Shinkai, Tomoyuki Koike, Miki Shimada, Kenichiro Nakagawa, Katsunori Iijima, Yotaro Matsumoto, Masamitsu Maekawa, Nariyasu Mano, Tooru Shimosegawa

Pharmacology & Pharmacy　4　(6)　502-509　2013/09

DOI： 10.4236/pp.2013.46073 　
東日本大震災後に薬品情報室に寄せられた問い合わせに関する調査

吉中千佳, 尾崎芙実, 小原拓, 草場美津江, 前川麻央, 松浦正樹, 佐賀利英, 中村浩規, 久道周彦, 佐藤真由美, 我妻恭行, 眞野成康

日本病院薬剤師会雑誌　49　(8)　877-881　2013/08
Publisher: (一社)日本病院薬剤師会
ISSN： 1341-8815
Quantitative determination of paclitaxel and its metabolites, 6α-hydroxypaclitaxel and p-3'-hydroxypaclitaxel, in human plasma using column-switching liquid chromatography/tandem mass spectrometry. International-journal Peer-reviewed

Hiroaki Yamaguchi, Asuka Fujikawa, Hajime Ito, Nobuaki Tanaka, Ayako Furugen, Kazuaki Miyamori, Natsuko Takahashi, Jiro Ogura, Masaki Kobayashi, Takehiro Yamada, Nariyasu Mano, Ken Iseki

Biomedical chromatography : BMC　27　(4)　539-44　2013/04

DOI： 10.1002/bmc.2826 　

ISSN： 0269-3879

More details Close

A column-switching liquid chromatography/electrospray ionization tandem mass spectrometry to determine paclitaxel and its metabolites, 6α-hydroxypaclitaxel and p-3'-hydroxypaclitaxel, in human plasma was developed. The analytical system had a Shim-Pack MAYI-ODS (10 × 4.6 mm i.d.) trapping column with deproteinization ability that concentrates analytes and removes water-soluble components. This method covered a linearity range of 5-5000 ng/mL of concentrations in plasma for paclitaxel, a range of 0.87-870 ng/mL for 6α-hydroxypaclitaxel and a range of 0.87-435 ng/mL for p-3'-hydroxypaclitaxel. The intra-day precision and inter-day precision of analysis were less than 11.1%, and the accuracy was within ±14.4% at concentrations of 5, 50, 500 and 5000 ng/mL for paclitaxel, 0.87, 8.7, 87 and 870 ng/mL for 6α-hydroxypaclitaxel, and 0.87, 8.7, 87 and 435 ng/mL for p-3'-hydroxypaclitaxel. The total run time was 30 min. Our method was successfully applied to clinical pharmacokinetic investigation.
腎機能の低下した肝細胞癌患者における血中sorafenib濃度の推移

前嶋隆弘, 大川星美, 近藤泰輝, 久道周彦, 松浦正樹, 下瀬川徹, 島田美樹, 眞野成康

日本薬学会年会要旨集　133年会　(4)　180-180　2013/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
次世代型専門薬剤師育成を目指した大学院教育システムの開発

鈴木直人, 大内麻由, 黒澤真帆, 金光祥臣, 松本周平, 三村享, 三枝大輔, 木皿重樹, 村井ユリ子, 眞野成康, 富岡佳久

日本薬学会年会要旨集　133年会　(4)　242-242　2013/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
[A multicenter trial of regional medical cooperation for cancer chemotherapy after the great East Japan earthquake]. Peer-reviewed

Shoko Akiyama, Yukiko Seya, Motoko Murayama, Kimiyo Ogasawara, Shigeki Kisara, Tadashi Ishii, Michie Sugawara, Yasunori Chida, Mariko Kanbe, Yuichi Kakudo, Nariyasu Mano, Chikashi Ishioka

Gan to kagaku ryoho. Cancer & chemotherapy　40　(3)　343-8　2013/03

ISSN： 0385-0684

More details Close

The Great East Japan Earthquake was the first disaster we experienced after the administration of oncology care had mostly shifted from hospitals to outpatient departments in Japan. Disaster medical assistance teams(DMATs)were deployed immediately after the disaster, and actively assisted during the acute phase of the catastrophe. After experiencing the earthquake, we realized the necessity of medical support teams, even for chronic disease. Here we report a multicenter trial of regional medical cooperation for cancer chemotherapy. First, soon after the earthquake, representatives from the regional hospitals discussed the proper roles for each institution. As agreed to in the discussion, cancer patients were redistributed from a disaster base hospital to a local general hospital, and oncologists supported the other regional hospitals on a regular basis. This broad regional network functioned well and patients resumed their treatment as soon as the situation allowed. Second, we performed a survey of the patients and found that the most important problem was patients' lack of understanding of their own illnesses. Third, we conducted an opinion survey of medical professionals on regional medical cooperation. Based on the trial, we found it important in disasters to establish regional cooperation and solid communication systems, and to promote patient education.
Quantification of intact carboplatin in human plasma ultrafitrates using hydrophilic interaction liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study Peer-reviewed

Hajime Ito, Hiroaki Yamaguchi, Asuka Fujikawa, Narumi Shiida, Nobuaki Tanaka, Jiro Ogura, Masaki Kobayashi, Takehiro Yamada, Nariyasu Mano, Ken Iseki

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　917　18-23　2013/02

DOI： 10.1016/j.jchromb.2012.11.024 　

ISSN： 1570-0232
土-P2-275 LC/ESI-MS/MSによるAxitinibの血中濃度測定法の構築(TDM・投与設計,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

柳利樹, 島田美樹, 眞野成康, 高崎新也, 鈴木裕之, 前川正充, 齋藤英郎, 伊藤明宏, 荒井陽一, 久道周彦, 松浦正樹

日本医療薬学会年会講演要旨集　23　(0)　297-297　2013
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.23.0_297_5 　
土-11-O20-10 小児の広汎性発達障害患者における処方推移 : レセプトデータに基づく検討(精神科領域2,一般演題(口頭)20,再興、再考、創ろう最高の医療の未来) Peer-reviewed

佐藤倫広, 栗山進一, 小原拓, 大場延浩, 森川和彦, 石黒真美, 目時弘仁, 西郡秀和, 菊谷昌浩, 眞野成康

日本医療薬学会年会講演要旨集　23　(0)　225-225　2013
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.23.0_225_5 　
土-P1-001 東北大学病院における能動的情報提供のための院内広報サイトの構築(一般演題ポスター発表,医療情報システム,再興、再考、創ろう最高の医療の未来) Peer-reviewed

前川麻央, 眞野成康, 草場美津江, 小原拓, 尾崎芙実, 中川直人, 佐藤真由美, 久道周彦, 松浦正樹, 我妻恭行

日本医療薬学会年会講演要旨集　23　(0)　252-252　2013
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.23.0_252_1 　
土-P1-019 東日本大震災後に当院職員が受けた薬に関連する問い合わせに関する調査(一般演題ポスター発表,医薬品情報・データベース,再興、再考、創ろう最高の医療の未来) Peer-reviewed

吉中千佳, 小原拓, 草場美津江, 松浦正樹, 眞野成康

日本医療薬学会年会講演要旨集　23　(0)　255-255　2013
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.23.0_255_1 　
日-P3-500 授乳と薬剤使用に関する問い合わせ内容の調査(妊婦・授乳婦,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来) Peer-reviewed

尾崎芙実, 佐賀利英, 佐藤真由美, 久道周彦, 松浦正樹, 眞野成康, 小原拓, 前川真央, 吉中千佳, 草場美津江, 中川直人, 飯田優太郎, 鈴木文子, 島田美樹

日本医療薬学会年会講演要旨集　23　(0)　434-434　2013
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.23.0_434_5 　
Change of the Management of Treated Hypertensive Patients with or without Diabetes in Japan Peer-reviewed

Taku Obara, Takayoshi Ohkubo, Kazuki Ishikura, Taku Shibamiya, Urara Ikeda, Hirohito Metoki, Masahiro Kikuya, Nariyasu Mano, Shinichi Kuriyama, Yutaka Imai

CLINICAL AND EXPERIMENTAL HYPERTENSION　35　(2)　79-86　2013

DOI： 10.3109/10641963.2012.732640 　

ISSN： 1064-1963

eISSN： 1525-6006
Compliance to the recommendations on blood pressure measurements in the clinical settings Peer-reviewed

Taku Obara, Takayoshi Ohkubo, Nariyasu Mano, Shinichi Kuriyama, Yutaka Imai

JOURNAL OF HYPERTENSION　31　(1)　213-213　2013/01

DOI： 10.1097/HJH.0b013e32835aaffd 　

ISSN： 0263-6352
葉酸の神経管閉鎖障害リスク低下効果に関する薬剤師の認識（Pharmacists’ Awareness of the Importance of Folic Acid Intake for the Prevention of Neural Tube Defects） Peer-reviewed

小原拓, 村井ユリ子, 猪狩有紀恵, 原梓, 岸川幸生, 早坂正孝, 鎌田裕, 眞野成康, 高橋將喜, 生出泉太郎, 北村哲治

医薬品情報学会誌　13　(4)　167-172　2013/01
米国ノバサウスイースタン大学薬学部における実務実習と6年制薬学教育における実務実習の比較 Peer-reviewed

中川直人, Leanne Lai, 眞野成康

医療薬学　39　(1)　25-32　2013/01

DOI： 10.5649/jjphcs.39.25 　
Associations Between Visit-to-visit Variability in Blood Pressure Measured in the Office and Antihypertensive Drugs: The J-HOME-Morning Study Peer-reviewed

Taku Obara, Masahiro Kikuya, Yuka Kobayashi, Kazuki Ishikura, Urara Ikeda, Mami Ishikuro, Hirohito Metoki, Nariyasu Mano, Shinichi Kuriyama, Takayoshi Ohkubo, Yutaka Imai

CLINICAL AND EXPERIMENTAL HYPERTENSION　35　(4)　285-290　2013

DOI： 10.3109/10641963.2013.780070 　

ISSN： 1064-1963
Do protease inhibitors influence visceral pain sensitivity in patients with irritable bowel syndrome ? Peer-reviewed

Kanazawa Motoyori, Morishita Joe, Tanaka Y, Inooka K, Kano Michiko, Hisamichi K, Mano N, Fukudo Shin

Gastroenterology 142 (5)　S306　2012/12
A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates Peer-reviewed

Hajime Ito, Hiroaki Yamaguchi, Asuka Fujikawa, Nobuaki Tanaka, Ayako Furugen, Kazuaki Miyamori, Natsuko Takahashi, Jiro Ogura, Masaki Kobayashi, Takehiro Yamada, Nariyasu Mano, Ken Iseki

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS　71　99-103　2012/12

DOI： 10.1016/j.jpba.2012.08.010 　

ISSN： 0731-7085
臨床検査への質量分析の応用治療薬物モニタリングにおける質量分析法の活用

島田美樹, 眞野成康

臨床病理　60　(補冊)　44-44　2012/10
Publisher: (一社)日本臨床検査医学会
ISSN： 0047-1860
Increased production of reactive oxygen species by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A in RAW 264 cells

Aya Yokomakura, Jang Ja Hong, Kazuo Ohuchi, Seong Eun Oh, Jin Yong Lee, Nariyasu Mano, Tsutomu Takahashi, Gi Wook Hwang, Akira Naganuma

Journal of Toxicological Sciences　37　(5)　1045-1048　2012/10

DOI： 10.2131/jts.37.1045 　

ISSN： 1880-3989

eISSN： 0388-1350
バイオ計測技術の新展開抱合型コレステロール代謝物のフォーカシングメタボローム解析法の構築

前川正充, 島田美樹, 眞野成康

臨床化学　41　(Suppl.1)　192-193　2012/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
東日本大震災後に薬品情報室に寄せられた問い合わせに関する調査

吉中千佳, 尾崎芙実, 小原拓, 前川麻央, 草場美津江, 佐賀利英, 我妻恭行, 久道周彦, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　15回　120-120　2012/06
Publisher: (一社)日本医薬品情報学会
Simultaneous quantitation of sphingoid bases and their phosphates in biological samples by liquid chromatography/electrospray ionization tandem mass spectrometry Peer-reviewed

Daisuke Saigusa, Kanako Shiba, Asuka Inoue, Kotaro Hama, Michiyo Okutani, Nagisa Iida, Masayoshi Saito, Kaori Suzuki, Tohru Kaneko, Naoto Suzuki, Hiroaki Yamaguchi, Nariyasu Mano, Junichi Goto, Takanori Hishinuma, Junken Aoki, Yoshihisa Tomioka

ANALYTICAL AND BIOANALYTICAL CHEMISTRY　403　(7)　1897-1905　2012/06

DOI： 10.1007/s00216-012-6004-9 　

ISSN： 1618-2642
LC/ESI-MS/MSによるSunitinibおよび活性代謝物SU12662の血中濃度測定法の構築

柳利樹, 荒屋世一, 前川正充, 鈴木裕之, 齋藤英郎, 荒井陽一, 久道周彦, 島田美樹, 眞野成康

TDM研究　29　(3)　273-273　2012/05
Publisher: (一社)日本TDM学会
ISSN： 0911-1026
Review of medication counseling records relating to pregnancy Peer-reviewed

小原拓, 尾崎芙実, 吉中千佳, 前川麻央, 草場美津江, 石黒真美, 飯田優太郎, 鈴木文子, 松浦正樹, 佐賀利英, 佐藤真由美, 久道周彦, 島田美樹, 栗山進一, 八重樫伸生, 眞野成康

医薬品相互作用研究　35　(3)　129-133　2012/04
Publisher:
ISSN： 0385-5015
Increased production of reactive oxygen species by the vacuolar-type (H(+))-ATPase inhibitors bafilomycin A1 and concanamycin A in RAW 264 cells. Peer-reviewed

Yokomakura Aya, Hong Jangja, Ohuchi Kazuo, Oh Seong-Eun, Lee Jin-Yong, Mano Nariyasu, Takahashi Tsutomu, Hwang Gi-Wook, Naganuma Akira

J Toxicol Sci　37　(5)　1045-1048　2012/04

DOI： 10.2131/jts.37.1045 　

ISSN： 0388-1350
A rapid and sensitive LC/ESI-MS/MS method for quantitative analysis of docetaxel in human plasma and its application to a pharmacokinetic study Peer-reviewed

Hiroaki Yamaguchi, Asuka Fujikawa, Hajime Ito, Nobuaki Tanak, Ayako Furugen, Kazuaki Miyamori, Natsuko Takahashi, Jiro Ogura, Masaki Kobayashi, Takehiro Yamada, Nariyasu Mano, Ken Iseki

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　893　157-161　2012/04

DOI： 10.1016/j.jchromb.2012.02.003 　

ISSN： 1570-0232
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells Peer-reviewed

Yuriko Saiki, Yuki Yoshino, Hiroko Fujimura, Tatsuya Manabe, Yuki Kudo, Miki Shimada, Nariyasu Mano, Tomohiro Nakano, Yoonha Lee, Shinjiro Shimizu, Shinya Oba, Sho Fujiwara, Hideyuki Shimizu, Na Chen, Zhaleh Kashkouli Nezhad, Guo Jin, Shinichi Fukushige, Makoto Sunamura, Masaharu Ishida, Fuyuhiko Motoi, Shinichi Egawa, Michiaki Unno, Akira Horii

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS　421　(1)　98-104　2012/04

DOI： 10.1016/j.bbrc.2012.03.122 　

ISSN： 0006-291X
葉酸の神経管閉鎖障害リスク低下効果に関する薬剤師の認識, (Pharmacists’ Awareness of the Importance of Folic Acid Intake for the Prevention of Neural Tube Defects) Peer-reviewed

小原拓, 村井ユリ子, 猪狩有紀恵, 原梓, 岸川幸行, 早坂正孝, 鎌田裕, 眞野成康, 高橋將喜, 生出泉太郎, 北村哲治

医薬品情報学会誌　13　(14)　164-172　2012/02/27
Associations Between Day-by-Day Variability in Blood Pressure Measured at Home and Antihypertensive Drugs: The J-HOME-Morning Study Peer-reviewed

Kazuki Ishikura, Taku Obara, Tetsuo Kato, Masahiro Kikuya, Taku Shibamiya, Takahiro Shinki, Urara Ikeda, Yuka Kobayashi, Hirohito Metoki, Nariyasu Mano, Shinichi Kuriyama, Takayoshi Ohkubo, Yutaka Imai

CLINICAL AND EXPERIMENTAL HYPERTENSION　34　(4)　297-304　2012

DOI： 10.3109/10641963.2012.681087 　

ISSN： 1064-1963
Pharmacists' Awareness and Attitude Toward Blood Pressure Measurement at Home and in the Pharmacy in Japan Peer-reviewed

Taku Obara, Takayoshi Ohkubo, Koji Tanaka, Michihiro Satoh, Kazuki Ishikura, Mitsuru Kobayashi, Hirohito Metoki, Kei Asayama, Masahiro Kikuya, Yuriko Murai, Nariyasu Mano, Sentaro Oide, Yutaka Imai

CLINICAL AND EXPERIMENTAL HYPERTENSION　34　(6)　447-455　2012

DOI： 10.3109/10641963.2012.666599 　

ISSN： 1064-1963

eISSN： 1525-6006
高血圧薬物治療における家庭血圧測定と薬剤師の介入, （Home Blood Pressure Measurement and Pharmacists’ Intervention in the Management of Hypertension） Peer-reviewed

吉町昌子, 小原拓, 川端ゆかり, 馬庭ちはる, 河野弘之, 眞野成康, 大久保孝義, 後藤輝明

医薬品相互作用研究　35　(2)　63-69　2011/12/01
妊娠前後における女性のサプリメント摂取：BOSHI研究 Peer-reviewed

原梓, 小原拓, 目時弘仁, 大久保孝義, 川口麻衣子, 佐藤友里恵, 佐々木彩乃, 星川美奈子, 石倉一樹, 佐藤倫広, 村井ユリ子, 眞野成康, 岩崎雅弘, 八木橋香津代, 森滋, 八重樫伸生, 鈴木雅洲, 今井潤

医薬品相互作用研究　35　11-16　2011/11
Quantification of intracellular and extracellular prostanoids stimulated by A23187 by liquid chromatography/electrospray ionization tandem mass spectrometry Peer-reviewed

Ayako Furugen, Hiroaki Yamaguchi, Nobuaki Tanaka, Hajime Ito, Kazuaki Miyamori, Asuka Fujikawa, Natsuko Takahashi, Jiro Ogura, Masaki Kobayashi, Takehiro Yamada, Nariyasu Mano, Ken Iseki

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　879　(30)　3378-3385　2011/11

DOI： 10.1016/j.jchromb.2011.09.003 　

ISSN： 1570-0232
Subtypes of Resistant Hypertension Based on Out-of-Office Blood Pressure Measurement Peer-reviewed

Taku Obara, Takayoshi Ohkubo, Nariyasu Mano, Nobuo Yaegashi, Shinichi Kuriyama, Yutaka Imai

HYPERTENSION　58　(4)　E28-E28　2011/10

DOI： 10.1161/HYPERTENSIONAHA.111.178996 　

ISSN： 0194-911X
Biliary bile acids in birds of the Cotingidae family: Taurine-conjugated (24R,25R)-3 alpha,7 alpha,24-trihydroxy-5 beta-cholestan-27-oic acid and two epimers (25R and 25S) of 3 alpha,7 alpha-dihydroxy-5 beta-cholestan-27-oic acid Peer-reviewed

Lee R. Hagey, Takashi Iida, Shoujiro Ogawa, Yuuki Adachi, Mizuho Une, Kumiko Mushiake, Masamitsu Maekawa, Miki Shimada, Nariyasu Mano, Alan F. Hofmann

STEROIDS　76　(10-11)　1126-1135　2011/09

DOI： 10.1016/j.steroids.2011.04.017 　

ISSN： 0039-128X
Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Peer-reviewed

Yamaguchi Hiroaki, Takeuchi Toshiko, Okada Masahiro, Kobayashi Minako, Unno Michiaki, Abe Takaaki, Goto Junichi, Hishinuma Takanori, Shimada Miki, Mano Nariyasu

Biol Pharm Bull　34　(3)　389-395　2011/04/02

DOI： 10.1248/bpb.34.389 　

ISSN： 0918-6158

eISSN： 1347-5215

More details Close

Hepatic organic anion transporters OATP1B1 and OATP1B3 are expressed at the sinusoidal membrane of hepatocytes and contribute to the hepatic uptake of a wide variety of clinically used drugs. To identify the antibiotics that interact with the human organic anion transporters OATP1B1 and OATP1B3, we applied a screening system using fluorescent probes. Twenty-six antibiotics with a variety of mechanisms of action were examined. The screening demonstrated that four antibiotics inhibited OATP1B1-mediated transport and 11 antibiotics inhibited OATP1B3-mediated transport in a concentration-dependent manner. Antibiotics that inhibited OATP1B3-mediated transport tended to exhibit higher affinity than those that inhibited OATP1B1-mediated transport. To clarify whether the antibiotics that interacted with OATP1B1 and/or OATP1B3 were substrates for these transporters, an uptake study was performed. Rifampicin and penicillin were transported by both OATP1B1 and OATP1B3. Moreover, OATP1B3 was involved in the transport of ceftriaxone, cefmetazole, cefoperazone, and cefotaxime. Macrolides were not significantly transported by either transporter. In conclusion, the results demonstrated that our system is a useful method for the rapid screening of transporter-antibiotic interaction, and we found novel substrates. Our results indicate that OATP1B1 and/or OATP1B3 contribute to the transport process of some antibiotics, and that drug-drug interactions associated with these transporters could occur after the administration of antibiotics.
Structure and Cytotoxic Activity of Enzymatic Hydrolysis Products of Secoiridoid Glucosides, Isoligustroside and Isooleuropein Peer-reviewed

Masafumi Kikuchi, Yasunori Yaoita, Nariyasu Mano, Masao Kikuchi

CHEMISTRY & BIODIVERSITY　8　(4)　651-657　2011/04

DOI： 10.1002/cbdv.201000092 　

ISSN： 1612-1872
An accurate quantitative LC/ESI-MS/MS method for sirolimus in human whole blood Peer-reviewed

Nariyasu Mano, Mayumi Sato, Marina Nozawa, Yotaro Matsumoto, Masaru Mori, Hiroaki Yamaguchi, Junichi Goto, Miki Shimada

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　879　(13-14)　987-992　2011/04

DOI： 10.1016/j.jchromb.2011.03.013 　

ISSN： 1570-0232
Identification and elimination of ion suppression in the quantitative analysis of sirolimus in human blood by LC/ESI-MS/MS Peer-reviewed

Nariyasu Mano, Marina Nozawa, Mayumi Sato, Masaru Mori, Hiroaki Yamaguchi, Katsuhiro Kanda, Makoto Nogami, Junichi Goto, Miki Shimada

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　879　(13-14)　968-974　2011/04

DOI： 10.1016/j.jchromb.2011.03.011 　

ISSN： 1570-0232
全自動PTP払出機の効率的運用に関する検討

佐藤祐司, 吉田真貴子, 猪岡京子, 堀川美帆, 村中太郎, 鈴木智尋, 加藤佳子, 片岡佑太, 長岡真理子, 高崎新也, 岸川友紀, 飯田優太郎, 松浦正樹, 我妻恭行, 久道周彦, 佐藤真由美, 島田美樹, 眞野成康

日本薬学会年会要旨集　131年会　(4)　255-255　2011/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
LC/ESI-MS/MSによる抱合型胆汁酸のメタボローム解析法の検討

前川正充, 森大, 鈴木裕之, 坂本修, 大浦敏博, 虻川大樹, 大野耕策, 入戸野博, 飯田隆, 島田美樹, 眞野成康

日本薬学会年会要旨集　131年会　(4)　96-96　2011/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
培養細胞中のソラフェニブおよび代謝物定量法の構築

大川星美, 鈴木裕之, 森大, 前川正充, 島田美樹, 眞野成康

日本薬学会年会要旨集　131年会　(4)　171-171　2011/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
HPLCによるゲムシタビンおよび代謝物の血中濃度測定法の構築

工藤由起, 田村淳, 前川正充, 鈴木裕之, 森大, 島田美樹, 眞野成康

日本薬学会年会要旨集　131年会　(4)　175-175　2011/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
P-0001 東日本大震災における東北大学病院薬剤部の対応(その1) : 震災の概要と薬剤部業務体制および各方面への支援状況(一般演題ポスター発表,東日本大震災,Enjoy Pharmacists' Lifestyles)

佐藤真由美, 久道周彦, 我妻恭行, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

日本医療薬学会年会講演要旨集　21　182-182　2011
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.21.0_182_1 　
P-0002 東日本大震災における東北大学病院薬剤部の対応(その2) : 通信網の破綻と外来診療体制の再構築(一般演題ポスター発表,東日本大震災,Enjoy Pharmacists' Lifestyles)

我妻恭行, 久道周彦, 佐藤真由美, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

日本医療薬学会年会講演要旨集　21　182-182　2011
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.21.0_182_2 　
P-0003 東日本大震災における東北大学病院薬剤部の対応(その3) : 本院の診療体制の維持と被災地支援に向けた医薬品の確保(一般演題ポスター発表,東日本大震災,Enjoy Pharmacists' Lifestyles)

久道周彦, 佐藤真由美, 我妻恭行, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

日本医療薬学会年会講演要旨集　21　182-182　2011
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.21.0_182_3 　
Glycosides from the leaves of Syringa vulgaris and their growth inhibitory activity against human cancer cell lines Peer-reviewed

Masafumi Kikuchi, Yasunori Yaoita Nariyasu Mano, Masao Kikuchi

Shoyakugaku Zasshi　64　(2)　104-105　2011/01
Publisher:
ISSN： 1349-9114

More details Close

From the leaves of Syringa vulgaris L. (Oleaceae), nine known glycosides were isolated and identified: 3,4-dihydroxyphenethyl β-D-glucopyranoside (1), acteoside (2), echinacoside (3), oleoacteoside (4), oleoechinacoside (5), isooleoacteoside (6), syringopicroside B (7), syringalactone B (8), and 2"-epi-frameroside (9). This is the first time that compounds 6, 7 and 9 have been isolated from the leaves of S. vulgaris. The growth inhibitory activity of compounds 1-9 against 39 human cancer cell lines was evaluated.
Association of Arterial Stiffness with Silent Cerebrovascular Lesions: The Ohasama Study Peer-reviewed

Rieko Hatanaka, Taku Obara, Daisuke Watabe, Tomofumi Ishikawa, Takeo Kondo, Kazuki Ishikura, Tomoyuki Aikawa, Yoko Aono, Azusa Hara, Hirohito Metoki, Kei Asayama, Masahiro Kikuya, Nariyasu Mano, Takayoshi Ohkubo, Shin-Ichi Izumi, Yutaka Imai

CEREBROVASCULAR DISEASES　31　(4)　329-337　2011

DOI： 10.1159/000322599 　

ISSN： 1015-9770
Low-Dose and Very Low-Dose Spironolactone in Combination Therapy for Essential Hypertension: Evaluation by Self-Measurement of Blood Pressure at Home Peer-reviewed

Tomohiro Hanazawa, Taku Obara, Kei Ogasawara, Takahiro Shinki, Sakiko Katada, Ryusuke Inoue, Hirohito Metoki, Kei Asayama, Masahiro Kikuya, Takayoshi Ohkubo, Nariyasu Mano, Yutaka Imai

CLINICAL AND EXPERIMENTAL HYPERTENSION　33　(7)　427-436　2011

DOI： 10.3109/10641963.2010.531844 　

ISSN： 1064-1963

eISSN： 1525-6006
Cytotoxic and EGFR tyrosine kinase inhibitory activities of aglycone derivatives obtained by enzymatic hydrolysis of oleoside-type secoiridoid glucosides, oleuropein and ligustroside Peer-reviewed

Masafumi Kikuchi, Nariyasu Mano, Yoshimasa Uehara, Koichi Machida, Masao Kikuchi

JOURNAL OF NATURAL MEDICINES　65　(1)　237-240　2011/01

DOI： 10.1007/s11418-010-0476-8 　

ISSN： 1340-3443
Role of Pharmacists in the Management of Hypertensive Patients Peer-reviewed

Taku Obara, Sentaro Oide, Takayoshi Ohkubo, Nariyasu Mano, Yutaka Imai

AMERICAN JOURNAL OF HYPERTENSION　24　(1)　2-3　2011/01

DOI： 10.1038/ajh.2010.208 　

ISSN： 0895-7061
Practice and awareness of physicians regarding casual-clinic blood pressure measurement in Japan Peer-reviewed

Mitsuru Kobayashi, Taku Obara, Takayoshi Ohkubo, Hidefumi Fukunaga, Michihiro Satoh, Hirohito Metoki, Kei Asayama, Ryusuke Inoue, Masahiro Kikuya, Nariyasu Mano, Masaaki Miyakawa, Yutaka Imai

HYPERTENSION RESEARCH　33　(9)　960-964　2010/09

DOI： 10.1038/hr.2010.89 　

ISSN： 0916-9636
Chemical synthesis of (22E)-3α,6α,7α,12α- Tetrahydroxy-5β-chol-22-en-24-oic acid and its N-acylamidated conjugates with glycine or taurine: Precursors of the [22,23-3H] labelled tracers Peer-reviewed

Shoujiro Ogawa, Yuuki Adachi, Genta Kakiyama, Miki Shimada, Nariyasu Mano, Junichi Goto, Takashi Iida

Chemical and Pharmaceutical Bulletin　58　(8)　1103-1106　2010/08

DOI： 10.1248/cpb.58.1103 　

ISSN： 0009-2363 1347-5223
Major Biliary Bile Acids of the Medaka (Oryzias latipes): 25R- and 25S-Epimers of 3 alpha,7 alpha,12 alpha-Trihydroxy-5 beta-cholestanoic Acid Peer-reviewed

Lee R. Hagey, Takashi Iida, Hideyuki Tamegai, Shoujiro Ogawa, Mizuho Une, Kiyoshi Asahina, Kumiko Mushiake, Takaaki Goto, Nariyasu Mano, Junichi Goto, Matthew D. Krasowski, Alan F. Hofmann

ZOOLOGICAL SCIENCE　27　(7)　565-573　2010/07

DOI： 10.2108/zsj.27.565 　

ISSN： 0289-0003
Production of O-18-Single Labeled Peptide Fragments during Trypsin Digestion of Proteins for Quantitative Proteomics Using nanoLC-ESI-MS/MS Peer-reviewed

Masaru Mori, Kohei Abe, Hiroaki Yamaguchi, Junichi Goto, Miki Shimada, Nariyasu Mano

JOURNAL OF PROTEOME RESEARCH　9　(7)　3741-3749　2010/07

DOI： 10.1021/pr900865p 　

ISSN： 1535-3893
アンジオテンシンII受容体拮抗薬カンデサルタンの家庭血圧測定に基づく降圧速度に関する検討 Peer-reviewed

小原拓, 安真美子, 花澤智大, 堅田早紀子, 目時弘仁, 浅山敬, 井上隆輔, 菊谷昌浩, 大久保孝義, 眞野成康, 今井潤

診断と治療　98　(6)　1039-1045　2010/06
Publisher:
ISSN： 0370-999X
Gene expression profiling defines the role of ATP-exposed keratinocytes in skin inflammation Peer-reviewed

Hiroshi Ohara, Rumiko Saito, Satoshi Hirakawa, Miki Shimada, Nariyasu Mano, Ryuhei Okuyama, Setsuya Aiba

JOURNAL OF DERMATOLOGICAL SCIENCE　58　(2)　143-151　2010/05

DOI： 10.1016/j.jdermsci.2010.02.007 　

ISSN： 0923-1811
Practice and awareness of physicians regarding home blood pressure measurement in Japan Peer-reviewed

Taku Obara, Takayoshi Ohkubo, Hidefumi Fukunaga, Mitsuru Kobayashi, Michihiro Satoh, Hirohito Metoki, Kei Asayama, Ryusuke Inoue, Masahiro Kikuya, Nariyasu Mano, Masaaki Miyakawa, Yutaka Imai

HYPERTENSION RESEARCH　33　(5)　428-434　2010/05

DOI： 10.1038/hr.2010.10 　

ISSN： 0916-9636

eISSN： 1348-4214
アンジオテンシンII受容体拮抗薬オルメサルタンの家庭血圧測定に基づく降圧速度に関する検討

小原拓, 安真美子, 花澤智大, 小笠原慧, 堅田早紀子, 目時弘仁, 浅山敬, 井上隆輔, 菊谷昌浩, 大久保孝義, 眞野成康, 今井潤

Therapeutic Research　31　(4)　569-575　2010/04
ヒト表皮角化細胞における細胞外ATPの機能解析

大原宏司, 齋藤るみ子, 平河聡, 島田美樹, 眞野成康, 菱沼隆則, 奥山隆平, 相場節也

日本薬学会年会要旨集　130年会　(3)　80-80　2010/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
18O一置換標識法とnanoLC/ESI-MS/MSによる血清プロテオーム解析法の有用性検証

森大, 島田美樹, 眞野成康

日本薬学会年会要旨集　130年会　(4)　94-94　2010/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
カプトプリル投与でのラット脳内ペプチドの変動

金澤佐知子, 下山律子, 森大, 島田美樹, 眞野成康, 佐藤公彦, 早狩誠

日本薬学会年会要旨集　130年会　(4)　312-312　2010/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
大学院生の薬剤師研修を通じた医師への処方支援 Peer-reviewed

三村享, 松本周平, 金光祥臣, 村井ユリ子, 久道周彦, 佐藤真由美, 鈴木直人, 齊藤直美, 土屋雅美, 木皿重樹, 三枝大輔, 眞野成康, 富岡佳久

日本薬学会年会要旨集　130年会　(4)　348-348　2010/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Potential corticoid metabolites: Chemical synthesis of 3- and 21-monosulfates and their double-conjugates of tetrahydrocorticosteroids in the 5 α- and 5 β-series Peer-reviewed

Rika Okihara, Kuniko Mitamura, Maki Hasegawa, Megumi Mori, Akina Muto, Genta Kakiyama, Shoujiro Ogawa, Takashi Iida, Miki Shimada, Nariyasu Mano, Shigeo Ikegawa

Chemical and Pharmaceutical Bulletin　58　(3)　344-353　2010/03

DOI： 10.1248/cpb.58.344 　

ISSN： 0009-2363 1347-5223
P2-456 医薬品-食品相互作用情報の食事オーダ連携システムの構築(一般演題ポスター発表,栄養管理・NST,臨床から学び臨床へと還元する医療薬学)

飯田優太郎, 眞野成康, 松浦正樹, 中村浩規, 佐賀利英, 我妻恭行, 布田美貴子, 岡本智子, 東海林晋, 國井重男

日本医療薬学会年会講演要旨集　20　465-465　2010
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.20.0_465_6 　
P2-559 プログラム選択方式により学生の自主性を重視した病院実習プログラムの構築(一般演題ポスター発表,薬学教育(実務実習),臨床から学び臨床へと還元する医療薬学)

村井ユリ子, 平塚真弘, 平澤典保, 富岡佳久, 島田美樹, 眞野成康, 佐賀利英, 佐藤真由美, 中村浩規, 久道周彦, 我妻恭行, 鈴木裕之, 森大, 鈴木直人

日本医療薬学会年会講演要旨集　20　483-483　2010
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.20.0_483_1 　
LC-MS/MS coupled with immunoaffinity extraction for determination of estrone, 17 beta-estradiol and estrone 3-sulfate in human plasma Peer-reviewed

Jun Hosogi, Hideyuki Tanaka, Kazuhiro Fujita, Takashi Kuwabara, Shigeo Ikegawa, Norihiro Kobayashi, Nariyasu Mano, Junichi Goto

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　878　(2)　222-227　2010/01

DOI： 10.1016/j.jchromb.2009.08.010 　

ISSN： 1570-0232

eISSN： 1873-376X
Transport of Estrone 3-sulfate Mediated by Organic Anion Transporter OATP4C1: Estrone 3-sulfate binds to the Different Recognition Site for Digoxin in OATP4C1 Peer-reviewed

Hiroaki Yamaguchi, Misa Sugie, Masahiro Okada, Tsuyoshi Mikkaichi, Takafumi Toyohara, Takaaki Abe, Junichi Goto, Takanori Hishinuma, Miki Shimada, Nariyasu Mano

DRUG METABOLISM AND PHARMACOKINETICS　25　(3)　314-317　2010

DOI： 10.2133/dmpk.25.314 　

ISSN： 1347-4367
Uncontrolled hypertension based on morning and evening home blood pressure measurements from the J-HOME study Peer-reviewed

Taku Obara, Kie Ito, Takayoshi Ohkubo, Taku Shibamiya, Takahiro Shinki, Manami Nakashita, Azusa Hara, Hirohito Metoki, Ryusuke Inoue, Kei Asayama, Masahiro Kikuya, Nariyasu Mano, Yutaka Imai

HYPERTENSION RESEARCH　32　(12)　1072-1078　2009/12

DOI： 10.1038/hr.2009.152 　

ISSN： 0916-9636

eISSN： 1348-4214
Introducing Hazard Prediction Training 'KYT' to Undergraduate Pharmacy Education on Patient Safety Peer-reviewed

Yuriko Murai, Mayumi Sato, Hiroaki Yamaguchi, Miki Shimada, Nariyasu Mano, Junichi Goto, Takanori Hishinuma

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN　129　(11)　1367-1373　2009/11

ISSN： 0031-6903
Analysis of Phosphorylated Peptides by Double Pseudoneutral Loss Extraction Coupled with Derivatization Using N-(4-Bromobenzoyl)aminoethanethiol Peer-reviewed

Nariyasu Mano, Sayaka Aoki, Takuma Yamazaki, Yoko Nagaya, Masaru Mori, Kohei Abe, Miki Shimada, Hiroaki Yamaguchi, Takaaki Goto, Junichi Goto

ANALYTICAL CHEMISTRY　81　(22)　9395-9401　2009/11

DOI： 10.1021/ac9017988 　

ISSN： 0003-2700
Introducing hazard prediction training 'KYT' to undergraduate pharmacy education on patient safety Peer-reviewed

Yuriko Murai, Mayumi Sato, Hiroaki Yamaguchi, Miki Shimada, Nariyasu Mano, Junichi Goto, Takanori Hishinuma

Yakugaku Zasshi　129　(11)　1367-1373　2009/11

DOI： 10.1248/yakushi.129.1367 　

ISSN： 0031-6903 1347-5231
家庭血圧測定に基づくアムロジピンベシル酸塩の臨床評価 -先発医薬品から後発医薬品への切り替え- Peer-reviewed

小原拓, 池田うらら, 新木貴大, 芝宮拓, 堅田早紀子, 小林満, 原梓, 目時弘仁, 大久保孝義, 眞野成康, 今井潤

医薬品相互作用研究　32　149-155　2009/10
Chemical synthesis of 3 beta-sulfooxy-7 beta-hydroxy-24-nor-5-cholenoic acid: An internal standard for mass spectrometric analysis of the abnormal Delta(5)-bile acids occurring in Niemann-Pick disease Peer-reviewed

Genta Kakiyama, Akina Muto, Miki Shimada, Nariyasu Mano, Junichi Goto, Alan F. Hofmann, Takashi Iida

STEROIDS　74　(9)　766-772　2009/09

DOI： 10.1016/j.steroids.2009.04.007 　

ISSN： 0039-128X
プロテオーム変動解析を目的としたトリプシンを用いる18O-置換法

森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

JSBMS Letters　34　(Suppl.)　89-89　2009/08
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
新規アフィニティー抽出法を用いたラット肝組織中ケノデオキシコール酸結合タンパク質の解析

三澤靖, 佐藤光市, 森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

JSBMS Letters　34　(Suppl.)　90-90　2009/08
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
Influence of home blood pressure measuring conditions in the evening on the morning-evening home blood pressure difference in treated hypertensive patients: the J-HOME study Peer-reviewed

Kie Ito, Taku Obara, Takayoshi Ohkubo, Kenta Gonokami, Takahiro Shinki, Taku Shibamiya, Manami Nakashita, Mitsuru Kobayashi, Jin Funahashi, Azusa Hara, Hirohito Metoki, Kei Asayama, Ryusuke Inoue, Masahiro Kikuya, Nariyasu Mano, Yutaka Imai

BLOOD PRESSURE MONITORING　14　(4)　160-165　2009/08

DOI： 10.1097/MBP.0b013e32832e2a40 　

ISSN： 1359-5237
LC/MS/MSを用いる血中シロリムス濃度測定法の改良

野澤真里奈, 島田美樹, 山口浩明, 後藤順一, 眞野成康

臨床化学　38　(Suppl.1)　129-129　2009/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
Effective on-line extraction of drugs from plasma using a restricted-access media column in column-switching HPLC equipped with a dilution system: Application to the simultaneous determination of ER-118585 and its metabolites in canine plasma Peer-reviewed

Eiichi Yamamoto, Takashi Kato, Nariyasu Mano, Naoki Asakawa

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS　49　(5)　1250-1255　2009/07

DOI： 10.1016/j.jpba.2009.02.022 　

ISSN： 0731-7085
A new, major C(27) biliary bile acid in the Red-winged tinamou (Rhynchotus rufescens):(25R)-1 beta,3 alpha,7 alpha-trihydroxy-5 beta-cholestan-27-oic acid Peer-reviewed

Lee R. Hagey, Genta Kakiyama, Akina Muto, Takashi Iida, Kumiko Mushiake, Takaaki Goto, Nariyasu Mano, Junichi Goto, Cleida A. Oliveira, Alan F. Hofmann

JOURNAL OF LIPID RESEARCH　50　(4)　651-657　2009/04

DOI： 10.1194/jlr.M800521-JLR200 　

ISSN： 0022-2275
危険予知トレーニングから得た"危険ストーリー"の新人教育への応用

前嶋隆弘, 吉田真貴子, 佐藤祥子, 渡辺範康, 佐賀利英, 佐藤真由美, 久道周彦, 村井ユリ子, 眞野成康

日本薬学会年会要旨集　129年会　(4)　352-352　2009/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
DI室Q&A 抗精神病薬の副作用による誤嚥性肺炎の危険性と、副作用の回避方法を知りたい抗精神病薬による嚥下障害

飯田優太郎, 鈴木文子, 佐藤真由美, 眞野成康

治療学　42　(11)　1288-1290　2008/11
Publisher: ライフサイエンス出版(株)
ISSN： 0386-8109
NanoLC/ESI-MS/MSを用いる血清プロテオーム解析法の構築に関する検討

森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

臨床化学　37　(Suppl.1)　131-131　2008/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
Simple quantification of lansoprazole and rabeprazole concentrations in human serum by liquid chromatography/tandem mass spectrometry Peer-reviewed

Takanori Hishinuma, Kaori Suzuki, Hiroaki Yamaguchi, Hatsushi Yamagishi, Tomoyuki Koike, Shuichi Ohara, Toru Shimosegawa, Nariyasu Mano, Junichi Goto

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　870　(1)　38-45　2008/07

DOI： 10.1016/j.jchromb.2008.05.034 　

ISSN： 1570-0232
[Analysis of bile acid-related proteins by mass spectrometry] (Rinsho Byori)

Abe Kohei, Goto Junichi, Mano Nariyasu

Rinsho Byori　56　(5)　416-424　2008/05
[Analysis of bile acid-related proteins by mass spectrometry]. Peer-reviewed

Abe K, Goto J, Mano N

Rinsho byori. The Japanese journal of clinical pathology　56　(5)　416-424　2008/05

ISSN： 0047-1860
暴露調査を目的とするシクロホスファミドの高感度LC/MS/MS分析

佐藤真由美, 阿部幸平, 山口浩明, 菱沼隆則, 後藤順一, 眞野成康

日本薬学会年会要旨集　128年会　(4)　171-171　2008/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes Peer-reviewed

Hiroaki Yamaguchi, Minako Kobayashi, Masahiro Okada, Toshiko Takeuchi, Michiaki Unno, Takaaki Abe, Junichi Goto, Takanori Hishinuma, Nariyasu Mano

CANCER LETTERS　260　(1-2)　163-169　2008/02

DOI： 10.1016/j.canlet.2007.10.040 　

ISSN： 0304-3835
Data Mining for Medicines Brought to Hospital by Inpatients and Evaluation of Pharmacists Checking of Medication by Doctors and Nurses

Nakamura Ikuko, Kamo Madoka, Sato Kaori, Hozumi Masato, Hisamichi Kanehiko, Goto Junichi, Mano Nariyasu

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)　34　(6)　522-529　2008
Publisher: Japanese Society of Pharmaceutical Health Care and Sciences
DOI： 10.5649/jjphcs.34.522 　

ISSN： 1346-342X

More details Close

The purposes of the present study were to analyze medication-related data stored in a database to reduce risks associated with the use of medicines brought to hospital by inpatients and to evaluate the effect of pharmacists' real-time checking of patient medication. Pharmacists interviewed patients concerning medicines they brought with them at the time of hospitalization in the Maxillo-Facial and Oral Surgery Departments of Tohoku University Hospital. The data obtained and additional information, such as that on contra-indications and adverse effects stemming from interactions of the medicines with food, were input to a computer database, and immediately made available to other medical staff. Between May 2005 and February 2006, nearly 50% of medicines brought by inpatients were for cardiovascular disorders, gastrointestinal problems and central nervous system disorders (19%, 16% and 15%, respectively). Further, 53% of them required caution to avoid interactions with drugs administered after hospitalization. Although numerous papers on pharmacist checking systems for medicines brought by inpatients have been published, little information of this type is available to medical staff, in particular to doctors. In the present study, we conducted a questionnaire survey of doctors and nurses to evaluate the necessity of pharmacists doing this kind of checking. The results showed that almost all of the medical staff surveyed felt that such checking by pharmacists was useful because the advice they gave prevented dangerous interactions with other medication given during hospitalization. The findings of the present study suggest that pharmacist management of medicines brought to hospital by patients is essential for ensuring their safety.
Isolation and chemical synthesis of a major, novel biliary bile acid in the common wombat (Vombatus ursinus): 15 alpha-hydroxylithocholic acid Peer-reviewed

Genta Kakiyama, Hideyuki Tamegai, Takashi Iida, Kuniko Mitamura, Shigeo Ikegawa, Takaaki Goto, Nariyasu Mano, Junichi Goto, Peter Holz, Lee R. Hagey, Alan F. Hofmann

JOURNAL OF LIPID RESEARCH　48　(12)　2682-2692　2007/12

DOI： 10.1194/jlr.M700340-JLR200 　

ISSN： 0022-2275
Multistep disulfide bond formation in Yap1 is required for sensing and transduction of H2O2 stress signal Peer-reviewed

Shoko Okazaki, Tsuyoshi Tachibana, Akira Naganuma, Nariyasu Mano, Shusuke Kuge

MOLECULAR CELL　27　(4)　675-688　2007/08

DOI： 10.1016/j.molcel.2007.06.035 　

ISSN： 1097-2765
LC/ESI-tandem mass spectrometric determination of bile acid 3-sulfates in human urine 3 beta-sulfooxy-12 alpha-hydroxy-5 beta-cholanoic acid is an abundant nonamidated sulfate Peer-reviewed

Takaaki Goto, Khin Than Myint, Koichi Sato, Osamu Wada, Genta Kakiyama, Takashi Iida, Takanori Hishinuma, Nariyasu Mano, Junichi Goto

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　846　(1-2)　69-77　2007/02

DOI： 10.1016/j.jchromb.2006.08.013 　

ISSN： 1570-0232
Regioselective oxyfunctionalization of unactivated carbons in steroids by a model of cytochrome P-450: Osmiumporphyrin complex/tert-butyl hydroperoxide system Peer-reviewed

Takashi Iida, Shoujiro Ogawa, Keiji Hosoi, Mitsuko Makino, Yasuo Fujimoto, Takaaki Goto, Nariyasu Mano, Junichi Goto, Alan F. Hofmann

JOURNAL OF ORGANIC CHEMISTRY　72　(3)　823-830　2007/02

DOI： 10.1021/jo061800g 　

ISSN： 0022-3263
30-P2-140 薬剤師による病棟常駐業務試行後の評価と今後の課題(薬剤管理指導,社会の期待に応える医療薬学を)

佐藤えり子, 猪岡京子, 鈴木文子, 田坂英久, 佐藤真由美, 我妻恭行, 村井ユリ子, 後藤順一, 眞野成康

日本医療薬学会年会講演要旨集　17　348-348　2007
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.17.0_348_2 　
Conjugation of bile acids Peer-reviewed

Takaaki Goto, Nariyasu Mano, Nariyasu Mano

Japanese Journal of Clinical Chemistry　36　(3)　173-180　2007

DOI： 10.14921/jscc1971b.36.3_173 　

ISSN： 0370-5633
Origin and function of brain bile acids Peer-reviewed

Nariyasu Mano, Kohei Abe, Takaaki Goto

Japanese Journal of Clinical Chemistry　36　(3)　189-196　2007

DOI： 10.14921/jscc1971b.36.3_189 　

ISSN： 0370-5633
Analysis of the modification site in a small molecule-modified peptide by ion trap/time-of-flight hybrid mass spectrometry Peer-reviewed

Nariyasu Mano, Mio Kamota, Yusuke Inohana, Shin-ichi Yamaguchi, Junichi Goto

ANALYTICAL AND BIOANALYTICAL CHEMISTRY　386　(3)　682-688　2006/10

DOI： 10.1007/s00216-006-0696-7 　

ISSN： 1618-2642
Simplified gradient generator for micro- and nano-liquid chromatography Peer-reviewed

Kaoru Murata, Nariyasu Mano, Naoki Asakawa, Yasushi Ishihama

JOURNAL OF CHROMATOGRAPHY A　1123　(1)　47-52　2006/08

DOI： 10.1016/j.chroma.2006.05.004 　

ISSN： 0021-9673

eISSN： 1873-3778
A direct method for the separation and quantification of bile acid acyl glycosides by high-performance liquid chromatography with an evaporative light scattering detector Peer-reviewed

Genta Kakiyama, Atsuko Hosoda, Takashi Iida, Yasuo Fujimoto, Takaaki Goto, Nariyasu Mano, Junichi Goto, Toshio Nambara

JOURNAL OF CHROMATOGRAPHY A　1125　(1)　112-116　2006/08

DOI： 10.1016/j.chroma.2006.05.037 　

ISSN： 0021-9673
Identification of a novel bile acid in swans, tree ducks, and geese: 3 alpha, 7 alpha, 15 alpha-trihydroxy-5 beta-cholan-24-oic acid Peer-reviewed

Genta Kakiyama, Takashi Iida, Takaaki Goto, Nariyasu Mano, Junichi Goto, Toshio Nambara, Lee R. Hagey, Claudio D. Schteingart, Alan F. Hofmann

JOURNAL OF LIPID RESEARCH　47　(7)　1551-1558　2006/07

DOI： 10.1194/jlr.M600149-JLR200 　

ISSN： 0022-2275
Specific affinity extraction method for small molecule-binding proteins Peer-reviewed

N Mano, K Sato, J Goto

ANALYTICAL CHEMISTRY　78　(13)　4668-4675　2006/07

DOI： 10.1021/ac060213s 　

ISSN： 0003-2700
Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3 Peer-reviewed

H Yamaguchi, M Okada, S Akitaya, H Ohara, T Mikkaichi, H Ishikawa, M Sato, M Matsuura, T Saga, M Unno, T Abe, N Mano, T Hishinuma, J Goto

JOURNAL OF LIPID RESEARCH　47　(6)　1196-1202　2006/06

DOI： 10.1194/jlr.M500532-JLR200 　

ISSN： 0022-2275
Nuclear magnetic resonance spectroscopy of 3P,7 beta-dihydroxy-5-cholen-24-oic acid multi-conjugates: unusual bile acid metabolites in human urine Peer-reviewed

G Kakiyama, S Ogawa, T Iida, Y Fujimoto, K Mushiake, T Goto, N Mano, J Goto, T Nambara

CHEMISTRY AND PHYSICS OF LIPIDS　140　(1-2)　48-54　2006/04

DOI： 10.1016/j.chemphyslip.2006.01.003 　

ISSN： 0009-3084
Immunoenzymometric assay for a small molecule,11-deoxycortisol, with attomole-range sensitivity employing an scFv-enzyme fusion protein and anti-idiotype antibodies Peer-reviewed

N Kobayashi, K Iwakami, S Kotoshiba, T Niwa, Y Kato, N Mano, J Goto

ANALYTICAL CHEMISTRY　78　(7)　2244-2253　2006/04

DOI： 10.1021/ac051858f 　

ISSN： 0003-2700
High sensitive analysis of rat serum bile acids by liquid chromatography/electrospray ionization tandem mass spectrometry Peer-reviewed

M Ando, T Kaneko, R Watanabe, S Kikuchi, T Goto, T Iida, T Hishinuma, N Mano, J Goto

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS　40　(5)　1179-1186　2006/03

DOI： 10.1016/j.jpba.2005.09.013 　

ISSN： 0731-7085
Ionization of unconjugated, glycine- and taurine-conjugated bile acids by electrospray ionization mass spectrometry Peer-reviewed

N Mano, M Mori, M Ando, T Goto, J Goto

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS　40　(5)　1231-1234　2006/03

DOI： 10.1016/j.jpba.2005.09.012 　

ISSN： 0731-7085
Immunoaffinity extraction of a peptide modified by a small molecule Peer-reviewed

N Mano, K Abe, J Goto

ANALYTICAL BIOCHEMISTRY　349　(2)　254-261　2006/02

DOI： 10.1016/j.ab.2005.11.025 　

ISSN： 0003-2697
Development of a large-volume, membrane-based injection system for gradient elution micro-liquid chromatography Peer-reviewed

K Murata, N Mano, N Asakawa

JOURNAL OF CHROMATOGRAPHY A　1106　(1-2)　146-151　2006/02

DOI： 10.1016/j.chroma.2005.09.047 　

ISSN： 0021-9673
Chemical synthesis of the 3-sulfooxy-7-N-acetylglucosaminyl-24-amidated conjugates of 3 beta,7 beta-dihydroxy-5-cholen-24-oic acid, and related compounds: Unusual, major metabolites of bile acid in a patient with Niemann-Pick disease type C1 Peer-reviewed

T Iida, G Kakiyama, Y Hibiya, S Miyata, T Inoue, K Ohno, T Goto, N Mano, J Goto, T Nambara, AF Hofmann

STEROIDS　71　(1)　18-29　2006/01

DOI： 10.1016/j.steroids.2005.07.008 　

ISSN： 0039-128X
AMSH, an ESCRT-III associated enzyme, deubiquitinates cargo on MVB/late endosomes Peer-reviewed

Masanao Kyuuma, Kazu Kikuchi, Katsuhiko Kojima, Yuriko Sugawara, Mariko Sato, Nariyasu Mano, Junichi Goto, Toshikazu Takeshita, Akitsugu Yamamoto, Kazuo Sugamura, Nobuyuki Tanaka

CELL STRUCTURE AND FUNCTION　31　(2)　159-172　2006

DOI： 10.1247/csf.06023 　

ISSN： 0386-7196

eISSN： 1347-3700
Formation of DNA adducts with cholyl adenylate, a putative intermediate for biosynthesis of cholyl-CoA Peer-reviewed

T Takamura-Enya, N Mano, N Kawahara, J Goto, K Wakabayashi

CHEMICAL RESEARCH IN TOXICOLOGY　18　(11)　1715-1720　2005/11

DOI： 10.1021/tx050159v 　

ISSN： 0893-228X
Generation of a single-chain Fv fragment for the monitoring of deoxycholic acid residues anchored on endogenous proteins Peer-reviewed

N Kobayashi, M Ohtoyo, E Wada, Y Kato, N Mano, J Goto

STEROIDS　70　(4)　285-294　2005/04

DOI： 10.1016/j.steroids.2004.11.012 　

ISSN： 0039-128X
Chemical synthesis of 24-beta-D-galactopyranosides of bile acids: a new type of bile acid conjugates in human urine Peer-reviewed

G Kakiyama, S Sadakiyo, T Iida, K Mushiake, T Goto, N Mano, J Goto, T Nambara

CHEMISTRY AND PHYSICS OF LIPIDS　134　(2)　141-150　2005/04

DOI： 10.1016/j.chemphyslip.2005.01.002 　

ISSN： 0009-3084
Identification of a novel conjugate in human urine: bile acid acyl galactosides Peer-reviewed

T Goto, A Shibata, D Sasaki, N Suzuki, T Hishinuma, G Kakiyama, T Iida, N Mano, J Goto

STEROIDS　70　(3)　185-192　2005/03

DOI： 10.1016/j.steroids.2004.12.006 　

ISSN： 0039-128X
A nonenzymatic modification of the amino-terminal domain of histone H3 by bile acid acyl adenylate Peer-reviewed

N Mano, K Kasuga, N Kobayashi, J Goto

JOURNAL OF BIOLOGICAL CHEMISTRY　279　(53)　55034-55041　2004/12

DOI： 10.1074/jbc.M409205200 　

ISSN： 0021-9258
Capillary gas chromatographic separation of bile acid acyl glycosides without thermal decomposition and isomerization Peer-reviewed

Takashi Iida, Shoujiro Ogawa, Genta Kakiyama, Takaaki Goto, Nariyasu Mano, Junichi Goto, Toshio Nambara

Journal of Chromatography A　1057　(1-2)　171-176　2004/11/19

DOI： 10.1016/j.chroma.2004.09.029 　

ISSN： 0021-9673
Capillary gas chromatographic separation of bile acid acyl glycosides without thermal decomposition and isomerization Peer-reviewed

T Iida, S Ogawa, G Kakiyama, T Goto, N Mano, J Goto, T Nambara

JOURNAL OF CHROMATOGRAPHY A　1057　(1-2)　171-176　2004/11

DOI： 10.1016/j.chroma.2004.09.029 　

ISSN： 0021-9673
Bioconversion of 3 beta-hydroxy-5-cholenoic acid into chenodeoxycholic acid by rat brain enzyme systems Peer-reviewed

N Mano, Y Sato, M Nagata, T Goto, J Goto

JOURNAL OF LIPID RESEARCH　45　(9)　1741-1748　2004/09

DOI： 10.1194/jlr.M400157-JLR200 　

ISSN： 0022-2275
Biomimetic oxidation of unactivated carbons in steroids by a model of cytochrome P-450, oxorutheniumporphyrinate complex Peer-reviewed

T Iida, S Ogawa, S Miyata, T Goto, N Mano, J Goto, T Nambara

LIPIDS　39　(9)　873-880　2004/09

DOI： 10.1007/s11745-004-1309-0 　

ISSN： 0024-4201
Novel methylcellulose-immobilized cation-exchange precolumn for on-line enrichment of cationic drugs in plasma Peer-reviewed

E Yamamoto, T Sakaguchi, T Kajima, N Mano, N Asakawa

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　807　(2)　327-334　2004/08

DOI： 10.1016/j.jchromb.2004.04.028 　

ISSN： 1570-0232
The Peculiar Existence of Protein-Bound Unconjugated Bile Acid in the Cytoplasmic Fraction of Rat Brain Peer-reviewed

Nariyasu Mano, Takaaki Goto, Junichi Goto

Chinese Journal of Chromatography (Se Pu)　22　(4)　346-348　2004/07/30

ISSN： 1000-8713
Chemical synthesis of (22E)-3 alpha,6 beta,7 beta-trihydroxy-5 beta-chol-22-en-24-oic acid and its taurine and glycine conjugates: a major bile acid in the rat Peer-reviewed

G Kakiyama, T Iida, A Yoshimoto, T Goto, N Mano, J Goto, T Nambara, LR Hagey, AF Hofmann

JOURNAL OF LIPID RESEARCH　45　(3)　567-573　2004/03

DOI： 10.1194/jlr.D300027-JLR200 　

ISSN： 0022-2275
Synthesis of 3 alpha,7 alpha,14 alpha-trihydroxy-5 beta-cholan-24-oic acid: A potential primary bile acid in vertebrates Peer-reviewed

G Kakiyama, T Iida, T Goto, N Mano, J Goto, T Nambara

CHEMICAL & PHARMACEUTICAL BULLETIN　52　(3)　371-374　2004/03

DOI： 10.1248/cpb.52.371 　

ISSN： 0009-2363
Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain Peer-reviewed

N Mano, T Goto, M Uchida, K Nishimura, M Ando, N Kobayashi, J Goto

JOURNAL OF LIPID RESEARCH　45　(2)　295-300　2004/02

DOI： 10.1194/jlr.M300369-JLR200 　

ISSN： 0022-2275
Analysis of the antigen binding site of anti-deoxycholate monoclonal antibody using a novel affinity labeling reagent, acyl adenylate Peer-reviewed

N Mano, Y Nagaya, S Saito, N Kobayashi, J Goto

BIOCHEMISTRY　43　(7)　2041-2048　2004/02

DOI： 10.1021/bi035855d 　

ISSN： 0006-2960
Sensitive mass spectrometric detection of neutral bile acid metabolites. Formation of adduct ions with an organic anion in atmospheric pressure chemical ionization Peer-reviewed

T Goto, A Shibata, T Iida, N Mano, J Goto

RAPID COMMUNICATIONS IN MASS SPECTROMETRY　18　(19)　2360-2364　2004

DOI： 10.1002/rcm.1630 　

ISSN： 0951-4198
The remote-oxyfunctionalization of unactivated carbons in (5 beta)-3-oxobile acids by 2,6-dichloropyridine N-oxide catalyzed by ruthenium-porphyrin and HBr: a direct lactonization at C-20 Peer-reviewed

S Ogawa, T Iida, T Goto, N Mano, J Goto, T Nambara

ORGANIC & BIOMOLECULAR CHEMISTRY　2　(7)　1013-1018　2004

DOI： 10.1039/b314965j 　

ISSN： 1477-0520
Exopeptidase degradation for the analysis of phosphorylation site in a mono-phosphorylated peptide with matrix-assisted laser desorption/ionization mass spectrometry Peer-reviewed

N Mano, M Iijima, K Kasuga, J Goto

ANALYTICAL SCIENCES　19　(11)　1469-1472　2003/11

DOI： 10.2116/analsci.19.1469 　

ISSN： 0910-6340
Inhibition of the rat hepatic microsomal flurbiprofen acyl glucuronidation by bile acids Peer-reviewed

N Mano, T Goto, A Nikaido, T Narui, J Goto

JOURNAL OF PHARMACEUTICAL SCIENCES　92　(10)　2098-2108　2003/10

DOI： 10.1002/jps.10475 　

ISSN： 0022-3549
Synthesis and characterization of deoxycholyl 2-deoxyglucuronide: A water-soluble affinity labeling reagent Peer-reviewed

N Mano, A Nishijima, S Saito, S Ikegawa, J Goto

LIPIDS　38　(8)　873-879　2003/08

DOI： 10.1007/s11745-003-1138-1 　

ISSN： 0024-4201
Highly selective molecular recognition of biologically active substances using liquid phase separation

Nariyasu Mano, Naoki Asakawa, Junichi Goto

Chinese Journal of Chromatography (Se Pu)　21　(4)　347-358　2003/07/30

ISSN： 1000-8713
Functionalization of unactivated carbons in 3 alpha,6- and 3 alpha,24-dihydroxy-5 beta-cholane derivatives by dimethyidioxirane Peer-reviewed

T Iida, K Shiraishi, S Ogawa, T Goto, N Mano, J Goto, T Nambara

LIPIDS　38　(3)　281-287　2003/03

DOI： 10.1007/s11745-003-1062-4 　

ISSN： 0024-4201
Biomedical and biological mass spectrometry

N Mano, J Goto

ANALYTICAL SCIENCES　19　(1)　3-14　2003/01

DOI： 10.2116/analsci.19.3 　

ISSN： 0910-6340
Biomedical and biological mass spectrometry Peer-reviewed

N Mano, J Goto

ANALYTICAL SCIENCES　19　(1)　3-14　2003/01

ISSN： 0910-6340
Potential bile acid metabolites. 25. Synthesis and chemical properties of stereoisomeric 3 alpha,7 alpha,16- and 3 alpha,7 alpha,15-trihydroxy-5 beta-cholan-24-oic acids Peer-reviewed

T Iida, M Hikosaka, G Kakiyama, K Shiraishi, CD Schteingart, LR Hagey, HT Ton-Nu, AF Hofmann, N Mano, J Goto, T Nambara

CHEMICAL & PHARMACEUTICAL BULLETIN　50　(10)　1327-1334　2002/10

DOI： 10.1248/cpb.50.1327 　

ISSN： 0009-2363
Rapid and simple quantitative assay method for diastereomeric glurbiprofen glucuronides in the incubation mixture Peer-reviewed

N Mano, A Nikaido, T Narui, D Yamasaki, J Goto

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　776　(1)　125-131　2002/08

ISSN： 1570-0232
Rapid and simple quantitative assay method for diastereomeric glurbiprofen glucuronides in the incubation mixture Peer-reviewed

N Mano, A Nikaido, T Narui, D Yamasaki, J Goto

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES　776　(1)　125-131　2002/08

DOI： 10.1016/S1570-0232(02)00032-6 　

ISSN： 1570-0232
ウシ胎仔血清由来新規神経保護活性物質の作用

田口良太, 久米利明, 白川久志, 森弘樹, 小坂田文隆, 香月博志, 金子周司, 赤池昭紀, 浅井直樹, 真野成康, 寺内太朗, 浅川直樹, 世永雅弘, 西澤幸夫, 杉本八郎

日本薬学会年会要旨集　122年会　(4)　23-23　2002/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Characterization of rat liver bile acid acyl glucuronosyltransferase Peer-reviewed

N Mano, K Nishimura, T Narui, S Ikegawa, J Goto

STEROIDS　67　(3-4)　257-262　2002/03

DOI： 10.1016/S0039-128X(01)00162-3 　

ISSN： 0039-128X
Isolation of a diterpenoid substance with potent neuroprotective activity from fetal calf serum Peer-reviewed

T Kume, N Asai, H Nishikawa, N Mano, T Terauchi, R Taguchi, H Shirakawa, F Osakada, H Mori, N Asakawa, M Yonaga, Y Nishizawa, H Sugimoto, S Shimohama, H Katsuki, S Kaneko, A Akaike

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA　99　(5)　3288-3293　2002/03

DOI： 10.1073/pnas.052693999 　

ISSN： 0027-8424
Potential bile acid metabolites. 24. An efficient synthesis of carboxyl-linked glucosides and their chemical properties Peer-reviewed

T Iida, R Nakamori, R Yabuta, S Yada, Y Takagi, N Mano, S Ikegawa, J Goto, T Nambara

LIPIDS　37　(1)　101-110　2002/01

DOI： 10.1007/s11745-002-0869-3 　

ISSN： 0024-4201
Separation and Determination of Diastereomeric Flurbiprofen Acyl Glucuronides in Human Urine by LC/ESI-MS with a Simple Column-Switching Technique Peer-reviewed

Nariyasu Mano, Takashi Narui, Ayako Nikaido, Junichi Goto

Drug Metabolism and Pharmacokinetics　17　(2)　142-149　2002

DOI： 10.2133/dmpk.17.142 　

ISSN： 1880-0920 1347-4367
Home blood pressure measurement among hypertensive patients treated in hypertension clinic Peer-reviewed

吉田愛琴, 小原拓, 石倉一樹, 池田うらら, 眞野成康, 大久保孝義, 今井潤

血圧　18　279-285　2001/11
A highly efficient, stereoselective oxyfunctionalization of unactivated carbons in steroids with dimethyldioxirane Peer-reviewed

T Iida, T Yamaguchi, R Nakamori, M Hikosaka, N Mano, J Goto, T Nambara

JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1　(18)　2229-2236　2001/09

ISSN： 1472-7781
Simultaneous detection of cholyl adenylate and coenzyme A thioester utilizing liquid chromatography/electrospray ionization mass spectrometry Peer-reviewed

N Mano, M Uchida, H Okuyama, Sasaki, I, S Ikegawa, J Goto

ANALYTICAL SCIENCES　17　(9)　1037-1042　2001/09

DOI： 10.2116/analsci.17.1037 　

ISSN： 0910-6340
The enantioselective immunoaffinity extraction of an optically active ibuprofen-modified peptide fragment Peer-reviewed

S Ikegawa, NMR Isriyanthi, M Nagata, K Yahata, H Ito, N Mano, J Goto

ANALYTICAL BIOCHEMISTRY　296　(1)　63-72　2001/09

DOI： 10.1006/abio.2001.5198 　

ISSN： 0003-2697
Direct injection method for quantitation of endogenous leukotriene E-4 in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry with a column-switching technique Peer-reviewed

N Kishi, N Mano, N Asakawa

ANALYTICAL SCIENCES　17　(6)　709-713　2001/06

DOI： 10.2116/analsci.17.709 　

ISSN： 0910-6340
The development of a staggered parallel separation liquid chromatography/tandem mass spectrometry system with on-line extraction for high-throughout screening of drug candidates in biological fluids Peer-reviewed

Junichi Goto, Masanori Nagata, Nariyasu Mano, Norihiro Kobayashi, Shigeo Ikegawa, Reiko Kiyonami

Rapid Communications in Mass Spectrometry　15　(2)　73-81　2001

DOI： 10.1002/1097-0231(20010130)15:2<73::AID-RCM193>3.0.CO;2-Q 　

ISSN： 0951-4198
Bile acid acyl adenylate: a possible intermediate to produce a protein-bound bile acid Peer-reviewed

J Goto, M Nagata, N Mano, N Kobayashi, S Ikegawa, R Kiyonami

RAPID COMMUNICATIONS IN MASS SPECTROMETRY　15　(2)　104-109　2001

DOI： 10.1002/1097-0231(20010130)15:2<104::AID-RCM198>3.0.CO;2-N 　

ISSN： 0951-4198
Substrate specificity of THCA-CoA oxidases from rat liver light mitochondrial fractions on dehydrogenation of 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholestanoic acid CoA thioester Peer-reviewed

S Ikegawa, T Goto, N Mano, J Goto

STEROIDS　63　(11)　603-607　1998/11

DOI： 10.1016/S0039-128X(98)00070-1 　

ISSN： 0039-128X
Structural analysis of N-linked carbohydrate chains of funnel web spider (Agelenopsis aperta) venom peptide isomerase Peer-reviewed

Y Shikata, H Ohe, N Mano, M Kuwada, N Asakawa

BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY　62　(6)　1211-1215　1998/06

DOI： 10.1271/bbb.62.1211 　

ISSN： 0916-8451

eISSN： 1347-6947
Investigation of interactions between drug enantiomers and flavoprotein as a chiral selector by affinity capillary electrophoresis Peer-reviewed

N. Mano, Y. Oda, Y. Ishihama, H. Katayama, N. Asakawa

Journal of Liquid Chromatography and Related Technologies　21　(9)　1311-1332　1998

DOI： 10.1080/10826079808005880 　
Simultaneous quantitative determination method for sphingolipid metabolites by liquid chromatography/ionspray ionization tandem mass spectrometry Peer-reviewed

N Mano, Y Oda, K Yamada, N Asakawa, K Katayama

ANALYTICAL BIOCHEMISTRY　244　(2)　291-300　1997/01

DOI： 10.1006/abio.1996.9891 　

ISSN： 0003-2697
Plasma direct injection high-performance liquid chromatographic method for simultaneously determining E3810 enantiomers and their metabolites by using flavoprotein-conjugated column Peer-reviewed

N Mano, Y Oda, S Takakuwa, S Chiku, H Nakata, N Asakawa

JOURNAL OF PHARMACEUTICAL SCIENCES　85　(9)　903-907　1996/09

DOI： 10.1021/js960172n 　

ISSN： 0022-3549
Simultaneous determination of thromboxane B-2, prostaglandin E(2) and leukotriene B-4 in whole blood by liquid chromatography mass spectrometry Peer-reviewed

Y Oda, N Mano, N Asakawa

JOURNAL OF MASS SPECTROMETRY　30　(12)　1671-1678　1995/12

ISSN： 1076-5174

eISSN： 1096-9888
ENANTIOSELECTIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR DETERMINATION OF THE ENANTIOMERS OF A NEW ANTIULCER AGENT, E3810, IN BEAGLE DOG PLASMA AND RAT PLASMA Peer-reviewed

S TAKAKUWA, S CHIKU, H NAKATA, T YUZURIHA, N MANO, N ASAKAWA

JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS　673　(1)　113-122　1995/11

DOI： 10.1016/0378-4347(95)00247-G 　

ISSN： 0378-4347
QUANTITATION OF PLATELET-ACTIVATING-FACTOR IN BIOLOGICAL SAMPLES USING LIQUID CHROMATOGRAPHY MASS SPECTROMETRY WITH COLUMN-SWITCHING TECHNIQUE Peer-reviewed

Y ODA, N MANO, N ASAKAWA

ANALYTICAL BIOCHEMISTRY　231　(1)　141-150　1995/10

DOI： 10.1006/abio.1995.1513 　

ISSN： 0003-2697
STEREOSPECIFIC DEHYDROGENATION OF (25R)-3-ALPHA,7-ALPHA,12-ALPHA-TRIHYDROXY-5-BETA-CHOLESTANOIC AND (25S)-3-ALPHA,7-ALPHA,12-ALPHA-TRIHYDROXY-5-BETA-CHOLESTANOIC ACIDS BY ACYL-COA OXIDASE IN RAT-LIVER LIGHT MITOCHONDRIAL-FRACTION Peer-reviewed

S IKEGAWA, H WATANABE, T GOTO, N MANO, J GOTO, T NAMBARA

BIOLOGICAL & PHARMACEUTICAL BULLETIN　18　(8)　1041-1044　1995/08

DOI： 10.1248/bpb.18.1041 　

ISSN： 0918-6158
Relationship between the Association Constant and Enantioselectivity on the Flavoprotein-Conjugated Chiral Stationary Phase for High-Performance Liquid Chromatography

Nariyasu Mano, Yasushi Ishihama, Yoshiya Oda, Naoki Asakawa

Analytical Sciences　11　(6)　983-987　1995/01/01
Publisher: The Japan Society for Analytical Chemistry
DOI： 10.2116/analsci.11.983 　

ISSN： 0910-6340
STUDIES OF OVOMUCOID-CONJUGATED, AVIDIN-CONJUGATED, CONALBUMIN-CONJUGATED AND FLAVOPROTEIN-CONJUGATED CHIRAL STATIONARY PHASES FOR SEPARATION OF ENANTIOMERS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY Peer-reviewed

N MANO, Y ODA, N ASAKAWA, Y YOSHIDA, T SATO, T MIWA

JOURNAL OF CHROMATOGRAPHY A　687　(2)　223-232　1994/12

ISSN： 0021-9673
SIMPLE AND SENSITIVE QUANTITATION METHOD FOR MEVALONIC ACID IN PLASMA USING GAS-CHROMATOGRAPHY MASS-SPECTROMETRY Peer-reviewed

Y ISHIHAMA, N MANO, Y ODA, H HIYOSHI, H IKUTA, Y YOSHIDA

RAPID COMMUNICATIONS IN MASS SPECTROMETRY　8　(5)　377-380　1994/05

DOI： 10.1002/rcm.1290080507 　

ISSN： 0951-4198
RESOLUTION OF 4-(4-CHLOROBENZYL)-2-(HEXAHYDRO-1-METHYL-1H-AZEPIN-4YL)-1(2H)-PHTHALAZINONE ENANTIOMERS IN PLASMA WITH FRIT-FAB LC MS USING A CONALBUMIN COLUMN Peer-reviewed

N MANO, Y ODA, H OHE, N ASAKAWA, Y YOSHIDA, T SATO

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS　12　(4)　557-567　1994/04

DOI： 10.1016/0731-7085(93)E0003-6 　

ISSN： 0731-7085
A New Postcolumn Addition Method of the Matrix for Microbore Liquid Chromatography/Frit-Fast Atom Bombardment Mass Spectrometry.

ASAKAWA Naoki, OHE Hiroshi, ODA Yoshiya, MANO Nariyasu, SHIKATA Yasushi, YOSHIDA Yutaka, SATO Tadashi

J. Mass Spectrom. Soc. Jpn.　42　(1)　25-33　1994
Publisher: The Mass Spectrometry Society of Japan
DOI： 10.5702/massspec.42.25 　

ISSN： 1340-8097

More details Close

In the combination of liquid chromatography (LC)-fast atom bombardment mass spectrometry (FABMS), a new frit postcolumn addition of matrix (frit-PAM) system was designed to overcome the problems such as the diffusion of analytes and the ineffective ionization on FAB probe under the slow mobile phase flow. This system had a coaxial flow of LC effluent and FAB matrix in two separate tubes, and a frit to mix the both flows. The potential of this system was explored in the Frit-FAB LC/MS analysis of the tryptic digest of lysozyme as a test sample. This system can allow to use the mobile phases for the optimum separation in LC and the FAB matrix solution for the optimum ionization of analytes in FABMS, respectively, and can provide a high sensitivity.
CHIRAL LUMAZINES - PREPARATION, PROPERTIES, ENANTIOMERIC SEPARATION Peer-reviewed

R KLEIN, TATISCHEFF, I, G THAM, N MANO

CHIRALITY　6　(7)　564-571　1994

DOI： 10.1002/chir.530060709 　

ISSN： 0899-0042
Comparison of Avidin and Ovomucoid as Chiral Selectors for the Resolution of Drug Enantiomers by High-Performance Liquid Chromatography Peer-reviewed

Yoshiya Oda, Nariyasu Mano, Naoki Asakawa, Yutaka Yoshida, Tadashi Sato, Terumichi Nakagawa

analytical sciences　9　(2)　221-228　1993

DOI： 10.2116/analsci.9.221 　

ISSN： 1348-2246 0910-6340
DEVELOPMENT OF A FLAVOPROTEIN COLUMN FOR CHIRAL SEPARATION BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY Peer-reviewed

N MANO, Y ODA, N ASAKAWA, Y YOSHIDA, T SATO, T MIWA

JOURNAL OF CHROMATOGRAPHY　623　(2)　221-228　1992/10

ISSN： 0021-9673
CONALBUMIN-CONJUGATED SILICA-GEL, A NEW CHIRAL STATIONARY PHASE FOR HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY Peer-reviewed

N MANO, Y ODA, T MIWA, N ASAKAWA, Y YOSHIDA, T SATO

JOURNAL OF CHROMATOGRAPHY　603　(1-2)　105-109　1992/06

ISSN： 0021-9673

Show all ︎Show first 5

Misc. 364

クロザピンの血中濃度変動における有機アニオン輸送ポリペプチドの関与

佐藤紀宏, 公文代將希, 林和未, 小野口豪, 小松浩, 平塚真弘, 平塚真弘, 前川正充, 前川正充, 富田博秋, 眞野成康, 眞野成康

臨床化学(Web)　53　2024

ISSN： 0370-5633
Proteome analysis using model cells to reveal the molecular mechanism of Niemann-Pick disease type C pathogenesis

三好慶太郎, 前川正充, 前川正充, 前川正充, 菱沼英史, 菱沼英史, 松川直美, 小柴生造, 小柴生造, 深澤征義, 眞野成康, 眞野成康

日本薬学会年会要旨集(Web)　144th　2024

ISSN： 0918-9823
A case of non-small cell lung cancer in which osimertinib was administered via a tube at home using a simple suspension method.

水口敦史, 菊地正史, 成田佳奈, 宮内栄作, 眞野成康

医薬品相互作用研究　48　(1)　2024

ISSN： 0385-5015
Functional characterization of CYP2B6 rare variants identified in 8,380 Japanese individuals

山崎柊紀, 菱沼英史, 菱沼英史, 上田昭子, 前川正充, 前川正充, 前川正充, 佐藤裕, 公文代將希, 眞野成康, 眞野成康, 仲吉朝希, 小田彰史, 齋藤さかえ, 齋藤さかえ, 田高周, 田高周, 木下賢吾, 木下賢吾, 木下賢吾, 平澤典保, 平澤典保, 平澤典保, 平塚真弘, 平塚真弘, 平塚真弘, 平塚真弘

日本薬学会年会要旨集(Web)　143rd　2023

ISSN： 0918-9823
東北大学病院薬剤部における情報通信技術の導入と職員ならびに業務に与える影響の調査

前川正充, 前川正充, 佐藤紀宏, 雨山智, 佐藤稔之, 佐藤祐司, 前川麻央, 五十嵐敏明, 松浦正樹, 菊地正史, 菊地正史, 眞野成康, 眞野成康

医療薬学フォーラム講演要旨集　31st　2023

ISSN： 1348-0863
宮城県における薬剤師確保対策-病院支援体制の構築-

松浦正樹, 松浦正樹, 佐藤真由美, 森下史代, 山内新, 赤坂和俊, 五十嵐敏明, 菊地正史, 前川正充, 千田恵, 眞野成康

医療薬学フォーラム講演要旨集　31st　2023

ISSN： 1348-0863
マイクロサンプリングデバイスを用いたヒト血漿中レンバチニブ濃度定量法の開発

菊地正史, 菊地正史, 齊藤明博, 佐藤祐司, 公文代將希, 佐藤裕, 佐藤紀宏, 二宮匡史, 井上淳, 前川正充, 前川正充, 眞野成康, 眞野成康

医療薬学フォーラム講演要旨集　31st　2023

ISSN： 1348-0863
HBV-DNA陽性患者における注射用抗がん薬使用時のガイドライン遵守状況調査

赤坂和俊, 松浦正樹, 二瓶貴幸, 大柳元, 堀川美帆, 前嶋隆弘, 菊地正史, 前川正充, 眞野成康

医療薬学フォーラム講演要旨集　31st　2023

ISSN： 1348-0863
シスプラチン治療における急性腎障害の診断に関する現状分析

大竹彩奈, 佐藤紀宏, 近藤宏輝, 大久保美祐, 臼井拓也, 佐藤祐司, 前川正充, 眞野成康

日本腎臓病薬物療法学会誌　12　2023

ISSN： 2187-0411
液体クロマトグラフィー/タンデム質量分析法を用いたニーマンピック病C型モデル細胞内メタボローム変動解析の基礎検討

渡邊真広, 三好慶太郎, 加藤みどり, 深澤征義, 前川正充, 前川正充, 前川正充, 眞野成康, 眞野成康, 眞野成康

次世代を担う若手のためのフィジカル・ファーマフォーラム講演要旨集　20th　2023
Liquid chromatography/tandem mass spectrometry of various metabolites for disease biomarkers searching

前川正充, 眞野成康

日本プロテオーム学会大会プログラム・抄録集　2023 (CD-ROM)　2023
質量分析技術を用いるニーマンピック病C型の新規バイオマーカー開発

前川正充, 前川正充, 前川正充, 前川正充, 眞野成康, 眞野成康, 眞野成康

日本医療検査科学会春季セミナープログラム・抄録集　37th　2023
TERATOGENIC RISK OF FIRST TRIMESTER EXPOSURE TO ANTIHYPERTENSIVES, INCLUDING AMLODIPINE AND METHYLDOPA: AN ANALYSIS OF AN ADMINISTRATIVE DATABASE 2010-2019

Tomofumi Ishikawa, Hidekazu Nishigori, Manabu Akazawa, Keiko Miyakoda, Aoi Noda, Mami Ishikuro, Hirohito Metoki, Noriyuki Iwama, Masatoshi Saito, Junichi Sugawara, Hiroshi Kawame, Nobuo Yaegashi, Shinichi Kuriyama, Nariyasu Mano, Taku Obara

JOURNAL OF HYPERTENSION　41　E422-E422　2023/01

ISSN： 0263-6352

eISSN： 1473-5598
【多職種連携のためのタスクシフティングを考える-効率的な医療提供のために-】医療のタスクシフティング実現に向けた課題と展望

山本修一, 秋山智弥, 眞野成康

カレントテラピー　40　(4)　402-409　2022/04
Publisher: (株)ライフメディコム
ISSN： 0287-8445
Online MS Colloquium by Kanto, Hokkaido, Tohoku and Chubu-Area Groups, and Diversity and Inclusion Committee: Lecture on Quantitative Analysis, Lab Tour, and Social Meeting

Asanuma Miwako, Kawasaki Nana, Kobayashi Yuki, Saikusa Kazumi, Sawa Ryuichi, Shimbo Kazutaka, Tanabe Kana, Nozawa Kohei, Harazono Akira, Motoyama Akira, Akutsu Hiroaki, Oka Seiko, Jin Shigeki, Takata Yusuke, Bajo Ken-ichi, Hirose Tomohiro, Mori Ayako, Saigusa Daisuke, Sato Emiko, Soga Tomoyoshi, Hirayama Akiyoshi, Maekawa Masamitsu, Mano Nariyasu, Yoshino Ken-ichi, Osaka Issey, Kurono Sadamu, Kuwata Keiko, Sakai Tatsuko, Setou Mitsutoshi, Takahashi Yutaka, Naito Yasuhide, Matsumoto Tomohiro

Journal of the Mass Spectrometry Society of Japan　70　(1)　85-89　2022/03/01
Publisher: The Mass Spectrometry Society of Japan
DOI： 10.5702/massspec.s22-18 　

ISSN： 1340-8097

eISSN： 1880-4225 1884-3271
循環器疾患患者における薬剤管理サマリーの内容分析とアンケート調査

小林大典, 黒澤桂子, 田中里奈, 高橋茜, 中村磨奈, 森下啓, 佐藤稔之, 高崎新也, 佐藤祐司, 前川麻央, 前嶋隆弘, 松浦正樹, 前川正充, 眞野成康

日本循環器学会学術集会抄録集　86回　CO1-5　2022/03
Publisher: (一社)日本循環器学会
薬剤師におけるタスク・シフティング

眞野成康

日本消化器病学会雑誌　119　(臨増総会)　A14-A14　2022/03
Publisher: (一財)日本消化器病学会
ISSN： 0446-6586

eISSN： 1349-7693
【お薬立ちBOOK2022 解剖生理・病態生理から薬学管理へ】病態生理を踏まえた薬物治療・薬学管理へ貧血薬理と薬学管理上の注意点

鈴木文子, 眞野成康

薬局　73　(4)　709-715　2022/03
Publisher: (株)南山堂
ISSN： 0044-0035
【お薬立ちBOOK2022 解剖生理・病態生理から薬学管理へ】病態生理を踏まえた薬物治療・薬学管理へ髄膜炎薬理と薬学管理のポイント

鈴木博也, 眞野成康

薬局　73　(4)　1306-1308　2022/03
Publisher: (株)南山堂
ISSN： 0044-0035
液体クロマトグラフィー/タンデム質量分析法を用いたニーマンピック病C型モデル細胞内プロテオーム変動解析

三好慶太郎, 前川正充, 前川正充, 前川正充, 菱沼英史, 菱沼英史, 松川直美, 小柴生造, 小柴生造, 深澤征義, 眞野成康, 眞野成康

次世代を担う若手のためのフィジカル・ファーマフォーラム講演要旨集　19th　2022
B型肝炎関連検査の実施率向上を目指した検査チェックシステムの構築と評価

二瓶貴幸, 松浦正樹, 堀川美帆, 前嶋隆弘, 大柳元, 赤坂和俊, 菊地正史, 前川正充, 井上隆輔, 勝見真琴, 井上淳, 大内康太, 高橋雅信, 石岡千加史, 眞野成康

日本医療薬学会年会講演要旨集(Web)　32　2022

ISSN： 2424-2470
LC/ESI-MS/MSを用いた経口分子標的抗がん薬及び代謝物の一斉定量法の開発

菊地正史, 菊地正史, 平澤天晴, 高崎新也, 公文代將希, 佐藤裕, 佐藤紀宏, 前川正充, 前川正充, 眞野成康, 眞野成康

日本医療薬学会年会講演要旨集(Web)　32　2022

ISSN： 2424-2470
LC/MS/MSを活用した薬物血中濃度測定法の構築と精神科領域の治療薬物モニタリングへの取り組み

前川正充, 前川正充, 佐藤紀宏, 鈴鹿雅人, 佐藤祐司, 菊地正史, 菊地正史, 眞野成康, 眞野成康

日本医療薬学会年会講演要旨集(Web)　32　2022

ISSN： 2424-2470
OATP4C1におけるフラボノイド類-薬物相互作用の解析

八木文佳, 佐藤紀宏, 山内碧, 川上佳織, 前川正充, 前川正充, 眞野成康, 眞野成康

日本薬学会東北支部大会講演要旨集　61st　2022
東北大学病院における新型コロナウイルスワクチン追加接種による副反応調査

佐藤朗, 佐藤朗, 佐藤裕, 佐藤智見, 鷹尾月舟, 菅原英里奈, 鈴木博也, 鈴木博也, 公文代將希, 佐藤紀宏, 前川正充, 徳田浩一, 眞野成康

日本医療薬学会年会講演要旨集(Web)　32　2022

ISSN： 2424-2470
Searching for Biomarker Candidates for Intraoperative Differential Diagnosis of Astrocytoma and Oligodendroglioma

渡邊真広, 前川正充, 前川正充, 前川正充, 金森政之, 冨永悌二, 眞野成康, 眞野成康, 眞野成康

質量分析総合討論会講演要旨集　70th　2022
Fundamental investigation of proteome analysis in Niemann Pick disease type C model cells

三好慶太郎, 前川正充, 前川正充, 前川正充, 菱沼英史, 菱沼英史, 松川直美, 小柴生造, 小柴生造, 深澤征義, 眞野成康, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　34th　2022

ISSN： 1347-2364
Fundamental Investigation of Change in Peak Intensity in Nontargeted Metabolomics using LC/MS/MS

渡邊真広, 前川正充, 眞野成康, 前川正充, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　34th　2022

ISSN： 1347-2364
Searching, Structural Determination, and Diagnostic Performance Evaluation of Biomarker Molecules for Niemann–Pick Disease Type C Using Liquid Chromatography/Tandem Mass Spectrometry

Masamitsu Maekawa, Nariyasu Mano

Mass Spectrometry　11　(1)　2022

DOI： 10.5702/massspectrometry.A0111 　

ISSN： 2187-137X

eISSN： 2186-5116
デジタルツール導入による東北大学病院薬剤部の業務改革

前川正充, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　24th　2022
オンライン化DI-病棟連携ミーティングに関するアンケート調査の解析

前川麻央, 前嶋隆弘, 大柳元, 松浦正樹, 前川正充, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　24th　2022
妊娠初期の消化管運動改善薬処方と児の大奇形との関連大規模レセプトデータベースを用いた評価

石川智史, 小原拓, 赤沢学, 野田あおい, 大柳元, 森下啓, 都田桂子, 西郡秀和, 川目裕, 八重樫伸生, 栗山進一, 眞野成康

Journal of Epidemiology　32　(Suppl.1)　141-141　2022/01
Publisher: (一社)日本疫学会
ISSN： 0917-5040

eISSN： 1349-9092
LC/MS/MSを用いる胆汁酸メタボローム解析法の構築と非アルコール性脂肪性肝炎患者検体の分析

マエカワマサミツ, マノナリヤス

4　(13)　1258-1264　2021/12
Publisher: (株)北隆館
ISSN： 2434-3625
宮城県における耐性菌サーベイランス2020

鈴木博也, 森下啓, 鈴木寿樹, 久道周彦, 勝見真琴, 徳田浩一, 眞野成康

日本臨床微生物学会雑誌　32　(Suppl.1)　248-248　2021/12
Publisher: (一社)日本臨床微生物学会
ISSN： 2434-866X
新型コロナウイルス感染症に対応した病院実務実習プログラムの評価

菊地正史, 佐藤裕, 佐藤紀宏, 前川正充, 眞野成康

日本病院薬剤師会雑誌　57　(11)　1256-1261　2021/11
Publisher: (一社)日本病院薬剤師会
ISSN： 1341-8815
臨床化学検査領域で活躍する質量分析技術(MS)-マーカー探索から実用化・標準化まで- 質量分析法による各種分子の定性・定量解析に基づくニーマンピック病C型の化学診断法の開発

前川正充, 眞野成康

日本臨床検査医学会誌　69　(補冊)　041-041　2021/10
Publisher: (一社)日本臨床検査医学会
ISSN： 2436-2727
薬剤師によるタスク・シフティングを考える手術室関連業務におけるタスク・シフティング

眞野成康

日本病院薬剤師会 Future Pharmacist Forum 抄録集　4回　64-64　2021/07
Publisher: (一社)日本病院薬剤師会
改正医療法施行後のTDM研究の実践と発展に向けて LC-MS/MSを用いた血中薬物濃度測定における精度管理

菊地正史, 高崎新也, 前川正充, 眞野成康

TDM研究　38　(2)　69-69　2021/05
Publisher: (一社)日本TDM学会
ISSN： 0911-1026
質量分析を用いたTDMの基礎と応用ならびに東北大学病院薬剤部における薬剤師教育体制について

前川正充, 菊地正史, 眞野成康

TDM研究　38　(2)　164-164　2021/05
Publisher: (一社)日本TDM学会
ISSN： 0911-1026
【病気とくすり2021 基礎と実践Expert's Guide】循環器系の病気とくすり血液・造血器系疾患貧血

斎藤陽, 張替秀郎, 鈴木文子, 眞野成康

薬局　72　(4)　1032-1043　2021/03
Publisher: (株)南山堂
ISSN： 0044-0035
第5回臨床化学の進歩が変える薬物治療〜高精度な臨床検査法確立への挑戦〜質量分析を用いるニーマンピック病C型の新規バイオマーカー探索と性能評価

前川正充, 眞野成康

日本薬学会年会要旨集　141年会　S26-5　2021/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
新型コロナウイルス感染症治療薬レムデシビルおよびGS-441524の腎排泄および薬物相互作用におけるOATP4C1の役割

佐藤紀宏, 前川正充, 阿部高明, 山口浩明, 眞野成康

日本薬学会年会要旨集　141年会　28V11-pm20　2021/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
新型コロナウイルス感染症に対応した病院実務実習プログラムの実践と評価

菊地正史, 佐藤裕, 佐藤紀宏, 前川正充, 眞野成康

日本薬学会年会要旨集　141年会　28P01-258　2021/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Identification and diagnostic performance evaluation of biomarkers for Niemann-Pick disease type C using mass spectrometry

Maekawa, M., Iwahori, A., Mano, N.

Japanese journal of clinical chemistry　50　(1)　2021

ISSN： 0370-5633
抗精神病薬および併用薬の処方状況とCYPを介した薬物間相互作用の可能性に関する調査

横田真希, 前川正充, 前川正充, 鈴木直人, 小林大典, 鈴鹿雅人, 佐藤祐司, 公文代將希, 佐藤裕, 佐藤紀宏, 菊地正史, 菊地正史, 眞野成康, 眞野成康

日本医療薬学会年会講演要旨集(Web)　31　2021

ISSN： 2424-2470
東北大学病院の薬剤管理サマリーの内容分析と有用性に関する調査

小林大典, 黒澤桂子, 田中里奈, 高橋茜, 森下啓, 佐藤稔之, 高崎新也, 佐藤祐司, 松浦正樹, 前川正充, 眞野成康

日本医療薬学会年会講演要旨集(Web)　31　2021

ISSN： 2424-2470
神経細胞外のグルタミン酸によるグルタチオン枯渇はProtein disulfide isomeraseのニトロシル化を誘導する

小倉次郎, 小倉次郎, 小野慎司, 杉浦弘樹, 山内碧, 佐藤紀宏, 前川正充, 前川正充, 前川正充, 山口浩明, 山口浩明, 眞野成康, 眞野成康, 眞野成康

日本医療薬学会年会講演要旨集(Web)　31　2021

ISSN： 2424-2470
東北大学病院で新型コロナウイルス感染症(COVID-19)治療に用いた薬物の血中濃度と臨床指標との相関解析

佐藤稔之, 高崎新也, 森下啓, 千葉僚, 小林大典, 鈴木博也, 佐藤裕, 佐藤紀宏, 菊地正史, 早川禎宏, 杉浦久敏, 青柳哲史, 前川正充, 眞野成康

日本医療薬学会年会講演要旨集(Web)　31　2021

ISSN： 2424-2470
バイオバンク情報を活用した40種のCYP3A4バリアントにおける機能変化解析

平塚真弘, 平塚真弘, 平塚真弘, 平塚真弘, 公文代將希, 公文代將希, GUTIERREZ Evelyn, 菱沼英史, 菱沼英史, 上田昭子, 齋藤さかえ, 齋藤さかえ, 三枝大輔, 三枝大輔, 田高周, 木下賢吾, 木下賢吾, 仲吉朝希, 小田彰史, 前川正充, 眞野成康, 平澤典保, 平澤典保, 平澤典保

日本人類遺伝学会大会プログラム・抄録集　66th (CD-ROM)　2021
Fundamental study for the development of LC/ESI-MS/MS method for simultaneous quantification of oral molecular targeted drugs and their metabolites

平澤天晴, 菊地正史, 菊地正史, 高崎新也, 公文代將希, 佐藤裕, 佐藤紀宏, 前川正充, 前川正充, 眞野成康, 眞野成康

JSBMS Letters　46　(Supplement)　2021

ISSN： 1881-5464
Simultaneous analysis of remdesivir, favipiravir, and etoposide used to treat COVID-19 infection using liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring

高崎新也, 佐藤稔之, 鈴木博也, 青柳哲史, 青柳哲史, 森下啓, 千葉僚, 佐藤裕, 佐藤紀宏, 菊地正史, 大島謙吾, 徳田浩一, 前川正充, 眞野成康

JSBMS Letters　46　(Supplement)　2021

ISSN： 1881-5464
Quantitative analysis of gut microbiota-derived metabolites by LC-MS sheds light on the gut-kidney axis on kidney disease

金光祥臣, 三島英換, 松本洋太郎, 前川正充, 前川正充, 菊地晃一, 三枝大輔, 阿部高明, 阿部高明, 眞野成康, 眞野成康, 富岡佳久

JSBMS Letters　46　(Supplement)　2021

ISSN： 1881-5464
Current situation of anticancer agents’ usage for Adolescents and Young Adult (AYA) females with cancer using an administrative claims database

土屋雅美, 土屋雅美, 田島健太郎, 小原拓, 小原拓, 眞野成康, 眞野成康

日本臨床腫瘍学会学術集会(CD-ROM)　18th　2021
Recent topics on novel biomarkers for lysosomal storage disorders

真嶋隆一, 前川正充, 前川正充, 大平麻里, 眞野成康, 眞野成康, 奥山虎之

質量分析総合討論会講演要旨集　69th　2021
グルタチオン合成阻害によるグルタチオン枯渇はProtein disulfide isomeraseのS-ニトロシル化を誘導する

小倉次郎, 小野慎司, 杉浦弘樹, 山内碧, 佐藤紀宏, 前川正充, 眞野成康, 山口浩明

日本臨床薬理学会学術総会抄録集　42　2-P-I-7　2021
Publisher: 一般社団法人日本臨床薬理学会
DOI： 10.50993/jsptsuppl.42.0_2-p-i-7 　

eISSN： 2436-5580

More details Close

【目的】Protein disulfide isomerase (PDI) は、タンパク質のジスルフィド結合の形成、異性化を担い、タンパク質の高次構造形成に重要な役割を果たしている。異常タンパク質の蓄積を特徴として持つアルツハイマー病などの神経変性疾患では、PDIのS-ニトロシル (SNO) 化が起こり、その発症に関わることが示唆されている。一方で、PDIのSNO化をもたらす原因や神経変性疾患の発症機構については、未だ不明な点が多い。本研究では、アルツハイマー病患者の脳内でグルタチオン濃度が低下することに着目し、グルタチオンの枯渇がPDIのSNO化に与える影響を検討した。【方法】実験にはグルタチオン合成酵素阻害剤buthionine sulfoximine (BSO) 添加後24時間経過したヒト神経芽腫由来SH-SY5Y細胞を用いた。細胞生存率はMTT assayにより、細胞内活性酸素種 (ROS) 量はDCHF-DAを用いて、細胞内グルタチオン量はEllman's assayにより測定した。また、PDIのSNO化はBiotin-switch assayにより、小胞体ストレスマーカーの活性化はWestern blottingにより評価した。【結果・考察】BSOを25, 50, 100 μMで添加し24時間後のSH-SY5Y細胞の細胞生存率に変化は見られなかった。一方、細胞内ROS量は、BSO添加群で濃度依存的に増加した。さらに、BSOを添加したときの細胞内グルタチオン量は、各濃度でコントロールと比較して70‐80%程度低下した。続いて、本条件により誘導されたグルタチオン枯渇により、SH-SY5Y細胞中のPDIにSNO化が生じるかを評価した。その結果、100 μMのBSOを添加し24時間後のSNO化PDI量は増加した。PDIのSNO化は小胞体ストレスマーカーであるIRE1αのリン酸化、PERKのリン酸化、ATF6の切断のうち、特にIRE1αのリン酸化を誘導することが明らかとなっている。そこで、PDIのSNO化が小胞体内に及ぼす影響を調べるために、IRE1αのリン酸化を評価したところ、100 μMのBSO添加後24時間でリン酸化IRE1αの増加が確認された。【結論】神経細胞内のグルタチオン合成阻害により細胞内グルタチオンが枯渇し、PDIのSNO化が誘導される。さらに、PDIのSNO化により小胞体ストレスが生じ、IRE1αのリン酸化が亢進する。本研究により、神経細胞内のグルタチオン量の低下がPDIのSNO化の一因となることが明らかとなり、神経変性疾患の発症メカニズムの解明、ひいては新たな治療法の開発につながることが期待される。
全国大学医学部における医薬品・医療機器等安全性情報報告制度に関わる授業内容の実態

佐藤倫広, 目時弘仁, 堀里子, 小原拓, 眞野成康

日本臨床薬理学会学術総会抄録集　42　2-P-O-3　2021
Publisher: 一般社団法人日本臨床薬理学会
DOI： 10.50993/jsptsuppl.42.0_2-p-o-3 　

eISSN： 2436-5580

More details Close

【目的】医薬品・医療機器等安全性情報報告制度（以下、本制度）により、医薬関係者は医薬品等によって発生する健康被害等の情報を厚生労働大臣に報告することとされている。全ての医療機関及び薬局等が対象であるが、医薬品の国内副作用・感染症症例報告に占める医療機関報告は少ない。本制度の理解度が副作用等報告の経験に強く関連するという先行研究から、大学生時代における教育が重要と考えられるが、医学部における教育実態は明らかではない。本研究では、全国の医学部を有する大学を対象に、本制度に関わる授業を明らかにすることを目的とした。 【方法】本研究は、医薬品等規制調和・評価研究事業（AMED）『医薬関係者による副作用報告の質向上に向けた情報連携のあり方の研究（代表：眞野成康）』の一環として実施された。全国の医学部を有する大学に、電話、メール、ホームページからの問い合わせ、または紙媒体の郵送により調査を依頼し、本制度に関わる授業科目とその内容、および自由記載により本制度の医学教育における改善点と意見を収集した。 【結果・考察】全82大学のうち25大学から当該授業科目の内容が回答された。その他、11大学から該当する授業がない旨の回答、4大学から回答拒否、および42大学からは未回答（現在郵送調査による再依頼中）であった。本制度に関わる講義をした科目は、薬理学が9件、臨床薬理学・薬物治療学が8件、衛生学・公衆衛生学が5件、医療安全・管理学が5件と多く、概論や実習を含むその他25件の科目も挙げられた。これら授業のコマ数を各大学で集計した結果、授業コマ数は1～2コマが17大学と最も多かった。履修学年は4年次が最も多く、5年次以上で回答された科目を実施している大学は3大学のみであった。医薬品安全性情報報告書を実際に「記載させる」と回答した科目は1件のみであった。意見の自由記載欄では、副作用発生の臨床薬理学的なバックグラウンドや薬害歴史の理解の重要性に言及した回答が比較的多く見られ、その他、報告に関わる実習の増加、医学部コアカリキュラムの改定、または5～6年や卒後の教育の充実などが具体的な提案として挙げられた。 【結論】医学部における本制度の講義は、主に薬理学および臨床薬理学・薬物治療学で実施されていた。実際に報告を経験させる授業は限られており、また、5～6年次における授業も不十分と考えられた。
医薬品の安全管理

眞野成康

看護薬理学カンファレンス　2021.3　SP-1　2021
Publisher: 公益社団法人日本薬理学会
DOI： 10.34597/npc.2021.3.0_sp-1 　

eISSN： 2435-8460

More details Close

平成 28 年 6月10日に医療法施行規則の一部を改正する省令が公布された。大学附属病院等で発生したいくつかの医療安全に関する重大な事案を受けて厚生労働省内に検討会が設置され、「大学附属病院等の医療安全確保に関するタスクフォース等を踏まえた特定機能病院の承認要件の見直しについて」がとりまとめられたが、本省令はこれに基づくものである。一方、本邦では 90年代から課題となっていた新規医薬品開発における「ドラッグ・ラグ」が、医薬品医療機器総合機構（PMDA）のこれまでの取り組みによってほぼ解消されており、場合によっては世界に先駆けて新規医薬品が上市されることもある。こうした背景から、医薬品の市販後安全対策の重要性が増しており、特に未知の副作用モニタリングへの医療者の取り組みの強化が求められている。医薬品・医療機器等安全性情報報告制度は、「医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律（薬機法）」の第 68 条の10 第 2項に基づくものであり、医師や薬剤師等の医薬関係者に、医薬品の使用による副作用と疑われる事項を知った場合に、それを厚生労働大臣に報告することが義務付けられている。しかしながら、医療者による本制度自体への理解度が十分でないことから、医療機関からの報告が伸び悩んでおり、引き続き啓発することが重要である。一方、病棟の薬剤師は、副作用管理のみならず治療効果の向上にも重要な役割を果たしている。がん薬物療法においては、近年多くの分子標的薬や免疫チェックポイント阻害薬が上市され、治療成績も大きく向上している。当院では、様々な薬物の治療薬物モニタリング（TDM）を実施しており、治療効果を最大化するために、副作用をコントロールしつつ治療継続する重要性を指摘している。こうした医薬品安全管理に関する取り組みは、薬剤師だけでなく、院内全体における共有が重要であり、上記の医療法施行規則の改正においても医薬品安全情報の周知が求められている。医療機関において発生するインシデントの3 分の1は薬剤に関することであり、その多くが実施の場面で発生していることから、看護師への的確な注意喚起が必要である。医師、看護師、薬剤師等、すべての医療スタッフがこうした情報を共有することが、患者に適切な医療を提供するうえで極めて重要である。
【臨床薬学研究における新たな定量分析法の開発・応用】質量分析法を用いるニーマンピック病C型バイオマーカーの同定と診断性能評価

前川正充, 岩堀杏南, 眞野成康

臨床化学　50　(1)　20-26　2021/01
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
癌細胞代謝からみた腎癌細胞におけるsunitinib耐性獲得機構の解明

佐藤友紀, 川崎芳英, 前川正充, 高崎新也, 諸角謙人, 佐藤真彦, 嶋田修一, 川守田直樹, 山下慎一, 三塚浩二, 眞野成康, 伊藤明宏

日本泌尿器科学会総会　108回　799-799　2020/12
Publisher: (一社)日本泌尿器科学会総会事務局
新薬学教育6年制を考える新型コロナウイルス感染症に対応した病院実務実習プログラムの構築と実践

菊地正史, 佐藤裕, 佐藤紀宏, 前川正充, 眞野成康

医薬品相互作用研究　44　(3)　191-195　2020/12
Publisher: 医薬品相互作用研究会
ISSN： 0385-5015
特定薬剤治療管理料1(TDM)が求める血中薬物濃度測定結果の活用治療効果の最大化を目指した経口抗がん薬の治療薬物モニタリング

高崎新也, 菊地正史, 眞野成康

臨床化学　49　(Suppl.1)　118-118　2020/10
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
ニーマンピック病診断スクリーニング検査法の開発を目指した血清リン脂質類のLC-MS/MS分析法の構築

岩堀杏南, 前川正充, 眞野成康

臨床化学　49　(Suppl.1)　219-219　2020/10
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
【貧血最新の薬物治療戦略と実践ポイント】鉄剤を使いこなす"知識"と"ノウハウ"! 鉄剤で留意すべき副作用・相互作用は?

大柳元, 眞野成康

薬局　71　(10)　3150-3154　2020/09
Publisher: (株)南山堂
ISSN： 0044-0035
ニーマンピック病の血清メタボローム解析と新規スクリーニング戦略

前川正充, 岩堀杏南, 眞野成康

JSBMS Letters　45　(Suppl.)　33-33　2020/08
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
アデニン誘発腎不全マウスにおけるエロビキシバットの効果

秋山由雅子, 前川正充, 金光祥臣, 菊地晃一, 何欣蓉, 三島英換, 鈴木健弘, 一條真梨子, 鈴木千登世, 眞野成康, 富岡佳久, 阿部高明

日本腎臓学会誌　62　(4)　337-337　2020/07
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385

eISSN： 1884-0728
パゾパニブ投与によりワルファリン服用患者のPT-INRが上昇した1例

高崎新也, 川崎芳英, 菊地正史, 伊藤明宏, 眞野成康

日本臨床腫瘍薬学会雑誌　15　376-376　2020/05
Publisher: (一社)日本臨床腫瘍薬学会
eISSN： 2189-129X
ワルファリン、5-フルオロウラシルおよびタゾバクタム・ピペラシリンの併用によりプロトロンビン時間が著明に延長した2症例

堀川美帆, 小山美菜, 赤井文香, 前川麻央, 佐藤祐司, 高橋阿希子, 菊地正史, 眞野成康

日本臨床腫瘍薬学会雑誌　15　377-377　2020/05
Publisher: (一社)日本臨床腫瘍薬学会
eISSN： 2189-129X
薬剤感受性に基づく病棟薬剤師の処方提案が、細菌性髄膜炎の抗菌薬適正使用につながった1例

千葉僚, 鈴木博也, 徳田浩一, 眞野成康

日本化学療法学会雑誌　68　(2)　290-290　2020/03
Publisher: (公社)日本化学療法学会
ISSN： 1340-7007

eISSN： 1884-5886
内視鏡的逆行性胆管膵管造影パスにおける予防的抗菌薬変更の妥当性検証

森下啓, 鈴木博也, 眞野成康

日本化学療法学会雑誌　68　(2)　304-304　2020/03
Publisher: (公社)日本化学療法学会
ISSN： 1340-7007

eISSN： 1884-5886
【病気とくすり2020 基礎と実践Expert's Guide】循環器系・泌尿器系・生殖器系の病気とくすり血液・造血器系疾患貧血

斎藤陽, 張替秀郎, 鈴木文子, 眞野成康

薬局　71　(4)　1046-1057　2020/03
Publisher: (株)南山堂
ISSN： 0044-0035
第4回臨床化学の進歩が変える薬物治療〜解析技術の革新と臨床応用〜質量分析法を基盤とするニーマンピック病C型の新規バイオマーカー探索

前川正充, 眞野成康

日本薬学会年会要旨集　140年会　S01-5　2020/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
LC/MS/MSを用いるクロザピンおよび脱メチル代謝物の血漿中濃度測定法の構築

佐藤紀宏, 鈴鹿雅人, 小林大典, 岩渕理子, 今野壮太, 佐藤祐司, 塚本多矩, 早川禎宏, 高崎新也, 小倉次郎, 菊地正史, 前川正充, 眞野成康

日本薬学会年会要旨集　140年会　26Q-pm025　2020/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
薬局勤務薬剤師における副作用等報告制度の認識と実践

原梓, 山口浩, 小原拓, 神藤愛実, 沢諒, 阿部真也, 吉町昌子, 後藤輝明, 宮崎生子, 眞野成康

日本薬学会年会要旨集　140年会　27P-pm032　2020/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
糖質負荷による神経変性とUnfolded Protein Response遺伝子の経時変化の関連

佐藤稔之, 小倉次郎, 杉浦弘樹, 小野慎司, 眞野成康

日本薬学会年会要旨集　140年会　27Q-pm142　2020/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
ワルファリンとメテノロンの併用によってPT-INRの延長が疑われた1例

山田健太, 高崎新也, 黒澤桂子, 福井重文, 眞野成康

日本薬学会年会要旨集　140年会　28P-pm133　2020/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
抗がん薬定量分析系を活用した環境汚染状況の現状調査と曝露対策の評価

鈴木寿樹, 小林美奈子, 高崎新也, 横田則子, 菊地正史, 前川正充, 眞野成康

日本医療薬学会年会講演要旨集(Web)　30　2020

ISSN： 2424-2470
乳癌におけるCDK4/6阻害薬及びホルモン療法薬の血中濃度一斉分析法の構築

佐藤裕, 重田健介, 平澤天晴, 菊地正史, 菊地正史, 佐藤紀宏, 小倉次郎, 前川正充, 前川正充, 江幡明子, 濱中洋平, 多田寛, 石田孝宣, 眞野成康, 眞野成康

日本医療薬学会年会講演要旨集(Web)　30　2020

ISSN： 2424-2470
アデニン誘発腎不全マウスにおけるエロビキシバットの効果

秋山由雅子, 前川正充, 金光祥臣, 菊地晃一, 何欣蓉, 三島英換, 鈴木健弘, 一條真梨子, 鈴木千登世, 眞野成康, 富岡佳久, 阿部高明

日本腎臓学会誌(Web)　62　(4)　2020

ISSN： 1884-0728
Structural determination of lysosphingomyelin-509 and development of diagnostic method for Niemann-Pick disease type C

前川正充, 前川正充, 岩堀杏南, 松本洋太郎, 松本洋太郎, 眞野成康, 眞野成康

質量分析総合討論会講演要旨集　68th　2020
ニーマンピック病C型の未知バイオマーカーLysosphingomyelin-509の同定

前川正充, 松本洋太郎, 真嶋隆一, 高橋秀典, 岩堀杏南, 成田綾, 奥山虎之, 衞藤義勝, 山口浩明, 眞野成康

日本先天代謝異常学会雑誌　35　111-111　2019/09
Publisher: 日本先天代謝異常学会
ISSN： 0912-0122
インソースCIDを利用したLC/ESI‐MS/MSによる抗がん薬の同時測定法の構築に向けた基礎的検討

平澤天晴, 重田健介, 前川正充, 小倉次郎, 菊地正史, 菊地正史, 眞野成康, 眞野成康

臨床化学　48　(Suppl.1)　251-251　2019/08/28
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
血清リン脂質類のLC‐MS/MS分析に基づくニーマンピック病C型の迅速スクリーニング法の検討

岩堀杏南, 前川正充, 山口浩明, 眞野成康, 眞野成康

臨床化学　48　(Suppl.1)　290-290　2019/08/28
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC‐MS/MSを用いる脂質メディエーター網羅的解析の基礎的検討

横田真希, 前川正充, 福田隼, 眞野成康, 眞野成康, 山口浩明

臨床化学　48　(Suppl.1)　290-290　2019/08/28
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC/MS/MSによるニーマンピック病C型モデル細胞中ステロイドホルモン類の挙動解析

阿部愛, 前川正充, 小倉次郎, 山口浩明, 山口浩明, 眞野成康, 眞野成康

臨床化学　48　(Suppl.1)　289-289　2019/08/28
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC/ESI‐MS/MSを用いる胆汁酸メタボローム解析系の基礎的検討

庄子彩織, 前川正充, 山口浩明, 山口浩明, 眞野成康, 眞野成康

臨床化学　48　(Suppl.1)　289-289　2019/08/28
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
グローバルメタボロミクスによるニーマンピック病C型患者血液に特徴的なピーク探索

前川正充, 前川正充, 岩堀杏南, 金光祥臣, 三枝大輔, 三枝大輔, 山口浩明, 山口浩明, 山口浩明, 眞野成康, 眞野成康

JSBMS Letters　44　(Supplement)　79-79　2019/08/25
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
分離科学を基盤とした臨床分析化学

眞野成康

臨床化学　48　(Suppl.1)　85-85　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
インソースCIDを利用したLC/ESI-MS/MSによる抗がん薬の同時測定法の構築に向けた基礎的検討

平澤天晴, 重田健介, 前川正充, 小倉次郎, 菊地正史, 眞野成康

臨床化学　48　(Suppl.1)　251-251　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC/ESI-MS/MSによる全血中シロリムス測定法の構築とリンパ脈管筋腫症患者への適用

重田健介, 菊地正史, 眞野成康, 山口浩明

臨床化学　48　(Suppl.1)　269-269　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC/MS/MSによるニーマンピック病C型モデル細胞中ステロイドホルモン類の挙動解析

阿部愛, 前川正充, 小倉次郎, 山口浩明, 眞野成康

臨床化学　48　(Suppl.1)　289-289　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC/ESI-MS/MSを用いる胆汁酸メタボローム解析系の基礎的検討

庄子彩織, 前川正充, 山口浩明, 眞野成康

臨床化学　48　(Suppl.1)　289-289　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
血清リン脂質類のLC-MS/MS分析に基づくニーマンピック病C型の迅速スクリーニング法の検討

岩堀杏南, 前川正充, 山口浩明, 眞野成康

臨床化学　48　(Suppl.1)　290-290　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
PDI基質結合部位のニトロソ化が誘導する小胞体ストレスマーカーの探索

小野慎司, 小倉次郎, 杉浦弘樹, 眞野成康

臨床化学　48　(Suppl.1)　292-292　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
糖質負荷によるUnfolded Protein Responseマーカーの経時変化の検証

杉浦弘樹, 小倉次郎, 佐藤稔之, 小野慎司, 眞野成康

臨床化学　48　(Suppl.1)　292-292　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
グローバルメタボロミクスによるニーマンピック病C型患者血液に特徴的なピーク探索

前川正充, 岩堀杏南, 金光祥臣, 三枝大輔, 山口浩明, 眞野成康

JSBMS Letters　44　(Suppl.)　79-79　2019/08
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
インソースCIDを利用したLC/ESI‐MS/MSによる薬物一斉定量法構築への取り組み

菊地正史, 菊地正史, 前川正充, 塚本多矩, 眞野成康, 眞野成康

臨床化学　48　(Suppl.1)　162-162　2019/08
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
第2回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線〜分子標的探索と個別化医療への挑戦〜経口分子標的薬の個別化投与設計に向けて

山口浩明, 高崎新也, 菊地正史, 川崎芳英, 荒井陽一, 眞野成康

薬学雑誌　139　(6)　911-915　2019/06
Publisher: (公社)日本薬学会
ISSN： 0031-6903

eISSN： 1347-5231
第2回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線〜分子標的探索と個別化医療への挑戦〜経口分子標的薬の個別化投与設計に向けて

山口浩明, 高崎新也, 菊地正史, 川崎芳英, 荒井陽一, 眞野成康

薬学雑誌　139　(6)　911-915　2019/06
Publisher: (公社)日本薬学会
ISSN： 0031-6903
日本人肺移植患者におけるミコフェノール酸およびミコフェノール酸アシルグルクロン酸抱合体のAUC0-12の推定式

田中雅樹, 菊地正史, 高崎新也, 野田あおい, 秋場美紀, 松田安史, 大石久, 野田雅史, 岡田克典, 眞野成康, 山口浩明

TDM研究　36　(2)　135-135　2019/05
Publisher: (一社)日本TDM学会
ISSN： 0911-1026
胆汁酸トランスポーター阻害薬エロビキシバットによる腎保護作用の検討

秋山由雅子, 何欣蓉, 金光祥臣, 前川正充, 菊地晃一, 鈴木健弘, 三島英換, 一條真梨子, 鈴木千登世, 眞野成康, 富岡佳久, 伊藤貞嘉, 阿部高明

日本腎臓学会誌　61　(3)　403-403　2019/05
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385

eISSN： 1884-0728
経口がん分子標的薬の個別投与設計に向けた取り組み

山口浩明, 高崎新也, 菊地正史, 川崎芳英, 伊藤明宏, 眞野成康

日本薬剤学会年会講演要旨集(Web)　34年会　34-34　2019/05
Publisher: (公社)日本薬剤学会
血中エベロリムス濃度と臨床効果の関連性~腎癌治療における長期追跡調査~

高崎新也, 川崎芳英, 菊地正史, 田中雅樹, 山口浩明, 伊藤明宏, 眞野成康

TDM研究　36　(2)　138-138　2019/05
Publisher: (一社)日本TDM学会
ISSN： 0911-1026
日本人肺移植患者におけるミコフェノール酸およびミコフェノール酸アシルグルクロン酸抱合体のAUC0-12の推定式

田中雅樹, 菊地正史, 高崎新也, 野田あおい, 秋場美紀, 松田安史, 大石久, 野田雅史, 岡田克典, 眞野成康, 山口浩明

TDM研究　36　(2)　135-135　2019/05
Publisher: (一社)日本TDM学会
ISSN： 0911-1026
グローバルメタボロミクスを用いた腎癌の診断と臨床病理学的因子に関わる代謝化合物の評価

佐藤友紀, 川崎芳英, 前川正充, 高崎新也, 三枝大輔, 大田英揮, 嶋田修一, 山下慎一, 三塚浩二, 伊藤明宏, 小柴生造, 眞野成康, 荒井陽一, 荒井陽一

日本泌尿器科学会総会(Web)　107回　OP-035　2019/04
Publisher: (一社)日本泌尿器科学会総会事務局
インソースCIDを利用したLC/ESI-MS/MSによる多種薬物の同時測定法の構築に向けた基礎検討

佐藤裕, 前川正充, 塚本多矩, 高崎新也, 菊地正史, 早川禎宏, 山口浩明, 眞野成康

日本薬学会年会要旨集　139年会　(4)　114-114　2019/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
ニーマンピック病C型患者に特徴的な5種の抱合型コレステロール代謝物の尿中濃度同時測定法の構築

神納勇, 前川正充, 成田綾, 飯田隆, 衛藤義勝, 大野耕策, Clayton Peter, 山口浩明, 眞野成康

日本薬学会年会要旨集　139年会　(2)　274-274　2019/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
インソースCIDを利用したLC/ESI-MS/MSによる多種薬物の同時測定法の構築に向けた基礎検討

佐藤裕, 前川正充, 塚本多矩, 高崎新也, 菊地正史, 早川禎宏, 山口浩明, 眞野成康

日本薬学会年会要旨集　139年会　(4)　114-114　2019/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
LC/ESI‐MS/MSを用いるニーマンピック病C型モデル細胞のステロイドホルモン代謝解析

阿部愛, 前川正充, 小倉次郎, 須賀隆浩, 檜垣克己, 山口浩明, 山口浩明, 山口浩明, 眞野成康, 眞野成康, 眞野成康

日本薬学会年会要旨集(CD-ROM)　139年会　(2)　274-274　2019/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
日本人1070人の全ゲノム解析で同定された21種のDihydropyrimidine dehydrogenaseレアバリアント活性変化

菱沼英史, 菱沼英史, 菱沼英史, 成田瑶子, 齋藤さかえ, 前川正充, 赤井文香, 中西悠悦, 安田純, 長崎正朗, 山本雅之, 山本雅之, 山口浩明, 眞野成康, 平澤典保, 平澤典保, 平塚真弘, 平塚真弘, 平塚真弘, 平塚真弘

医薬品毒性機序研究会要旨(Web)　1st　2019
インソースCIDを利用したLC-MS/MSによる向精神薬の同時測定法の構築に向けた基礎的検討

小林大典, 前川正充, 鈴鹿雅人, 岩渕理子, 高崎新也, 菊地正史, 菊地正史, 塚本多矩, 早川禎宏, 小倉次郎, 佐藤祐司, 眞野成康, 眞野成康

日本医療薬学会年会講演要旨集(Web)　29　2019

ISSN： 2424-2470
タクロリムスと含脂肪経腸栄養製品の相互作用による血中濃度変動が疑われた一症例

手塚千裕, 佐藤祐司, 小林大典, 前嶋隆弘, 小倉次郎, 佐藤真由美, 前川正充, 眞野成康

日本医療薬学会年会講演要旨集(Web)　29　2019

ISSN： 2424-2470
腎癌組織中代謝物のメタボローム解析

高崎新也, 佐藤友紀, 川崎芳英, 前川正充, 三枝大輔, 三枝大輔, 伊藤明宏, 眞野成康

日本医療薬学会年会講演要旨集(Web)　29　2019

ISSN： 2424-2470
ニーマンピック病C型の未知バイオマーカーLysosphingomyelin-509の同定と新規クラス脂質の発見

前川正充, 前川正充, 松本洋太郎, 神納勇, 岩堀杏南, 高橋秀典, 山口浩明, 山口浩明, 山口浩明, 眞野成康, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　32nd　2019

ISSN： 1347-2364
ニーマンピック病C型の迅速スクリーニング法

岩堀杏南, 前川正充, 前川正充, 山口浩明, 山口浩明, 山口浩明, 眞野成康, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　32nd　2019

ISSN： 1347-2364
腎癌治療における日本人のスニチニブ血中濃度と有害事象の関連性評価

高崎新也, 川崎芳英, 菊地正史, 田中雅樹, 細野寛貴, 伊藤明宏, 山口浩明, 眞野成康

日本臨床腫瘍薬学会学術大会講演要旨集　2019　151　2019
スニチニブのTDM普及に向けて

山口浩明, 高崎新也, 菊地正史, 川崎芳英, 荒井陽一, 眞野成康

日本臨床腫瘍薬学会学術大会講演要旨集　2019　138　2019
Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents

山口浩明, 高崎新也, 菊地正史, 川崎芳英, 荒井陽一, 眞野成康

薬学雑誌(Web)　139　(6)　911‐915(J‐STAGE)　2019

ISSN： 1347-5231
薬剤師に求められる医薬品安全性情報の創出

小原拓, 眞野成康, 堀雄史

日本医療薬学会年会講演要旨集　28　337-341　2018/11/23
Publisher: 一般社団法人日本医療薬学会
DOI： 10.20825/amjsphcs.28.0_337 　

eISSN： 2424-2470
Antihypertensives Prescribed for Pregnant Women in Japan: Prevalence and Timing Determined from a Database of Health Insurance Claims

Tomofumi Ishikawa, Taku Obara, Hidekazu Nishigori, Keiko Miyakoda, Mami Ishikuro, Hirohito Metoki, Takayoshi Ohkubo, Junichi Sugawara, Nobuo Yaegashi, Manabu Akazawa, Shinichi Kuriyama, Nariyasu Mano

Drug Safety　41　(11)　1168-1169　2018/11
Publisher: Springer Science and Business Media LLC
DOI： 10.1007/s40264-018-0719-2 　
宮城県における臨床分離緑膿菌の薬剤耐性率

鈴木博也, 久道周彦, 徳田浩一, 賀来満夫, 眞野成康

緑膿菌感染症研究会講演記録　52回　112-114　2018/10
Publisher: 緑膿菌感染症研究会
ISSN： 1340-6477
医薬品と医療機器の相互作用に関する情報管理体制の検討

中村浩規, 鮎澤純子, 佐藤景二, 嶋森好子, 眞野成康, 杉浦伸一, はい島由二, 藤盛啓成

医療の質・安全学会誌　13　(Suppl.)　391-391　2018/10
Publisher: (一社)医療の質・安全学会
ISSN： 1881-3658

eISSN： 1882-3254
20190429

石川智史, 栗山進一, 眞野成康, 小原拓, 神一敬, 西郡秀和, 都田桂子, 鈴鹿雅人, 赤沢学, 中里信和, 八重樫伸生

Japanese Journal of Pharmacoepidemiology/Yakuzai ekigaku　24回　(0)　98-98　2018/10
Publisher: Japanese Society for Pharmacoepidemiology
DOI： 10.3820/jjpe.23.s98 　

ISSN： 1342-0445

eISSN： 1882-790X
臨床化学研究における質量分析の貢献治療効果の最大化を目指した経口抗がん薬の治療薬物モニタリング

高崎新也, 川崎芳英, 菊地正史, 田中雅樹, 山口浩明, 眞野成康

JSBMS Letters　43　(Suppl.)　49-49　2018/08
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
治療効果の最大化を目指した経口抗がん薬の治療薬物モニタリング

高崎新也, 川崎芳英, 菊地正史, 田中雅樹, 山口浩明, 眞野成康

JSBMS Letters　43　(Suppl.)　49-49　2018/08
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
質量分析の活用事例とピットフォール個別化医療における血中薬物濃度の精密測定

眞野成康, 前川正充, 菊地正史, 山口浩明

臨床化学　47　(Suppl.1)　179-179　2018/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
薬学研究が支える臨床化学臨床化学を基盤とした肺移植患者の個別化薬物療法構築への取り組み

菊地正史, 山口浩明, 眞野成康

臨床化学　47　(Suppl.1)　204-204　2018/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
10年後の臨床化学を考える分子の動きをとらえるミクロとマクロの視点

眞野成康

臨床化学　47　(Suppl.1)　209-209　2018/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC/ESI-MS/MSを用いるコレステロール代謝物網羅的解析法の基礎的検討

前川正充, 河俣圭太, 阿部愛, 三枝大輔, 山口浩明, 眞野成康

臨床化学　47　(Suppl.1)　320-320　2018/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
薬学研究が支える臨床化学臨床化学を基盤とした肺移植患者の個別化薬物療法構築への取り組み

菊地正史, 山口浩明, 眞野成康

臨床化学　47　(Suppl.1)　204-204　2018/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
質量分析の活用事例とピットフォール個別化医療における血中薬物濃度の精密測定

眞野成康, 前川正充, 菊地正史, 山口浩明

臨床化学　47　(Suppl.1)　179-179　2018/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC/ESI-MS/MSを用いるコレステロール代謝物網羅的解析法の基礎的検討

前川正充, 河俣圭太, 阿部愛, 三枝大輔, 山口浩明, 眞野成康

臨床化学　47　(Suppl.1)　320-320　2018/07
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
医薬品安全性情報報告の基準と手順を考える医薬品・医療機器等安全性情報報告制度を活用するために

小原拓, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　21回　66-66　2018/06
Publisher: (一社)日本医薬品情報学会
添付文書および医薬品インタビューフォームにおける血液透析患者への投与方法に関する記載内容調査

八島一史, 小原拓, 中川直人, 中曽根正皓, 大柳元, 荒木勇太, 細谷絵美, 前川麻央, 前嶋隆弘, 高橋阿希子, 木皿重樹, 眞野成康

医薬品相互作用研究　42　(2)　111-115　2018/06
Publisher: 医薬品相互作用研究会
ISSN： 0385-5015
肺移植患者における個別化薬物療法

山口浩明, 菊地正史, 田中雅樹, 高崎新也, 野田あおい, 重田健介, 白木美香, 高木秀侑, 松田安史, 野田雅史, 岡田克典, 眞野成康

臨床薬理の進歩　(39)　104-116　2018/06
Publisher: (公財)臨床薬理研究振興財団
ISSN： 0914-4366
肺移植患者における個別化薬物療法

山口浩明, 菊地正史, 田中雅樹, 高崎新也, 野田あおい, 重田健介, 白木美香, 高木秀侑, 松田安史, 野田雅史, 岡田克典, 眞野成康

臨床薬理の進歩　(39)　104-116　2018/06
Publisher: (公財)臨床薬理研究振興財団
ISSN： 0914-4366
救急、集中治療で押さえておきたい薬物治療のピットフォール特定機能病院の承認要件の見直しを踏まえた医薬品安全管理体制の強化

眞野成康

日本臨床救急医学会雑誌　21　(2)　224-224　2018/04
Publisher: (一社)日本臨床救急医学会
ISSN： 1345-0581

eISSN： 2187-9001
【病気とくすり2018 基礎と実践Expert's Guide】血液・造血器系の病気とくすり貧血

斎藤陽, 張替秀郎, 鈴木文子, 眞野成康

薬局　69　(4)　1054-1064　2018/03
Publisher: (株)南山堂
ISSN： 0044-0035
第2回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線〜分子標的探索と個別化医療への挑戦〜経口分子標的薬の個別化投与設計に向けて

山口浩明, 高崎新也, 菊地正史, 川崎芳英, 荒井陽一, 眞野成康

日本薬学会年会要旨集　138年会　(1)　134-134　2018/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
インソースCIDを利用したLC/ESI-MS/MSによるチロシンキナーゼ阻害薬一斉測定法の構築

佐藤裕, 高崎新也, 田中雅樹, 前川正充, 菊地正史, 川崎芳英, 荒井陽一, 山口浩明, 眞野成康

日本薬学会年会要旨集　138年会　(4)　175-175　2018/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
レセプトデータを利用した小児ADHD患者における処方実態の把握

吉田真貴子, 小原拓, 菊地紗耶, 菊地正史, 山口浩明, 眞野成康

日本薬学会年会要旨集　138年会　(4)　185-185　2018/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
レセプトデータを利用した小児ADHD患者における処方実態の把握

吉田真貴子, 小原拓, 菊地紗耶, 菊地正史, 山口浩明, 眞野成康

日本薬学会年会要旨集　138年会　(4)　185-185　2018/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
第2回臨床化学の進歩が変える薬物治療〜臨床病態解析からのアプローチ〜オミクス解析を基盤とした臨床化学分析

眞野成康, 前川正充, 山口浩明

日本薬学会年会要旨集　138年会　(1)　174-174　2018/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
第2回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線〜分子標的探索と個別化医療への挑戦〜経口分子標的薬の個別化投与設計に向けて

山口浩明, 高崎新也, 菊地正史, 川崎芳英, 荒井陽一, 眞野成康

日本薬学会年会要旨集　138年会　(1)　134-134　2018/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
インソースCIDを利用したLC/ESI-MS/MSによるチロシンキナーゼ阻害薬一斉測定法の構築

佐藤裕, 高崎新也, 田中雅樹, 前川正充, 菊地正史, 川崎芳英, 荒井陽一, 山口浩明, 眞野成康

日本薬学会年会要旨集　138年会　(4)　175-175　2018/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Discovery of diagnostic markers for Niemann-Pick disease type C by focused metabolomics

Maekawa, M., Yamaguchi, H., Mano, N.

Japanese journal of clinical chemistry　47　(2)　2018

ISSN： 0370-5633
臨床化学を基盤としたニーマンピック病C型の診断・治療への挑戦

前川正充, 成田綾, 崎山快夫, 山口浩明, 眞野成康

日本医療薬学会年会講演要旨集(Web)　28　2018

ISSN： 2424-2470
ニーマンピック病C型患者血清中のLyso-SM-509とスフィンゴシルホスホリルコリンの同時分析

神納勇, 前川正充, 真嶋隆一, 成田綾, 山口浩明, 山口浩明, 眞野成康, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　31st　2018

ISSN： 1347-2364
ニーマンピック病C型モデル細胞中ステロイドホルモン類のLC/MS/MS分析

阿部愛, 前川正充, 檜垣克美, 山口浩明, 山口浩明, 眞野成康, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　31st　2018

ISSN： 1347-2364
抗がん薬による手足症候群発現時期に関する検討

小林美奈子, 土屋雅美, 土屋雅美, 菊地正史, 小原拓, 木皿重樹, 高村千津子, 眞野成康, 眞野成康

日本臨床腫瘍薬学会学術大会講演要旨集　2018　255　2018
アキシチニブにより薬剤性破壊性甲状腺炎を呈した腎癌患者の一例

鈴鹿雅人, 高崎新也, 川崎芳英, 坪井真友子, 佐藤祐司, 山口浩明, 荒井陽一, 眞野成康

日本臨床腫瘍薬学会学術大会講演要旨集　2018　183　2018
LC/ESI-MS/MSを用いたシロリムスの全血中濃度測定法の構築

重田健介, 菊地正史, 山口浩明, 眞野成康

臨床化学　46　(Suppl.1)　292-292　2017/09
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
LC/ESI-MS/MSを用いる胆汁酸メタボローム解析系の基礎的検討

庄子彩織, 前川正充, 神納勇, 須賀隆浩, 山口浩明, 眞野成康

臨床化学　46　(Suppl.1)　301-301　2017/09
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
5種の尿中抱合型代謝物をマルチバイオマーカーとして用いるニーマンピック型C型の化学診断法の開発

前川正充, 神納勇, 成田綾, 山口浩明, 眞野成康

日本先天代謝異常学会雑誌　33　156-156　2017/09
Publisher: 日本先天代謝異常学会
ISSN： 0912-0122
PETINIAとLC-MS/MSで得られた肺移植患者のミコフェノール酸血中濃度の比較

菊地正史, 田中雅樹, 高崎新也, 高橋阿希子, 秋場美紀, 松田安史, 野田雅史, 久道周彦, 山口浩明, 岡田克典, 眞野成康

臨床化学　46　(Suppl.1)　302-302　2017/09
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
UHPLC-UVによるエルロチニブ及び代謝物の同時測定法と非小細胞肺がん患者血中濃度測定への応用

須賀隆浩, 島田美樹, 前川正充, 鈴木裕之, 森大, 岡崎達馬, 井上彰, 山口浩明, 眞野成康

臨床化学　46　(Suppl.1)　291-291　2017/09
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
尿中アシルカルニチンの一斉定量法の構築

山口浩明, 阿部一樹, 鈴木裕之, 前川正充, 島田美樹, 眞野成康

臨床化学　46　(Suppl.1)　292-292　2017/09
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
医薬品情報(DI)室より注目の新薬情報(18)一般名 : ロミタピドメシル酸塩ジャクスタピッドカプセル5mg,同10mg,同20mg

細谷絵美, 中川直人, 眞野成康

医薬ジャーナル　53　(7)　165-167　2017/07
Publisher: 医薬ジャーナル社
DOI： 10.20837/1201707165 　

ISSN： 0287-4741
Analytical Technologies Used in the Medical Front

Masamitsu Maekawa, Hiroaki Yamaguchi, Nariyasu Mano

BUNSEKI KAGAKU　66　(6)　413-419　2017/06

DOI： 10.2116/bunsekikagaku.66.413 　

ISSN： 0525-1931
医薬品情報(DI)室より注目の新薬情報(17)一般名 : イダルシズマブ(遺伝子組換え) プリズバインド静注液2.5g

荒木勇太, 中川直人, 眞野成康

医薬ジャーナル　53　(6)　165-167　2017/06
Publisher: 医薬ジャーナル社
DOI： 10.20837/1201706165 　

ISSN： 0287-4741
連載医薬品情報(DI)室より注目の新薬情報〈16〉エムプリシティⓇ点滴静注用300mg, 同400mg

八島一史, 中川直人, 眞野成康

医薬ジャーナル　53　(5)　1327-1329　2017/05/01
Publisher: 医薬ジャーナル社
DOI： 10.20837/12017051327 　

ISSN： 0287-4741
医薬品情報(DI)室より注目の新薬情報(16)一般名 : エロツズマブ(遺伝子組換え) エムプリシティ点滴静注用300mg,同400mg

八島一史, 中川直人, 眞野成康

医薬ジャーナル　53　(5)　157-159　2017/05
Publisher: 医薬ジャーナル社
DOI： 10.20837/1201705157 　

ISSN： 0287-4741
スニチニブ投与により4年間完全奏功が維持できた腎細胞癌患者1症例のスニチニブ血中濃度推移

高崎新也, 山下慎一, 田中雅樹, 菊地正史, 木皿重樹, 山口浩明, 川崎芳英, 伊藤明宏, 荒井陽一, 眞野成康

日本泌尿器科学会総会　105回　PP07-08　2017/04
Publisher: (一社)日本泌尿器科学会総会事務局
脂肪肝における低酸素応答はアクアポリン8の発現抑制により胆石形成を促進する

浅井洋一郎, 山田哲也, 突田壮平, 高橋圭, 前川正充, 本間緑, 池田真教, 村上圭吾, 近藤泰輝, 澤田正二郎, 中村保宏, 田中耕三, 笹野公伸, 眞野成康, 上野義之, 下瀬川徹, 片桐秀樹

糖尿病　60　(Suppl.1)　S-138　2017/04
Publisher: (一社)日本糖尿病学会
ISSN： 0021-437X

eISSN： 1881-588X
脂肪肝における低酸素応答はアクアポリン8の発現抑制により胆石形成を促進する

浅井洋一郎, 山田哲也, 突田壮平, 高橋圭, 前川正充, 本間緑, 池田真教, 村上圭吾, 近藤泰輝, 澤田正二郎, 中村保宏, 田中耕三, 笹野公伸, 眞野成康, 上野義之, 下瀬川徹, 片桐秀樹

糖尿病　60　(Suppl.1)　S-491　2017/04
Publisher: (一社)日本糖尿病学会
ISSN： 0021-437X

eISSN： 1881-588X
LC/ESI-MS/MSを用いた薬毒物中毒原因物質迅速スクリーニングの有用性

田中雅樹, 前川正充, 小梶哲雄, 菊地正史, 高崎新也, 池端泰奈, 矢内一成, 鈴木博也, 赤坂和俊, 木皿重樹, 野村亮介, 久志本成樹, 山口浩明, 眞野成康

日本薬学会年会要旨集　137年会　(4)　129-129　2017/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
LC/ESI-MS/MSを用いた抗がん薬調製者の尿中シクロホスファミド測定による曝露モニタリング

野田あおい, 前川正充, 田中雅樹, 高崎新也, 菊地正史, 鈴木寿樹, 木皿重樹, 山口浩明, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　30th　2017

ISSN： 1347-2364
ニーマンピック病C型患者に特徴的な尿中抱合型異常代謝物のLC/ESI-MS/MS分析法の構築

神納勇, 前川正充, 飯田隆, 成田綾, 山口浩明, 眞野成康, 山口浩明, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　30th　2017

ISSN： 1347-2364
がん専門薬剤師による副作用等情報の集積とJADERの評価

土屋雅美, 土屋雅美, 小原拓, 眞野成康, 眞野成康, 高村千津子

日本医療薬学会年会講演要旨集(Web)　27　2017

ISSN： 2424-2470
コレステロール代謝物網羅的解析法の基礎的検討

前川正充, 河俣圭太, 庄子彩織, 須賀隆浩, 三枝大輔, 三枝大輔, 小川祥二郎, 東達也, 山口浩明, 山口浩明, 山口浩明, 眞野成康, 眞野成康, 眞野成康

キャピラリー電気泳動シンポジウム講演要旨集　37th　2017
【新薬展望2017】(第III部)治療における最近の新薬の位置付け<薬効別> 新薬の広場免疫抑制剤

菊地正史, 眞野成康

医薬ジャーナル　53　(増刊)　314-320　2017/01
Publisher: (株)医薬ジャーナル社
DOI： 10.20837/1201713314 　

ISSN： 0287-4741
外来治療中に経口抗がん薬の血中濃度測定により服薬アドヒアランスが向上した2例

高崎新也, 川崎芳英, 田中雅樹, 菊地正史, 木皿重樹, 山口浩明, 伊藤明宏, 荒井陽一, 眞野成康

日本臨床腫瘍薬学会学術大会講演要旨集　2017　170　2017
脂肪肝における低酸素応答はアクアポリン8の発現抑制により胆石形成を促進する

浅井洋一郎, 山田哲也, 突田壮平, 高橋圭, 前川正充, 本間緑, 池田真教, 村上圭吾, 近藤泰輝, 澤田正二郎, 中村保宏, 田中耕三, 笹野公伸, 眞野成康, 上野義之, 下瀬川徹, 片桐秀樹

糖尿病(Web)　60　(Suppl)　S.491(J‐STAGE)　2017

ISSN： 1881-588X
脂肪肝における低酸素応答はアクアポリン8の発現抑制により胆石形成を促進する

浅井洋一郎, 山田哲也, 突田壮平, 高橋圭, 前川正充, 本間緑, 池田真教, 村上圭吾, 近藤泰輝, 澤田正二郎, 中村保宏, 田中耕三, 笹野公伸, 眞野成康, 上野義之, 下瀬川徹, 片桐秀樹

糖尿病(Web)　60　(Suppl)　S.138(J‐STAGE)　2017

ISSN： 1881-588X
20190323

眞野成康, 益山光一

The Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences　27　(0)　348-352　2017
Publisher: Japanese Society of Pharmaceutical Health Care and Sciences
DOI： 10.20825/amjsphcs.27.0_348 　

eISSN： 2424-2470
Current Status and Issues for the Use of the Spontaneous Reporting System of Adverse Drug Reaction in Japan

小原拓, 眞野成康

医薬品医療機器レギュラトリーサイエンス = Pharmaceutical and medical device regulatory science　48　(3)　163-169　2017
Publisher: 日本公定書協会
ISSN： 1884-6076
Questionnaire Survey on Collection, Management, and Report of Adverse Drug Reactions in a Hospital

小原拓, 山口浩明, 松浦正樹, 中川直人, 村井ユリ子, 土屋文人, 北田光一, 眞野成康

日本病院薬剤師会雑誌 = Journal of Japanese Society of Hospital Pharmacists　53　(1)　73-77　2017/01
Publisher: 日本病院薬剤師会
ISSN： 1341-8815
腎腎がん分子標的治療の現況切除不能腎癌治療におけるSunitinibの至適血中濃度の検討

川崎芳英, 高崎新也, 伊藤明宏, 山下慎一, 川守田直樹, 泉秀明, 安達尚宣, 三塚浩二, 海法康裕, 田中雅樹, 菊地正史, 山口浩明, 眞野成康, 荒井陽一

日本癌治療学会学術集会抄録集　54回　MS4-4　2016/10
Publisher: (一社)日本癌治療学会
能動的な副作用情報の収集 (特集副作用情報を収集・活用する!) -- (副作用情報の収集から活用まで)

中川直人, 久道周彦, 眞野成康

月刊薬事 = The pharmaceuticals monthly　58　(13)　2833-2836　2016/10
Publisher: じほう
ISSN： 0016-5980
医薬品・医療機器等安全性情報報告制度の活用に関する現状と課題 (特集副作用情報を収集・活用する!)

小原拓, 眞野成康

月刊薬事 = The pharmaceuticals monthly　58　(13)　2863-2868　2016/10
Publisher: じほう
ISSN： 0016-5980
わが国の外来患者における家庭血圧測定の現状:10年の変遷

小原拓, 小原拓, 阿部真也, 吉町昌子, 佐藤倫広, 大久保孝義, 眞野成康, 後藤輝明, 今井潤

日本高血圧学会総会プログラム・抄録集　39th　426-426　2016/09/30
Publisher: (NPO)日本高血圧学会
NAFLDにおけるHypoxia‐inducible factor1αの活性化はコレステロール胆石形成を促進する

浅井洋一郎, 山田哲也, 突田壮平, 高橋圭, 前川正充, 本間緑, 近藤泰輝, 澤田正二郎, 中村保宏, 笹野公伸, 眞野成康, 上野義之, 下瀬川徹, 片桐秀樹

肥満研究　22　(Supplement)　182-182　2016/09/20
Publisher: (一社)日本肥満学会
ISSN： 1343-229X
肺移植後遠隔期におけるミコフェノール酸モフェチルの至適血中濃度の検討

松田安史, 矢吹皓, 三友英紀, 江場俊介, 星史彦, 野田雅史, 桜田晃, 秋場美紀, 菊地正史, 真野成康, 岡田克典

移植　51　(総会臨時)　316-316　2016/09
Publisher: (一社)日本移植学会
ISSN： 0578-7947
イトラコナゾールの併用によりシロリムスの全血中トラフ濃度が高値を示したリンパ脈管筋腫症患者の2例

菊地正史, 野田あおい, 田中雅樹, 高橋阿希子, 秋場美紀, 松田安史, 星川康, 久道周彦, 山口浩明, 岡田克典, 眞野成康

TDM研究　33　(3)　104-108　2016/09
Publisher: (一社)日本TDM学会
ISSN： 0911-1026
わが国の外来患者における家庭血圧測定の現状 10年の変遷

小原拓, 阿部真也, 吉町昌子, 佐藤倫広, 大久保孝義, 眞野成康, 後藤輝明, 今井潤

日本高血圧学会総会プログラム・抄録集　39回　426-426　2016/09
Publisher: (NPO)日本高血圧学会
日本人の腎細胞癌患者におけるスニチニブの有効血中濃度域の検討

高崎新也, 川崎芳英, 田中雅樹, 菊地正史, 久道周彦, 山口浩明, 伊藤明宏, 荒井陽一, 眞野成康

日本泌尿器科学会総会　104回　PP3-181　2016/04
Publisher: (一社)日本泌尿器科学会総会事務局
薬剤師による手術用薬品調製への関与と評価

矢内一成, 鈴木博也, 赤坂和俊, 松浦正樹, 久道周彦, 小林直也, 志賀卓弥, 江島豊, 山内正憲, 眞野成康

日本薬学会年会要旨集　136年会　(4)　101-101　2016/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
ニーマンピック病C型の化学診断を目的とする尿中抱合型コレステロール代謝物のLC/ESI-MS/MS分析

前川正充, 山口浩明, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　29th　2016

ISSN： 1347-2364
Safe, long-term sorafenib treatment of patients with hepatocellular carcinoma is associated with metabolic ratio and exposure to a major metabolite, sorafenib N-oxide: a preliminary study

Miki Shimada, Hoshimi Okawa, Yasuteru Kondo, Takahiro Maejima, Yuta Kataoka, Kanehiko Hisamichi, Masamitsu Maekawa, Masaki Matsuura, Yuko Jin, Tooru Shimosegawa, Nariyasu Mano

DRUG METABOLISM REVIEWS　48　136-136　2016

ISSN： 0360-2532

eISSN： 1097-9883
Awareness of Pharmacy Students regarding the Importance of Folic Acid Intake for the Prevention of Neural Tube Defects

Takahashi Atsushi, Murai Yuriko, Obara Taku, Ohara Hiroshi, Satoh Michihiro, Asano Fumiya, Onogi Hiroshi, Hayasaka Masataka, Satoh Hiroshi, Mano Nariyasu

Iyakuhin Johogaku　17　(4)　185-191　2016
Publisher: Japanese Society of Drug Informatics
DOI： 10.11256/jjdi.17.185 　

ISSN： 1345-1464

More details Close

Objective: Adequate periconceptional folic acid intake decreases the risk of neural tube defects in infants.&nbsp;&nbsp;The present study aimed to investigate the awareness of pharmacy students regarding the importance of folic acid intake for the prevention of neural tube defects. Design: Questionnaire survey. Methods: A self-administered questionnaire regarding the importance of folic acid intake for the prevention of neural tube defects was distributed to 750 pharmacy students at Tohoku and Ohu Universities. Results: Among the 685 respondents (response rate; 91.3%), 74 (10.8%) were aware that folic acid intake decreases the risk of neural tube defects.&nbsp;&nbsp;In multivariate logistic regression analysis, awareness of the importance of folic acid intake was evident among 5th- and 6th-year pharmacy students (odds ratio=3.352, 95% confidence interval=1.797-6.253) and among those who used dietary supplements (2.275, 1.306-3.966).&nbsp;&nbsp;Among the 74 pharmacy students who recognized the importance of folic acid intake, 17 (23.0%) and 3 (4.1%) were aware that women should begin taking a folic acid supplement before conception and should take about 400 &mu;g per day during pregnancy, respectively. Conclusion: Only about 10% of the pharmacy students in this study recognized that folic acid intake decreases the risk of neural tube defects, and many were unaware of the recommended intake amount.&nbsp;&nbsp;Therefore, awareness of the importance of folic acid intake must be more aggressively promoted among pharmacy students.
Awareness of Nursing Students about the Importance of Folic Acid Intake for the Prevention of Neural Tube Defects

ONOGI Hiroshi, OBARA Taku, ASANO Fumiya, SATOH Michihiro, MANO Nariyasu, SATOH Kineko, MURAI Yuriko

Japanese Journal of Complementary and Alternative Medicine　13　(1)　7-11　2016
Publisher: The Japanese Society for Complementary and Alternative Medicine
DOI： 10.1625/jcam.13.7 　

ISSN： 1348-7922

More details Close

Objective: Adequate periconceptional intake of folic acid decreases the risk of neural tube defects of infant. The present study aimed to investigate the awareness of nursing students about the importance of folic acid intake for the prevention of neural tube defects.Design: Questionnaire survey.Methods: A self-administered questionnaire regarding the importance of folic acid intake for the prevention of neural tube defects was distributed to 423 nursing students of Tohoku University and Tohoku Fukushi University.Results: Among the 408 respondents (response rate; 96.5%), 129 (31.6%) nursing students were aware that folic acid intake decreases the risk of neural tube defects. In the multivariate logistic regression analysis, grade 3-4 (odds ratio = 11.779, 95% confident interval = 5.739-24.177) were associated with the awareness of the importance of folic acid intake among nursing students. Of 129 nursing students who recognized the importance of folic acid intake, 52 (40.3%) and 11 (8.5%) recognized that women should begin folic acid intake before conception and should take about 400μg of folic acid per day during pregnancy respectively.Conclusion: About 30% of nursing students recognized that folic acid intake decreases the risk of neural tube defects and many did not know the details of the effective intake for the prevention of neural tube defects. Therefore, more aggressive promotion of the awareness of the importance of folic acid intake among nursing students is warranted.
6年制薬学教育に望むこと

眞野成康

ファルマシア　52　(7)　672-674　2016
Publisher: 公益社団法人日本薬学会
DOI： 10.14894/faruawpsj.52.7_672 　

ISSN： 0014-8601

More details Close

6年制薬学教育が開始されてから今年で10年が経過した．当院薬剤部でも6年制卒の1期生が既に薬剤師歴5年目を迎え，これまでに6年制薬学教育を受けた薬剤師を50人以上採用している．たしかに医療薬学関連教育の充実もあって業務全般の習得速度は速いように感じるが，薬剤師としての能力を考えてみると，それまでの4年制卒の薬剤師たちとそれほど大きな差があるようにも思えない．日頃，筆者の感じていることを述べながら，その理由を考えてみたい．
Clinical Applications of Mass Spectrometric Techniques for Chemical Diagnosis and Therapeutic Drug Monitoring

MAEKAWA Masamitsu, YAMAGUCHI Hiroaki, MANO Nariyasu

Journal of the Mass Spectrometry Society of Japan　64　(4)　121-125　2016
Publisher: The Mass Spectrometry Society of Japan
DOI： 10.5702/massspec.S16-26 　

ISSN： 1340-8097
熊本地震における災害医療支援報告

渡邉暁洋, 眞野成康

日本医療薬学会年会講演要旨集　26　(0)　152-157　2016
Publisher: 一般社団法人日本医療薬学会
肝臓におけるhypoxia-inducible factor 1αの活性化はコレステロール胆石形成を促進する

浅井洋一郎, 山田哲也, 突田壮平, 高橋圭, 前川正充, 本間緑, 宗像佑一郎, 白井勇太, 児玉慎二郎, 椙澤貴志, 千葉弓子, 高橋広延, 穂坂真一郎, 近藤泰輝, 金子慶三, 宇野健司, 澤田正二郎, 今井淳太, 中村保宏, 山口浩明, 岡芳知, 笹野公伸, 眞野成康, 上野義之, 下瀬川徹, 片桐秀樹

日本生化学会大会・日本分子生物学会年会合同大会講演要旨集　88回・38回　[4T特L-12(3P1203)]　2015/12
Publisher: (公社)日本生化学会
ORGANIC ANION TRANSPORTING POLYPEPTIDES 1B1 AND 1B3 PLAY AN IMPORTANT ROLE IN UREMIC TOXIN HANDLING AND DRUG-UREMIC TOXIN INTERACTIONS IN THE LIVER

Toshihiro Sato, Hiroaki Yamaguchi, Takuma Kogawa, Takaaki Abe, Nariyasu Mano

DRUG METABOLISM REVIEWS　47　264-265　2015/11

ISSN： 0360-2532

eISSN： 1097-9883
IDENTIFICATION OF THE OATP1B3-SPECIFIC COMPOUND LST-02

Hiroaki Yamaguchi, Takaaki Abe, Nariyasu Mano

DRUG METABOLISM REVIEWS　47　255-256　2015/11

ISSN： 0360-2532

eISSN： 1097-9883
22-7-O42-17 薬毒物中毒原因物質のLC/MS/MS分析システムの検討(TDM,口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)

前川正充, 小梶哲雄, 菊地正史, 田中雅樹, 中曽根正皓, 野田あおい, 矢内一成, 鈴木博也, 赤坂和俊, 久道周彦, 山口浩明, 眞野成康

日本医療薬学会年会講演要旨集　25　(0)　238-238　2015/10/23
Publisher: 日本医療薬学会
アキシチニブの血中濃度が上昇しなかった腎細胞癌患者の一例

野田あおい, 田中雅樹, 高崎新也, 鈴木裕之, 菊地正史, 川崎芳英, 伊藤明宏, 久道周彦, 山口浩明, 荒井陽一, 眞野成康

日本医療薬学会年会講演要旨集　25th　326-326　2015/10/23
Publisher: 日本医療薬学会
P0375-21-PM イトラコナゾールの併用によりシロリムスのトラフ濃度が高値を示したリンパ脈管筋腫症患者の2例(TDM・投与設計,ポスター発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)

菊地正史, 野田あおい, 田中雅樹, 高橋阿希子, 松田安史, 星川康, 久道周彦, 山口浩明, 岡田克典, 眞野成康

日本医療薬学会年会講演要旨集　25　328-328　2015/10/23
Publisher: 日本医療薬学会
Profiles of Immune Cells and Reproduction of Immune-mediated Drug-induced Liver Injury

Yasuyuki Fujisaka, Yasuteru Kondo, Takamitsu Sasaki, Takayuki Kogure, Jun Inoue, Yu Nakagome, Yuuta Wakui, Tomoaki Iwata, Tatsuki Morosawa, Teruyuki Umetsu, Hiroyuki Suzuki, Hiroaki Yamaguchi, Nariyasu Mano, Kiyoshi Nagata, Tooru Shimosegawa

AMERICAN JOURNAL OF GASTROENTEROLOGY　110　S871-S871　2015/10

ISSN： 0002-9270

eISSN： 1572-0241
震災時の高血圧対策我々はどうすべきかこれまでの経緯を踏まえて家庭血圧を用いた震災後の血圧管理の重要性とその対策

佐藤倫広, 目時弘仁, 浅山敬, 菊谷昌浩, 眞野成康, 大久保孝義, 今井潤

日本高血圧学会総会プログラム・抄録集　38回　252-252　2015/10
Publisher: (NPO)日本高血圧学会
家庭血圧に基づくアジルサルタンの臨床的評価

芳賀俊和, 佐藤倫広, 保坂実樹, 渡部大介, 小原拓, 目時弘仁, 浅山敬, 菊谷昌浩, 眞野成康, 大久保孝義, 今井潤

日本高血圧学会総会プログラム・抄録集　38回　397-397　2015/10
Publisher: (NPO)日本高血圧学会
Bevacizumab投与の非小細胞肺癌におけるRenin-Angiotensin系阻害薬の蛋白尿低減効果

木皿重樹, 佐藤淳也, 二瓶哲, 八島一史, 伊原大輔, 森川直人, 井上彰, 眞野成康

日本癌治療学会誌　50　(3)　1576-1576　2015/09
Publisher: (一社)日本癌治療学会
ISSN： 0021-4671
乳がんFEC100療法におけるホスアプレピタント注とアプレピタントカプセルの有効性と安全性の比較

渡邊桂子, 菊地正史, 木皿重樹, 小笠原喜美代, 久道周彦, 石田孝宣, 鈴木直人, 村井ユリ子, 島田美樹, 富岡佳久, 石岡千加史, 眞野成康

医薬品相互作用研究　39　(1)　29-35　2015/08
Publisher: 医薬品相互作用研究会
ISSN： 0385-5015
高血圧患者におけるβ遮断薬の家庭心拍減少および降圧効果検証のための介入研究―J‐HOME‐HR研究―

SHINKI TAKAHIRO, OHARA TAKU, ATONOKAMI KENTA, SHIBAMIYA TAKU, SATO MICHIHIRO, MANO NARIYASU, IMAI JUN, OKUBO TAKAYOSHI

Ther Res　36　(5)　429-438　2015/05/20
Publisher: ライフサイエンス出版(株)
ISSN： 0289-8020
therapeutic drug monitoring(TDM)が有用な分子標的薬使用症例の臨床像の検討

川崎芳英, 高崎新也, 菊地正史, 齋藤英郎, 眞野成康, 伊藤明宏, 荒井陽一

日本泌尿器科学会総会　103回　555-555　2015/04
Publisher: (一社)日本泌尿器科学会総会事務局
フッ化ピリミジン系抗がん剤の副作用発現を予測するDPYS遺伝子多型

赤井文香, 山下洋, 森隆弘, 細野寛貴, 菱沼英史, 前川正充, 眞野成康, 平澤典保, 平塚真弘

日本薬学会年会要旨集　135年会　(4)　198-198　2015/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
レセプトデータを用いた東北大学病院の本態性高血圧患者における降圧薬の処方動向調査

黒澤桂子, 佐藤倫広, 飯田優太郎, 小原拓, 松浦正樹, 井上隆輔, 高橋信行, 佐藤博, 村井ユリ子, 眞野成康

日本薬学会年会要旨集　135年会　(4)　134-134　2015/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
一般地域住民におけるセルフメディケーションの実態とその要因に関する調査大迫研究

佐藤倫広, 松本章裕, 原梓, 岩森紗希, 小原拓, 菊谷昌浩, 目時弘仁, 保坂実樹, 淺山敬, 高橋信行, 佐藤博, 眞野成康, 今井潤, 大久保孝義

薬学雑誌　134　(12)　1347-1355　2014/12
Publisher: (公社)日本薬学会
ISSN： 0031-6903

eISSN： 1347-5231
新規高感度ヘムオキシゲナーゼ活性測定法の開発

岩森紗希, 佐藤恵美子, 吉成浩一, 島田美樹, 眞野成康, 伊藤貞嘉, 佐藤博, 高橋信行

日本高血圧学会総会プログラム・抄録集　37回　332-332　2014/10
Publisher: (NPO)日本高血圧学会
妊婦における尿中塩分排泄量と塩分・栄養診断システム算出の塩分摂取量の相関

佐藤倫広, 丹野由美, 保坂実樹, 目時弘仁, 小原拓, 淺山敬, 眞野成康, 星和彦, 鈴木雅洲, 今井潤

日本高血圧学会総会プログラム・抄録集　37回　370-370　2014/10
Publisher: (NPO)日本高血圧学会
新規高感度ヘムオキシゲナーゼ活性測定法の開発

岩森紗希, 佐藤恵美子, 吉成浩一, 島田美樹, 眞野成康, 伊藤貞嘉, 佐藤博, 高橋信行

JSBMS Lett　39　(Supplement)　98-98　2014/09/01
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
28-O4AM-15 注射用抗菌薬の新たな在庫指標と直下型地震時におけるシミュレーション(災害医療,一般演題(口頭),新時代を拓く医療薬学フロンティア)

安田千賀, 寺岡知寿, 岸川有紀, 鈴木博也, 松浦正樹, 佐藤真由美, 久道周彦, 眞野成康

日本医療薬学会年会講演要旨集　24　242-242　2014/08/25
Publisher: 日本医療薬学会
28-P4PM-072 カラムスイッチングLC/ESI-MS/MSを用いるミコフェノール酸の血中濃度測定法の構築(TDM・投与設計2,一般演題(ポスター),新時代を拓く医療薬学フロンティア)

相馬真志, 菊地正史, 前川正充, 鈴木裕之, 久道周彦, 山口浩明, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　24　(0)　439-439　2014/08/25
Publisher: 日本医療薬学会
膵島移植における細胞性免疫能モニタリングの試み

五十嵐康宏, 鈴木裕之, 相馬真志, 宮城重人, 戸子台和哲, 稲垣明子, 猪村武弘, 澤田正二郎, 金子慶三, 片桐秀樹, 藤盛啓成, 大内憲明, 里見進, 島田美樹, 眞野成康, 後藤昌史

日本移植学会総会プログラム抄録集　50回　461-461　2014/08
Publisher: (一社)日本移植学会
抗精神病薬と高血糖・糖尿病発症の関連レセプトデータに基づく検討

佐藤倫広, 小原拓, 大場延浩, 森川和彦, 西郡秀和, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　17回　158-158　2014/07
Publisher: (一社)日本医薬品情報学会
医薬品リスク管理計画に関する薬剤師の認識

山口浩明, 小原拓, 佐藤倫広, 大久保孝義, 村井ユリ子, 井関健, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　17th　112-112　2014/07
Publisher: (一社)日本医薬品情報学会
妊娠中の医薬品使用と児の先天奇形との関連:レセプトデータに基づく検討

小原拓, 佐藤倫広, 西郡秀和, 目時弘仁, 大久保孝義, 赤沢学, 八重樫伸生, 栗山進一, 眞野成康

日本医薬品情報学会総会・学術大会講演要旨集　17th　81-81　2014/07
Publisher: (一社)日本医薬品情報学会
新規高感度ヘムオキシゲナーゼ活性測定法の開発

岩森紗希, 佐藤恵美子, 吉成浩一, 島田美樹, 眞野成康, 伊藤貞嘉, 佐藤博, 高橋信行

日本腎臓学会誌　56　(3)　283-283　2014/05/25
Publisher: (一社)日本腎臓学会
ISSN： 0385-2385

eISSN： 1884-0728
家庭血圧に基づく血漿アルドステロン濃度/血漿レニン活性化とNon‐dippingの関連―大迫研究―

SATO TOMOHIRO, HOSAKA MIKI, KIKUYA MASAHIRO, ASAYAMA KEI, INOUE RYUSUKE, TSUBOTA MEGUMI, HARA AZUSA, HIROSE TAKUO, OHARA TAKU, METOKI HIROHITO, TOTSUNE KAZUHITO, HOSHI HARUHISA, MANO NARIYASU, IMAI JUN, OKUBO TAKAYOSHI

日本高血圧学会臨床高血圧フォーラムプログラム・抄録集　3rd　115-115　2014/05/24
Publisher: (NPO)日本高血圧学会
PHARMACOKINETICS OF SORAFENIB CORRELATES WITH ADVERSE EFFECTS UPON DOSAGE REDUCTION OR WITHDRAWAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

Miki Shimada, Hoshimi Okawa, Takahiro Maejima, Yasuteru Kondo, Tooru Shimosegawa, Kanehiko Hisamichi, Masaki Matsuura, Nariyasu Mano

DRUG METABOLISM REVIEWS　45　238-239　2014/01

ISSN： 0360-2532

eISSN： 1097-9883
エコチル調査・宮城ユニットセンターにおける妊婦の医薬品使用状況の評価-宮城ユニットセンター薬剤詳細調査より-

西郡秀和, 小原拓, 目時弘仁, 石黒真美, 水野聖士, 櫻井香澄, 岩間憲之, 村井ユリ子, 杉山隆, 菅原準一, 眞野成康, 栗山進一, 八重樫伸生

DOHaD研究　3　(1)　49-49　2014
Publisher: 日本DOHaD研究会
ISSN： 2187-2597

More details Close

第3回日本DOHaD研究会学術集会抄録集【ポスター発表】
レセプトデータに基づく妊娠中の医薬品使用と児の先天奇形との関連に関する検討

小原拓, 西郡秀和, 目時弘仁, 眞野成康, 八重樫伸生, 栗山進一

DOHaD研究　3　(1)　58-58　2014
Publisher: 日本DOHaD研究会
ISSN： 2187-2597

More details Close

第3回日本DOHaD研究会学術集会抄録集【ポスター発表】
周産期の葉酸摂取の重要性に関する薬剤師の認識

小原拓, 佐藤倫広, 小野木弘志, 眞野成康, 村井ユリ子

日本補完代替医療学会学術集会プログラム・抄録集　16回　64-64　2013/11
Publisher: 日本補完代替医療学会
日本の一般地域住民におけるセルフメディケーションに関する実態調査

佐藤倫広, 松本章裕, 原梓, 岩森紗希, 菊谷昌浩, 小原拓, 目時弘仁, 小野木弘志, 高橋信行, 佐藤博, 眞野成康, 今井潤, 大久保孝義

日本補完代替医療学会学術集会プログラム・抄録集　16th　58-58　2013/11
Publisher: 日本補完代替医療学会
一般地域住民における,家庭血圧および24時間血圧に基づく真性および部分白衣高血圧と脳卒中発症の関連―大迫研究―

佐藤倫広, 菊谷昌浩, 浅山敬, 井上隆輔, 宇津木(坪田, 恵, 原梓, 廣瀬卓男, 小原拓, 目時弘仁, 戸恒和人, 星晴久, 眞野成康, 今井潤, 大久保孝義

日本高血圧学会総会プログラム・抄録集　36th　321-321　2013/10/24
Publisher: (NPO)日本高血圧学会
PTX療法におけるラニチジン注とファモチジン注のアレルギー発現率の後方視的コホート研究

片岡佑太, 菊地正史, 中川直人, 木皿重樹, 高橋哉子, 小笠原喜美代, 我妻恭行, 久道周彦, 鈴木直人, 村井ユリ子, 富岡佳久, 石岡千加史, 島田美樹, 眞野成康

日本病院薬剤師会雑誌　49　(10)　1091-1095　2013/10
Publisher: (一社)日本病院薬剤師会
ISSN： 1341-8815
この人に聞く特別版眞野成康氏東北大学病院教授・薬剤部長第23回日本医療薬学会年会開催間近! 年会長インタビュー

眞野成康

月刊薬事 = The pharmaceuticals monthly　55　(9)　1582-1584　2013/09
Publisher: じほう
ISSN： 0016-5980
土-P2-218 肝細胞がん患者においてsodium alginateによりsorafenibの吸収阻害が示唆された1例(薬物相互作用,一般演題ポスター発表,再興、再考、創ろう最高の医療の未来)

片岡佑太, 久道周彦, 近藤泰輝, 松浦正樹, 田坂英久, 下瀬川徹, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　23　288-288　2013/08/28
Publisher: 日本医療薬学会
日-P1-027 「ピボキシル基」を有する抗菌薬の副作用情報周知に関する東北大学病院の取り組み(医療安全,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

尾崎芙実, 前川真央, 中川直人, 松浦正樹, 久道周彦, 眞野成康

日本医療薬学会年会講演要旨集　23　357-357　2013/08/28
Publisher: 日本医療薬学会
土-P2-141 大規模災害時の病院機能の維持と被災地支援の可能な医薬品在庫量の検討(一般演題ポスター発表,医薬品管理,再興、再考、創ろう最高の医療の未来)

寺岡知寿, 穂積雅人, 北村奈央子, 岸川友紀, 松浦正樹, 佐藤真由美, 久道周彦, 眞野成康

日本医療薬学会年会講演要旨集　23　275-275　2013/08/28
Publisher: 日本医療薬学会
土-P2-265 カラムスイッチングLC/ESI-MS/MSを用いたダプトマイシンの血中濃度測定法(TDM・投与設計,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

相馬真志, 柳利樹, 前川正充, 鈴木裕之, 松浦正樹, 久道周彦, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　23　296-296　2013/08/28
Publisher: 日本医療薬学会
土-9-O11-21 小児におけるインフルエンザワクチン接種の有効性評価(感染制御(その他)2,一般演題(口頭)11,再興、再考、創ろう最高の医療の未来)

小原拓, 島崎信次郎, 金子健二, 福田純, 中村泰之, 眞野成康, 栗山進一, 八木直人

日本医療薬学会年会講演要旨集　23　216-216　2013/08/28
Publisher: 日本医療薬学会
日-P1-070 東北大学病院薬剤部及び米国ノバサウスイースタン大学薬学部における医薬品情報実務実習の比較(薬学教育(実務実習),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

中川直人, 草場美津江, 尾崎芙実, 前川麻央, 松浦正樹, 久道周彦, 村井ユリ子, Jennifer Gershman, Leanne Lai, 眞野成康

日本医療薬学会年会講演要旨集　23　364-364　2013/08/28
Publisher: 日本医療薬学会
土-5-S11-3 薬剤師に必要な栄養療法の知識とNST専門療法士の役割(薬剤師に求められる栄養療法の知識とは,シンポジウム11,再興、再考、創ろう最高の医療の未来)

吉仲千佳, 久道周彦, 眞野成康

日本医療薬学会年会講演要旨集　23　87-87　2013/08/28
Publisher: 日本医療薬学会
日-10-O40-25 東北大学薬学研究科4年制博士課程におけるスーパージェネラリスト・ファーマシスト養成教育の試み : 医学部臨床修練への参加(薬学教育(実務実習・その他)、卒後研修・研修制度,一般演題(口頭)40,再興、再考、創ろう最高の医療の未来)

瀬川良佑, 高橋亜希, 平塚真弘, 眞野成康, 富岡佳久, 佐藤博, 平澤典保

日本医療薬学会年会講演要旨集　23　245-245　2013/08/28
Publisher: 日本医療薬学会
日-P2-164 東北大学病院におけるカルバペネム薬使用届出制の導入とその効果(感染制御(治療薬),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

鈴木博也, 飯田優太郎, 久道周彦, 徳田浩一, 賀来満夫, 眞野成康

日本医療薬学会年会講演要旨集　23　379-379　2013/08/28
Publisher: 日本医療薬学会
土-10-O14-06 消化管上皮細胞におけるソラフェニブ輸送への尿酸の影響についてのin vitroでの検討(薬物動態,一般演題(口頭)14,再興、再考、創ろう最高の医療の未来)

前嶋隆弘, 大川星美, 近藤泰輝, 下瀬川徹, 久道周彦, 松浦正樹, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　23　219-219　2013/08/28
Publisher: 日本医療薬学会
土-11-O22-18 薬剤師における後発医薬品に関する認識の変遷(使用状況調査・意識調査1,一般演題(口頭)22,再興、再考、創ろう最高の医療の未来)

佐藤倫広, 小原拓, 高橋則男, 猪狩有紀恵, 眞野成康, 早坂正孝, 高橋將喜, 北村哲治

日本医療薬学会年会講演要旨集　23　227-227　2013/08/28
Publisher: 日本医療薬学会
日-8-O25-01 薬剤師における後発医薬品に関する認識の変遷(ジェネリック医薬品、有害事象・副作用,一般演題(口頭)25,再興、再考、創ろう最高の医療の未来)

佐藤倫広, 小原拓, 高橋則男, 猪狩有紀恵, 眞野成康, 早坂正孝, 高橋將喜, 鎌田裕, 北村哲治

日本医療薬学会年会講演要旨集　23　230-230　2013/08/28
Publisher: 日本医療薬学会
土-P3-344 高機能抗がん薬自動混合調製装置の開発(がん薬物療法(無菌調製・曝露対策),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

正木拓陽, 白石有紗, 岸川友紀, 高崎新也, 田中明, 斉藤数弘, 加藤雅之, 前川正充, 島田美樹, 木皿重樹, 佐藤真由美, 松浦正樹, 久道周彦, 眞野成康

日本医療薬学会年会講演要旨集　23　309-309　2013/08/28
Publisher: 日本医療薬学会
土-P3-439 ランマーク皮下注適正使用への取り組み(がん薬物療法(緩和ケア),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

村木浅理, 草場美津江, 尾崎芙実, 鈴木直人, 菊地正史, 中川直人, 佐賀利英, 久道周彦, 佐藤真由美, 木皿重樹, 松浦正樹, 眞野成康

日本医療薬学会年会講演要旨集　23　(0)　325-325　2013/08/28
Publisher: 日本医療薬学会
乳癌FEC100療法におけるホスアプレピタント注の有効性と安全性の検討

渡邊桂子, 菊地正史, 木皿重樹, 小笠原喜美代, 久道周彦, 石田孝宣, 鈴木直人, 村井ユリ子, 島田美樹, 富岡佳久, 石岡千加史, 眞野成康

日本医療薬学会年会講演要旨集　23rd　319　2013/08/28
抗がん薬調製後から投与実施までの過程における被曝の現状調査

鈴木寿樹, 森大, 高橋哉子, 小笠原喜美子, 木皿重樹, 石岡千加史, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　23rd　308　2013/08/28
がん化学療法における病院と保険薬局間の情報共有への取り組み

菊地正史, 日野沙綾香, 高田紀子, 中川直人, 木皿重樹, 松浦正樹, 久道周彦, 我妻恭行, 山田卓郎, 加藤俊介, 石岡千加史, 佐々木孝雄, 眞野成康

日本医療薬学会年会講演要旨集　23rd　304　2013/08/28
一般地域住民におけるセルフメディケーションに関する実態調査

岩森紗希, 松本章裕, 佐藤倫広, 原梓, 菊谷昌浩, 小原拓, 目時弘仁, 廣瀬卓男, 井上隆輔, 浅山敬, 高橋信行, 眞野成康, 佐藤博, 今井潤, 大久保孝義

日本医療薬学会年会講演要旨集　23rd　354-354　2013/08/28
Publisher: 日本医療薬学会
レセプトデータに基づく妊娠中の抗菌薬処方状況の把握に関する研究

堀川いずみ, 小原拓, 目時弘仁, 大久保孝義, 八重樫伸生, 眞野成康, 佐藤博, 栗山進一

日本医療薬学会年会講演要旨集　23rd　217-217　2013/08/28
Publisher: 日本医療薬学会
妊婦に対する気管支喘息治療薬の処方状況の把握に関する研究

保坂実樹, 小原拓, 目時弘仁, 佐藤倫広, 大久保孝義, 八重樫伸生, 眞野成康, 栗山進一

日本医療薬学会年会講演要旨集　23rd　435　2013/08/28
治療中高血圧患者の高血圧管理における保険調剤薬局の関与:J‐HOME‐Morning研究

小原拓, 小林由香, 池田うらら, 保坂実樹, 佐藤倫広, 菊谷昌浩, 目時弘仁, 井上隆輔, 大久保孝義, 眞野成康, 栗山進一, 今井潤

日本医療薬学会年会講演要旨集　23rd　405-405　2013/08/28
Publisher: 日本医療薬学会
病院薬剤師の医薬品安全性評価に関する認識および実践に関する調査

飯田優太郎, 小原拓, 尾崎芙実, 高田紀子, 鈴木理紗子, 鈴木理紗子, 佐藤倫広, 青木良子, 天沼喜美子, 大久保孝義, 松浦正樹, 佐藤真由美, 眞野成康

日本医療薬学会年会講演要旨集　23rd　256-256　2013/08/28
Publisher: 日本医療薬学会
小児の注意欠陥/多動性障害患者に対する医薬品処方

小原拓, 佐藤倫広, 村井ユリ子, 眞野成康, 栗山進一

日本医薬品情報学会総会・学術大会講演要旨集　16回　131-131　2013/08
Publisher: (一社)日本医薬品情報学会
葉酸と出生児の神経管閉鎖障害リスク抑制に関する薬学生の認識

大原宏司, 小原拓, 佐藤倫広, 眞野成康, 佐藤博, 早坂正孝, 村井ユリ子

日本医薬品情報学会総会・学術大会講演要旨集　16回　140-140　2013/08
Publisher: (一社)日本医薬品情報学会
PTX前投薬におけるラニチジン注とファモチジン注によるアレルギー発現率の比較

片岡佑太, 菊地正史, 中川直人, 木皿重樹, 高橋哉子, 小笠原喜美代, 我妻恭行, 久道周彦, 鈴木直人, 村井ユリ子, 富岡佳久, 石岡千加史, 島田美樹, 眞野成康

医薬品相互作用研究　37　(1)　84-84　2013/08
Publisher: 医薬品相互作用研究会
ISSN： 0385-5015
薬剤師における医薬品安全性評価に関する認識および実践に関する調査

山口浩明, 小原拓, 佐藤倫広, 青木良子, 天沼喜美子, 村井ユリ子, 宮本剛典, 高村茂生, 山田武宏, 眞野成康, 井関健

日本医薬品情報学会総会・学術大会講演要旨集　16回　122-122　2013/08
Publisher: (一社)日本医薬品情報学会
東日本大震災後のがん薬物療法における地域連携の試み

秋山聖子, 瀬谷裕貴子, 村山素子, 小笠原喜美代, 木皿重樹, 石井正, 菅原美千恵, 千田康徳, 神部眞理子, 角道祐一, 眞野成康, 石岡千加史

癌と化学療法　40　(3)　343-348　2013/03
Publisher: (株)癌と化学療法社
ISSN： 0385-0684
ラニチジン注とファモチジン注のパクリタキセル注前投与におけるアレルギー発現率の比較

片岡佑太, 菊地正史, 中川直人, 木皿重樹, 高橋哉子, 小笠原喜美代, 我妻恭行, 久道周彦, 小原拓, 鈴木直人, 村井ユリ子, 島田美樹, 富岡佳久, 石岡千加史, 眞野成康

日本薬学会年会要旨集　133年会　(4)　184-184　2013/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
妊婦における薬剤の使用に関する疫学調査

小原拓, 石黒真美, 目時弘仁, 菊谷昌浩, 栗山進一, 西郡秀和, 八重樫伸生, 大久保孝義, 眞野成康

宮城県公衆衛生学会会誌　(45)　6-6　2013/03
Publisher: 宮城県公衆衛生学会
ISSN： 0912-747X
PPIをめぐる新たな展開プロトンポンプ阻害薬の薬物動態に及ぼす食事の影響の検討

新海洋彦, 小池智幸, 島田美樹, 中川健一郎, 飯島克則, 今谷晃, 松本洋太郎, 前川正充, 眞野成康, 下瀬川徹

月刊消化器内科　56　(2)　167-171　2013/02/28
Publisher: (有)科学評論社
ISSN： 1884-2895
LC/MS/MSによる抗がん薬の治療薬物モニタリング

島田美樹, 前川正充, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　26th　2013

ISSN： 1347-2364
UHPLC-UVを用いるエルロチニブ及び代謝物の血中濃度測定法の構築

須賀隆浩, 前川正充, 森大, 鈴木裕之, 島田美樹, 眞野成康, 島田美樹, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　26th　2013

ISSN： 1347-2364
土-P2-266 同種臍帯血移植直後にボリコナゾールの血中濃度が低下した一症例(TDM・投与設計,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

鈴木裕之, 眞野成康, 北村奈央子, 柳利樹, 相馬真志, 佐藤祐司, 前川正充, 石澤賢一, 張替秀郎, 島田美樹

日本医療薬学会年会講演要旨集　23　(0)　296-296　2013
Publisher: 日本医療薬学会
DOI： 10.20825/amjsphcs.23.0_296_2 　
土-10-O16-17 がん化学療法レジメンで用いられる薬物の血中濃度一斉分析法(TDM・投与設計1,一般演題(口頭)16,再興、再考、創ろう最高の医療の未来)

庄司依莉子, 前川正充, 森大, 鈴木裕之, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　23　(0)　221　2013
Publisher: 日本医療薬学会
DOI： 10.20825/amjsphcs.23.0_221_2 　

eISSN： 2424-2470
土-10-O16-16 LC/ESI-MS/MSによる患者血清中のパクリタキセル及び代謝物とカルボプラチンの同時測定法(TDM・投与設計1,一般演題(口頭)16,再興、再考、創ろう最高の医療の未来)

中村昌由, 鈴木裕之, 森大, 内田敬, 前川正充, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　23　(0)　221-221　2013
Publisher: 日本医療薬学会
妊婦における葉酸サプリメント摂取の評価 BOSHI研究

小林由香, 小原拓, 目時弘仁, 岩崎雅弘, 佐藤博, 村井ユリ子, 眞野成康, 鈴木雅洲, 今井潤, BOSHI研究グループ

医薬品相互作用研究　37　(1)　37-43　2013
がん化学療法に関する薬薬医連携セミナーの開催とその効果

菊地正史, 木皿重樹, 松浦正樹, 久道周彦, 我妻恭行, 山田卓郎, 加藤俊介, 石岡千加史, 佐々木孝雄, 眞野成康

日本臨床腫瘍学会学術集会(CD-ROM)　11th　ROMBUNNO.P3-145　2013
P2-162 視点計測機を用いた散薬調剤における確認行動の解析(リスクマネージメント,ポスター,一般演題,岐路に立つ医療〜千年紀の目覚め〜よみがえれ!ニッポン!薬の改革は我らが手で!)

中村浩規, 飯田優太郎, 猪岡京子, 村井ユリ子, 眞野成康

日本医療薬学会年会講演要旨集　22　405-405　2012/10/10
Publisher: 日本医療薬学会
LC/MS/MSを用いたマウス脳組織中スフィンゴシン一リン酸の超高感度定量分析について

三枝大輔, 高橋友大, 大宅史織, 井上飛鳥, 奥谷倫代, 鈴木直人, 眞野成康, 青木淳賢, 富岡佳久

JSBMS Letters　37　(Suppl.)　66-66　2012/09
Publisher: (一社)日本医用マススペクトル学会
ISSN： 1881-5464
Prescription of Drugs during Pregnancy in Japan Peer-reviewed

Obara Taku, Akazawa Manabu, Ohkubo Takayoshi, Ishikuro Mami, Metoki Hirohito, Shono Aiko, Nishigori Hidekazu, Mano Nariyasu, Yaegashi Nobuo, Kuriyama Shinichi

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY　21　380　2012/08

ISSN： 1053-8569
連載薬剤師による処方設計<11>脳死肺移植患者に対する薬学的介入と処方設支援 (医薬ジャーナル)

土屋雅美, 眞野成康

医薬ジャーナル　48　(8)　131-135　2012/08
Publisher: 医薬ジャーナル社
ISSN： 0287-4741
妊婦コホートにおける医薬品使用状況に関する調査方法の検討

小林由香, 小原拓, 目時弘仁, 眞野成康, 佐藤博, 今井潤, 八重樫伸生, 栗山進一

日本医薬品情報学会総会・学術大会講演要旨集　15回　107-107　2012/06
Publisher: (一社)日本医薬品情報学会
レセプトデータに基づく妊娠中の医薬品使用状況の把握に関する研究

小原拓, 石黒真美, 目時弘仁, 西郡秀和, 大久保孝義, 眞野成康, 八重樫伸生, 栗山進一

日本医薬品情報学会総会・学術大会講演要旨集　15回　105-105　2012/06
Publisher: (一社)日本医薬品情報学会
Influence of Meals on the Pharmacokinetics of Proton Pump Inhibitors in Healthy Japanese Subjects

Hirohiko Shinkai, Tomoyuki Koike, Nobuyuki Ara, Kaname Uno, Naoki Asano, Yasuhiko Abe, Katsunori Iijima, Akira Imatani, Masamitsu Maekawa, Yotaro Matsumoto, Miki Shimada, Nariyasu Mano, Tooru Shimosegawa

GASTROENTEROLOGY　142　(5)　S215-S215　2012/05

ISSN： 0016-5085
治療中高血圧患者の高血圧管理における保険調剤薬局の関与 J-HOME-Morning研究より

小原拓, 小林由香, 池田うらら, 菊谷昌浩, 目時弘仁, 井上隆輔, 大久保孝義, 眞野成康, 栗山進一, 今井潤

日本高血圧学会臨床高血圧フォーラムプログラム・抄録集　1回　101-101　2012/04
Publisher: (NPO)日本高血圧学会
膵がんゲムシタビン療法のPK/PGx

鈴木裕之, 工藤由起, 相馬真志, 菊地正史, 木皿重樹, 松浦正樹, 久道周彦, 江川新一, 海野倫明, 島田美樹, 眞野成康

日本薬学会年会要旨集　132nd　(4)　175　2012/03/05

ISSN： 0918-9823
内服抗がん薬処方監査補助システムの構築

飯田優太郎, 内田敬, 猪岡京子, 菊地正史, 木皿重樹, 吉田真貴子, 安井誠, 松浦正樹, 我妻恭行, 眞野成康

日本薬学会年会要旨集　132年会　(4)　168-168　2012/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
妊婦における医療用医薬品の安全性に関するエビデンスの構築のための薬剤疫学研究の基盤整備および実践

栗山進一, 八重樫伸生, 眞野成康, 赤沢学, 大久保孝義, 目時弘仁, 久保田潔, 佐藤嗣道, 庄野あい子, 小原拓

厚生労働科学研究費補助金医薬品・医療機器等レギュラトリーサイエンス総合研究事業妊婦における医療用医薬品の安全性に関するエビデンスの構築のための薬剤疫学研究の基盤整備および実践（H23-医薬-一般-006）平成２３年度総括・分担研究報告書　1-11　2012/03
長期実務実習での次世代型専門薬剤師を目指した取り組み CKDにおける薬物投与設計

高橋亜希, 平塚真弘, 村井ユリ子, 眞野成康, 平澤典保

日本薬学会年会要旨集　132年会　(4)　345-345　2012/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
LC/MS/MSを用いた生体試料中スフィンゴ脂質同時定量法の構築

芝可奈子, 三枝大輔, 井上飛鳥, 濱弘太郎, 奥谷倫世, 鈴木千登世, 佐藤恵美子, 眞野成康, 菱沼隆則, 鈴木直人, 佐藤博, 阿部高明, 青木淳賢, 富岡佳久

日本薬学会年会要旨集　132年会　(4)　138-138　2012/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
被災地の災害医療支援 (特集災害医療と被害管理)

眞野成康

医薬ジャーナル　48　(2)　653-658　2012/02
Publisher: 医薬ジャーナル社
ISSN： 0287-4741
シンバスタチン服用前後の脂質・血糖・血圧の変化市販後調査データを用いた検討

小原拓, 猪狩有紀恵, 小林寛子, 高橋武, 高橋則男, 岸川幸生, 村井ユリ子, 眞野成康, 高橋將喜

医薬品相互作用研究　36　(2)　15-20　2012
Changes in serum cholesterol, blood glucose, and blood pressure after administration of simvastatin:

Obara T, Igari Y, Kobayashi H, Takahashi T, Takahashi N, Kishikawa Y, Murai Y, Mano N, Takahashi M

J. Drug Interaction Res.　36　(2)　15-20　2012
LC/ESI‐MS/MSによる患者血清中のゲムシタビン及び代謝物測定法の構築

鈴木裕之, 工藤由起, 田村淳, 相馬真志, 内田敬, 菊地正史, 木皿重樹, 松浦正樹, 久道周彦, 高橋哉子, 小笠原喜美代, 江川新一, 海野倫明, 島田美樹, 眞野成康

日本薬学会東北支部大会講演要旨集　51st　93　2012
経口薬併用化学療法地域連携チームによる実践的取組み(平成23年度厚生労働省チーム医療実証事業による活動の報告)

秋山聖子, 瀬谷裕貴子, 菊地正史, 上原厚子, 菅原しのぶ, 神尾奈穂, 高田紀子, 小笠原喜美代, 柴田弘子, 舟田彰, 崎野健一, 畠山法己, 河原正典, 眞野成康, 石岡千加史

日本臨床腫瘍学会学術集会プログラム・抄録集　10th　122　2012
【東日本大震災】被災地の様子宮城県における取り組み (日本病院薬剤師会雑誌)

眞野成康

日本病院薬剤師会雑誌　47　(9)　1120-1123　2011/11/07
レセプトデータを用いた妊娠高血圧患者に対する降圧薬処方状況の把握

小原拓, 大久保孝義, 目時弘仁, 西郡秀和, 石黒真美, 眞野成康, 赤沢学, 八重樫伸生, 栗山進一

日本薬剤疫学会学術総会抄録集　17回　76-77　2011/11
Publisher: (一社)日本薬剤疫学会
ステロイドQ&A A剤形を考慮したステロイドの適正使用？合剤（吸入ステロイド＋β2刺激薬）を小児に使うメリットは？ (薬局)

古舘ひとみ, 松浦正樹, 眞野成康

薬局　62　240-245　2011/11/01
A rapid and sensitive LC/ESI-MS/MS method for quantitative analysis of docetaxel in human plasma and its application to a pharmacokinetic study

山口浩明, 藤川あす歌, 伊藤創, 田中伸明, 山田武宏, 眞野成康, 井関健

Chromatography　32　(Supplement 2)　89-90　2011/10/10

ISSN： 1342-8284
Quantitation of antineoplastic drug oxaliplatin from human plasma using HILIC/MS/MS

伊藤創, 山口浩明, 藤川あす歌, 山田武宏, 眞野成康, 井関健

Chromatography　32　(Supplement 2)　135-136　2011/10/10

ISSN： 1342-8284
降圧治療中患者における家庭血圧日間変動の規定因子 J-HOME-Morning研究

小原拓, 石倉一樹, 菊谷昌浩, 加藤哲夫, 芝宮拓, 新木貴大, 池田うらら, 小林由香, 目時弘仁, 眞野成康, 栗山進一, 大久保孝義, 今井潤

日本高血圧学会総会プログラム・抄録集　34回　527-527　2011/10
Publisher: (NPO)日本高血圧学会
高血圧薬物治療における家庭血圧測定と薬剤師の介入

吉町昌子, 小原拓, 川端ゆかり, 馬庭ちはる, 河野弘之, 眞野成康, 大久保孝義, 後藤輝明

日本高血圧学会総会プログラム・抄録集　34回　621-621　2011/10
Publisher: (NPO)日本高血圧学会
6年制薬学教育と薬剤師生涯教育(シンポジウム25 薬剤師に求められるサイエンスをベースにした生涯研鑽,Enjoy Pharmacists' Lifestyles)

眞野成康

日本医療薬学会年会講演要旨集　21　104-104　2011/09/09
Publisher: 日本医療薬学会
P-1248 大学院生による集団糖尿病教室の実施 : 実践型薬剤師教育を目指して(一般演題ポスター発表,薬学教育(その他),Enjoy Pharmacists' Lifestyles)

高橋亜希, 平塚真弘, 室井祐佳, 本田雅志, 田巻佑一朗, 新沼優衣, 由浪有希子, 石井大輔, 田坂英久, 眞野成康

日本医療薬学会年会講演要旨集　21　389-389　2011/09/09
Publisher: 日本医療薬学会
HPLCによるイリノテカンおよび代謝物の同時定量法の構築

鈴木澄子, 松浦正樹, 赤坂和俊, 土屋雅美, 木皿重樹, 久道周彦, 石岡千加史, 島田美樹, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　24th　92-93　2011/08/24

ISSN： 1347-2364
PS-122-3 胃切除術後栄養管理におけるエレンタールゼリーの認容性と有用性の検討(PS-122 ポスターセッション(122)胃:周術期管理-2,第111回日本外科学会定期学術集会)

田中直樹, 柴田近, 鹿郷昌之, 木内誠, 生澤史江, 三浦康, 内藤剛, 小川仁, 安藤敏典, 森川孝則, 矢崎伸樹, 羽根田祥, 渡辺和宏, 佐々木巌, 岡本智子, 武田みゆき, 眞野成康, 杣木麻利恵, 前川麻央, 久道周彦

日本外科学会雑誌　112　(1)　715-715　2011/05/25
Publisher: 一般社団法人日本外科学会
ISSN： 0301-4894
カラムスイッチング‐LC/MS/MSによるパクリタキセル血中濃度測定法の確立

藤川あす歌, 山口浩明, 伊藤創, 田中伸明, 古堅彩子, 宮森和明, 高橋夏子, 小倉次郎, 小林正紀, 山田武宏, 眞野成康, 井関健

日本薬学会年会要旨集　131st　(4)　178-178　2011/03/05
Publisher: (公社)日本薬学会
ISSN： 0918-9823
胃切除術後栄養管理におけるエレンタールゼリーの認容性と有用性の検討

田中直樹, 柴田近, 鹿郷昌之, 木内誠, 生澤史江, 三浦康, 内藤剛, 小川仁, 矢崎伸樹, 羽根田祥, 渡辺和宏, 佐々木巖, 岡本智子, 武田みゆき, 眞野成康, 杣木麻利恵, 前川麻央, 久道周彦

日本消化器病学会雑誌　108　(臨増総会)　A291-A291　2011/03
Publisher: (一財)日本消化器病学会
ISSN： 0446-6586
次世代型専門薬剤師育成を目指した診療従事型教育プログラムの構築

平塚真弘, 高橋亜希, 田巻佑一朗, 本田雅志, 室井祐佳, 村井ユリ子, 眞野成康, 佐藤博, 平澤典保

日本薬学会年会要旨集　131年会　(4)　334-334　2011/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
大学院生の集団糖尿病教室を通じたチーム医療教育

高橋亜希, 平塚真弘, 室井祐佳, 本田雅志, 田巻佑一朗, 新沼優衣, 由浪有希子, 石井大輔, 田坂英久, 眞野成康, 平澤典保

日本薬学会年会要旨集　131年会　(4)　363-363　2011/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
高血圧専門外来に通院中の高血圧患者における家庭血圧測定

吉田愛琴, 小原拓, 石倉一樹, 池田うらら, 眞野成康, 大久保孝義, 今井潤

血圧　18　(3)　279-285　2011/03
Publisher: (株)先端医学社
ISSN： 1340-4598
肝細胞癌患者のソラフェニブおよび代謝物の血中モニタリング

大川星美, 前嶋隆弘, 柳利樹, 赤坂和俊, 土屋雅美, 松浦正樹, 久道周彦, 近藤泰輝, 下瀬川徹, 島田美樹, 島田美樹, 眞野成康, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　24th　2011

ISSN： 1347-2364
多職種チーム研修-レジメン審査に重点を置いて

秋山聖子, 加藤俊介, 木皿重樹, 我妻恭行, 久道周彦, 大桐規子, 石澤賢一, 井上彰, 大槻健郎, 三浦康, 塩野雅俊, 下平秀樹, 森隆弘, 眞野成康, 石岡千加史

日本臨床腫瘍学会学術集会プログラム・抄録集　9th　2011
タンデム質量分析法を活用した抱合型胆汁酸メタボローム解析法の検討

前川正充, 森大, 鈴木裕之, 大野耕策, 入戸野博, 小川祥二郎, 柿山玄太, 飯田隆, 後藤順一, 島田美樹, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　24th　2011

ISSN： 1347-2364
次世代型専門薬剤師育成を目指した東北大学病院における大学院教育

鈴木直人, 木皿重樹, 村井ユリ子, 村井ユリ子, 黒澤真帆, 大内麻由, 三枝大輔, 眞野成康, 眞野成康, 富岡佳久

日本薬学会東北支部大会講演要旨集　50th　2011
家庭血圧測定に基づくカルシウム拮抗薬シルニジピンの降圧効果および薬効持続の検討 Peer-reviewed

吉田愛琴, 小原拓, 石倉一樹, 佐々木彩乃, 池田うらら, 小林由香, 大久保孝義, 眞野成康, 宮川政昭, 今井潤

Therapeutic Research　31　(12)　1719-1726　2010/12

ISSN： 0289-8020

More details Close

降圧薬服用中の本態性高血圧患者で、シルニジピン10mgを1日1回就寝前に追加処方した早朝血圧管理不良患者37名(男21名、女16名、平均65.5±11.2歳)におけるシルニジピンの降圧効果を、家庭血圧測定により評価した。処方日、服用開始4週間後、8週間後のそれぞれ直近5日間の平均値を家庭血圧および家庭心拍の値とした。早朝血圧値は4週間後、8週間後共に有意な低下を認めたが、心拍数には有意な変化を認めなかった。4週後には早朝収縮期血圧が-11.2mmHg、拡張期血圧が-5.8mmHg、就寝前収縮期血圧が-2.1mmHg、拡張期血圧が-1.7mmHgの降圧が得られた。以上より、シルニジピンは1日1回の服用であっても十分な降圧効果および良好な早期血圧管理が得られることが示唆された。また、シルニジピンは血圧管理不良の血圧値に対して、より効果的に作用する可能性があり、早期血圧管理不良高血圧に有効な降圧薬であると考えられた。
P1-232 シロリムス血中濃度測定におけるACMIA法、MEIA法およびLC/MS/MSの比較検討(一般演題ポスター発表,薬物動態・TDM・投与設計,臨床から学び臨床へと還元する医療薬学)

松本洋太郎, 藤吉正哉, 上西智子, 佐藤真由美, 森大, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　20　325-325　2010/10/25
Publisher: 日本医療薬学会
P2-502 家庭血圧測定に基づくアンジオテンシンII受容体拮抗薬イルベサルタンの降圧効果および薬効持続に関する検討(一般演題ポスター発表,薬物療法(その他),臨床から学び臨床へと還元する医療薬学)

吉田愛琴, 小原拓, 石倉一樹, 小林由香, 廣瀬卓男, 大久保孝義, 眞野成康, 今井潤

日本医療薬学会年会講演要旨集　20　473-473　2010/10/25
Publisher: 日本医療薬学会
胃切除術後栄養管理におけるエレンタールゼリーの認容性と有用性の検討

田中直樹, 柴田近, 鹿郷昌之, 木内誠, 佐藤学, 生澤史江, 三浦康, 内藤剛, 小川仁, 安藤敏典, 矢崎伸樹, 羽根田祥, 渡辺和宏, 佐々木巖, 岡本智子, 武田みゆき, 眞野成康, 杣木麻利恵, 前川麻央, 久道周彦

日本消化器外科学会雑誌　43　(Suppl.2)　192-192　2010/10
Publisher: (一社)日本消化器外科学会
ISSN： 0386-9768

eISSN： 1348-9372
家庭血圧測定に基づくカルシウム拮抗薬シルニジピンの降圧効果および薬効持続の検討

吉田愛琴, 小原拓, 石倉一樹, 佐々木彩乃, 池田うらら, 目時弘仁, 浅山敬, 井上隆輔, 菊谷昌浩, 大久保孝義, 眞野成康, 今井潤

日本高血圧学会総会プログラム・抄録集　33回　372-372　2010/10
Publisher: (NPO)日本高血圧学会
臨床現場に貢献する分析科学 (ぶんせき)

島田美樹, 眞野成康

ぶんせき　(430)　502-505　2010/10/01
Publisher: (公社)日本分析化学会
ISSN： 0386-2178
東北大学化学療法センターの現状と問題点取り組み紹介と今後の課題

秋山聖子, 加藤俊介, 木皿重樹, 大桐規子, 高橋克史, 久道周彦, 森隆弘, 下平秀樹, 石澤賢一, 井上彰, 大槻健郎, 角道祐一, 我妻恭行, 眞野成康, 石岡千加史

日本癌治療学会誌　45　(2)　852-852　2010/09
Publisher: (一社)日本癌治療学会
ISSN： 0021-4671
DI室Q&A ステロイド薬や免疫抑制薬を服用している間質性肺炎患者に、インフルエンザワクチンの効果はあるのか間質性肺炎患者の薬物療法と感染予防 (治療学)

鈴木文子, 佐藤真由美, 眞野成康

治療学　44　(5)　617-619　2010/05
次世代型専門薬剤師育成を目指した大学院教育プログラムの開発-がん化学療法処方設計支援基礎実習カリキュラムの構築

鈴木直人, 金光祥臣, 松本周平, 三村享, 三枝大輔, 村井ユリ子, 村井ユリ子, 久道周彦, 佐藤真由美, 齊藤直美, 木皿重樹, 眞野成康, 眞野成康, 富岡佳久

日本薬学会年会要旨集　130th　(4)　2010

ISSN： 0918-9823
薬剤費を基準にした注射用抗がん剤複数規格選択システムの開発とその効果

鈴木寿樹, 松浦正樹, 高橋克史, 吉川三保子, 有山智博, 飯田優太郎, 相馬真志, 木皿重樹, 我妻恭行, 久道周彦, 眞野成康

日本薬学会東北支部大会講演要旨集　49th　2010
LC/ESI-MS/MSを用いたNiemann-Pick病C型患者尿中の多重抱合型胆汁酸測定法

前川正充, 三澤靖, 外浦亜耶子, 坂本修, 大浦敏博, 虻川大樹, 井上岳彦, 大野耕策, 武藤晃奈, 武井一, 入戸野博, 小川祥二郎, 柿山玄太, 飯田隆, HOFMANN Alan F., 後藤順一, 島田美樹, 島田美樹, 眞野成康, 眞野成康

バイオメディカル分析科学シンポジウム講演要旨集　23rd　2010

ISSN： 1347-2364
次世代型専門薬剤師育成を目指した東北大学病院化学療法センターにおける大学院教育

鈴木直人, 村井ユリ子, 村井ユリ子, 三枝大輔, 木皿重樹, 眞野成康, 眞野成康, 富岡佳久

日本薬学会東北支部大会講演要旨集　49th　2010
化学診断並びに薬物療法の適正化に寄与する質量分析法 (臨床化学)

眞野成康, 島田美樹, 後藤順一

臨床化学　39　(1)　70-78　2010/01
Publisher: (一社)日本臨床化学会
ISSN： 0370-5633
メタボローム・プロテオーム解析法 (日本臨床化学会東北支部会誌)

眞野成康

日本臨床化学会東北支部会誌　19　1-10　2010/01
Home and office blood pressure control among treated hypertensive patients in Japan: Findings from the Japan home versus office blood pressure measurement evaluation (J-HOME) study

Taku Obara, Takayoshi Ohkubo, Michihiro Satoh, Nariyasu Mano, Yutaka Imai

Pharmaceuticals　3　(2)　419-432　2010

DOI： 10.3390/ph3020419 　

ISSN： 1424-8247
高齢者高血圧患者における早朝家庭血圧管理と降圧治療 J-HOME-Elderly研究

小原拓, 芝宮拓, 新木貴大, 目時弘仁, 浅山敬, 井上隆輔, 菊谷昌浩, 大久保孝義, 眞野成康, 今井潤

日本高血圧学会総会プログラム・抄録集　32回　214-214　2009/10
Publisher: (NPO)日本高血圧学会
治療中高血圧患者における家庭血圧コントロール改善・悪化の要因に関する検討 J-HOME-Morning研究

小原拓, 小林満, 芝宮拓, 新木貴大, 原梓, 目時弘仁, 浅山敬, 井上隆輔, 菊谷昌浩, 眞野成康, 大久保孝義, 今井潤

日本高血圧学会総会プログラム・抄録集　32回　263-263　2009/10
Publisher: (NPO)日本高血圧学会
特集がん化学療法レジメン審査における薬剤師の役割 ―化学療法センター事務局機能について― (日病薬誌)

久道周彦, 眞野成康

日病薬誌　45　1088-1090　2009/10
P1-034 視点計測機を用いた調剤ミスの要因解析(一般演題ポスター発表,調剤・処方鑑査・リスクマネジメント,医療薬学の創る未来科学と臨床の融合)

中村浩規, 猪岡京子, 村井ユリ子, 眞野成康

日本医療薬学会年会講演要旨集　19　298-298　2009/09/15
Publisher: 日本医療薬学会
次世代型専門薬剤師育成を目指した大学院教育プログラムの開発(その1)

富岡佳久, 平澤典保, 眞野成康, 村井ユリ子, 鈴木直人, 三枝大輔, 平塚真弘, 高橋亜希, 島田美樹, 岡芳知, 伊藤貞嘉, 石岡千加史, 寺崎哲也, 永沼章

日本医療薬学会年会講演要旨集　19th　469　2009/09/15
P1-555 医学部臨床修練における「医師-薬剤師協働型医療情報実習」への取り組み(一般演題ポスター発表,その他,医療薬学の創る未来科学と臨床の融合)

鈴木文子, 飯田優太郎, 松本洋太郎, 上西智子, 村井ユリ子, 浅田成紀, 荒井啓行, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　19　385-385　2009/09/15
Publisher: 日本医療薬学会
P2-287 カラムスイッチングHPLCによるボリコナゾールの血中濃度測定法の確立(一般演題ポスター発表,薬物動態(臨床、TDM),医療薬学の創る未来科学と臨床の融合)

松本洋太郎, 上西智子, 佐賀利英, 山口浩明, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　19　435-435　2009/09/15
Publisher: 日本医療薬学会
外来がん化学療法におけるレジメン別患者用説明書の有用性

土屋雅美, 伊藤千晶, 菊池聡, 赤坂和俊, 木皿重樹, 久道周彦, 眞野成康, 加藤俊介, 石岡千加史, 大桐規子

日本癌治療学会誌　44　(2)　855-855　2009/09
Publisher: (一社)日本癌治療学会
ISSN： 0021-4671
CHARACTERISTICS OF UNCONTROLLED HYPERTENSIVE PATIENTS DETERMINED BY MORNING AND EVENING HOME BLOOD PRESSURE MEASUREMENT FROM THE J-HOME STUDY

T. Obara, K. Ito, T. Ohkubo, K. Gonokami, T. Shibamiya, T. Shinki, A. Hara, H. Metoki, K. Asayama, R. Inoue, M. Kikuya, N. Mano, Y. Imai

JOURNAL OF HYPERTENSION　27　S259-S259　2009/06

ISSN： 0263-6352
INFLUENCE OF HOME BLOOD PRESSURE MEASURING CONDITION IN EVENING ON THE MORNING-EVENING HOME BLOOD PRESSURE DIFFERENCE IN TREATED HYPERTENSIVE PATIENTS; THE J-HOME STUDY

T. Obara, K. Ito, T. Ohkubo, K. Gonokami, T. Shibamiya, T. Shinki, M. Nakashita, A. Hara, H. Metoki, K. Asayama, R. Inoue, M. Kikuya, N. Mano, Y. Imai

JOURNAL OF HYPERTENSION　27　S190-S190　2009/06

ISSN： 0263-6352
家庭血圧測定に基づくアムロジピンベシル酸塩の後発医薬品の臨床評価

小原拓, 池田うらら, 新木貴大, 芝宮拓, 大久保孝義, 眞野成康, 今井潤

ジェネリック研究　3　(増刊号)　93-93　2009/06
Publisher: 日本ジェネリック医薬品・バイオシミラー学会
ISSN： 1881-9117
薬剤師における後発医薬品導入における認識

小原拓, 高橋將喜, 高橋則男, 北村哲治, 大久保孝義, 眞野成康, 今井潤

ジェネリック研究　3　(増刊号)　110-110　2009/06
Publisher: 日本ジェネリック医薬品・バイオシミラー学会
ISSN： 1881-9117
家庭血圧測定と降圧薬使用 J-HOME研究およびJ-HOME追跡(Morning)研究より

小原拓, 大久保孝義, 小林満, 眞野成康, 今井潤

薬剤疫学　13　(Suppl.)　S62-S63　2008/10
Publisher: (一社)日本薬剤疫学会
ISSN： 1342-0445
21-P1-025 錠剤・カプセル剤粉砕時の最大投与日数の判断基準の設定及びその運用(医薬品情報,来るべき時代への道を拓く)

鈴木文子, 松浦正樹, 飯田優太郎, 鴨田美緒, 吉中千佳, 戸澤亜紀, 佐藤真由美, 後藤順一, 眞野成康

日本医療薬学会年会講演要旨集　18　379-379　2008/09/01
Publisher: 日本医療薬学会
脂質異常症患者における先発医薬品(ベザトールSR)から後発医薬品(ベザテートSR)への切り替えに関する臨床評価 Peer-reviewed

小原拓, 高橋將喜, 高橋則男, 高橋武, 小林寛子, 猪狩有紀恵, 大久保孝義, 齋藤真一郎, 眞野成康, 今井潤

医薬品相互作用研究　32　(1)　33-37　2008/07
Publisher: 医薬品相互作用研究会
ISSN： 0385-5015
脂質異常症治療薬の後発医薬品への切り替えと服薬コンプライアンスの変化

小原拓, 高橋將喜, 高橋則男, 高橋武, 小林寛子, 猪狩有紀恵, 齋藤真一郎, 大久保孝義, 眞野成康, 今井潤

ジェネリック研究　2　(増刊号)　74-74　2008/06
Publisher: 日本ジェネリック医薬品・バイオシミラー学会
ISSN： 1881-9117
Mass spectrometry

57　(1)　110-116　2008/01
Publisher: 永井書店
ISSN： 0371-1900
Functional analysis of organic anion transporter, OATP4C1, expressed in kidney

Hiroaki Yamaguchi, Misa Sugie, Masahiro Okada, Takaaki Abe, Junichi Goto, Takanori Hishinuma, Miki Shimada, Nariyasu Mano

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN　128　51-52　2008

ISSN： 0031-6903
質量分析法による胆汁酸関連タンパク質の解析

眞野成康, 阿部幸平, 後藤順一

臨床病理 = THE OFFICIAL JOURNAL OF JAPANESE SOCIETY OF LABORATORY MEDICINE　55　98-98　2007/10/31

ISSN： 0047-1860
LC/MS/MSによる化学診断

眞野成康, 菱沼隆則, 後藤順一

ぶんせき　(394)　496-501　2007/10/05
Publisher: 日本分析化学会
ISSN： 0386-2178
29-P3-47 卒前病院実習への危険予知トレーニングの導入(薬学教育,社会の期待に応える医療薬学を)

村井ユリ子, 佐藤真由美, 山口浩明, 眞野成康, 後藤順一, 菱沼隆則

日本医療薬学会年会講演要旨集　17　288-288　2007/09/01
Publisher: 日本医療薬学会
29-P1-142 シロリムスからミコフェノール酸モフェチルに投与変更した膵島移植患者におけるTDM(TDM/薬物動態,社会の期待に応える医療薬学を)

松本洋太郎, 上西智子, 山口浩明, 佐藤真由美, 小川則彦, 後藤昌史, 里見進, 菱沼隆則, 後藤順一, 眞野成康

日本医療薬学会年会講演要旨集　17　240-240　2007/09/01
Publisher: 日本医療薬学会
Study on the visualization of carrier-mediated transport

Masahiro Okada, Hiroaki Yamaguchi, Minako Kobayashi, Toshiko Takeuchi, Masayuki Tanemoto, Michiaki Unno, Takaaki Abe, Takanori Hishinuma, Junichi Goto, Nariyasu Mano

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN　127　181-182　2007

ISSN： 0031-6903
SULFATION OF CHENODEOXYCHOLIC ACID BY RAT BRAIN CYTOPLASMIC FRACTION

Mano Nariyasu, Abe Shin-ichiro, Maekawa Masamitsu, Myint Khin Than, Goto Takaaki, Goto Junichi

Abstracts of Annual meeting of Japanese Society for the Study of Xenobiotics　21　(0)　285-285　2006
Publisher: The Japanese Society for the Study of Xenobiotics
DOI： 10.14896/jssxmeeting.21.0.285.1 　
脳内胆汁酸の発見と脳内生合成活性

眞野成康, 後藤貴章, 後藤順一

臨床病理 = THE OFFICIAL JOURNAL OF JAPANESE SOCIETY OF LABORATORY MEDICINE　53　70-70　2005/10/30

ISSN： 0047-1860
P-38 Analysis of DNA adducts formed with cholyl adenylate, a putative intermediate for biosynthesis of cholyl-CoA(Poster Presentations(1))

Takamura-Enya T, Mano N, Kawahara N, Goto J, Wakabayashi K

(34)　123-123　2005
Publisher: 日本環境変異原学会
プロテオミクスのよる病態・病因解析と創薬への応用

真野成康, 菱沼隆則, 後藤順一

化学と生物　43　(6)　391-398　2005
Publisher: Japan Society for Bioscience, Biotechnology, and Agrochemistry
DOI： 10.1271/kagakutoseibutsu1962.43.391 　

ISSN： 0453-073X 1883-6852
Development of Highly Selective Analytical Systems for Biological Substances Using Chromatography Combined with Mass Spectrometry : With Special Reference to Bio-Analytical Studies of Bile Acids

GOTO Junichi, MANO Nariyasu, GOTO Takaaki

Chromatography　25　(1)　1-8　2004/03/19
Publisher: クロマトグラフィ-科学会
ISSN： 1342-8284
脳内胆汁酸の発見

眞野成康, 内田将史, 西村浩司, 後藤順一

日本小児栄養消化器肝臓学会雑誌 = Japanese journal of pediatric gastroenterology, hepatology and nutrition　17　(1)　2-2　2003/09/20

ISSN： 1346-9037
胆汁酸刺激による培養細胞内変動蛋白質の解析

飯島摂子, 八幡憲治, 春日紀恵, 眞野成康, 後藤順一

日本小児栄養消化器肝臓学会雑誌 = Japanese journal of pediatric gastroenterology, hepatology and nutrition　17　(1)　1-1　2003/09/20

ISSN： 1346-9037
Highly selective molecular recognition of biologically active substances using liquid phase separation (Chromatography)

Nariyasu Mano, Naoki Asakawa, Junichi Goto

Chromatography　24　(1)　298-305　2003
Publisher: クロマトグラフィ-科学会
ISSN： 1342-8284
1H and 13 C NMR signal assignments of carboxyl-linked glucosides of bile acids

Takashi Iida, Genta Kakiyama, Akira Shimada, Kumiko Mushiake, Nariyasu Mano, Junichi Goto, Toshio Nambara

Magn. Reson. Chem　41　260-264　2003

DOI： 10.1002/mrc.1173 　
A comparative study of remote-oxyfunctionalization of unactivated carbons in 5b-steroids by dimethyldioxirane and 2,6-dichloropyridine N-oxyde/Ruthenium porphyrin/HBr

Takashi Iida, Shoujiro Ogawa, Keisuke Shiraishi, Genta Kakiyama, Takaaki Goto, Nariyasu Mano, Junichi Goto

ARKIVOC　2004　(vii)　170-179　2003
Structure elucidation of serofendic acids, novel neuroprotective substances isolated from fetal calf serum.

T Terauchi, N Asai, M Yonaga, H Sugimoto, T Kume, A Akaike, N Mano

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY　224　U53-U53　2002/08

ISSN： 0065-7727
Separation and Determination of Diastereomeric Flurbiprofen Acyl Glucuronides in Human Urine by LC/ESI-MS with a Simple Column-Switching Technique

MANO Nariyasu, NARUI Takashi, NIKAIDO Ayako, GOTO Junichi

Drug Metab. Pharmacokinet.　17　(2)　142-149　2002/05/31

ISSN： 0916-1139
代謝活性中間体と蛋白質付加体生成 (J.Mass Spectrom. Soc. Jpn)

眞野成康, 池川繁男, 後藤順一

J.Mass Spectrom. Soc. Jpn　50　(3)　162-170　2002
Publisher: The Mass Spectrometry Society of Japan
DOI： 10.5702/massspec.50.162 　

ISSN： 1340-8097 1880-4225 1884-3271

More details Close

In the body, drugs and biological active substances having a carboxyl group in those molecules have been known to transform various metabolites. Commonly, these compounds such as α-aryl propionic acid derivatives are activated to corresponding intermediates like a coenzyme A thiol ester prior to both isomerizations and conjugations with amino acids. The acyl adenylate has been also noted as an intermediate of coenzyme A ligation. In addition, the carboxyl group is known to be metabolized to acyl glucuronides in hepatocyte. Both the acyl adenylate and the acyl glucuronide are chemically very active, and they may produce the protein-bound adducts by reaction with the nucleophilic groups such as an amino group on the protein molecule. The authors have synthesized acyl glucuronides and acyl adenylates of bile acids, which are endogeous carboxylic acid derivatives, biosynthesized from cholesterol in the hepatocyte, and investigated their reactivity with peptide or protein. Both results clearly indicated that these active intermediates produced protein-bound adducts nonenzymatically. The formation of such adducts has attracted attention as a possible explanation for hypersensitivity, and non-enzymatic post-translational modifications to proteins in the body.
分析値の取り扱いと信頼性質量分析における分析値の取り扱い (ぶんせき)

眞野成康, 後藤順一

ぶんせき　12　(321)　448-453　2001/09
A large volume injection system for HPLC using membrane II ; Development of micro-scale gradient elution system

MURATA Kaoru, ISHIHAMA Yasushi, MANO Nariyasu, ASAKAWA Naoki

20　(2)　200-201　1999/06/24

ISSN： 1342-8284
A large volume injection system for HPLC using membrane

MURATA Kaoru, MANO Nariyasu, ASAKAWA Naoki

Chromatography　19　(4)　388-389　1998/11/10

ISSN： 1342-8284
Simultaneous Determination of Drug Enantiomers and Their Metabolites by Plasma Direct Injection HPLC

MANO Nariyasu, ODA Yoshiya, ASAKAWA Naoki

Chromatography : journal of separation and detection sciences = クロマトグラフィー : 分離・検出科学　19　(4)　372-373　1998/11/10

ISSN： 1342-8284
DEVELOPMENT OF A NEW CHIRAL SEPARATION COLUMN AND ITS APPLICATION

MANO Nariyasu, ODA Yoshiya, ASAKAWA Naoki

薬物動態 = Xenobiotic metabolism and disposition　13　S128-S129　1998/10/23

ISSN： 0916-1139
Consideration on chiral recognition of protein immobilizing column using affinity capillary electrophoresis.

真野成康, 小田吉哉, 石浜泰, 浅川直樹

日本薬学会年会要旨集　118th　(4)　95　1998/03

ISSN： 0918-9823
Quantitative Method for Biological Active Substance in Biological Samples by Hyphenated MS Techniques : What is the key point?

MANO Nariyasu, ODA Yoshiya, ASAKAWA Naoki

J. Mass Spectrom. Soc. Jpn.　45　(3)　401-415　1997/06/01
Publisher: The Mass Spectrometry Society of Japan
DOI： 10.5702/massspec.45.401 　

ISSN： 1340-8097

More details Close

Mass spectrometry (MS) has been recognized as an integral method in biological research and our ability to analyze a wide variety of biologically relevant molecules has been greatly advanced by MS. Highly sensitive, highly selective, and reproducible hyphenated MS (GC/MS, LC/MS) or MS/MS method is necessary to get high quality information. We show that the optimization of MS interface is very important for high sensitivity. Chromatography techniques are also indispensable to distinguish identical mass substances. In addition to avoiding adsorption and contaminants problem, our optimized conditions have resulted in a suitable quantitative analysis method for endogenous biological active substances in biological materials.
Ouantitative Method for Biological Active Substance by LC/MS/MS

MANO Nariyasu, ODA Yoshiya, ASAKAWA Naoki

講演要旨集　22　32-32　1997/03/01
HPLC用タンパク固定化カラムによる光学異性体分離に関する考察

真野成康, 石浜泰, 小田吉哉, 浅川直樹

日本薬学会年会要旨集　115th　(Pt 4)　175　1995/03

ISSN： 0918-9823
Quantitation Method for Mevalonic Acid in Plasma using Gas Chromatography/Chemical Ionization-Mass Spectrometry.

真野成康, 石浜泰, 小田吉哉, 浅川直樹, 日吉裕展, 生田博憲

生体成分の分析化学シンポジウム講演要旨集　11th　19-22　1994/09

Show all ︎Show first 5

Books and Other Publications 8

今日の臨床検査2011-2012，36. 薬物検査

南江堂 ed, 久道周彦, 古舘ひとみ, 佐藤真由美, 眞野成康

南江堂　2011/11/01
南江堂

毒物濃度, 佐藤真由美, 古舘ひとみ, 久道周彦, 眞野成康

南江堂　2011/11/01
丸善出版

臨床における医薬品分析, ed. 眞野成康, 島田美樹

丸善出版　2011/11/01
Steroid Analysis Second Edition

H. L. J. Makin, D. B. Gower, ed. Jan, Sjovall William, J. Griffiths Kenneth, D. R. Setchell Nariyasu Mano Junichi Goto

Springer　2010/04/01
薬学分析科学の最前線

薬学会分析化学担当教員会議, d. 眞野成康

じほう　2009/10
パートナー分析化学？

山口政俊, 升島努, 斎藤寛, 能田均, ed, 眞野成康

南江堂　2007/08
スタンダード薬学シリーズ第２巻物理系薬学 III．生体分子・化学物質の構造決定

日本薬学会, d, 眞野成康, 後藤順一

東京化学同人　2006/08
先端の分析法

梅澤喜夫, 澤田嗣郎, 寺部茂 ed, 眞野成康, 菱沼隆則, 後藤順一

エヌ・ティー・エス　2004/08

Show all Show first 5

Presentations 375

P1201-22-PM 向精神薬服用妊婦に対して行った授乳に関する情報提供の現状(妊婦・授乳婦,ポスター発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)

八島一史, 菊地紗耶, 小林奈津子, 久道周彦, 眞野成康, 中川直人, 小原拓, 千葉和美, 山本美由紀, 西郡秀和, 加藤佳子, 松浦正樹, 秋山志津子

日本医療薬学会年会講演要旨集　2015
P0375-21-PM イトラコナゾールの併用によりシロリムスのトラフ濃度が高値を示したリンパ脈管筋腫症患者の2例(TDM・投与設計,ポスター発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)

菊地正史, 眞野成康, 野田あおい, 田中雅樹, 高橋阿希子, 松田安史, 星川康, 久道周彦, 山口浩明, 岡田克典

日本医療薬学会年会講演要旨集　2015
P0364-22-AM アキシチニブの血中濃度が上昇しなかった腎細胞癌患者の一例(TDM・投与設計,ポスター発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)

野田あおい, 荒井陽一, 眞野成康, 田中雅樹, 高崎新也, 鈴木裕之, 菊地正史, 川崎芳英, 伊藤明宏, 久道周彦, 山口浩明

日本医療薬学会年会講演要旨集　2015
22-7-O42-17 薬毒物中毒原因物質のLC/MS/MS分析システムの検討(TDM,口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)

前川正充, 久道周彦, 山口浩明, 眞野成康, 小梶哲雄, 菊地正史, 田中雅樹, 中曽根正皓, 野田あおい, 矢内一成, 鈴木博也, 赤坂和俊

日本医療薬学会年会講演要旨集　2015
28-P4PM-072 カラムスイッチングLC/ESI-MS/MSを用いるミコフェノール酸の血中濃度測定法の構築(TDM・投与設計2,一般演題(ポスター),新時代を拓く医療薬学フロンティア)

相馬真志, 菊地正史, 前川正充, 鈴木裕之, 久道周彦, 山口浩明, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　2014
28-O4AM-15 注射用抗菌薬の新たな在庫指標と直下型地震時におけるシミュレーション(災害医療,一般演題(口頭),新時代を拓く医療薬学フロンティア)

安田千賀, 寺岡知寿, 岸川有紀, 鈴木博也, 松浦正樹, 佐藤真由美, 久道周彦, 眞野成康

日本医療薬学会年会講演要旨集　2014
本邦における小児の注意欠陥/多動性障害および広汎性発達障害に対する医薬品処方

小原拓, 大場延浩, 森川和彦, 石黒真美, 目時弘仁, 菊谷昌浩, 西郡秀和, 眞野成康, 栗山進一

第23回日本疫学会学術総会　2013/01/24
日-P3-503 妊婦に対する気管支喘息治療薬の処方状況の把握に関する研究(妊婦・授乳婦,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

保坂実樹, 小原拓, 目時弘仁, 佐藤倫広, 大久保孝義, 八重樫伸生, 眞野成康, 栗山進一

日本医療薬学会年会講演要旨集　2013
日-P3-500 授乳と薬剤使用に関する問い合わせ内容の調査(妊婦・授乳婦,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

尾崎芙実, 佐賀利英, 佐藤真由美, 久道周彦, 松浦正樹, 眞野成康, 小原拓, 前川真央, 吉中千佳, 草場美津江, 中川直人, 飯田優太郎, 鈴木文子, 島田美樹

日本医療薬学会年会講演要旨集　2013
日-P2-319 治療中高血圧患者の高血圧管理における保険調剤薬局の関与 : J-HOME-Morning研究(治療・臨床試験,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

小原拓, 眞野成康, 栗山進一, 今井潤, 小林由香, 池田うらら, 保坂実樹, 佐藤倫広, 菊谷昌浩, 目時弘仁, 井上隆輔, 大久保孝義

日本医療薬学会年会講演要旨集　2013
日-P2-304 宮城県における薬剤業務実施調査報告 : アンケートに見る震災の影響(災害医療,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

石田和, 紫桃君子, 眞野成康, 佐藤庸一, 小林美奈子, 松浦夏子, 小野寺昭宏, 山寺文博, 外岡久和, 岸川幸生, 岩崎雅弘

日本医療薬学会年会講演要旨集　2013
日-P2-164 東北大学病院におけるカルバペネム薬使用届出制の導入とその効果(感染制御(治療薬),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

鈴木博也, 飯田優太郎, 久道周彦, 徳田浩一, 賀来満夫, 眞野成康

日本医療薬学会年会講演要旨集　2013
日-P1-070 東北大学病院薬剤部及び米国ノバサウスイースタン大学薬学部における医薬品情報実務実習の比較(薬学教育(実務実習),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

中川直人, 眞野成康, 草場美津江, 尾崎芙実, 前川麻央, 松浦正樹, 久道周彦, 村井ユリ子, Jennifer Gershman, 眞野成康

日本医療薬学会年会講演要旨集　2013
日-P1-027 「ピボキシル基」を有する抗菌薬の副作用情報周知に関する東北大学病院の取り組み(医療安全,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

尾崎芙実, 前川真央, 中川直人, 松浦正樹, 久道周彦, 眞野成康

日本医療薬学会年会講演要旨集　2013
日-P1-006 一般地域住民におけるセルフメディケーションに関する実態調査(OTC・セルフメディケーション,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

岩森紗希, 浅山敬, 高橋信行, 眞野成康, 佐藤博, 今井潤, 大久保孝義, 松本章裕, 佐藤倫広, 原梓, 菊谷昌浩, 小原拓, 目時弘仁, 廣瀬卓男, 井上隆輔

日本医療薬学会年会講演要旨集　2013
土-P3-439 ランマーク皮下注適正使用への取り組み(がん薬物療法(緩和ケア),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

村木浅理, 木皿重樹, 松浦正樹, 眞野成康, 草場美津江, 尾崎芙実, 鈴木直人, 菊地正史, 中川直人, 佐賀利英, 久道周彦, 佐藤真由美

日本医療薬学会年会講演要旨集　2013
土-P3-428 宮城県病院薬剤師会会員施設での麻薬に関する実態調査から[第1報] : 緩和ケアへの薬剤師関与がオピオイド使用密度に及ぼす影響(がん薬物療法(緩和ケア),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

今野耕英, 野澤寿吉, 櫻井淳二, 木皿重樹, 岸川幸生, 尾形勉, 後藤美紀子, 石澤文章, 眞野成康

日本医療薬学会年会講演要旨集　2013
土-P3-407 乳癌FEC100療法におけるホスアプレピタント注の有効性と安全性の検討(がん薬物療法(制吐支持療法),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

渡邊桂子, 富岡佳久, 石岡千加史, 眞野成康, 菊地正史, 木皿重樹, 小笠原喜美代, 久道周彦, 石田孝宣, 鈴木直人, 村井ユリ子, 島田美樹

日本医療薬学会年会講演要旨集　2013
土-P3-344 高機能抗がん薬自動混合調製装置の開発(がん薬物療法(無菌調製・曝露対策),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

正木拓陽, 木皿重樹, 佐藤真由美, 松浦正樹, 久道周彦, 眞野成康, 白石有紗, 岸川友紀, 高崎新也, 田中明, 斉藤数弘, 加藤雅之, 前川正充, 島田美樹

日本医療薬学会年会講演要旨集　2013
土-P3-339 抗がん薬調製後から投与実施までの過程における被曝の現状調査(がん薬物療法(無菌調製・曝露対策),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

鈴木寿樹, 森大, 高橋哉子, 小笠原貴美子, 木皿重樹, 石岡千加史, 島田美樹, 眞野成康

日本医療薬学会年会講演要旨集　2013
土-P2-315 がん化学療法における病院と保険薬局間の情報共有への取り組み(がん薬物療法(多職種連携),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

菊地正史, 加藤俊介, 石岡千加史, 佐々木孝雄, 眞野成康, 日野沙綾香, 高田紀子, 中川直人, 木皿重樹, 松浦正樹, 久道周彦, 我妻恭行, 山田卓郎

日本医療薬学会年会講演要旨集　2013
土-P2-274 透析患者の血中スニチニブ濃度を測定した1症例(TDM・投与設計,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

高崎新也, 眞野成康, 柳利樹, 鈴木裕之, 斉藤英郎, 伊藤明宏, 鈴木文子, 松浦正樹, 荒井陽一, 島田美樹

日本医療薬学会年会講演要旨集　2013
土-P2-275 LC/ESI-MS/MSによるAxitinibの血中濃度測定法の構築(TDM・投与設計,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

柳利樹, 島田美樹, 眞野成康, 高崎新也, 鈴木裕之, 前川正充, 齋藤英郎, 伊藤明宏, 荒井陽一, 久道周彦, 松浦正樹

日本医療薬学会年会講演要旨集　2013
土-P2-266 同種臍帯血移植直後にボリコナゾールの血中濃度が低下した一症例(TDM・投与設計,ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)

鈴木裕之, 眞野成康, 北村奈央子, 柳利樹, 相馬真志, 佐藤祐司, 前川正充, 石澤賢一, 張替秀郎, 島田美樹

日本医療薬学会年会講演要旨集　2013
治療薬物モニタリングにおける質量分析法の活用

島田美樹, 眞野成康

第59回日本臨床検査医学会学術集会　2012/11/30
Prescription of drugs for children with attention deficit/hyperactivity disorder (AD/HD) in Japan

Taku Obara, Nobuhiro Ooba, Yoshihiko Morikawa, Mami Ishikuro, Hirohito Metoki, Masahiro Kikuya, Hidekazu Nishigori, Nariyasu Mano, Shinichi Kuriyama

The 7th Asian Conference on Pharmacoepidemiology (ACPE 7) meeting　2012/10/26
Prescription of drugs for children with attention deficit/hyperactivity disorder (AD/HD) in Japan International-presentation

Taku Obara, Nobuhiro Ooba, Yoshihiko Morikawa, Mami Ishikuro, Hirohito Metoki, Masahiro Kikuya, Hidekazu Nishigori, Nariyasu Mano, Shinichi Kuriyama

The 7th Asian Conference on Pharmacoepidemiology (ACPE 7) meeting　2012/10/26
Prescription of drugs for children with attention-deficit/hyperactivity disorder (AD/HD) in Japan. International-presentation

Taku Obara, Nobuhiro Ooba, Yoshihiko Morikawa, Mami Ishikuro, Hirohito Metoki, Masahiro Kikuya, Hidekazu Nishigori, Nariyasu Mano, Shinichi Kuriyama

7th Asian Conference on Pharmacoepidemiology　2012/10/26
アメリカの薬剤師教育から学ぶ〜ノバサウスイースタン大学薬学部国際プログラムを例に〜

中川直人

日本薬学会東北支部第11回医療薬学若手研究者セミナー　2012/10/20
LC/ESI-MS/MSによる患者血清中のゲムシタビン及び代謝物測定法の構築

鈴木裕之, 工藤由起, 田村淳, 相馬真志, 内田敬, 菊地正史, 木皿重樹, 松浦正樹, 久道周彦, 高橋哉子, 小笠原喜美代, 江川新一, 海野倫明, 島田美樹, 眞野成康

第51回日本薬学会東北支部大会　2012/10/07
本邦の注意欠陥/多動性障害（ADHD）小児患者に対する薬物治療の現状

小原拓, 大場延浩, 森川和彦, 石黒真美, 目時弘仁, 菊谷昌浩, 西郡秀和, 眞野成康, 栗山進一

第51回日本薬学会東北支部大会　2012/10/07
広汎性発達障害児における薬物治療状況：レセプトデータに基づく検討

佐藤倫広, 小原拓, 大場延浩, 森川和彦, 石黒真美, 目時弘仁, 西郡秀和, 菊谷昌浩, 眞野成康, 栗山進一

第51回日本薬学会東北支部大会　2012/10/07
レセプトデータに基づく妊娠中の抗ヒスタミン薬処方状況の把握に関する研究

小林由香, 小原拓, 石黒真美, 目時弘仁, 菊谷昌浩, 大久保孝義, 眞野成康, 佐藤博, 八重樫伸生, 栗山進一

第51回日本薬学会東北支部大会　2012/10/07
第51回日本薬学会東北支部大会

小原拓, 大場延浩, 森川和彦, 石黒真美, 目時弘仁, 菊谷昌浩, 西郡秀和, 眞野成康, 栗山進一

第51回日本薬学会東北支部大会　2012/10/07
広汎性発達障害児における薬物治療状況：レセプトデータに基づく検討

佐藤倫広, 小原拓, 大場延浩, 森川和彦, 石黒真美, 目時弘仁, 西郡秀和, 菊谷昌浩, 眞野成康, 栗山進一

第51回日本薬学会東北支部大会　2012/10/07
レセプトデータに基づく妊娠中の抗ヒスタミン薬処方状況の把握に関する研究

小林由香, 小原拓, 石黒真美, 目時弘仁, 菊谷昌浩, 大久保孝義, 眞野成康, 佐藤博, 八重樫伸生, 栗山進一

第51回日本薬学会東北支部大会　2012/10/07
多発性骨髄腫に対する化学療法後の疼痛管理への薬剤師の関与-自家移植前後で神経障害性疼痛の悪化を認めずアミトリプチリンが著効した一例-

北村奈央子, 猪倉恭子, 木幡桂, 福原規子, 武田真恵, 田島つかさ, 田坂英久, 鈴木文子, 張替秀郎, 眞野成康

第6回日本緩和医療薬学会年会　2012/10/06
内服抗がん薬処方監査補助システムの構築

内田敬, 飯田優太郎, 猪岡京子, 菊地正史, 木皿重樹, 吉田真貴子, 安井誠, 松浦正樹, 我妻恭行, 眞野成康

日本病院薬剤師会東北ブロック第2回学術大会　2012/09/29
分子標的治療薬投与における皮膚障害への取り組み

木皿重樹, 眞野成康

日本病院薬剤師会東北ブロック第 2回学術大会　2012/09/29
持参薬報告システムの構築とその運用

松浦正樹, 飯田優太郎, 鈴木文子, 田坂英久, 赤坂和俊, 佐藤真由美, 眞野成康

日本病院薬剤師会東北ブロック第2回学術大会　2012/09/29
バンコマイシン及びテイコプラニンの適正投与量の予測とその評価

相馬真志, 柳利樹, 荒木加世子, 有山智博, 十日市文子, 田坂英久, 鈴木文子, 松浦正樹, 久道周彦, 眞野成康

日本病院薬剤師会東北ブロック第2回学術大会　2012/09/29
東北大学病院における病棟薬剤業務の実際

田坂英久, 鈴木文子, 赤坂和俊, 松浦正樹, 佐藤真由美, 眞野成康

日本病院薬剤師会東北ブロック第2回学術大会　2012/09/26
Development of an analytical method for focused metabolomics of bile acid conjugatesFalk International-presentation

Masamitsu Maekawa, Takehiko Inoue, Kousaku Ohno, Hiroshi Nittono, Takashi Iida, Alan F. Hofmann, Junichi Goto, Miki Shimada, Nariyasu Mano

symposium 184 XXII International Bile Acid Meeting　2012/09/14
抱合型コレステロール代謝物のフォーカシングメタボローム解析法の構築

前川正充, 島田美樹, 眞野成康

第52回日本臨床化学会年次学術集会　2012/09/06
Shinichi Kuriyama. Prescription of Drugs during Pregnancy in Japan. International-presentation

Taku Obara, Manabu Akazawa, Takayoshi Ohkubo, Mami Ishikuro, Hirohito Metoki, Aiko Shono, Hidekazu Nishigori, Nariyasu Mano, Nobuo Yaegashi

28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management　2012/08/23
「抗がん剤の血中濃度モニタリング：治療効果と副作用管理」

島田美樹, 眞野成康

日本医療薬学会第46回公開シンポジウム　2012/07/28
経口薬併用化学療法地域連携チームによる実践的取組み（平成２３年度厚生労働省チーム医療実証事業による活動の報告）

秋山聖子, 瀬谷裕貴子, 菊地正史, 上原厚子, 菅原しのぶ, 神尾奈穂, 高田紀子, 小笠原喜美代, 柴田弘子, 舟田彰, 崎野健一, 畠山法己, 河原正典, 眞野成康, 石岡千加史

第10回日本臨床腫瘍学会学術集会　2012/07/26
妊婦における薬剤の使用に関する疫学調査

小原拓, 石黒真美, 目時弘仁, 西郡秀和, 菊谷昌浩, 大久保孝義, 眞野成康, 八重樫伸生, 栗山進一

第48回宮城県公衆衛生学会学術総会　2012/07/12
降圧治療中患者における外来血圧変動の規定因子: J-HOME-Morning研究

小原拓, 石倉一樹, 芝宮拓, 池田うらら, 目時弘仁, 菊谷昌浩, 眞野成康, 栗山進一, 大久保孝義, 今井潤, HOME-Morning研究グループ

第14回時間循環血圧研究会　2012/07/07
妊婦コホートにおける薬剤調査方法の検討

小林由香, 小原拓, 目時弘仁, 眞野成康, 佐藤博, 今井潤, 八重樫伸生, 栗山進一

第15回日本医薬品情報学会総会・学術大会　2012/07/07
レセプトデータに基づく妊娠中の医薬品使用状況の把握に関する研究

小原拓, 石黒真美, 目時弘仁, 西郡秀和, 大久保孝義, 眞野成康, 八重樫伸生, 栗山進一

第15回日本医薬品情報学会総会・学術大会　2012/07/07
東日本大震災後に薬品情報室に寄せられた問い合わせに関する調査

吉中千佳, 尾崎芙実, 小原拓, 前川麻央, 草場美津江, 佐賀利英, 我妻恭行, 久道周彦, 眞野成康

第15回日本医薬品情報学会総会・学術大会　2012/07/07
LC/ESI-MS/MSによるSunitinibおよび代謝活性物SU12662の血中濃度測定法の構築

柳利樹, 荒屋世一, 前川正充, 鈴木裕之, 齋藤英郎, 荒井陽一, 久道周彦, 島田美樹, 眞野成康

第29回日本TDM学会・学術大会　2012/06/16
治療中高血圧患者の高血圧管理における保険調剤薬局の関与：J-HOME-Morning研究より

小原拓, 小林由香, 池田うらら, 菊谷昌浩, 目時弘仁, 井上隆輔, 大久保孝義, 眞野成康, 栗山進一, 今井潤

第1回臨床高血圧フォーラム　2012/05/12
内服抗がん薬処方監査補助システムの構築

飯田優太郎, 内田敬, 猪岡京子, 菊地正史, 木皿重樹, 吉田真貴子, 安井誠, 松浦正樹, 我妻恭行, 眞野成康

日本薬学会第132年会　2012/03/28
膵がんゲムシタビン療法のPK/PGx

鈴木裕之, 工藤由起, 相馬真志, 菊地正史, 木皿重樹, 松浦正樹, 久道周彦, 江川新一, 海野倫明, 島田美樹, 眞野成康

日本薬学会第132年会　2012/03/28
グループ制による継続的症例フォローアップ実習

田坂英久, 鈴木文子, 森大, 鈴木裕之, 村井ユリ子, 眞野成康

日本薬学会第132年会　2012/03/28
シンバスタチンによる脂質・血糖・血圧の変化：市販後調査データを用いた検討

小原拓, 猪狩有紀恵, 小林寛子, 高橋武, 高橋則男, 村井ユリ子, 眞野成康, 高橋將喜

日本薬学会第132年会　2012/03/28
妊娠高血圧患者における降圧治療状況:レセプトデータに基づく検討

小原拓, 大久保孝義, 目時弘仁, 西郡秀和, 石黒真美, 眞野成康, 赤沢学, 八重樫伸生, 栗山進一

第22回日本疫学会学術総会　2012/01/26
災害時に必要とされる医薬品とその供給

眞野成康

第32回日本臨床薬理学会年会　2011/12/01
東日本大震災における東北大学病院の取り組みと薬剤部の対応

佐藤真由美, 久道周彦, 我妻恭行, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
脳死肺移植患者支援における薬剤師の役割

土屋雅美, 秋場美紀, 田坂英久, 鈴木文子, 眞野成康

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
がん領域における大学院生の実践的臨床活動を通じた薬剤師教育プログラムの構築

鈴木直人, 黒澤真帆, 大内麻由, 木皿重樹, 村井ユリ子, 三枝大輔, 眞野成康, 富岡佳久

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
次世代型薬剤師育成を指向したがん領域における薬学教育の取り組み

鈴木直人, 村井ユリ子, 黒澤真帆, 大内麻由, 三枝大輔, 眞野成康, 富岡佳久

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
抗がん剤の血中濃度モニタリングと副作用管理

島田美樹, 眞野成康

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
抗がん剤調製支援システムの構築

稲本正之, 松浦正樹, 赤坂和俊, 有山智博, 村中太郎, 菊地正史, 木皿重樹, 我妻恭行, 久道周彦, 眞野成康

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
軟膏配合変化システムシステムの構築

村中太郎, 松浦正樹, 高崎新也, 半澤嘉之, 飯田優太郎, 尾崎茉実, 吉田真貴子, 草場美津江, 我妻恭行, 久道周彦, 眞野成康

日本病院薬剤師会東北ブロック第１回学術大会　2011/11/26
GLP-1受容体作動薬導入患者の消化器系副作用への介入

鈴木文子, 佐藤敦, 有山智博, 石井大輔, 高橋亜希, 眞野成康

日本病院薬剤師会東北ブロック第１回学術大会　2011/11/26
当院化学療法センターにおける薬剤師の役割

木皿重樹, 我妻恭行, 久道周彦, 村井ユリ子, 島田美樹, 眞野成康

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
東日本大震災後の医薬品の確保？診療体制の維持と被災地支援

久道周彦, 佐藤真由美, 我妻恭行, 中村浩規, 村井ユリ子, 島田美樹, 眞野成康

日本病院薬剤師会東北ブロック第１回学術大会　2011/11/26
薬剤費を基準にした注射用抗がん剤の規格選択システムの開発

鈴木寿樹, 松浦正樹, 高橋克史, 吉川三保子, 有山智博, 菊地正史, 飯田優太郎, 相馬真志, 木皿重樹, 我妻恭行, 久道周彦, 眞野成康

日本病院薬剤師会東北ブロック第１回学術大会　2011/11/26
医薬品-食品相互作用情報の食事オーダ連携システムの構築

飯田優太郎, 松浦正樹, 中村浩規, 佐賀利英, 我妻恭行, 布田美貴子, 岡本智子, 東海林晋, 國井重男, 眞野成康

日本病院薬剤師会東北ブロック第１回学術大会　2011/11/26
診療支援システムにおける患者限定処方用ツールの作成

松浦正樹, 飯田優太郎, 吉中千佳, 寺岡知寿, 堀川美帆, 穂積雅人, 草場美津江, 我妻恭行, 久道周彦, 眞野成康

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
東日本大震災が引き起こした通信網の破綻と外来診療体制の再構築

我妻恭行, 久道周彦, 佐藤真由美, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

日本病院薬剤師会東北ブロック第1回学術大会　2011/11/26
全自動PTP払出機の効率的運用に関する検討

佐藤祐司, 吉田真貴子, 猪岡京子, 飯田優太郎, 松浦正樹, 我妻恭行, 久道周彦, 佐藤真由美, 島田美樹, 眞野成康

日本病院薬剤師会東北ブロック第１回学術大会　2011/11/26
レセプトデータを用いた妊娠高血圧患者に対する降圧薬処方状況の把握

小原拓, 大久保孝義, 目時弘仁, 西郡秀和, 石黒真美, 眞野成康, 赤沢学, 八重樫伸生, 栗山進一

日本薬剤疫学会第17回学術総会　2011/11/05
妊娠と医薬品使用に関する問い合わせ内容の調査

小原拓, 尾崎芙美, 吉中千佳, 前川麻央, 草場美津江, 飯田優太郎, 鈴木文子, 松浦正樹, 佐賀利英, 佐藤真由美, 久道周彦, 島田美樹, 栗山進一, 八重樫伸生, 眞野成康

第50回日本薬学会東北支部大会　2011/10/30
次世代型専門薬剤師育成を目指した東北大学病院における大学院教育

鈴木直人, 木皿重樹, 村井ユリ子, 黒澤真帆, 大内麻由, 三枝大輔, 眞野成康, 富岡佳久

第50回日本薬学会東北支部大会　2011/10/30
LC/ESI-MS/MSによる血中ドセタキセルの簡易定量法の構築とその臨床応用

山口浩明, 藤川あす歌, 伊藤創, 田中伸明, 山田武宏, 眞野成康, 井関健

第22回クロマトグラフィー科学会議　2011/10/21
LC/ESI-MS/MSによるシクロホスファミドの高感度分析法の構築

森大, 藤吉正哉, 佐藤真由美, 山口浩明, 島田美樹, 眞野成康

第22回クロマトグラフィー科学会議　2011/10/21
抗悪性腫瘍薬オキサリプラチンのHILIC/MS/MSによる血中濃度測定法の確立

伊藤創, 山口浩明, 藤川あす歌, 山田武宏, 眞野成康, 井関健

第22回クロマトグラフィー科学会議　2011/10/21
降圧治療中患者における家庭血圧日間変動の規定因子:

小原拓, 石倉一樹, 菊谷昌浩, 加藤哲夫, 芝宮拓, 新木貴大, 池田うらら, 小林由香, 目時弘仁, 眞野成康, 栗山進一, 大久保孝義, 今井潤, HOME-Morning研究グループ

第34回日本高血圧学会学術総会　2011/10/20
高血圧薬物治療における家庭血圧測定と薬剤師の介入

吉町昌子, 小原拓, 川端ゆかり, 馬庭ちはる, 河野弘之, 眞野成康, 大久保孝義, 後藤輝明

第34回日本高血圧学会学術総会　2011/10/20
内服前投与薬処方を可能とした化学療法支援システムの構築

中島美奈子, 飯田優太郎, 松浦正樹, 菊地正史, 木皿重樹, 久道周彦, 我妻恭行, 眞野成康

第141回宮城県病院薬剤師会学術研究発表会　2011/10/15
がん化学療法の現状

眞野成康

第1回プラズマプロセスナノカーボンのバイオ医療応用研究会　2011/10/07
東日本大震災における東北大学病院薬剤部の対応（その1）―震災の概要と薬剤部業務体制および各方面への支援状況―

佐藤真由美, 久道周彦, 我妻恭行, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

第21回日本医療薬学会年会　2011/10/01
東日本大震災における東北大学病院薬剤部の対応（その2）―通信網の破綻と外来診療体制の再構築―

我妻恭行, 久道周彦, 佐藤真由美, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

第21回日本医療薬学会年会　2011/10/01
東日本大震災における東北大学病院薬剤部の対応（その3）―本院の診療体制の維持と被災地支援に向けた医薬品の確保―

久道周彦, 佐藤真由美, 我妻恭行, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

第21回日本医療薬学会年会　2011/10/01
大学院生による集団糖尿病教室の実施―実践型薬剤師教育を目指して―

高橋亜希, 平塚真弘, 室井祐佳, 本田雅志, 田巻佑一郎, 新沼優衣, 由良有希子, 石井大輔, 田坂英久, 眞野成康

第21回日本医療薬学会年会　2011/10/01
6年制薬学教育と薬剤師生涯教育

眞野成康

第21回日本医療薬学会年会　2011/10/01
東日本大震災における東北大学病院薬剤部の対応（その２）？通信網の破綻と外来診療体制の再構築？

我妻恭行, 久道周彦, 佐藤真由美, 村井ユリ子, 島田美樹, 中村浩規, 眞野成康

第21回日本医療薬学会年会　2011/10/01
東北大学病院における腎機能低下患者の割合と腎排泄型薬剤の使用状況調査

高橋亜希, 平塚真弘, 本田雅志, 田巻佑一朗, 室井祐佳, 新沼優衣, 眞野成康, 平澤典保

第５回日本腎と薬剤研究会2011　2011/09/17
がん化学療法の副作用管理とその取り組み

島田美樹

平成23年度日本薬学会東北支部第10回医療薬学若手研究者セミナー　2011/09/17
タンデム質量分析法を活用した抱合型胆汁酸メタボローム解析法の検討

前川正充, 森大, 鈴木裕之, 大野耕策, 入戸野博, 小川祥二郎, 柿山玄太, 飯田隆, 後藤順一, 島田美樹, 眞野成康

第24回バイオメディカル分析科学シンポジウム　2011/08/31
HPLCによるイリノテカンおよび代謝物の同時定量法の構築

鈴木澄子, 松浦正樹, 赤坂和俊, 土屋雅美, 木皿重樹, 久道周彦, 石岡千加史, 島田美樹, 眞野成康

第24回バイオメディカル分析科学シンポジウム　2011/08/31
肝細胞癌患者のソラフェニブおよび代謝物の血中モニタリング

大川星美, 前嶋隆弘, 柳利樹, 赤坂和俊, 土屋雅美, 松浦正樹, 久道周彦, 近藤泰輝, 下瀬川徹, 島田美樹, 眞野成康

第24回バイオメディカル分析科学シンポジウム　2011/08/31
タンデム質量分析法を活用した抱合型胆汁酸メタボローム解析法の構築

前川正充, 森大, 鈴木裕之, 大野耕策, 入戸野博, 小川祥二郎, 柿山玄太, 飯田隆, 後藤順一, 島田美樹, 眞野成康

第24回バイオメディカル分析科学シンポジウム　2011/08/31
臨床における医薬品分析

眞野成康

第24回バイオメディカル分析科学シンポジウム　2011/08/31
血中シロリムスの高精密定量法の構築―マトリックス効果の排除―

眞野成康

第24回バイオメディカル分析科学シンポジウム　2011/08/31
TDMにおけるLC/ESI-MS/MSの貢献

眞野成康

第51回日本臨床化学会年次学術集会　2011/08/26
葉酸摂取の重要性に関する薬剤師の認識

村井ユリ子, 小原拓, 猪狩有紀恵, 原梓, 岸川幸生, 早坂正孝, 鎌田裕, 高橋將喜, 生出泉太郎, 眞野成康, 北村哲治

第14回日本医薬品情報学会総会・学術大会　2011/07/23
多職種チーム研修―レジメン審査に重点を置いて

秋山聖子, 加藤俊介, 木皿重樹, 我妻恭行, 久道周彦, 大桐規子, 石澤賢一, 井上彰, 大槻健郎, 三浦康, 塩野雅俊, 下平秀樹, 森隆弘, 眞野成康, 石岡千加史

第9回日本臨床腫瘍学会学術集会　2011/07/21
LC/ESI-MS/MS method for focusing metabolome of bile acid conjugates International-presentation

Masamitsu Maekawa, Masaru Mori, Hiroyuki Suzuki, Takashi Iida, Miki Shimada, Nariyasu Mano

59th ASMS Conference　2011/06/05
培養細胞中のソラフェニブおよび代謝物定量法の構築

大川星美, 鈴木裕之, 森大, 前川正充, 島田美樹, 眞野成康

日本薬学会第131年会　2011/03/28
HPLCによるゲムシタビンおよび代謝物の血中濃度測定法の構築

工藤由起, 田村淳, 前川正充, 鈴木裕之, 森大, 島田美樹, 眞野成康

日本薬学会第131年会　2011/03/28
LC/ESI-MS/MSによる抱合型胆汁酸のメタボローム解析法の検討

前川正充, 森大, 鈴木裕之, 坂本修, 大浦敏博, 虻川大樹, 大野耕策, 入戸野博, 飯田隆, 島田美樹, 眞野成康

日本薬学会第131年会　2011/03/28
次世代型専門薬剤師育成を目指した診療従事型教育プログラムの構築

平塚真弘, 高橋亜希, 田巻佑一郎, 本田雅志, 室井祐佳, 村井ユリ子, 眞野成康, 佐藤博, 平澤典保

日本薬学会第131年会　2011/03/28
全自動PTP払出機の効率的運用に関する検討

佐藤祐司, 吉田真貴子, 猪岡京子, 堀川美帆, 村中太郎, 鈴木智尋, 加藤佳子, 片岡佑太, 長岡真理子, 高崎新也, 岸川友紀, 飯田優太郎, 松浦正樹, 我妻恭行, 久道周彦

日本薬学会第131年会　2011/03/28
カラムスイッチング-LC/MS/MSによるパクリタキセル血中濃度測定法の確立

藤川あす歌, 山口浩明, 伊藤創, 田中伸明, 古堅彩子, 宮森和明, 高橋夏子, 小倉次郎, 小林正紀, 山田武弘, 眞野成康, 井関健

日本薬学会第131年会　2011/03/28
ハゲガオカザリドリ（Perissocephalus tricolor）とハゲノドスズドリ（Procnias nudicollis）の胆汁成分に関する研究

小川祥二郎, 足立祐樹, 眞野成康, 後藤順一, 宇根瑞穂, Lee R. Hagey, Alan, F. Hofmann, 飯田隆

日本薬学会第131年　2011/03/28
大学院生の集団糖尿病教室を通じたチーム医療教育

高橋亜希, 平塚真弘, 室井佑佳, 本田雅志, 田巻佑一郎, 新沼優衣, 由良有希子, 石井大輔, 田坂英久, 眞野成康, 平澤典保

日本薬学会第131年　2011/03/28
カラムスイッチング-LC/MS/MSによるパクリタキセル血中濃度測定法の確立

藤川あす歌, 山口浩明, 伊藤創, 田中伸明, 古堅彩子, 宮森和明, 高橋夏子, 小倉次郎, 小林正紀, 山田武宏, 眞野成康, 井関健

日本薬学会第131年会　2011/03/28
イムノアッセイを用いたシロリムス血中濃度モニタリングの妥当性の評価

松本洋太郎, 藤吉正哉, 上西智子, 佐藤真由美, 森大, 島田美樹, 眞野成康

第7回みやぎ薬剤師学術大会　2010/11/21
東北大学病院における薬学長期実務実習プログラムの構築―次世代型薬剤師養成に向けて―

村井ユリ子, 佐賀利英, 佐藤真由美, 中村浩規, 久道周彦, 我妻恭行, 鈴木裕之, 森大, 鈴木直人, 平塚真弘, 平澤典保, 富岡佳久, 島田美樹, 眞野成康

第7回みやぎ薬剤師学術大会　2010/11/21
プログラム選択方式により学生の自主性を重視した病院実習プログラムの構築

村井ユリ子, 佐賀利英, 佐藤真由美, 中村浩規, 久道周彦, 我妻恭行, 鈴木裕之, 森大, 鈴木直人, 平塚真弘, 平澤典保, 富岡佳久, 島田美樹, 眞野成康

第20回日本医療薬学会　2010/11/13
シロリムス血中濃度測定におけるACMIA法、MEIA法およびLC/MS/MSの比較検討

松本洋太郎, 藤吉正哉, 上西智子, 佐藤真由美, 森大, 島田美樹, 眞野成康

第20回日本医療薬学会　2010/11/13
医薬品-食品相互作用情報の食事オーダ連携システムの構築

飯田優太郎, 松浦正樹, 中村浩規, 佐賀利英, 我妻恭行, 布田美貴子, 岡本智子, 東海林晋, 國井重男, 眞野成康

第20回日本医療薬学会　2010/11/13
家庭血圧測定に基づくアンジオテンシンII受容体拮抗薬イルベサルタンの高圧効果および薬効持続に関する検討

吉田愛琴, 小原拓, 石倉一樹, 小林由香, 広瀬卓男, 大久保孝義, 眞野成康, 今井潤

第20回日本医療薬学会　2010/11/13
疾患マーカー探索を目指した抱合型胆汁酸メタボローム解析手法の検討

前川正充, 森大, 鈴木裕之, 島田美樹, 眞野成康

第32回胆汁酸研究会　2010/11/06
血中ソラフェニブおよび代謝物のHPLC分析

大川星美, 森大, 鈴木裕之, 前川正充, 島田美樹, 眞野成康

第49回日本薬学会東北支部大会　2010/10/24
LC/ESI-MS/MSによる血中の多剤併用薬同時分析法

福士理沙, 森大, 鈴木裕之, 前川正充, 島田美樹, 眞野成康

第49回日本薬学会東北支部大会　2010/10/24
薬剤費を基準にした注射用抗がん剤複数規格選択システムの開発とその効果

鈴木寿樹, 松浦正樹, 高橋克史, 吉川三保子, 有山智博, 飯田優太郎, 相馬真志, 木皿重樹, 我妻恭行, 久道周彦, 眞野成康

第49回日本薬学会東北支部大会　2010/10/24
次世代型専門薬剤師養成を目指した東北大学病院化学療法センターにおける大学院教育

鈴木直人, 村井ユリ子, 三枝大輔, 木皿重樹, 眞野成康, 富岡佳久

第49回日本薬学会東北支部大会　2010/10/24
血中シロリムスのLC/ESI-MS/MS分析におけるマトリクス効果の排除

佐藤真由美, 野澤真里奈, 森大, 山口浩明, 神田勝弘, 野上真, 後藤順一, 島田美樹, 眞野成康

第21回クロマトグラフィー科学会議　2010/10/21
家庭血圧測定に基づくカルシウム拮抗薬シルニジピンの降圧効果および薬効持続の検討

吉田愛琴, 小原拓, 石倉一樹, 佐々木彩乃, 池田うらら, 目時弘仁, 浅山敬, 井上隆輔, 菊谷昌浩, 大久保孝義, 眞野成康, 今井潤

第33回日本高血圧学会総会　2010/10/15
Analysis of chenodeoxycholate-binding proteins in rat brain and pituitary by mass spectrometry coupled with cleavable affinity extraction International-presentation

Nariyasu Mano, Kohei Abe, Masaru Mori, Koichi Sato, Hiroaki Yamaguchi, Miki Shimada, Takaaki Goto, Junichi Goto

XXI International Bile Acid Meeting　2010/10/07
Determination of multi-conjugated bile acids in the urine of patients with Niemann-Pick disease, type C by liquid chromatography/electrospray ionization tandem mass spectrometry International-presentation

Masamitsu Maekawa, Yasushi Misawa, ayako Sotoura, Osamu Sakamoto, Toshihiro Ohura, Daiki Abukawa, Takehiko Inoue, Kousaki Ohno, Hiroshi Nittono, Shoujiro Ogawa, Genta Kakiyama, Takashi Iida, Alan F. Hofmann, Junich Goto, Miki Shimada, Nariyasu Mano

XXI International Bile Acid Meeting; Bile Acids as Metabolic Integrators and Therapeutics　2010/10/07
Isolation, identification and comparative study of bile acids in the capuchinbird (Perissocephalus tricolor) and bare-throated bellbird (Procnias nudicollis) International-presentation

Shoujiro Ogawa, Yuuki Adachi, Takashi Iida, Mizuho Une, Nariyasu Mano, Junichi Goto, Matthew D. Krasowski, Lee R. Hagey, Alan F. Hofmann

XXI International Bile Acid Meeting　2010/10/07
18. Nariyasu Mano, Kohei Abe, Masaru Mori, Koichi Sato, Hiroaki Yamaguchi, Miki Shimada, Takaaki Goto, Junichi Goto:

Nariyasu Mano, Kohei Abe, Masaru Mori, Koichi Sato, Hiroaki Yamaguchi, Miki Shimada, Takaaki Goto

Bile Acids as Metabolic Integrators and Therapeutics　2010/10/07
Determination of multi-conjugated bile acids in the urine of patients with Niemann-Pick disease, type C by liquid chromatography/electrospray ionization tandem mass spectrometry. International-presentation

Masamitsu Maekawa, Yasushi Misawa, Ayako Sotoura, Osamu Sakamoto, Toshihiro Ohura, Daiki Abukawa, Takehiko Inoue, Kousaku Ohno, Akina Muto, Hajime Takei, Junichi Goto, Miki Shimada, Nariyasu Mano

XXI International Bile Acid Meeting;　2010/10/07
Isolation, identification and comparative study of bile acids in the capuchinbird (Perissocephalus tricolor) and bare-throated bellbird (Procnias nudicollis) International-presentation

Shoujiro Ogawa, Yuuki Adachi, Takashi Iida, Mizuho Une, Nariyasu Mano, Junichi Goto, Matthew D. Krasowski, Lee R. Hagey, Alan F. Hofmann

XXI International Bile Acid Meeting; Bile Acids as Metabolic Integrators and Therapeutics　2010/10/07
LC/ESI-MS/MSによるNiemann-Pick病C型患者尿中異常胆汁酸の高感度分析

三澤靖, 外浦亜耶子, 後藤順一, 島田美樹, 眞野成康, 前川正充, 坂本修, 大浦敏博, 虻川大樹, 井上岳彦, 大野耕策, 武藤晃奈, 武井一, 入戸野博, 小川祥二郎, 柿山玄

第6回東日本胆汁酸研究会　2010/07/31
薬剤師の家庭血圧測定に関する実践と認識

小原拓, 小林満, 田中宏治, 佐藤倫広, 村井ユリ子, 生出泉太郎, 眞野成康, 今井潤

第13回日本医薬品情報学会　2010/07/24
LC/ESI-MS/MSを用いたNiemann-Pick病C型患者尿中の多重抱合型胆汁酸測定法

前川正充, 三澤靖, 外浦亜耶子, 坂本修, 大浦敏博, 虻川大樹, 井上岳彦, 大野耕策, 武藤晃奈, 武井一, 入戸野博, 小川祥二郎, 柿山玄太, 飯田隆, Alan F. Hofmann, 後藤順一

第23回バイオメディカル分析科学シンポジウム　2010/07/21
プロテオーム変動解析を目的としたトリプシン酵素反応を活用する18O一置換標識法の性能評価

森大, 島田美樹, 眞野成康

第23回バイオメディカル分析科学シンポジウム　2010/07/21
血中シロリムスのLC/ESI-MS/MS分析におけるイオン化抑制因子の特定とその除去に関する検討

佐藤真由美, 野澤真里奈, 森大, 山口浩明, 神田勝弘, 野上真, 後藤順一, 島田美樹, 眞野成康

第23回バイオメディカル分析科学シンポジウム　2010/07/21
当院薬剤部の試験研究における分析科学

島田美樹, 眞野成康

第23回バイオメディカル分析科学シンポジウム　2010/07/21
LC/ESI-MS/MSによるNiemann-Pick病C型患者尿中多重抱合型胆汁酸の高感度分析

前川正充, 三澤靖, 外浦亜耶子, 坂本修, 大浦敏博, 虻川大樹, 井上岳彦, 大野耕策, 武藤晃奈, 武井一, 入戸野博, 小川祥二郎, 柿山玄太, 飯田隆, Alan F. Hofmann, 後藤順一

第17回クロマトグラフィーシンポジウム　2010/06/03
Double pseudo-neutral loss extraction coupled with specific derivatization for analysis of phosphoproteins International-presentation

Nariyasu Mano, Takuma Yamazaki, Sayaka Aoki, Masaru Mori, Takaaki Goto, Miki Shimada

58th ASMS Conference　2010/05/23
Quantitative performance of a novel trypsin-catalyzed 18O-single labeling method for serum proteomics International-presentation

Masaru Mori, Miki Shimada, Nariyasu Mano

58th ASMS Conference　2010/05/23
Double pseudo-neutral loss extraction coupled with specific derivatization for analysis of phosphoproteins International-presentation

Nariyasu Mano, Takuma Yamazaki, Sayaka Aoki, Masaru Mori, Takaaki Goto, Miki Shimada

58th ASMS Conference　2010/05/23
カプトプリル投与によるラット脳内ペプチドの変動

金澤佐知子, 下山律子, 森大, 島田美樹, 眞野成康, 佐藤公彦, 早狩誠

第21回日本臨床化学会東北支部総会　2010/05/15
NanoLC/MS/MSを用いるタンパク質解析

眞野成康

第21回日本臨床化学会東北支部総会　2010/05/15
ヒト表皮角化細胞における細胞外ATPの機能解析

大原宏司, 齋藤るみ子, 平河聡, 島田美樹, 眞野成康, 菱沼隆則, 奥山隆平, 相場節也

日本薬学会第130年会　2010/03/28
18O一置換標識法とnanoLC/ESI-MS/MSによる血清プロテオーム解析法の有用性

森大, 島田美樹, 眞野成康

日本薬学会第130年会　2010/03/28
カプトプリル投与でのラット脳内ペプチドの変動

金澤佐知子, 下山律子, 森大, 島田美樹, 眞野成康, 佐藤公彦, 早狩誠

日本薬学会第130年会　2010/03/28
大学院生の薬剤師研修を通じた医師への処方支援

三村亨, 松本周平, 金光祥臣, 村井ユリ子, 久道周彦, 佐藤真由美, 鈴木直人, 齊藤直美, 土屋雅美, 木皿重樹, 三枝大輔, 眞野成康, 富岡佳久

日本薬学会第130年会　2010/03/28
次世代型専門薬剤師養成を目指した大学院教育プログラムの開発―がん化学療法処方設計支援基礎実習カリキュラムの構築

鈴木直人, 金光祥臣, 松本周平, 三村亨, 三枝大輔, 村井ユリ子, 久道周彦, 佐藤真由美, 齊藤直美, 木皿重樹, 眞野成康, 富岡佳久

日本薬学会第130年会　2010/03/28
The role of ATP-stimulated normal human epidermal keratinocytes in skin inflammation revealed by DNA microarray analysis

Hiroshi Ohara, Rumiko Saito, Satoshi Hirakawa, Yumiko Ito, Miki Shimada, Nariyasu Mano, Takanori Hishinuma, Setsuya Aiba

日本研究皮膚科学会第34回年次学術大会・総会　2009/12/04
クロマトグラフィーと分子認識

後藤順一, 眞野成康

第20回クロマトグラフィー科学会議　2009/11/11
メダカ（Oryzias latipes）の胆汁成分に関する研究

小川祥二郎, 飯田隆, 眞野成康, 後藤順一, Lee R. Hagey, Alan, F. Hofmann

第31回胆汁酸研究会　2009/11/07
視点計測器を用いた調剤ミスの要因解析

中村浩規, 猪岡京子, 村井ユリ子, 眞野成康

第19回日本医療薬学会年会　2009/10/24
医学部臨床修練における「医師-薬剤師協同型医療情報実習」への取り組み

鈴木文子, 飯田優太郎, 松本洋太郎, 上西智子, 村井ユリ子, 浅田成紀, 荒井啓行, 島田美樹, 眞野成康

第19回日本医療薬学会年会　2009/10/24
カラムスイッチングHPLCによるボリコナゾールの血中濃度測定法の確立

松本洋太郎, 上西智子, 佐賀利英, 山口浩明, 島田美樹, 眞野成康

第19回　2009/10/24
高度救命救急センターにおける薬剤師常駐業務の特殊性調査

鈴木博也, 高畠昌代, 松浦正樹, 久道周彦, 眞野成康

第19回　2009/10/24
次世代型専門薬剤師育成を目指した大学院教育プログラムの開発（その1）

富岡佳久, 平沢典保, 眞野成康, 村井ユリ子, 鈴木直人, 三枝大輔, 平塚真弘, 高橋亜希, 島田美樹, 岡芳知, 伊藤貞嘉, 石岡千加史, 寺崎哲也, 永沼章

第19回　2009/10/24
家庭血圧測定に基づくカルシウム拮抗薬シルニジピンの降圧効果の検討

吉田愛琴, 小原拓, 石倉一樹, 佐々木彩乃, 池田うらら, 大久保孝義, 眞野成康, 今井潤

第48回日本薬学会東北支部大会　2009/10/18
LC/MS/MSを用いる血中シロリムス濃度測定法の改良

野澤真里菜, 島田美樹, 山口浩明, 後藤順一, 眞野成康

第49回日本臨床化学会年次学術集会　2009/09/18
プロテオーム変動解析を目的としたトリプシンを用いる18O一置換法

森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

第34回日本医用マススペクトル学会年会　2009/09/10
新規アフィニティー抽出法を用いたラット肝組織中ケノデオキシコール酸結合タンパク質の解析

三澤靖, 佐藤光市, 森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

第34回日本医用マススペクトル学会年会　2009/09/10
病院薬剤部における臨床分析科学

眞野成康

みちのく分析科学シンポジウム2009　2009/07/25
臨床現場で活躍する分析科学

眞野成康

第22回バイオメディカル分析科学シンポジウム　2009/07/15
18O一置換標識法によるプロテオームの量的変動解析に関する検討

森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

第22回　2009/07/15
LC/ESI-MS/MSによる三重抱合型異常胆汁酸の高感度定量法の構築

三澤靖, 外浦亜耶子, 阿部幸平, 山口浩明, 柿山玄太, 飯田隆, 後藤順一, 島田美樹, 眞野成康

第22回バイオメディカル分析科学シンポジウム　2009/07/15
LC/MS/MSによる血中シロリムスの高感度測定法

島田美樹, 野澤真里菜, 山口浩明, 神田勝弘, 野上真, 後藤順一, 眞野成康

第22回　2009/07/15
薬剤師における後発医薬品導入における認識

小原拓, 高橋將喜, 高橋則男, 北村哲治, 大久保孝義, 眞野成康, 今井潤

第3回日本ジェネリック医薬品学会学術大会　2009/06/27
家庭血圧測定に基づくアムロジピンベシル酸塩の後発医薬品の臨床評価

小原拓, 池田うらら, 新木貴大, 芝宮拓, 大久保孝義, 眞野成康, 今井潤

第3回日本ジェネリック医薬品学会学術大会　2009/06/27
Characteristics of uncontrolled hypertensive patients determined by morning and evening home blood pressure measurement from the J-HOME Study International-presentation

Taku Obara, Kie Ito, Takayoshi Ohkubo, Kenta Gonokami, Takahiro Shinki, Taku Shibamiya, Azusa Hara, Hirohito Metoki, Kei Asayama, Ryusuke Inoue, Masahiro Kikuya, Nariyasu Mano, Yutaka Imai, the J-HOME, Study Group

European Society of Hypertension Congress 2009　2009/06/12
Influence of home blood pressure measuring condition in evening on the morning–evening home blood pressure difference in treated hypertensive patients International-presentation

Taku Obara, Kie Ito, Takayoshi Ohkubo, Kenta Gonokami, Takahiro Shinki, Taku Shibamiya, Manami Nakashita, Azusa Hara, Hirohito Metoki, Kei Asayama, Ryusuke Inoue, Masahiro Kikuya, Nariyasu Mano, Yutaka Imai, the J-HOME, Study Group

European Society of Hypertension Congress 2009　2009/06/12
タンパク質変動解析のための18O一置換反応に関する検討

森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

日本薬学会第129年会　2009/03/26
危険予知トレーニングから得た”危険ストーリー”の新人教育への応用

前島隆弘, 吉田真貴子, 佐藤祥子, 渡辺範康, 佐賀利英, 佐藤真由美, 久道周彦, 村井ユリ子, 眞野成康

日本薬学会　2009/03/26
アカハネシギダチョウ（R. Rufescens）から新規1β-水酸化C27胆汁酸（1β,3α,7α-trihydroxy-5β-cholestan-27-oyl taurine）の単離と構造決定

柿山玄太, 武藤晃奈, 眞野成康, 後藤順一, Lee R. Hagey, Alan, F. Hofmann, 飯田隆

日本薬学会　2009/03/26
胆汁酸関連タンパク質のMS解析

眞野成康

第18回日本小児胆汁酸研究会　2009/02/21
Normal human epidermal keratinocyte (NHEK)におけるATP誘導性免疫応答因子の探索

大原宏司, 齊藤るみ子, 眞野成康, 菱沼隆則, 相場節也

第81回日本生化学会大会合同大会　2008/12/09
Specific analysis of small molecule binding proteins by mass spectrometry coupled with affinity extraction International-presentation

Nariyasu Mano

The 33rd International Symposium on High Performance Liquid Phase Separations and Related Techniques　2008/12/02
胆汁酸関連タンパク質のマススペクトロメトリー

眞野成康

第32回医療薬学公開シンポジウム　2008/11/22
有機アニオントランスポーターOATP4C1によるEstrone-3-sulfateの輸送特性

杉江美佐, 山口浩明, 岡田匡弘, 阿部高明, 後藤順一, 菱沼隆則, 島田美樹, 眞野成康

第４７回日本薬学会東北支部大会　2008/10/26
有機アニオントランスポーターOATP1B1及びOATP1B3と相互作用する抗生物質の探索

竹内俊子, 山口浩明, 岡田匡弘, 阿部高明, 菱沼隆則, 後藤順一, 島田美樹, 眞野成康

第４７回日本薬学会東北支部大会　2008/10/26
錠剤・カプセル剤粉砕時の最大投与日数の判断基準の設定及びその運用

鈴木文子, 松浦正樹, 飯田優太郎, 鴨田美緒, 吉中千佳, 戸澤亜紀, 佐藤真由美, 後藤順一, 眞野成康

第18回日本医療薬学会年会　2008/09/20
NanoLC/ESI-MS/MSを用いる血清プロテオーム解析法の構築に関する検討

森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

第４８回日本臨床化学会年次学術集会　2008/08/29
腎臓特異的発現有機アニオントランスポーターOATP4C1の機能解析

山口浩明, 杉江美佐, 岡田匡弘, 阿部高明, 後藤順一, 菱沼隆則, 島田美樹, 眞野成康

第３０回生体膜と薬物の相互作用シンポジウム　2008/08/06
NanoLC/ESI-MS/MSによる血清プロテオームの高感度分析のための基盤研究

森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

第２１回バイオメディカル分析化学シンポジウム　2008/08/06
LC/MS/MSを用いたランソプラゾール及びラベプラゾール簡易定量法の構築とその血清中濃度解析

鈴木香織, 菱沼隆則, 山口浩明, 山岸初志, 大原秀一, 下瀬川徹, 後藤順一, 島田美樹, 眞野成康

第２１回バイオメディカル分析化学シンポジウム　2008/08/06
プロテオミクス手法を用いる肝細胞質画分中の胆汁酸結合タンパク質の解析

外浦亜耶子, 佐藤光市, 森大, 阿部幸平, 眞野成康, 後藤順一

第5回東日本胆汁酸研究会　2008/07/19
医療従事者の抗がん剤暴露調査を目的とするシクロホスファミドの高感度LC/MS/MS分析

山口浩明, 佐藤真由美, 阿部幸平, 菱沼隆則, 後藤順一, 眞野成康

第１５回クロマトグラフィーシンポジウム　2008/05/29
脳局在型胆汁酸トランスポーターSLC10A4の機能解析

山口浩明, 岡田匡弘, 三日市剛, 海野倫明, 阿部高明, 小野栄夫, 大和田祐二, 近藤尚武, 菱沼隆則, 後藤順一, 島田美樹, 眞野成康

第５回東北大学バイオサイエンスシンポジウム　2008/05/19
NanoLC/ESI-MS/MSを用いた血清プロテオームの高感度分析に関する検討

森大, 阿部幸平, 山口浩明, 後藤順一, 島田美樹, 眞野成康

第５回東北大学バイオサイエンスシンポジウム　2008/05/19
有機アニオントランスポーターOATP4C1を介したestrone-3-sulfate輸送

杉江美佐, 山口浩明, 岡田匡弘, 豊原敬文, 種本雅之, 阿部高明, 後藤順一, 菱沼隆則, 島田美樹, 眞野成康

第５回東北大学バイオサイエンスシンポジウム　2008/05/19
蛍光プローブを用いたOATP1B3輸送抗がん剤のスクリーニング

竹内俊子, 山口浩明, 小林美奈子, 岡田匡弘, 種本雅之, 海野倫明, 阿部高明, 菱沼隆則, 後藤順一, 島田美樹, 眞野成康

第５回東北大学バイオサイエンスシンポジウム　2008/05/19
プロテオミクス手法を用いる肝細胞質画分中ケノデオキシコール酸結合タンパク質の解析

外浦亜耶子, 佐藤光市, 森大, 阿部幸平, 後藤順一, 島田美樹, 眞野成康

第５回東北大学バイオサイエンスシンポジウム　2008/05/19
胆汁酸刺激によるHeLa S3細胞内タンパク質の変動解析

眞野成康, 柳澤勇, 阿部幸平, 八幡憲治, 森大, 後藤順一, 島田美樹

第5回東北大学バイオサイエンスシンポジウム　2008/05/19
LC/MS/MSを用いた生体内スフィンゴ脂質同時定量法の確立

齋藤昌良, 鈴木香織, 中島晶, 千葉健冶, 眞野成康, 菱沼隆則

日本薬学会第１２８年会　2008/03/28
薬学生・医学生および歯科研修医師の感染制御に関する認識度調査

久道周彦, 中村郁子, 鈴木博也, 横枕史, 山口浩明, 後藤順一, 眞野成康

日本薬学会第１２８年会　2008/03/26
NanoLC/ESI-MS/MSによる血清プロテオーム解析の高感度化に関する研究

森大, 阿部幸平, 山口浩明, 後藤順一, 眞野成康

日本薬学会第１２８年会　2008/03/26
胆汁酸刺激による細胞内プロテオーム変動解析

眞野成康, 阿部幸平, 柳澤勇, 森大, 山口浩明, 後藤順一

日本薬学会第１２８年会　2008/03/26
脳黒質に発現する胆汁酸トランスポーターの機能解析

岡田匡弘, 山口浩明, 三日市剛, 海野倫明, 阿部高明, 小野栄夫, 大和田祐二, 近藤尚武, 菱沼隆則, 後藤順一, 眞野成康

日本薬学会第１２８年会　2008/03/26
腎臓に局在する有機アニオントランスポーターOATP4C1によるエストロン-3-サルフェート輸送

杉江美佐, 山口浩明, 岡田匡弘, 豊原敬文, 種本雅之, 阿部高明, 後藤順一, 菱沼隆則, 眞野成康

日本薬学会第１２８年会　2008/03/26
暴露調査を目的とするシクロホスファミドの高感度LC/MS/MS分析

佐藤真由美, 阿部幸平, 山口浩明, 菱沼隆則, 後藤順一, 眞野成康

日本薬学会第１２８年会　2008/03/26
Niemann-Pick病Type C1鑑別診断法の確立を目的とする三重抱合型胆汁酸の高感度LC/MS/MS分析

外浦亜耶子, 細田敦子, 柿山玄太, 飯田隆, 阿部幸平, 後藤順一, 眞野成康

日本薬学会第１２８年会　2008/03/26
肝可溶性画分中ケノデオキシコール酸結合タンパク質の解析

佐藤光市, 阿部幸平, 鈴木麻央, 後藤貴章, 後藤順一, 眞野成康

日本薬学会第１２８年会　2008/03/26
LC/MS/MSを用いた7種プロスタノイド同時微量定量法の開発と宮城県産ローマ野菜Puntarelleの抗炎症効果についての検討

鈴木香織, 西川正純, 菰田俊一, 阿部拓哉, 中島晶, 眞野成康, 菱沼隆則

日本薬学会第１２８年会　2008/03/26
新潟中越沖地震における東北大学DMAT活動報告

飯田優太郎, 高畑昌代, 松浦正樹, 佐藤真由美, 山内聡, 眞野成康

日本薬学会第１２８年会　2008/03/26
抗がん剤調製過程の標準化とシステム化

松浦正樹, 新関昌宏, 赤坂和俊, 穂積雅人, 木皿重樹, 安井誠, 杉浦明仁, 久道周彦, 後藤順一, 眞野成康

日本薬学会第１２８年会　2008/03/26
パクリタキセルの体内動態に影響を及ぼす薬剤反応性遺伝子多型

山口浩明, 菱沼隆則, 遠藤尚美, 塚本宏樹, 岸川幸生, 佐藤真由美, 村井ユリ子, 平塚真弘, 伊藤潔, 八重樫伸生, 後藤順一, 眞野成康

第１回次世代を担う若手医療薬科学シンポジウム　2007/12/15
トランスポーター輸送の可視化に関する研究

岡田匡弘, 山口浩明, 小林美奈子, 竹内俊子, 種本雅之, 海野倫明, 阿部高明, 菱沼隆則, 後藤順一, 眞野成康

第29回生体膜と薬物の相互作用シンポジウム　2007/11/26
ケノデオキシコール酸とgrowth hormoneの相互作用

阿部幸平, 佐藤光市, 後藤貴章, 後藤順一, 眞野成康

第２９回胆汁酸研究会　2007/11/24
質量分析法による胆汁酸関連タンパク質の解析

眞野成康, 阿部幸平, 後藤順一

第５４回日本臨床検査医学会学術大会、第４７回日本臨床化学会年次学術集会連合大会　2007/11/22
LC/MS/MSを用いた微量ヒト血清中ランソプラゾール及びラベプラゾール簡易定量法の構築とその臨床応用

鈴木香織, 齋藤昌良, 山口浩明, 村井ユリ子, 山岸初志, 小池智幸, 大原秀一, 下瀬川徹, 菱沼隆則, 眞野成康, 後藤順一

第１８回クロマトグラフィー科学会議　2007/11/07
阿部幸平、鈴木麻央、佐藤光市、後藤貴章、後藤順一、眞野成康

ラット肝組織中ケノデオキシコール酸結合タンパク質の抽出

第１８回クロマトグラフィー科学会議　2007/11/07
胆汁酸刺激によるHeLa S3細胞内変動タンパク質の解析

柳澤勇, 阿部幸平, 森大, 八幡憲治, 後藤順一, 眞野成康

第１８回クロマトグラフィー科学会議　2007/11/07
シロリムスからミコフェノール酸モフェチルに投与変更した膵島移植患者におけるTDM

松本洋太郎, 上西智子, 山口浩明, 佐藤真由美, 小川則彦, 後藤昌史, 里見進, 菱沼隆則, 後藤順一, 眞野成康

第１７回日本医療薬学会年会　2007/09/29
卒前病院実習への危険予知トレーニングの導入

村井ユリ子, 佐藤真由美, 山口浩明, 眞野成康, 後藤順一, 菱沼隆則

第１７回日本医療薬学会年会　2007/09/29
薬剤師による病棟常駐業務試験後の評価と今後の課題

佐藤えり子, 猪岡京子, 鈴木文子, 田坂英久, 佐藤真由美, 我妻恭行, 村井ユリ子, 後藤順一, 眞野成康

第１７回日本医療薬学会年会　2007/09/29
NanoLC/ESI-MS/MSによる血清プロテオーム解析に関する検討

森大, 後藤順一, 眞野成康

第20回バイオメディカル分析科学シンポジウム　2007/07/02
ケノデオキシコール酸とgrowth hormoneの相互作用解析

阿部幸平, 佐藤光市, 後藤貴章, 眞野成康, 後藤順一

第20回バイオメディカル分析科学シンポジウム　2007/07/02
LC/ESI-MSによるラット脳内のケノデオキシコール酸硫酸抱合活性の測定

後藤貴章, 前川正充, 阿部真一郎, Khin Than Myint, 眞野成康, 後藤順一

日本薬学会第127年会　2007/03/27
アフィニティー抽出による小分子結合タンパク質へのタグ導入

佐藤光市, 眞野成康, 後藤順一

日本薬学会第127年会　2007/03/27
胆汁酸アシルアデニレートによる付加タンパク質の生成とそのMS解析

鴨田美緒, 眞野成康, 後藤順一

日本薬学会第127年会　2007/03/27
質量分析法を用いるgrowth hormoneとケノデオキシコール酸の結合解析

阿部幸平, 佐藤光市, 眞野成康, 後藤順一

日本薬学会第127年会　2007/03/27
特異的誘導体化を組み合わせるリン酸化タンパク質のnanoLC/ESI-MS/MS

山嵜琢磨, 眞野成康, 後藤順一

日本薬学会第127年会　2007/03/27
ウォンバットの新規主要胆汁酸，3α,15α-Dihydroxy-5β-cholan-24-oic acidタウリン抱合体，の合成と同定

柿山玄太, 細井敬之, 飯田隆, 眞野成康, 後藤貴章, 後藤順一

日本薬学会第127年会　2007/03/27
シトクロムP-450の酵素類似機能を持つ新規オスミウムポルフィリン触媒/酸素ドナー系の創製とステロイド合成への応用

小川祥二郎, 細井敬之, 飯田隆, 牧野三津子, 藤本康雄, 後藤貴章, 眞野成康, 後藤順一

日本薬学会第127年会　2007/03/27
HPLC/ELSDシステムによる胆汁酸3-サルフェートの直接一斉分析法の開発

柿山玄太, 武藤晃奈, 細田敦子, 飯田隆, 眞野成康, 後藤貴章, 後藤順一

日本薬学会第127年会　2007/03/27
Sulfation of chenodeoxycholic acid by rat brain cytoplasmic fraction（ラット脳細胞質画分によるケノデオキシコール酸の硫酸抱合）

Nariyasu Mano, Shin-ichiro Abe, Masamitsu Maekawa, Khin Than Myint, Takaaki Goto, Junichi Goto

日本薬物動態学会第21回年会　2006/11/29
Specific analysis of small molecule-binding proteins（小分子結合タンパク質の選択的解析法）

Koichi Sato, Nariyasu Mano, Junichi Goto

日本薬物動態学会第21回年会　2006/11/29
Chenodeoxycholic acid-binding protein in rat hypophysis（ラット脳下垂体中のケノデオキシコール酸結合タンパク質）

Kohei Abe, Koichi Sato, Takaaki Goto, Nariyasu Mano, Junichi Goto

日本薬物動態学会第21回年会　2006/11/29
Characterization of novel bile acid transporter SLC10A4 (SNBT) expressed in the substantia nigral neuron（脳黒質局在新規胆汁酸トランスポーターSLC10A4(SNBT)の機能解析）

Takanori Hishinuma, Tsuyoshi Mikkaichi, Hiroaki Yamaguchi, Masahiro Okada, Nariyasu Mano, Takaaki Abe, Junichi Goto

日本薬物動態学会第21回年会　2006/11/29
高分解能nanoLC/ESI-MS/MSによるリン酸化タンパク質解析法の開発

山嵜琢磨, 青木さや香, 森大, 眞野成康, 後藤順一

第17回クロマトグラフィー科学会議　2006/11/01
デキストラン修飾キャピラリーのタンパク質吸着抑制に関する検討

菊池直香, 眞野成康, 後藤順一

第17回クロマトグラフィー科学会議　2006/11/01
NanoLC/ESI-MS/MSによるタンパク質同定に対するグラジエント勾配の影響

森大, 眞野成康, 後藤順一

第17回クロマトグラフィー科学会議　2006/11/01
Sensitive determination of bile acid 3-sulfates in human urine and serum by LC/ESI-MS/MS

Khin Than Myint, 後藤貴章, 柿山弦太, 飯田隆, 菱沼隆則, 眞野成康, 後藤順一

第17回クロマトグラフィー科学会議　2006/11/01
LC/MSにおける中性化合物の検出指向誘導体化

後藤貴章, 眞野成康, 後藤順一

化学系学協会東北大会　2006/09/22
質量分析法を用いるタンパク質の精密分子識別

眞野成康, 後藤貴章, 後藤順一

第19回バイオメディカル分析科学シンポジウム　2006/08/01
ラット脳内の胆汁酸結合蛋白質の探索

眞野成康, 阿部幸平, 佐藤光市, 後藤順一

第４回東日本胆汁酸研究会　2006/07/22
硫酸転移酵素を用いるステロイドのCharge Derivatization

橋達也, 後藤貴章, 佐々木大介, 池川繁男, 菱沼隆則, 眞野成康, 後藤順一

第13回クロマトグラフィーシンポジウム　2006/06/08
モノクローナル抗ケノデオキシコール酸抗体の調製とその諸性質

後藤貴章, 阿部奈々, 丹羽俊文, 小林典裕, 眞野成康, 後藤順一

第3回東北大学バイオサイエンスシンポジウム　2006/05/29
LC/ESI-MS/MSによる尿中硫酸抱合型胆汁酸一斉分析法の開発と新規硫酸抱合型胆汁酸の同定

Khin Than Myint, 後藤貴章, 柿山弦太, 飯田隆, 菱沼隆則, 眞野成康, 後藤順一

第3回東北大学バイオサイエンスシンポジウム　2006/05/29
イオントラップ-TOF MSによる小分子結合ペプチドの解析

鴨田美緒, 猪鼻祐介, 山田真一, 眞野成康, 後藤順一

第3回東北大学バイオサイエンスシンポジウム　2006/05/29
一本鎖Fvフラグメント-酵素融合タンパク質とβ型抗イディオタイプ抗体を用いる置換型イムノメトリックアッセイ

小沢一仁, 後藤貴章, 阿部幸平, 岩上景一, 小林典裕, 眞野成康, 後藤順一

第3回東北大学バイオサイエンスシンポジウム　2006/05/29
メタボローム解析を目的としたステロイドのCharge Derivatization

橋達也, 後藤貴章, 佐々木大介, 池川繁男, 菱沼隆則, 眞野成康, 後藤順一

第3回東北大学バイオサイエンスシンポジウム　2006/05/29
Cleavable affinity gelによる小分子結合タンパク質の特異的抽出

佐藤光市, 眞野成康, 後藤順一

第3回東北大学バイオサイエンスシンポジウム　2006/05/29
ラット脳内ケノデオキシコール酸結合タンパク質の解析

阿部幸平, 佐藤光市, 眞野成康, 後藤順一

第3回東北大学バイオサイエンスシンポジウム　2006/05/29
LC/ESI-MS/MSによるリン酸化タンパク質の特異的解析法

眞野成康, 青木さや香, 後藤順一

第3回東北大学バイオサイエンスシンポジウム　2006/05/29
ヒト尿中3-ヒドロキシ胆汁酸サルフェートの同定

Khin Than Myint, 後藤貴章, 柿山弦太, 飯田隆, 菱沼隆則, 眞野成康, 後藤順一

日本薬学会第126年会　2006/03/28
Cleavable affinity gelを用いる小分子結合蛋白質の効率的抽出法の検討

佐藤光市, 眞野成康, 後藤順一

日本薬学会第126年会　2006/03/28
特異的誘導体化によるリン酸化蛋白質解析に関する検討

青木さや香, 眞野成康, 後藤順一

日本薬学会第126年会　2006/03/28
Cleavable affinity gelによる脳内胆汁酸結合蛋白質抽出に関する検討

阿部幸平, 佐藤光市, 眞野成康, 後藤順一

日本薬学会第126年会　2006/03/28
高分解能質量分析法による小分子結合ペプチドの精密解析

鴨田美緒, 猪鼻祐介, 山口真一, 眞野成康, 後藤順一

日本薬学会第126年会　2006/03/28
ScFv-酵素融合タンパク質を用いるハプテンの置換型イムノメトリックアッセイ

小沢一仁, 後藤貴章, 阿部幸平, 岩上景一, 小林典裕, 眞野成康, 後藤順一

日本薬学会第126年会　2006/03/28
蒸発光散乱検出高速液体クロマトグラフィーによる胆汁酸アシルグリコシドの直接一斉分析法の開発

柿山玄太, 薮田理永, 飯田隆, 藤本康雄, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第126年会　2006/03/28
新規オスミウム-ポルフィリン触媒系によるコラン酸のバイオミメティック酸化反応

細井敬之, 小川祥二郎, 飯田隆, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第126年会　2006/03/28
Black-Necked Swanから新規胆汁酸，3,7,15-トリヒドロキシ-5-コラン酸タウリン抱合体の単離・同定

柿山玄太, 細田敦子, 飯田隆, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第126年会　2006/03/28
抗ケノデオキシコール酸モノクローナル抗体の調製とその諸性質

後藤貴章, 阿部奈々, 丹羽俊文, 小林典裕, 眞野成康, 後藤順一

日本薬学会第126年会　2006/02/28
Chemical synthesis of the 3-sulfo-7-N-acetylglucosaminyl-24-aminoacyl amidated conjugates of 3,7-dihydroxy-5-cholen-24-oic acid and related compounds: Major bile acid metabolites in a patient with Niemann-Pick Disease type C1 International-presentation

Genta Kakiyama, Takashi Iida, Takaaki Goto, Nariyasu Mano, Junichi Goto, Toshio Nambara, Alan F. Hofmann

Pacifichem 2005　2005/12/15
脳内胆汁酸の発見と脳内生合成活性

眞野成康, 後藤貴章, 後藤順一

第52回日本臨床検査医学会総会・第45回日本臨床化学会年会連合大会　2005/11/17
胆汁酸アデニレートにより生成するDNA付加体の解析

高村岳樹, 眞野成康, 川原信夫, 後藤順一, 若林敬二

日本環境変異原学会第34回大会　2005/11/16
Proteomic research by mass spectrometry combined with highly selective molecular recognition International-presentation

Nariyasu Mano, Junichi Goto

International Symposium on Pharmaceutical Sciences in Sendai 2005, Tohoku University 21st Century COE Program “CRESCENDO” Symposium　2005/10/28
LC/ESI-MSを用いるヒト血清中の3位硫酸抱合型胆汁酸高感度定量法の開発

後藤貴章, Khin Than Myint, 眞野成康, 後藤順一

日本分析化学会第54年会　2005/09/14
質量分析法による蛋白質の高精密解析に関する研究

眞野成康

第30回日本医用マススペクトル学会年会　2005/09/08
Cleavable affinity gelによる抽出蛋白質の分子内ジスルフィド結合の安定性解析

佐藤光市, 眞野成康, 後藤順一

第30回日本医用マススペクトル学会年会　2005/09/08
特異的誘導体化によるリン酸化蛋白質解析法の構築

青木さや香, 眞野成康, 後藤順一

第18回バイオメディカル分析科学シンポジウム　2005/08/05
アフィニティーを活用する蛋白質解析

眞野成康

第28回分析化学若手交流会　2005/07/22
ヒト尿中新規抱合型胆汁酸-アシルガラクトシド-の高感度定量

後藤貴章, 坂下佳子, 眞野成康, 後藤順一

第12回クロマトグラフィーシンポジウム　2005/05/19
アフィニティーラベル化とイムノアフィニティー抽出を組み合わせた低分子結合蛋白質の解析

阿部幸平, 眞野成康, 小林貴行, 丹羽俊文, 小林典裕, 後藤順一

第２回東北大学バイオサイエンスシンポジウム　2005/05/16
LC/APCI-MSを用いるヒト尿中新規抱合型胆汁酸アシルガラクトシドの高感度定量法の開発

後藤貴章, 坂下佳子, 眞野成康, 後藤順一

第２回東北大学バイオサイエンスシンポジウム　2005/05/16
低分子結合蛋白質の超高選択的抽出法の構築

佐藤光市, 眞野成康, 後藤順一

第２回東北大学バイオサイエンスシンポジウム　2005/05/16
アシルアデニレートによる胆汁酸付加ヒストンの生成と解析

春日紀恵, 眞野成康, 後藤順一

第２回東北大学バイオサイエンスシンポジウム　2005/05/16
特異的誘導体化を用いるリン酸化ペプチド解析法の構築

青木さや香, 永冶陽子, 眞野成康, 後藤順一

第２回東北大学バイオサイエンスシンポジウム　2005/05/16
蛍光標識胆汁酸を用いたトランスポーター機能評価法

岡田匡弘, 菱沼隆則, 大原宏司, 三日市剛, 眞野成康, 海野倫明, 阿部高明, 後藤順一

第２回東北大学バイオサイエンスシンポジウム　2005/05/16
酵母Yap1転写因子の分子内チオール−ジスルフィド交換反応を介した過酸化水素感知機構

岡崎祥子, 永冶陽子, 眞野成康, 後藤順一, 永沼章, 久下周佐

第２回東北大学バイオサイエンスシンポジウム　2005/05/16
質量分析法によるIKK依存性Np51Bタンパク質リン酸化部位同定

矢吹仁人, 名越弘和, 眞野成康, 後藤順一, 帯刀益夫, 井川俊太郎

第２回東北大学バイオサイエンスシンポジウム　2005/05/16
Proteomic research on bile acids by mass spectrometry International-presentation

Nariyasu Mano, Junichi Goto

AAPD-PSJ Joint Symposium “Bioanalytical Chemistry”，日本薬学会第125年会（東京）　2005/03/29
胆汁酸アシルアデニレートによるヒストンH3の非酵素的翻訳後修飾の解析

春日紀恵, 眞野成康, 後藤順一

日本薬学会第125年会　2005/03/29
低分子リガンド結合蛋白質の特異的抽出法の構築

佐藤光市, 眞野成康, 後藤順一

日本薬学会第125年会　2005/03/29
リン酸化ペプチドの特異的誘導体化に関する基礎検討

青木さや香, 永冶陽子, 眞野成康, 後藤順一

日本薬学会第125年会　2005/03/29
低分子付加ペプチドのイムノアフィニティー抽出条件の最適化

阿部幸平, 眞野成康, 小林貴行, 丹羽俊文, 小林典裕, 後藤順一

日本薬学会第125年会　2005/03/29
LC/APCI-MSによる胆汁酸アシルガラクトシドの高感度分析法の開発

後藤貴章, 坂下佳子, 柿山玄太, 飯田隆, 眞野成康, 後藤順一

日本薬学会第125年会　2005/03/29
げっ歯類主要胆汁酸のLC/ESI-MS/MSによる一斉分析法の開発

安藤昌幸, 眞野成康, 後藤貴章, 鈴木直人, 菱沼隆則, 嶋田健次, 後藤順一

日本薬学会第125年会　2005/03/29
蛍光プローブを用いたトランスポーター機能評価法

岡田匡弘, 菱沼隆則, 大原宏司, 三日市剛, 眞野成康, 海野倫明, 阿部高明, 後藤順一

日本薬学会第125年会　2005/03/29
胆汁酸24-アシルグリコシドの至適クロマトグラフ測定法の確立

小川祥二郎, 藪田理永, 貞清臣史, 細井敬之, 藤本康雄, 飯田隆, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第125年会　2005/03/29
構造活性相関ドラッグデザインに基づくヒト17β-HSD1酵素阻害候補化合物の合成

柿山玄太, 安斎孝哉, 飯田隆, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第125年会　2005/03/29
ニーマン・ピック病C1型の特異マーカー，多重抱合型3β,7β-ジヒドロキシ-5-コレン酸異常代謝産物の合成

吉本篤史, 柿山玄太, 日比谷陽平, 飯田隆, 眞野成康, 後藤貴章, 後藤順一, 南原利夫

日本薬学会第125年会　2005/03/29
分子内チオールジスルフィド交換反応を介した酵母Yap1転写因子の過酸化水素感知機構

岡崎祥子, 永冶陽子, 眞野成康, 後藤順一, 永沼章, 久下周佐

第27回日本分子生物学会年会　2004/12/08
イムノアフィニティー抽出による低分子付加ペプチドの精製

眞野成康, 春日紀恵, 永冶陽子, 小林典裕, 後藤順一

第15回クロマトグラフィー科学会議　2004/11/11
LC/ESI-MSを用いるヒト尿中の胆汁酸３位硫酸抱合体高感度定量法の開発

後藤貴章, Khin Than Myint, 佐藤光市, 眞野成康, 後藤順一

第15回クロマトグラフィー科学会議　2004/11/11
胆汁酸結合蛋白質の相互作用部位解析法の構築

眞野成康, 永冶陽子, 小林典裕, 後藤順一

第3回東日本胆汁酸研究会　2004/07/24
ヒト尿中新規抱合体−胆汁酸アシルガラクトシド−

後藤貴章, 柴田晶弘, 佐々木大介, 眞野成康, 飯田隆, 後藤順一

第3回東日本胆汁酸研究会　2004/07/24
プロテオーム解析における低分子-蛋白質相互作用解析手法

眞野成康, 佐藤光市, 永冶陽子, 小林典裕, 後藤順一

平成16年度日本薬学会東北支部学術講演会　2004/07/17
The presence of chenodeoxycholic acid in the cytoplasmic fraction of rat brain International-presentation

Nariyasu Mano, Takaaki Goto, Junichi Goto

Falk Symposia 2004; Bile Acids and Cholesterol Metabolism and its Therapeutical Implications (XVIII International Bile Acid Meeting)　2004/06/18
Biomimetic oxidation of bile acids by 2,6-dichloropyridine N-oxide/ruthenium-porphyrin?HBr system International-presentation

Shoujiro Ogawa, Takashi Iida, Takaaki Goto, Nariyasu Mano, Junichi Goto, Toshio Nambara

Falk Symposia 2004; Bile Acids and Cholesterol Metabolism and its Therapeutical Implications (XVIII International Bile Acid Meeting)　2004/06/18
Chemical synthesis of some bile acid metabolites in vertebrates International-presentation

Genta Kakiyama, Takashi Iida, Takaaki Goto, Nariyasu Mano, Junichi Goto, Toshio Nambara, Lee R. Hagey, Alan F. Hofmann

Falk Symposia 2004; Bile Acids and Cholesterol Metabolism and its Therapeutical Implications (XVIII International Bile Acid Meeting)　2004/06/18
新規抱合型胆汁酸アシルガラクトシド

後藤貴章, 柴田晶弘, 佐々木大介, 飯田隆, 眞野成康, 後藤順一

第17回バイオメディカル分析科学シンポジウム　2004/06/03
Mass spectrometry in drug development and therapy International-presentation

Junichi Goto, Nariyasu Mano, Takaaki Goto

Pharmaceutical Sciences World Congress (PSWC 2004)　2004/05/29
Acyl adenylate as the novel affinity labeling reagent and its application International-presentation

Nariyasu Mano, Yoko Nagaya, Shuntaro Saito, Norihiro Kobayashi, Junichi Goto

Pharmaceutical Sciences World Congress (PSWC 2004)　2004/05/29
Conversion of 3-hydroxy-5-cholenoic acid into chenodeoxycholic acid by rat brain tissue, in vitro International-presentation

Takaaki Goto, Yoshiaki Sato, Nariyasu Mano, Junichi Goto

Pharmaceutical Sciences World Congress (PSWC 2004)　2004/05/29
Analysis of histone-bile acid adducts using mass spectrometry coupled with immunoaffinity extraction International-presentation

Kie Kasuga, Nariyasu Mano, Norihiro Kobayashi, Junichi Goto

Pharmaceutical Sciences World Congress (PSWC 2004)　2004/05/29
新規アフィニティーラベル化剤：アシルアデニレートを用いる低分子−蛋白質相互作用解析法

眞野成康, 永冶陽子, 斎藤俊太郎, 小林典裕, 後藤順一

第1回東北大学バイオサイエンスシンポジウム　2004/05/14
MALDI-TOFMSとラダーシークエンス法を組み合わせるリン酸化部位解析法

春日紀恵, 飯島摂子, 眞野成康, 後藤順一

第1回東北大学バイオサイエンスシンポジウム　2004/05/14
低分子−蛋白質相互作用解析手法の構築

佐藤光市, 眞野成康, 後藤順一

第1回東北大学バイオサイエンスシンポジウム　2004/05/14
病態プロテオーム解析による視神経変性機構解明への挑戦

鈴木直人, 小澤実香, 眞野成康, 富岡佳久, 菱沼隆則, 中澤徹, 玉井信, 後藤順一

第1回東北大学バイオサイエンスシンポジウム　2004/05/14
The peculiar existence of protein-bound unconjugated bile acid in the cytoplasmic fraction of rat brain International-presentation

Nariyasu Mano, Takaaki Goto, Junichi Goto

3rd Sino-Japanese Joint Seminar on Separation Sciences　2004/04/03
Cleavable affinity gelを用いる低分子-蛋白質相互作用解析法に関する検討

佐藤光市, 眞野成康, 後藤順一

日本薬学会第124年会　2004/03/29
連続二次元クロマトグラフィーによる蛋白質の高速分離

永冶陽子, 眞野成康, 後藤順一

日本薬学会第124年会　2004/03/29
固定化抗体カラムを用いるヒストン-胆汁酸付加体解析手法の検討

春日紀恵, 眞野成康, 小林典裕, 後藤順一

日本薬学会第124年会　2004/03/29
ヒト尿中の新規胆汁酸24-グリコシドの同定

後藤貴章, 柴田晶弘, 佐々木大介, 飯田隆, 眞野成康, 後藤順一

日本薬学会第124年会　2004/03/29
蛍光標識胆汁酸を用いた胆汁酸・薬物トランスポーター機能評価系の構築

岡田匡弘, 菱沼隆則, 三日市剛, 眞野成康, 海野倫明, 阿部高明, 後藤順一

日本薬学会第124年会　2004/03/29
脊椎動物における潜在的主要胆汁酸，3,7,14-トリヒドロキシコラン酸，の合成

柿山玄太, 藪田理恵, 飯田隆, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第124年会　2004/03/29
ラット主要胆汁酸，22--ムリコール酸，とそのアミド抱合体の合成

吉本篤史, 柿山玄太, 飯田隆, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第124年会　2004/03/29
ルテニウムポルフィリン触媒を用いる3-オキソ胆汁酸の遠隔酸化反応：一段階C-20位ラクトン化

小川祥二郎, 白石圭助, 飯田隆, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第124年会　2004/03/29
18O標識胆汁酸をトレーサーとして用いる脳内胆汁酸生合成に関する検討

眞野成康, 佐藤義明, 後藤貴章, 後藤順一

第25回胆汁酸研究会　2003/11/01
アシルアデニレートを利用するカルボン酸のアフィニティーラベル化

眞野成康, 永冶陽子, 小林典裕, 後藤順一

日本分析化学会第52年会　2003/09/23
LC/ESI-MSによるヒト尿中胆汁酸3-サルフェート一斉分析法の開発

後藤貴章, 佐藤光市, Khin Than Myint, 眞野成康, 後藤順一

日本分析化学会第52年会　2003/09/23
アルカリホスファターゼを活用するリン酸化蛋白質の解析

眞野成康, 飯島摂子, 春日紀恵, 後藤順一

第16回バイオメディカル分析科学シンポジウム　2003/08/03
ラット脳における胆汁酸生合成

後藤貴章, 佐藤義明, 眞野成康, 後藤順一

第16回バイオメディカル分析科学シンポジウム　2003/08/03
蛍光ラベルリガンドを用いた薬物トランスポーターの機能評価系の開発

菱沼隆則, 岡田匡弘, 三日市剛, 眞野成康, 海野倫明, 阿部高明, 後藤順一

第16回バイオメディカル分析科学シンポジウム　2003/08/03
肝疾患の病態プロテオミクスに用いる分子標的機能性素子の創製

池川繁男, 山本哲志, 伊藤裕美, 石渡俊二, 眞野成康, 後藤順一, 前田昌子

第16回バイオメディカル分析化学シンポジウム　2003/08/03
不安定代謝物による蛋白質付加体生成とその生成抑制機構の解析

眞野成康, 後藤貴章, 後藤順一

第10回クロマトグラフィーシンポジウム　2003/08/02
脳内胆汁酸結合蛋白質のプロテオミクス解析

眞野成康, 山崎大典, 後藤順一

第2回東日本胆汁酸研究会　2003/07/12
胆汁酸誘導体による生体内カルボン酸の毒性発現抑制

後藤貴章, 二階堂綾子, 眞野成康, 後藤順一

第2回東日本胆汁酸研究会　2003/07/12
ラット肝細胞内胆汁酸アシルアデニレート生成酵素の特性解析

伊藤裕美, 眞野成康, 後藤順一, 池川繁男

第16回西日本臨床胆汁酸研究会　2003/06/28
プロテオーム解析

後藤順一, 眞野成康

第10回日本臓器保存生物医学総会　2003/05/23
ファーマコプロテオミクスにおける翻訳後修飾蛋白質の解析

眞野成康

日本薬学会第123年会　2003/03/27
プロテオミクス手法を用いる脳内胆汁酸結合蛋白質の解析

山崎大典, 眞野成康, 後藤順一

日本薬学会第123年会　2003/03/27
ラット脳におけるケノデオキシコール酸生合成

佐藤義明, 後藤貴章, 眞野成康, 後藤順一

日本薬学会第123年会　2003/03/27
胆汁酸によるフルルビプロフェンアシルグルクロニデーションの阻害

二階堂綾子, 鳴井隆, 後藤貴章, 眞野成康, 後藤順一

日本薬学会第123年会　2003/03/27
胆汁酸刺激によるペルオキシレドキシン？の脱リン酸化

飯島摂子, 中島めぐみ, 八幡憲治, 眞野成康, 後藤順一

日本薬学会第123年会　2003/03/27
大気圧化学イオン化法による中性分子のイオン化に対する疎水性有機酸の影響

後藤貴章, 柴田晶弘, 飯田隆, 眞野成康, 後藤順一

日本薬学会第123年会　2003/03/27
抗デオキシコール酸抗体一本鎖Fvフラグメントの調製と諸性質

大豊衛, 和田絵理子, 眞野成康, 小林典裕, 後藤順一

日本薬学会第123年会　2003/03/27
リトコール酸−蛋白付加体の検出に用いるモノクローナル抗体の調製

伊藤裕美, 大西惠, 山本哲志, 石渡俊二, 前田昌子, 眞野成康, 後藤順一, 池川繁男

日本薬学会第123年会　2003/03/27
3,6-および3,24-ジヒドロキシコラン誘導体のジメチルジオキシランによるバイオミメティック反応

柿山玄太, 飯田隆, 後藤貴章, 眞野成康, 後藤順一, 南原利夫

日本薬学会第123年会　2003/03/27
脳内胆汁酸結合蛋白質のプロテオーム解析

山崎大典, 眞野成康, 後藤順一

第24回胆汁酸研究会　2002/12/17
ラット脳内胆汁酸生合成に関する検討

後藤貴章, 佐藤義明, 眞野成康, 後藤順一

第24回胆汁酸研究会　2002/12/17
試料処理とリン酸残基の特定法

後藤順一, 眞野成康

平成１４年度創薬等ヒューマンサイエンス総合研究推進事業研究成果等普及啓発事業「プロテオーム・メタボローム研究の最近の進歩」　2002/12/13
シアノバクテリア（Synechocystis.sp PCC6803）の化学架橋剤を用いたプロテオーム解析

中澤昌高, 眞野成康, 後藤順一, 東谷篤志

第25回日本分子生物学会年会　2002/12/11
液体クロマトグラフィーによる生体成分の高精密分子認識と捕捉に関する研究

眞野成康

第13回クロマトグラフィー科学会議　2002/10/10
リトコール酸-蛋白付加体の捕捉と構造解析を目的とするエピトープ特異抗体の調製

山本哲志, 伊藤裕美, 池川繁男, 前田昌子, 眞野成康, 後藤順一

日本分析化学会第51年会　2002/09/19
LC-TOFMSを用いた硫酸抱合型胆汁酸の分析

森田徹一郎, 高橋豊, 大須賀潤一, 田村淳, 眞野成康, 後藤順一

第27回日本医用マススペクトル学会年会　2002/09/12
アシルアデニレートを利用する新規アフィニティーラベル化剤の創製

眞野成康, 斎藤俊太郎, 小林典裕, 後藤順一

第15回バイオメディカル分析科学シンポジウム　2002/08/20
Quantitative analysis of bile acid 3-sulfates by liquid chromatography-time of flight mass spectrometry International-presentation

Yutaka Takahashi, Tetsuichiro Morita, Jun Tamura, Kiyotaka Konuma, Yoshihisa Ueda, Fumio Kunihiro, Nariyasu Mano, Junichi Goto

50th ASMS Conference　2002/06/02
バイオメディカル分析科学におけるLC/MS

眞野成康, 後藤順一

第63回分析化学討論会　2002/05/25
薬学における分析化学とMS

後藤順一, 眞野成康

第50回質量分析総合討論会　2002/05/15
脳内胆汁酸の生理的意義？

後藤順一, 眞野成康, 小林典裕

日本薬学会第122年会　2002/03/26
ラット脳内胆汁酸結合蛋白質の解析

眞野成康, 斎藤俊太郎, 春日紀恵, 小林典裕, 後藤順一

日本薬学会第122年会　2002/03/26
ラット脳ミクロソーム画分による3-ヒドロキシ-5-コレン酸の7位水酸化

永多正憲, 佐藤義明, 眞野成康, 後藤順一

日本薬学会第122年会　2002/03/26
LC/ESI-MSを用いるコール酸並びにそのCoAチオエステル、アシルアデニレート誘導体の一斉分析法の開発

内田将史, 奥山裕子, 佐々木育子, 眞野成康, 池川繁男, 後藤順一

日本薬学会第122年会　2002/03/26
LC/ESI-MSによるヒト尿中フルルビプロフェングルクロニドの高感度定量法

二階堂綾子, 鳴井隆, 眞野成康, 後藤順一

日本薬学会第122年会　2002/03/26
2-アリールプロピオン酸肝アシルグルクロン酸転移酵素活性測定法の開発

鳴井隆, 二階堂綾子, 山崎大典, 眞野成康, 後藤順一

日本薬学会第122年会　2002/03/26
アルカリホスファターゼによるゲル内脱リン酸化反応を用いる翻訳後修飾蛋白質の解析

飯島摂子, 眞野成康, 後藤順一

日本薬学会第122年会　2002/03/26
肝疾患マーカーとして期待される胆汁酸アシルグルコシド標品の高効率合成とその特異的性質

春日祐佳, 中森龍生, 飯田隆, 眞野成康, 池川繁男, 後藤順一, 南原利夫

日本薬学会第122年会　2002/03/26
胆汁酸刺激による培養細胞内変動蛋白質の解析

飯島摂子, 八幡憲治, 春日紀恵, 眞野成康, 後藤順一

第11回日本小児胆汁酸研究会　2002/03/02
脳内胆汁酸の発見

眞野成康, 内田将史, 西村浩司, 後藤順一

第11回日本小児胆汁酸研究会　2002/03/02
The peculiar existence of unconjugated lipophilic bile acid in brain International-presentation

Junichi Goto, Nariyasu Mano, Koji Nishimura, Masayuki Ando, Norihiro Kobayashi

International Symposium on High Performance Liquid Phase separations and Related Techniques　2001/09/11
抗体による低分子生理活性物質−ペプチド付加体の高精密分離

池川繁男, 眞野成康, 小林典裕, 後藤順一

クロマトグラフィー科学会議　2001/09/10
アシルアデニレートを介する胆汁酸-蛋白質付加体の生成とその構造解析

池川繁男, 永多正憲, 眞野成康, 小林典裕, 後藤順一, 清波麗子

第15回西日本臨床胆汁酸研究会　2001/07/14
脳内胆汁酸の生理的意義は？

眞野成康, 内田将史, 西村浩司, 小林典裕, 後藤順一

第14回バイオメディカル分析科学シンポジウム　2001/07/11
代謝活性中間体と蛋白付加体生成

眞野成康

第28回BMSコンファレンス　2001/07/08
胆汁酸アシルグルクロン酸転移酵素の生成物阻害

眞野成康, 西村浩司, 鳴井隆, 池川繁男, 後藤順一

第1回東日本胆汁酸研究会　2001/07/07
プロテオミクスによる胆汁酸刺激培養細胞内変動蛋白質の解析

春日紀恵, 八幡憲治, 飯島摂子, 眞野成康, 池川繁男, 後藤順一

第1回東日本胆汁酸研究会　2001/07/07
新規アフィニティーラベル化剤：アシル-2-デオキシグルクロニドの開発とその応用

斎藤俊太郎, 西島明, 眞野成康, 後藤順一, 池川繁男

第62回分析化学討論会　2001/06/01
ファーマコプロテオミクスに関する基礎的研究：胆汁酸刺激培養細胞内変動蛋白質の解析

春日紀恵, 八幡憲治, 飯島摂子, 眞野成康, 後藤順一

第８回クロマトグラフィーシンポジウム　2001/05/17
ラット肝胆汁酸アシルグルクロニルトランスフェラーゼの特性解析

西村浩司, 眞野成康, 池川繁男, 後藤順一

日本薬学会第121年会　2001/03/28
特異抗体を用いる光学活性2-アリールプロピオン酸修飾ペプチドのエナンチオ選択的抽出と構造解析

眞野成康, 池川繁男, 後藤順一

第25回日本医用マススペクトル学会年会　2000/09/28
蛋白質固定化光学分割カラムによる医薬品の分析

真野成康

シンポジウムモレキュラー・キラリティー２０００　2000/06/01
血漿直接注入による光学異性薬物及び代謝物の一斉分析

真野成康, 小田吉哉, 浅川直樹

第９回クロマトグラフィー科学会議　1998/11/19
新規光学分割カラムの開発と薬物動態研究への応用

真野成康, 小田吉哉, 浅川直樹

第１３回日本薬物動態学会年会　1998/11/11
アフィニティーキャピラリー電気泳動を用いたタンパク質固定化カラムのキラル認識に関する考察

真野成康, 小田吉哉, 石濱泰, 浅川直樹

日本薬学会第118年会　1998/03/31
LC/MS/MSによる生体内微量生理活性物質の定量

真野成康, 小田吉哉, 浅川直樹

第２２回日本農薬学会　1997/03/27
Simultaneous quantitative determination method for endogenous sphingolipid metabolites in cells by liquid chromatography/ionspray ionization mass spectrometry International-presentation

Nariyasu Mano, Yoshiya Oda, Koji Yamada, Naoki Asakawa, Kouichi Katayama

Gordon Reserach Conferences　1996/09/29
A new quantitation method for sphingolipids by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry International-presentation

Nariyasu Mano, Yoshiya Oda, Naoki Asakawa, Koji Yamada

20th International Symposium on High Performance Liquid Phase Separations　1996/06/16
Development of a flavoprotein column for chiral separation of enantiomers by high-performance liquid chromatography and its application International-presentation

Nariyasu Mano, Yoshiya Oda, Naoki Asakawa, Toshinobu Miwa

The 6th International Symposium on Chiral Discrimination　1995/04/26
HPLC用タンパク固定化カラムによる光学異性体分離に関する考察

真野成康, 石濱泰, 小田吉哉, 浅川直樹

日本薬学会第115年会　1995/03/29
GC/MSによる血漿中メバロン酸定量法の開発

真野成康, 石濱泰, 小田吉哉, 浅川直樹, 日吉裕展, 生田博憲

第11回生体成分の分析化学シンポジウム　1994/09/21
タンパク結合型HPLC用逆相系光学異性体分離カラムの性質検討

真野成康, 小田吉哉, 浅川直樹, 吉田豊, 里忠

日本薬学会第113年会　1993/03/29
Determination and resolution of drug enantiomers in plasma by LC/MS combined new chiral resolution column International-presentation

Nariyasu Mano, Yoshiya Oda, Hiroshi Ohe, Naoki Asakawa, Yutaka Yoshida, Tadashi Sato

International Conference on Biological Mass Spectrometry　1992/09/20
タンパク質をリガンドとして用いた光学異性体分離カラムに関する基礎的検討

真野成康, 小田吉哉, 三輪敏紳, 浅川直樹, 吉田豊, 里忠

日本薬学会第112年会　1992/03/29

Show all Show first 5

Research Projects 17

非アルコール性脂肪肝炎の精密予後予測マーカー探索を指向した機能性脂質の網羅的解析

眞野成康

Offer Organization: 日本学術振興会

System: 科学研究費助成事業

Category: 基盤研究(C)

Institution: 東北大学

2024/04/01 - 2027/03/31
Elucidation of the molecular mechanism and pathophysiology of Niemann-Pick disease type C by a multifaceted approach

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2021/04/01 - 2024/03/31
糖負荷による小胞体ストレスおよびUnfolded Protein Response(UPR)の検出

佐藤稔之, 小倉次郎, 杉浦弘樹, 小野慎司, 眞野成康

Offer Organization: 日本学術振興会

System: 科学研究費助成事業奨励研究

Category: 奨励研究

Institution: 東北大学

2019 - 2019

More details Close

ヒト神経芽細胞腫由来SH-SY5Y細胞を用い、通常培地(1.0g/L Glucose)、グルコース付加培地(4.5g/L Glucose)、フルクトース付加培地(1.0g/L Glucose+3.5g/L Fructose)で1-28日間培養した. まず, 細胞生存率を評価したところ、糖負荷条件ではともに28日目に生存率の低下がみられた. 次に、UPR関連遺伝子を評価したところ、CHOP mRNAの挙動と生存率が、グルコース負荷では相関し、フルクトース負荷では相関しなかった. 以上よりグルコースおよびフルクトース負荷はともに細胞生存率を低下させるが、UPR遺伝子の経時変化はそれぞれ異なり、両者の細胞生存率低下の誘起メカニズムは異なることが示唆された.
Precision medicine for molecular-targeted drugs using pharmacokinetics and metabolomics

Shimada Miki, MANO NARIYASU, MAEKAWA MASAMITSU

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tottori University

2013/04/01 - 2016/03/31

More details Close

To establish the precision medicine for molecular-targeted drugs, we have performed the study on the pharmacokinetics and the pharmacodynamics in this study.Our data obtained the monitoring the blood concentration of drug and its major metabolite in patients suggests that pharmacokinetic parameters of molecular-targeted drugs are predictive markers for therapeutic and adverse effects. Prelinarly, we have performed proteome analysis on the blood of patients prior/after taking molecular-targeted drugs. Between prior/after taking molecular-targeted drugs, we observed the difference of several endogenous compounds related to glycolysis/gluconeogenesis, TCA cycle, or citric acid cycle.
Highly accurate medical therapy management by universal TDM and global metabolomics

MANO NARIYASU, SHIMADA Miki, MAEKAWA Masamitsu

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research

Category: Grant-in-Aid for Challenging Exploratory Research

Institution: Tohoku University

2012/04/01 - 2014/03/31

More details Close

We investigated linearities of phenytoin as a model drug by peak intensity plot of stable isotopes, and found saturation more than 10 thousand-fold and difference of slopes of each stable isotope line. Plotting peak area ratios using an internal standard broadens linearity range to 100 thousand-fold, and equalized approximately slopes. However, obtained results suggested that the saturation of peak intensities was caused by the saturation of ionization. Therefore, expansion of measurement range by using peak intensities of stable isotopes was limited to 100 thousand-fold. By the above results we developed a simultaneous determination method of all drugs and their metabolites used in a cancer chemotherapy regimen.
Construction of a practical education system for pharmacy students, pharmacists, and teachers with case follow-up

MURAI YURIKO, MANO Nariyasu, TOMIOKA Yoshihisa

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2011 - 2013

More details Close

Objective of this study is to establish the sustainable system of pharmacy education to cultivate human resources who contribute to healthcare with pharmaceutical sciences. We conducted on-site training in hospital with 6 times during the 3-year study period. Weekly case conferences were held in the training for 11 weeks by one term. Advising pharmacists, teachers, and fifth-year pharmacy students who were on the training attended the conferences. Basic points to discuss about pharmacotherapy or pharmaceutical care were demonstrated and presented to the students in the guidance of case conferences. According to the points, students had group discussions and presentations in case conferences about their patients. Students' levels of understanding or satisfaction improved comparing with that before. Through continuous follow-up of patients, discussion, and information sharing, it considered that participants including pharmacists and teachers gained clinical competency.
Establishment of system for supporting formulation in cancer chemotherapy

SHIMADA Miki, MANO Nariyasu

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2010 - 2012

More details Close

We developed the simultaneous analysis for anti-cancer drug and its metabolite about irinotecan and gemcitabine. Then, we analyzed serum concentration of anti-cancer drug and it's metabolite with time in patients obtained the agreement to be part of this study and calculated pharmacokinetic parameters. As observed no adverse effect in this period for all of patients, we would assess changes over time in future.When we preliminary added gemcitabine to medium of pancreas cancer cell lines derived from patients with pancreas cancer to know the correlation between the pharmacokinetic profile and gemcitabine-induced cytotoxicity. These results suggest that enhancement of incorporation of gemcitabine to cells, metabolism of gemcitabine to dFdU, or elimination of dFdU extracellularly.
Development of a new analytical system for bile acid metabolome

MANO Nariyasu, SHIMADA Miki, MAEKAWA Masamitsu

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research

Category: Grant-in-Aid for Challenging Exploratory Research

Institution: Tohoku University

2010 - 2011

More details Close

We set up an HPLC separation method for various bile acid conjugates, and characterized each fragmentation of bile acid conjugates by the investigation of product ion patterns on low-energy collision-induced dissociation. Based on their data, we produced focusing methods for bile acid metabolome by conjugated forms using precursor ion scan and neutral loss scan analysis. In addition, we analyzed urine from patients producing metabolic abnormalities of cholesterol, and found to analyze disease-specific bile acid metabolites.
Development of a new therapeutic treatment for metabolic diseases based on the solution of the relationship between bile acids and homeostasis of lipids and sugars

MANO Nariyasu, SHIMADA Miki

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2009 - 2011

More details Close

We analyzed proteome in cultured cells after bile acid stimulation, and found quantitative variation for posttranslational modifications of α-enolase and peroxiredoxin-1. By cleavable affinity gel extraction, we found intracellular carrier proteins and some enzymes for bile acid metabolism besides peroxiredoxin-1 as bile acid binding proteins in hepatocytes. We developed a method for one 18O-atom labeling at C-terminal of tryptic digested peptides, which allowed application to quantitative proteomics. The method for comprehensive analysis of bile acid conjugates developed in this study was useful for finding specific metabolites in some diseases.
Proteomics of bile acid signals

GOTO Junichi, MANO Nariyasu, SHIMADA Miki, YAMAGUCHI Hiroaki

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2008 - 2010

More details Close

According to proteomics approach, we tried to develop an analytical method for bile acid signal transduction and clarify the function of bile acids in the brain. The results by the affinity labeling analysis of growth hormone using chenodeoxycholyl adenylate showed that chenodeoxycholate binds to the region different from the growth hormone receptor binding site. Next, we developed an analytical method of phosphorylated proteins using the specific derivatization and the double pseudo-neutral loss extraction on nanoLC/ESI-MS/MS. We found its usefulness for identification of phosphorylated proteins in complex protein mixtures and identification of phosphorylated sites. In addition, we extracted chenodeoxycholate-binding proteins in hepatocytes by using the chenodeoxycholate-immobilized cleavable affinity gel, and identified dihydrodiol dehydrogenase, which is known as a bile acid-binding protein in the hepatocyte, and peroxiredoxin 1.
Analysis of functional significance of a newly discovered brain-specific transporter

NAKAJIMA Akira, MANO Nariyasu, TOMIOKA Yoshihisa, YAMAGUCHI Hiroaki

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

2008 - 2010

More details Close

We have focused on a newly discovered human brain-specific transporter SLC10A4, which is specifically localized in the substantia nigra. Over-expression cell of human SLC10A4 was successfully generated using human HepG2 cell. A low SLC10A4-mediated uptake of bile acids, such as chenodeoxycholic acid and ursodeoxycholic acid, was observed in the transformant. The expression of SLC10A4 was investigated in various cultured cells using immunoblot analysis. Finally, human brain-derived TE671(medulloblastoma) cells were found that they had a stable expression of SLC10A4. It was noteworthy finding that the uptake of taurocholic acid was induced by thrombin pretreatment in the TE671 cells and the Km value was higher than that of known sodium taurocholate co-transporting polypeptides, such as ASBT and NTCP. We considered that SLC10A4 was special brain transporter, could be activated and responsible for the uptake of bile acids when blood clotting was occurred following blood vessel damage or tissue injury.
Proteomic and metabolomic analysis of a new function of biological small molecules

MANO Nariyasu, HISHINUMA Takanori

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2007 - 2008
ANALYSIS OF NEW PHYSIOLOGICAL FUNCTIONS OF BILE ACIDS BY HIGHLY ACCURATE MOLECULAR RECOGNITION SYSTEM

GOTO Junichi, HISHINUMA Takanori, MANO Nariyasu

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

Institution: Tohoku University

2005 - 2006

More details Close

Recently, we found three bile acids, which were bound with some proteins, in the cytoplasmic fraction of the rat brain. Also, we demonstrated that deoxycholate, which may act as colon tumor promoters in high-risk populations, irreversibly and preferentially bound to e-amino group of Lys4 on histone H3 via acyl adenylate. We tried to clarify new physiological functions of bile acids by the highly selective molecular recognition system. First, we developed a new specific extraction method for capturing small molecule-binding proteins from biological fluids by the cleavable affinity gel. We extracted the chenodeoxycholate-binding proteins in the rat brain tissue, cerebrum, midbrain, cerebellum, brainstem, hippocampus, and pituitarium, by using the cleavable affinity gel immobilized chenodeoxycholate via the disulfide linker. The captured proteins were separated by SDS-PAGE, and analyzed by MALDI-TOF MS following in-gel tryptic digestion. The extracted fraction from all tissues included α-, β-tubulin, β-actin, and 14-3-3 protein as chenodeoxycholate-binding proteins. Moreover, two abundant protein bands were observed in the extraction fraction from pituitarium, and identified as serum albumin and growth hormone. The affinity labeling of chenodeoxycholate onto growth hormone demonstrated that Lys55, Lysl92, Lysl96, and Lys205 were specifically labeled by chenodeoxycholate acyl adenylate. We found a new bile acid-transporting protein in human substantia nigra. In addition, we developed a new analytical method of transporting activity by using the fluorescent probe, a NBD derivative of chenodeoxycholate. In cells, bile acid acyl adenylate reacted with many proteins to produce irreversible protein adducts, and we identified all protein adducts detected by western blot analysis using anti-chenodeoxycholate antibody by MALDI-TOF MS and nanoLC/ESI-MS/MS following in-gel digestion. We developed a new specific analytical method for detection of phosphorylated sites of proteins by using derivatization reagent containing Br.
HIGHLY SPECIFIC ANALYTICAL METHOD FOR SMALL MOLECULE-TARGETED PROTEINS

MANO Nariyasu

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

Category: Grant-in-Aid for Scientific Research (C)

Institution: Tohoku University

2005 - 2006

More details Close

I developed a new specific extraction method for capturing small molecule-binding proteins from biological fluids by the cleavable affinity gel. This gel has the small molecule ligand immobilized onto the agarose gel via the disulfide linker, and the captured proteins can be extracted to the supernatant as the ligand-protein complex by reductive cleavage reaction without any conformational change of proteins. In the model experiment, this method was applied to extraction of deoxycholate-binding proteins in mouse ascites containing anti-deoxycholate monoclonal antibody. In SDS-PAGE, three protein bands were observed in the extraction fraction, and the mass spectrometric analysis and database search following in-gel tryptic digestion indicated that they were serum albumin and heavy chain and light chain of anti-deoxycholate monoclonal antibody. Next, I tried to extract the chenodeoxycholate-binding proteins in the rat brain tissue. The cytoplasmic fraction of cerebrum, midbrain, cerebellum, brainstem, hippocampus, and pituitarium were separately mixed to the chenodeoxycholate-immobilized cleavable affinity gel, and the captured proteins were analyzed by SDS-PAGE. All tissues contain three protein bands in the extraction fraction. After in-gel tryptic digestion and analysis by MALDI-TOF MS, they were identified as α-, β-tubulin, β-actin, and 14-3-3 protein by the database search. Moreover, two abundant protein bands were observed in the extraction fraction from pituitarium, and identified as serum albumin and growth hormone by MALDI-TOF MS and database search. Serum albumin is one of the carrier proteins of bile acids, and plays an important role in bile acid transport in blood stream. The extraction of serum albumin indicated that this extraction method was useful for specifically capturing small molecule-binding proteins from biological fluids.
STUDY ON PHYSIOLOGICAL SIGNIFICANCE OF BRAIN BILE ACID

GOTO Junichi, IIDA Takashi, MANO Nriyasu, KOBAYASHI Norihiro

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B)

Category: Grant-in-Aid for Scientific Research (B)

Institution: TOHOKU UNVERSITY

2002 - 2003

More details Close

Bile acids are synthesized in the liver from cholesterol. In the intestinal lumen, they assist lipolysis and the absorption of fats, and then return to the liver upon absorption in the ileum and proximal colon. Because of their efficient hepatic uptake, bile acids have low concentrations in the peripheral blood. Using LC/ESI-MS, we have recently found three unconjugated bile acids in the rat brain cytoplasmic fraction. Chenodeoxycholic acid (CDCA) was detected only upon extraction with high concentrations of guanidine hydrochloride, indicating that it is bound non-covalently to protein. In the present study, we demonstrated the enzyme activity from 3β-hydroxy-5-cholenoic acid to CDCA in rat brain tissue, and we identified the candidates of CDCA-binding proteins. To distinguish from endogenous contaminants, ^<18>O-hydroxy-5-cholenoic acid, 3β,7α-dihydroxy-5-cholenoic acid, and 7α-hydroxy-3-oxo-4-cholenoic acid were prepared and used as substrates for the in vitro incubation. The results suggested that 3β-hydroxy-5-cholenoic acid was NADPH-dependently converted to 3β,7α-dihydroxy-5-cholenoic acid in microsomal preparation. And 7α-hydroxy-3-oxo-4-cholenoic acid was NAD^+-dependently produced from 3β,7α-dihydroxy-5-cholenoic acid in microsomal preparation, and finally, Δ4-3-keto form was NADPH-dependently converted to CDCA by rat brain cytosolic enzyme. These findings indicated the presence of the enzyme activity from 3β-hydroxy-5-cholenoic acid to CDCA in rat brain tissue. Affinity gel was prepared by immobilization of CDCA. The rat brain cytoplasmic fraction was applied to the gel, and proteins were extracted by using high concentrations of guanidine hydrochloride. The protein mixture was separated by two-dimensional gel electrophoresis, and the protein map was compared with the control protein map. Several proteins were specifically enriched by the affinity extraction. The peptide fragment mixtures obtained from in-gel tryptic digestion was analyzed by MALDI-TOFMS, and the protein identification was performed by peptide mass fingerprinting method., Nine proteins were identified, and they have included tubulin α and β, 14-3-3 protein ζ, which may relate to Alzheimer's disease.
脳内胆汁酸の由来の解明とその生理的意義解明に関する研究

眞野成康

Offer Organization: 日本学術振興会

System: 科学研究費助成事業若手研究(B)

Category: 若手研究(B)

Institution: 東北大学

2002 - 2003

More details Close

胆汁酸は、肝においてコレステロールより生合成され、腸肝循環する炭素数24個のカルボン酸であり、その生合成や動態は厳密に制御されているため、通常血中や末梢組織中にはごく僅かにしか存在しない。最近、LC/ESI-MSを用いてラット脳組織中の胆汁酸の検索を行ったところ、可溶性画分中に3種の遊離型胆汁酸の存在することが明らかとなった。しかもそれらのうち、ケノデオキシコール酸はグアニジン塩酸塩を用いる蛋白質変成操作を加えることにより初めて検出されることから、脳内においてある種の蛋白質と強くバウンドしていることが示唆された。そこで今回、ケノデオキシコール酸を固定化したアフィニティーゲルを調製し、これを用いて結合蛋白質の特異的抽出を試みるとともに、プロテオミクス手法を用いてその結合蛋白質の解析を行った。まず、ケノデオキシコール酸のβ-アラニン抱合体を調製し、これをカルボジイミド法を用いてアガロースゲルに固定化した。これに、ラット脳細胞質画分を添加し、緩やかに混合してケノデオキシコール酸結合蛋白質を捕捉した。次いで、リン酸緩衝液、水/メタノール混液などを用いて順次洗浄して非特異的結合蛋白質を除去した。先と同様に高濃度のグアニジン塩酸塩溶液を添加してケノデオキシコール酸と強く結合した蛋白質をアンフォールドすることによって抽出し、得られた蛋白質混合物を二次元ゲル電気泳動法を用いて分離したところ、数種の蛋白質が特異的に濃縮されることが判明した。トリプシンを用いるゲル内消化後、MALDI-TOFMSによるペプチドマスマッピングに付し、ペプチドマスフィンガープリンティング法によるデータベース検索を行ったところ、ビタミンD依存性Ca結合蛋白質の他、チューブリンや14-3-3蛋白質ζなどのアルツハイマー病に関与する蛋白質が同定された。
創薬を目指すファーマコプロテオミクスの基盤研究

後藤順一, 眞野成康, 小林典裕

Offer Organization: 日本学術振興会

System: 科学研究費助成事業萌芽研究

Category: 萌芽研究

Institution: 東北大学

2001 - 2002

More details Close

本格的なポストゲノム時代が到来し、世界の各製薬企業はゲノム情報を活用する新規医薬品開発の方向性を模索している。こうした中、薬物や生理活性物質刺激が誘起する変化を分子レベルで捕らえ、標的蛋白質の機能を解析することにより、新たな創薬標的分子を探索するファーマコプロテオミクス手法の確立に多大な期待が寄せられている。本年度は、リン酸による翻訳後修飾蛋白質解析法を検討するとともに、アフィニティーラベル化法とイムノアフィニティー抽出法を駆使した低分子-蛋白質相互作用解析法の構築を試みた。前年度の結果から、デオキシコール酸刺激によるペルオキシレドキシンIの変動には、リン酸による翻訳後修飾が関与している可能性が示唆された。そこで、2次元ゲル電気泳動マップのディファレンシャルディスプレイを用いるリン酸化蛋白質特定法につき検討した。試料をあらかじめアルカリホスファターゼにより脱リン酸化反応に付した後、2次元ゲル電気泳動法により蛋白質を分離し、マップ化した。次いで、脱リン酸化処理を行わない試料と比較したところ、容易にリン酸化蛋白質を特定できることが判明した。しかも、分離した蛋白質スポットをゲル内にてアルカリホスファターゼ反応に付した後、負イオン検出MALDI-TOFMSにて測定することにより、リン酸化ペプチドを高感度に検出できることが判明した。加えてエキソペプチダーゼを用いるペプチドラダーシークエンス法を用いることにより、そのリン酸化部位の特定も可能であることが明らかとなった。一方、低分子-蛋白質相互作用解析を目的としてアシルアデニレートをアフィニティーラベル化剤として用い、その有用性を吟味したところ、相互作用部位に選択的なラペル化が可能であることが判明した。しかもイムノアフィニティー抽出法を駆使して酵素消化により得たラベル化ペプチドを選択的に抽出し、ラベル化部位の構造解析も可能であることを実証した。

Show all Show first 5

Other 7

注射剤自動調製装置の開発

More details Close

注射剤自動調製装置の開発
LC/MS/MS定量法による固相抽出ＭＳ法の制度検証

More details Close

LC/MS/MS定量法による固相抽出ＭＳ法の制度検証
固相抽出MS法による免疫抑制剤測定時の妨害成分の解析

More details Close

固相抽出MS法による免疫抑制剤測定時の妨害成分の解析
プロトンポンプ阻害薬の薬物動態に及ぼす食事の影響の検討―オメプラゾールとラベプラゾールのクロスオーバー比較試験―

More details Close

プロトンポンプ阻害薬の薬物動態に及ぼす食事の影響の検討―オメプラゾールとラベプラゾールのクロスオーバー比較試験―
固相抽出MS法による免疫抑制剤測定時の妨害成分の解析

More details Close

固相抽出MS法による免疫抑制剤測定時の妨害成分の解析
MS検出応用による高圧型LCレス方式のTDM向け簡易メソッドの開発

More details Close

MS検出応用による高圧型LCレス方式のTDM向け簡易メソッドの開発
市販後医薬品の効能拡大を目的とする臨床研究実施環境構築

More details Close

市販後医薬品の効能拡大を目的とする臨床研究実施環境構築

Show all Show first 5